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Abstract 
 This dissertation describes the development of cooperative catalyst systems for the regio-
and enantio-selective D- and E-amino CH functionalization of N-alkylamines, inspired by the 
concepts of frustrated Lewis pairs (FLPs). Prior to this dissertation research, the development of 
effective and broadly applicable catalytic protocol to transform amino CH bonds with high 
enantioselectivity remained as a formidable problem. In Chapter 1, the recent advances in the field 
of amino CH functionalization through hydride transfer process that served as intellectual 
foundations for this dissertation research is presented. As highlighted in the first chapter, key 
challenges of amino CH functionalization are: (1) unreactive nature of D, E- and/or J-amino CH 
bonds, (2) requirement for the use of precious metal-based catalysts and external oxidants under 
acidic/basic and harsh conditions, (3) use of directing groups for regioselectivity, and (4) poor 
functional group tolerance. Inspired by the unique capability of FLPs to activate otherwise 
unreactive molecules while disfavoring undesirable acidbase complexation, we have developed 
a protocol for enantioselective D-amino CH functionalization of N-alkylamines, where chiral and 
achiral Lewis acid catalysts work cooperatively (Chapter 2). The application of the cooperative 
catalyst system comprising of B(C6F5)3, a chiral Lewis acid, and a Brønsted base to the 
enantioselective E-amino CH functionalization is described in Chapter 3.    
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Chapter One 
Recent Advances in CH Functionalization of N-Alkylamines 
 
N-Alkylamines are ubiquitous in natural products, pharmaceuticals, polymers, as well as  
catalysts and ligands used in organic synthesis.1 In particular, amines possessing stereogenic 
centers at D, E, and/or J-positions can be found in approximately 40% of pharmaceuticals and 20% 
of agrochemicals.1 Therefore, the synthesis of chiral amines with high enantiomeric purity 
represents one of the most essential and widely studied topics in organic synthesis. 2-3 Previously 
established approaches for the preparation of N-alkylamines in enantio- and/or diastereo-
merically-enriched forms include the resolution of rac-amines,4 hydroamination,5-6 reduction of 
imines or enamines,7 and nucleophilic addition to imines.8 A complementary strategy for the 
synthesis of enantio-enriched N-alkylamines involves stereoselective transformations of D, E, 
and/or J-amino CH bonds that are contained in prochiral amine substrates (Scheme 1.1).9 Recent 
advances in the arena of C H functionalization established that various organometallic complexes 
                                                          
1 (a) McGrath, N. A.; Brichacek, M.; Njardarson, J. T. J. Chem. Educ. 2010, 87, 1348 1349. (b) Ghi ie i, D.; T e , 
N. J. Top Catal. 2014, 57, 284300. (c) Schrittwieser, J. H.; Velikogne, S.; Kroutil, W. Adv. Synth. Catal., 2015, 357, 
16551685. 
2 (a) Chiral Amine Synthesis: Methods, Developments and Applications; Nugent, T. C., Ed.; Wiley-VCH Verlag 
GmbH & Co. KGaA: Weinheim, 2010, p 15457. (b) Vardanyan, R. in Piperidine-Based Drug Discovery; Vardanyan, 
R., Ed.; Elsevier: 2017, p 147. 
3 (a) Campos, K. R.; Coleman, P. J.; Alvarez, J. C.; Dreher, S. D.; Garbaccio, R. M.; Terrett, N. K.; Tillyer, R. D.; 
Truppo, M. D.; Parmee, E. R. Science 2019, 363, eaat0805. (b) Trowbridge, A.; Walton, S. M.; Gaunt, M. J. Chem. 
Rev. 2020, 120, 2613 2692. (c) Yin, Q.; Shi, Y.; Wang, J.; Zhang, X. Chem. Soc. Rev. 2020, 49, 61416153. 
4 Wosinska-Hrydczuk, M.; Skarzewski, J. Molecules 2020, 25, 49074941. 
5 Huang, L.; Arndt, M.; Gooßen, K.; Heydt, H.; Gooßen, L. J. Chem. Rev.  2015, 115, 25962697. 
6 (a) Zhu, S.; Buchwald, S. L. J. Am. Chem. Soc. 2014, 136, 1591315916. (b) Yang, Y.; Shi, S.-L.; Niu, D.; Liu, P,; 
Buchwald, S. L. Science 2015, 349, 6266. (c) Roos, C. B.; Demaerel, J.; Graff, D. E.; Knowles, R. R. J. Am. Chem. 
Soc. 2020, 142, 59745979. 
7 Barrios-Rivera, J.; Xu, Y.; Wills, M.; Vyas, V. K. Org. Chem. Front. 2020, 7, 33123342. 
8 (a) Kobayashi, S.; Ishitani, H. Chem. Rev. 1999, 99, 10691094. (b) Kobayashi, S.; Mori, Y.; Fossey, J. S.; Salter, 
M. M. Chem. Rev. 2011, 111, 26262704. 
9 Cernak, T.; Dykstra, K. D.; Tyagarajan, S.; Vachal, P.; Krska, S. W. Chem. Soc. Rev., 2016, 45, 546576. 
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(e.g., Rh-, Pd-, Ir-, Pt-based complexes)3b promote efficient conversion of C(sp3)H bonds 
contained in a variety of N-alkylamines into C(sp3)C and C(sp3)heteroatom bonds.10 Moreover, 
the use of chiral organometallic complexes allow for enantioselective synthesis of N-alkylamines 
from the prochiral substrates (Scheme 1.1A and 1.1B). 11  Highly attractive but less explored 
processes are those that enable enantioselective late-stage functionalization of bioactive amines 
(e.g., Scheme 1.1C).3a 
Scheme 1.1. Regio- and Enantio-selective Functionalization of Amino CH Bonds 
 
 
Despite the significant potentials of the stereoselective amino C H functionalization 
strategy, there exist fundamental hurdles that need to be overcome in order for such methods to 
find practical applications. The challenges associated with the state-of-the-art include the 
following: 
                                                          
10 Hong, B.; Luo, T.; Lei, X. ACS Cent. Sci., 2020, 6, 622635. 
11 (a) Davies, H. M.; Venkataramani, C.; Hansen, T.; Hopper, D. W. J. Am. Chem. Soc. 2003, 125, 64626468. (b) 
Smalley, A. P.; Cuthbertson, J. D.; Gaunt, M, J. J. Am. Chem. Soc. 2017, 139, 14121415. 
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1) D, E, and/or J-amino CH bonds are inherently unreactive; they have high bond dissociation 
energy (8796 kcal/mol) and low acidity (pKa = 4560).12-13   
2) For the cleavage of the poorly reactive amino CH bonds, many methods rely on the use of 
highly reactive and precious metal-based catalysts, external oxidants to turn over the catalysts, and 
are performed under acidic/basic conditions under elevated temperatures (e.g., Scheme 1.1A and 
1.1B).11, 12c 
3) CH Bonds are ubiquitous in bioactive amines; thus, the activation and functionalization of a 
specific CH bond is a formidable problem. To achieve such regioselectivity, the preexisting 
methods can only be applied to substrates that possess appropriate functional groups that can serve 
as directing groups (e.g., Scheme 1.1B), or demand installation and removal of directing groups.3b 
Consequently, many of the amino C H functionalization processes reported to date have poor 
functional group tolerance; the late-stage modification of bioactive compounds that possess 
various Lewis acid- and/or Lewis base-sensitive functional groups are not within the purview of 
the present state-of-the-art.3,11 
The key aim of this dissertation research is to develop a powerful catalyst system which 
promotes regio- and stereo-selective transformations of D- and/or E-amino CH bonds contained 
in various N-alkylamines (e.g., Scheme 1.1C). Furthermore, our goal is to devise methods that take 
place under mild and redox neutral conditions, while circumventing the use of precious metal-
based catalysts and installation/removal of directing groups. Through the innovation of such novel 
catalysts, we aspire to address the critical unsolved problems listed above and achieve the late-
                                                          
12 (a) Lyons, T. W.; Sanford, M. S. Chem. Rev. 2010, 110, 1147-1169. (b) Baudoin, O. Chem. Soc. Rev. 2011, 40, 
4902-4911. (c) Ohno, S.; Miyoshi, M.; Murai, K.; Arisawa, M. Synthesis, 2021, doi:10.1055/a-1483-4575. 
13 (a) Wayner, D. D. M.; Clark, K. B.; Rauk, A.; Yu, D.; Armstrong, D. A. J. Am. Chem. Soc. 1997, 119, 89258932. 
(b) Lalevee, J.; Allonas, X.; Fouassier, J.-P. J. Am. Chem. Soc. 2002, 124, 96139621. 
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stage derivatization of bioactive amines and other industrially important N-alkylamines that 
contain an array of Lewis acid- and/or base-sensitive functional groups. Thus, an array of enantio- 
and diastereo-merically-pure amines that find applications in drug discovery, agrochemicals and 
materials chemistry, and are difficult to access through conventional synthetic methods, can be 
readily prepared.14 
Below, a summary on the selected state-of-the-art methods in D- and E-amino C H 
functionalization reactions that served as intellectual foundations of this dissertation research is 
provided. This chapter is focused on describing transformations of amino C H bonds that proceed 
through intra- or inter-molecular hydride transfer process. Representative examples to be discussed 
in this chapter are as listed below: 
1.1. Enzyme-Mediated Hydride Abstraction of Amines  
1.2. Lewis Acid-Mediated Hydride Abstraction of Amines 
Carbocation-Mediated Hydride Abstraction from N-Alkylamines  
Organoborane-Mediated Hydride Abstraction from N-Alkylamines 
1.3. (F5C6)3B-Catalyzed Transfer Hydrogenation/Dehydrogenation of Amines 
1.4. (F5C6)3B-Catalyzed D-Amino CH Functionalization 
1.5. (F5C6)3B-Catalyzed E-Amino CH Functionalization 
 CSi Bond Formation 
 CC and C C Bond Formation 
1.6. (F5C6)3B-Catalyzed CN Bond Cleavage 
                                                          
14 Börgel, J.; Ritter, T. Chem 2020, 6, 18771887. 
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1.1. Enzyme-Mediated Hydride Abstraction of Amines  
 An effective catalytic method to convert an N-alkylamine into an iminium ion through 
hydride abstraction can be found in enzymatic processes (e.g., Scheme 1.2).15-16 Monoamine 
oxidases (MAOs) are flavoenzymes that are known to transform biogenic amines such as 
dopamine (1.1), adrenaline or serotonin into their corresponding imines (1.2).15-16 The oxidation 
of an amine is proposed to proceed through hydride abstraction from 1.1 b  he f a i  N5 a  
which results in the formation of an iminium intermediate (I II). Ensuing deprotonation of the 
iminium furnishes imine 1.2 (II III) which then undergoes hydrolysis to afford aldehyde 1.3 and 
ammonia.  
Scheme 1.2. Hydride Abstraction Mechanism for MAO-Catalyzed Oxidative Deamination 
 
                                                          
15 (a) Fitzpatrick, P. F. Archives of Biochemistry and Biophysics 2010, 493, 1325. (b) Vianello, R.; Repi , M.; Mavri, 
J. Eur. J. Org. Chem. 2012, 36, 70577065. (c) Mar avelski, A.; Vianello, R. Chem. Eur. J. 2017, 23, 29152925. (d) 
Mar avelski, A.; Petrovi , D.; Bauer, P.; Vianello, R.; Kamerlin, S. C. L. ACS Omega 2018, 3, 36653674. (e) 
Tandari , T.; P ah, A.; S a e, J.; Ma i, J.; Via e , R. Int. J. Mol. Sci. 2020, 21, 61516163. 
16 (a) Segura-Aguilar, J.; Paris, I.; Munoz, P.; Ferrari, E.; Zecca, L.; Zucca, F. A. J. Neurochem, 2014, 129, 898915. 
(b) Masato, A.; Plotegher, N.; Boassa, D.; Bubacco, L. Molecular Neurodegeneration, 2019, doi:10.1186/s13024-
019-0332-6. 
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 Artificial methods to convert amines into iminium intermediates through hydride 
abstraction have also been investigated.17 In the following sections, selected seminal reports on 
Lewis acid-mediated hydride abstraction of amines are described.  
                                                          
17 (a) Ma, Y.; Lou, S.-J.; Hou, Z. Chem. Soc. Rev. 2021, 50, 19451967. (b) Basak, S.; Winfrey, L.; Kustiana, B. A.; 
Melen, R. L.; Morrill, L. C.; Pulis, A. P. Chem. Soc. Rev. 2021, 50, 37203737. 
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1.2. Lewis Acid-Mediated Hydride Abstraction of Amines 
An array of N-alkylamines that contain electron-rich nitrogen centers and possess easily 
accessible D-CH bonds are known to engage in Lewis acid-mediated hydride abstraction, 
generating an iminium cation.18 Below are representative examples. 
1.2.1. Carbocation-Mediated Hydride Abstraction from N-Alkylamines 
In 1966, Damico and Broaddus reported that hydride abstraction occurs when tertiary 
amines are treated with a trityl cation (Scheme 1.3).19 Specifically, the reaction of tribenzylamine 
(1.4) and tritylium tetrafluoroborate (1.5) gave an iminium salt 1.6 and triphenylmethane (1.7). 
However, further transformation of the iminium ion was not demonstrated in this report. 
Scheme 1.3. Tritylium-Mediated Hydride Abstraction from Tertiary Amines 
 
Lambert and coworkers developed a method for transforming an D-amino C H bond into 
a C CN bond which was mediated by a tropylium ion, a 6S-electron aromatic carbocation. The 
tropylium ion is responsible for converting amine 1.8 into an iminium salt IV (Scheme 1.4).20 The 
iminium generated in this manner could react with KCN (IV V) to afford an aminonitrile product 
1.10. This work demonstrated that the N-alkylamine-derived iminium ion formed through 
carbocation-mediated hydride abstraction can deliver D-substituted amine products upon its 
reaction with nucleophilic species. 
 
                                                          
18 Meerwein, H.; Hederich, J.; Morschel, H.; Wunderlich, K. Justus Liebigs Ann. Chem. 1960, 635, 121. 
19 Damico, R.; Broaddus, C. D. J. Org. Chem. 1966, 31, 16071612. 
20 Allen, J. M.; Lambert, T. H. J. Am. Chem. Soc. 2011, 133, 12601262.  
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Scheme 1.4. a-Cyanation of Amines through Tropylium Ion-Mediated Hydride Abstraction  
 
1.2.2. Organoborane-Mediated Hydride Abstraction from N-Alkylamines  
In 2002, Santini and coworkers disclosed that when B(C6F5)3 and N,N-dimethylaniline 
(1.12) were reacted in C6D6 at 22 ºC, an ion pair consisting of an iminium and a borohydride 1.13 
can be generated (Scheme 1.5a).21  Furthermore, the reaction of N,N-diethylaniline (1.14) and 
B(C6F5)3 gave a zwitterionic species 1.15 together with an ionic complex of ammonium and 
borohydride 1.16 (Scheme 1.5b). In the latter process, iminium ion VI is generated upon (F5C6)3B-
mediated hydride abstraction of aniline 1.14. Subsequently, deprotonation of iminium (VI) by 
another molecule of 1.14 affords an enamine intermediate (VII), which then reacts with B(C6F5)3 
to provide the zwitterionic product 1.15. This seminal work elucidated that sterically encumbered 
and strongly Lewis acidic B(C6F5)3 can promote hydride abstraction from N-alkylaniline 
derivatives, and also that the in situ-generated iminium ion can be deprotonated to afford enamines. 
  
                                                          
21 Millot, N.; Santini, C. C.; Fenet, B.; Basset, J. M. Eur. J. Inorg. Chem. 2002, 2002, 3328 3335. 
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Scheme 1.5. (F5C6)3B-Mediated Hydride Abstraction from Amine 
 
The group of Erker investigated intramolecular organoborane-mediated hydride 
abstraction, which occurs within a frustrated N/B Lewis pair 1.17 (Scheme 1.6).22 The resulting 
zwitterionic intermediate VIII reacts with benzaldehyde to provide 1.18 containing iminium ion 
and boroalkoxide units. Thus, this work showed that the borohydride anion, which was generated 
in situ through hydride abstraction from an amine, could transfer the hydride to an appropriate 
electrophile.  
Scheme 1.6. Hydride Abstraction within Intramolecular Frustrated N/B Lewis Pair 
 
                                                          
22 Schwendemann, S.; Frohlich, R.; Kehr, G.; Erker, G. Chem. Sci. 2011, 2, 18421849. 
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In a subsequent work, Erker and coworkers achieved (F5C6)3B-mediated Mannich-type 
reaction between N,N-dimethylaniline 1.19 and acetylenedicarboxylate 1.20  (Scheme 1.7).23 This 
transformation is proposed to proceed through the reaction of 1.19 and 1.0 equivalent of B(C6F5)3 
to generate an iminium and a borohydride (IX). Ensuing borohydride reduction of 1.20 furnishes 
an allenoate (X), which undergoes CC bond forming reaction with 1.19-derived iminium ion to 
afford intermediate XI. Finally, a zwitterionic product 1.21 can be obtained upon isomerization of 
XI. Nonetheless, (F5C6)3B-catalyzed variant of this process was not reported. 




                                                          
23 Chen, G.-Q.; Kehr, G.; Daniliuc, C. G.; Bursch, M.; Grimme, S.; Erker, G. Chem. Eur. J. 2017, 23, 47234729. 
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1.3. (F5C6)3B-Catalyzed Transfer Hydrogenation/Dehydrogenation of Amines 
The ability of B(C6F5)3 to abstract a hydride from N-alkylamines has found applications in 
catalytic processes involving transfer hydrogenation of imines as well as dehydrogenation of N-
heterocycles. 
The Stephan group demonstrated that B(C6F5)3 can promote transfer hydrogenation of 
ketimine 1.22 using i-Pr2NH as a source of hydride and proton (Scheme 1.8).24 (F5C6)3B-catalyzed 
hydride abstraction from i-Pr2NH generates an ionic complex containing a borohydride and an 
iminium ion (XII). Deprotonation of the iminium by another equivalent of i-Pr2NH affords an 
enamine and an ammonium ion (XIII). Imine 1.22 then undergoes sequential borohydride 
reduction and protonation by the ammonium ion to furnish sertraline 1.23. 
Scheme 1.8. (F5C6)3B-Catalyzed Transfer Hydrogenation  
 
The group of Grimme and Paradies,25 and that of Kanai26 independently reported (F5C6)3B-
catalyzed dehydrogenation of N-heterocycles (Scheme 1.9); notably, these reactions can be 
                                                          
24 Farrell, J. M.; Heiden, Z. M.; Stephan, D. W. Organometallics 2011, 30, 44974500. 
25 Maier, A. F. G.; Tussing, S.; Schneider, T.; Flörke, U.; Qu, Z.-W.; Grimme, S.; Paradies, J. Angew. Chem., Int. Ed. 
2016, 55, 1221912223. 
26 Kojima, M.; Kanai, M. Angew. Chem., Int. Ed. 2016, 55, 1222412227. 
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performed in the absence of transition metal based-complexes and acceptors for H2. The proposed 
mechanism involves (F5C6)3B-catalyzed hydride abstraction of amine 1.24 to produce an ion pair 
of iminium and borohydride (XIV, Scheme 1.9a). Subsequent deprotonation of the iminium ion 
by a second molecule of Brønsted basic 1.24 affords indole 1.25. The release of H2 from an ionic 
complex of [H B(C6F5)3]  and protonated 1.24 regenerates B(C6F5)3. In a related work, Kanai and 
co-workers reported (F5C6)3B-catalyzed dehydrogenation of tetrahydroquinoline 1.26 for the 
synthesis of quinoline 1.27 (Scheme 1.9b).  Despite these important advances in (F5C6)3B-
catalyzed hydride transfer processes, capturing of the iminium intermediate by nucleophilic 
entities to produce D-functionalized amines stood as an unsolved problem. 
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1.4. (F5C6)3B-Catalyzed D-Amino CH Functionalization 
In this section, catalytic protocols for D-amino CH functionalization via iminium 
promoted by B(C6F5)3 will be discussed. 
(F5C6)3B-Catalyzed intramolecular transformations of alkene-substituted N,N-
dialkylanilines through hydride abstraction were developed by the group of Grimme and 
Paradies, 27  and that of Wang, 28  independently (Scheme 1.10). After the (F5C6)3B-mediated 
hydride abstraction from D-amino position of aniline 1.28, the in situ generated iminium ion XV 
undergoes intramolecular CC bond formation with the electron-rich alkene unit to afford a 
carbocation (XVI, Scheme 1.10a). Borohydride reduction of carbocation XVI provides rac-1.29. 
Scheme 1.10. (F5C6)3B-Catalyzed Intramolecular Reaction  
 
                                                          
27 Maier, A. F. G.; Tussing, S.; Zhu, H.; Wicker, G.; Tzvetkova, P.; Flörke, U.; Daniliuc, C. G.; Grimme, S.; Paradies, 
J. Chem. Eur. J. 2018, 24, 1628716291. 
28 Tian, J. J.; Zeng, N. N.; Liu, N.; Tu, X. S.; Wang, X.-C. ACS Catal. 2019, 9, 295300. 
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In Wang and co- ke  e a ed d   i a ec a  Ma ich-type reaction for the 
synthesis of 1.31, Me3SiOTf was used as an additive to facilitate the turnover-limiting hydride 
transfer step (Scheme 1.10b).28 It is proposed that hydride exchange between [HB(C6F5)3] and 
Me3SiOTf forms [HSi(OTf)Me3], a better hydride donor, enhancing the reaction efficiency. 
In 2021, the Wang group reported (F5C6)3B-catalyzed intramolecular dehydrogenative 
cyclization of 2-cyclopropyl-N,N,-dimethylanilines (1.32, Scheme 1.11). 29  B(C6F5)3 promotes 
cyclopropane ring opening to form XVII, which can be deprotonated by Ba  ba e  aff d 
allylic borane (XVIII). B(C6F5)3 can also abstract hydride from aniline unit, generating iminium-
containing zwitterionic intermediate XIX, which undergoes cyclization to furnish the 
corresponding tetrahydroquinoline derivative 1.33. Borohydride and a ed Ba  ba e 
(XIX) can release H2 to regenerate the catalysts. 
Scheme 1.11. (F5C6)3B-Catalyzed Dehydrogenative Cyclization  
 
                                                          
29 Zhang, Z. Y.; Ren, J.; Zhang, M.; Xu, X.-F.; Wang, X.-C. Chin. J. Chem. 2021, 39, doi:10.1002/cjoc.202100056. 
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Paradies and co-workers developed an intramolecular cyclization of o-amino-substituted 
D,E-unsaturated ketones (1.34) through endo-1,7-hydride shift catalyzed by B(C6F5)3 (Scheme 
1.12).30 It is proposed that hydride transfer is promoted by Lewis acid activation of the carbonyl 
moiety (XX) rather than B(C6F5)3 abstracting a hydride from D-amino position of 1.34. Ensuing 
intramolecular CC bond forming reaction takes place between the boron enolate and iminium 
ion (XXI) to produce a dihydroquinoline derivative 1.35. 
Scheme 1.12. (F5C6)3B-Catalyzed 1,7-Hydride Transfer  
 
The literature precedents discussed above (Schemes 1.101.12) showed that the amine-
derived iminium intermediate can be used to effect D-amino CH alkylation processes. However, 
these methods have been confined to non-enantioselective intramolecular transformations of N-
alklylaniline derivatives. 
                                                          
30 Wicker, G.; Schoch, R.; Paradies, J. Org. Lett. 2021, doi:10.1021/acs.orglett.1c01018 
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1.5. (F5C6)3B-Catalyzed E-Amino CH Functionalization 
Direct transformation of less reactive E-amino CH bond under redox- and pH-neutral 
conditions is a central challenge in catalysis.7c One of the emerging strategies to access the E-
amino CH bonds is (F5C6)3B/NR3-catalyzed conversion of N-alkylamines into enamine.21 The 
enamine intermediate can then react with an appropriate electrophile to afford E-substituted 
amines. 
1.5.1. CSiBond Formation 
The Chang group developed a protocol for the synthesis of bridged sila-N-heterocycles 
(1.37) through silylation of N-aryl piperidines (1.36) with hydrosilanes, that is catalyzed by 
B(C6F5)3 (Scheme 1.13).31 After borane-mediated hydride abstraction of aniline 1.36, the resultant  
Scheme 1.13. (F5C6)3B-Catalyzed Synthesis of Bridged Sila-N-Heterocycles from Piperidines  
 
                                                          
31 Zhang, J.; Park, S.; Chang, S. J. Am. Chem. Soc. 2018, 140, 1320913213. 
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iminium (XXII) can be deprotonated to form an enamine (XXIII). Following hydrosilylation of 
enamine XXIII gives -silylated piperidine (XXIV), which undergoes intramolecular 
dehydrogenative sp2 C H i a i  (XXV) to afford the bridged sila-N-heterocycle 1.37.  
In 2021, Oestreich and co-workers reported (F5C6)3B-catalyzed E-amino CH silylation of 
acyclic trialkylamines (1.38) to construct 4-silapiperidine derivatives (1.39, Scheme 1.14). 32 
Sequential hydride abstraction and deprotonation of 1.38 affords an enamine (XXVI), which 
undergoes intermolecular CSi bond forming reaction with (F5C6)3B-activated hydrosilane 
(XXVI XXVII). The resulting iminium ion can undergo isomerization (XXVII XXVIII) and 
deprotonation to furnish an enamine intermediate (XXIX). Then, (F5C6)3B-promoted 
intramolecular hydrosilylation and borohydride reduction provide the 4-silapiperidine 1.39.  
Scheme 1.14. (F5C6)3B-Catalyzed EE -Silylation of Acyclic Tertiary Amines 
 
                                                          
32 Fang, H.; Xie, K.; Kemper, S.; Oestreich, M. Angew. Chem., Int. Ed. 2021, 60, 85428546. 
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The studies described above (Schemes 1.13, 1.14) demonstrated that E-amino CH bond 
can be converted into C Si bond via the enamine that is generated in situ through consecutive 
(F5C6)3B-promoted hydride abstraction and Brønsted base-mediated deprotonation.  
1.5.2. CC Bond and C C Bond Formation 
The groups of Yang, Zhao, and Ma disclosed intermolecular E-alkylation of acyclic tertiary 
amines (1.40) promoted by B(C6F5)3 (Scheme 1.15).33 This transformation involves conjugate 
addition of 1.40-derived enamine (XXX) to p-quinone methide 1.41 that affords zwitterionic 
intermediate XXXI. The borohydride reduction and ammonium-mediated protonation of XXXI 
delivers the E-alkylation product 1.42 and regenerates the catalysts. Although (F5C6)3B-catalyzed 
E-amino CH alkylation was achieved, bulky 2,6-di-t-Bu substituents in p-quinone methide 1.41 
was required and the amine substrate scope was confined to triethylamine (1.40) and its two 
analogues. 
Scheme 1.15. (F5C6)3B-Catalyzed E-Alkylation of Acyclic Tertiary Amines  
 
                                                          
33 Li, R.; Chen, Y.; Jiang, K.; Wang, F.; Lu, C.; Nie, J.; Chen, Z.; Yang, G.; Chen, Y.-C.; Zhao, Y. Ma, C. Chem. 
Commun. 2019, 55, 12171220. 
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Yang, Ma, and co-workers developed (F5C6)3B-catalyzed union of N-aryl pyrrolidines 
(1.43) and isatins (1.44) for the synthesis of E-substituted pyrrolidines (1.45, Scheme 1.16).34 The 
aniline 1.43-derived enamine (XXXII) reacts with 1.44 to generate zwitterionic intermediate 
XXXIII. Subsequent protonation of alkoxide (XXXIII) by ammonium and dehydration would 
furnish a C C bond (XXXIV). Upon borohydride reduction of the iminium ion (XXXIV), a 
pyrrolidine that bears exocyclic alkene (1.45) can be obtained. 
Although these work demonstrated that redox-neutral E-functionalizations of N-
alkylamines to construct a new CC bond or C C bond can be achieved, both transformations 
were confined to a narrow range of N-alkylamine substrates and electrophiles. 




                                                          
34 Chen, Y.; Wan, H.-L.; Huang, Y.; Liu, S.; Wang, F.; Lu, C.; Nie, J.; Chen, Z.; Yang, G.; Ma, C. Org. Lett. 2020, 
22, 77977803. 
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1.6. (F5C6)3B-Catalyzed CN Bond Cleavage 
The deconstructive functionalization of amines has recently gained attention as a means to 
obtain products with complex structures that cannot be efficiently synthesized by other methods.35 
Accordingly, the strategies to cleave CN bond in N-alkylamines involving (F5C6)3B-catalyzed 
hydride abstraction have been investigated independently by several laboratories. 
The Chang group reported (F5C6)3B-catalyzed cine-silylative CN cleavage of tertiary 
amines (1.46, Scheme 1.17).36 This reaction proceeds by dehydrogenation of N-alkylamine to form 
an enamine intermediate (XXXV), which undergoes hydrosilylation promoted by B(C6F5)3 to 
afford E-silylpiperidine (XXXVI). After the formation of 2-silazetidinium (XXXVII), cis-E-amino 
elimination takes place to form the intermediate XXXVIII. Finally, hydrosilylation of the terminal 
alkene unit provides the desired product 1.47.  
Scheme 1.17. (F5C6)3B-Catalyzed CN Bond Cleavage of Tertiary Amines 
 
                                                          
35 (a) Roque, J. B.; Kuroda, Y.; Göttemann, L. T.; Sarpong, R. Science 2018, 361, 171174. (b) Roque, J. B.; Kuroda, 
Y.; Göttemann, L. T.; Sarpong, R. Nature 2018, 564, 244248. 
36 Zhang, J.; Chang, S. J. Am. Chem. Soc. 2020, 142, 1258512590. 
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The groups of Melen, Morrill, and Pulis reported a method for direct C3 alkylation of 
indoles (1.48) using N-alkylanilines (1.49) as an alkylating reagent (Scheme 1.18).37 The N-aryl 
pyrrolidine 1.49-derived iminium ion reacts with a nucleophilic indole 1.48 to forge a new CC 
bond (XXXIX XL). Proton transfer enables the cleavage of CN bond and generates a 
conjugated iminium ion (XLI), which is reduced by borohydride to furnish alkylated indole 1.50. 
It was shown that N-alkylamines can serve as an alkylating reagent through (F5C6)3B-catalyzed 
CN bond cleavage.  
Scheme 1.18. (F5C6)3B-Catalyzed C3 Alkylation of Indoles 
 
The Oestreich group developed a protocol for (F5C6)3B-catalyzed reductive deamination 
of benzylic amines (e.g., 1.51, Scheme 1.19).38  B(C6F5)3 promotes the SiN bond forming reaction 
between N-alkylamine (1.51) and PhSiH3, affording an ion pair consisting of a silylammonium 
and a borohydride (XLII). Upon the release of silazane 1.53, benzylic carbocation (XLIII) is 
generated, which can then be reduced by a borohydride to deliver product 1.52. This method was 
                                                          
37 Basak, S.; Alvarez-Montoya, A.; Winfrey, L.; Melen, R. L.; Morrill, L. C.; Pulis, A. P. ACS Catal. 2020, 10, 
48354840. 
38 Fang, H.; Oestreich, M. Angew. Chem., Int. Ed. 2020, 59, 1139411398. 
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also applicable to the cleavage of CN bonds contained in isocyanate, isothiocyanate, and thionyl 
imide. 
Scheme 1.19. (F5C6)3B-Catalyzed Reductive Deamination Using Hydrosilanes 
 
 
The approaches highlighted above (Schemes 1.171.19) demonstrated that B(C6F5)3 can 
promote the cleavage of CN bonds contained in N-alkylamines, however, application of such 
methods to more complex amine substrates remain as an unresolved problem. 
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1.7. Specific Aims of the Dissertation Research 
Iminium ions have been utilized as highly versatile intermediates for stereoselective 
synthesis of N-alkylamines.39-40 Iminiums have often been generated in a catalytic manner through 
condensation of primary or secondary amine catalysts with carbonyl molecules (1.54 XLIV, 
Scheme 1.20),40a protonation of imines by Brønsted acids (1.55 XLIV),40b and anion abstraction 
from D-haloamines or D-pseudohaloamines by hydrogen bond donors (1.56 XLIV),40c-d among 
other approaches.39 The processes highlighted in this chapter involving the organoborane-
mediated hydride abstraction from N-alkylamines (e.g., Schemes 1.5 1.19) represent a 
complimentary strategy to furnish iminiums (1.57 XLIV, Scheme 1.20). Although there was no 
literature report on catalytic transformations of iminiums generated in this manner at the time this 
dissertation research was started in 2016, the organoborane- catalyzed hydride abstraction  
Scheme 1.20. Catalytic Formation of Iminium Ion 
 
                                                          
39 Rostoll-Berenguer, J.; Blay, G.; Pedro, J. R.; Vila, C. Adv. Synth. Catal. 2021, 363, 602 628. 
40 (a) Erkkila, A.; Majander, I.; Pihko, P. M. Chem. Rev. 2007, 107, 54165470. (b) Yamanaka, M.; Itoh, J.; Fuchibe, 
K.; Akiyama, T. J. Am. Chem. Soc. 2007, 129, 67566764. (c) Wasa, M.; Liu, R.; Roche, S. P.; Jacobsen, E. N. J. Am. 
Chem. Soc. 2014, 136, 1287212875. (d) Osberger, T. J.; Rogness, D. C.; Kohrt, J. T.; Stepan, A. F.; White, M. C. 
Nature, 2016, 537, 214219. 
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approach holds the potential to offer the following distinctive advantages over the previously 
established methods (e.g., 1.54, 1.55 or 1.56 XLIV): 
1) iminiums may be generated directly from a broad array of secondary and tertiary amines (vs a 
narrow scope of iminium intermediates that can be formed by reacting the primary and secondary 
amine catalysts and carbonyl compounds that must be able to undergo condensation readily, 
1.54 XLIV, Scheme 1.20). 
2) cumbersome and wasteful preparation of aldimines and ketimines that are often required in the 
Brønsted acid-catalyzed processes can be circumvented (vs 1.55 XLIV). 
3) obviates the installation of halogen- or pseudo-halogen leaving groups (vs 1.56 XLIV). 
Thus, a significantly broader scope of iminium intermediates may be generated in a direct manner 
from N-alkylamines; particularly attractive would be processes in which D- and/or E-C H bonds 
contained in N-based bioactive amines may be directly converted into different functional groups 
via the iminium formation (i.e., late-stage C H functionalization, Scheme 1.21A C).14 Moreover, 
in comparison to C H functionalization reactions that are catalyzed by precious metal-based 
complexes (c.f., Schemes 1.1A and 1.1B),11 there may be significant benefits in implementing the 
organoborane-catalyzed hydride abstraction: 
1) the catalysts to be used are based on sustainable elements. 
2) does not require the installation/removal of directing groups; thus, is applicable to a broader 
scope of amines. 
3) can be performed under pH neutral and oxidant-free conditions. 
Based on the considerations as described above, we envisioned the development of enantio- and 
diastereo-selective D- and E-amino C H functionalization processes that proceed through the 
organoborane-catalyzed hydride abstraction (Schemes 1.21A C).  
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Scheme 1.21. Our Approach for Regio- and Enantioselective C H Functionalization of N-
Alkylamines to be Discussed in this Dissertation 
 
To begin our investigation, we decided to test the hypothesis that B(C6F5)3 can catalyze 
reactions between various silicon enolates (1.58) and N-alkylamines, including N-based 
pharmaceuticals (e.g., citalopram, Scheme 1.21A), through their conversion into iminiums (XLV, 
Scheme 1.21A). It has previously been demonstrated that frustrated Lewis pairs (FLPs) consisting 
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of organoboranes and Lewis bases form relatively stable adducts with an array of small molecules 
such as amines (c.f., Scheme 1.5a, tertiary amine 1.12 and B(C6F5)3 furnishes ammonium and 
borohydride complex 1.13),21 H2, 41 CO242 (Scheme 1.22), CO,43 SO244, and alkynes45 among 
others. Therefore, development of (F5C6)3B-catalyzed C C bond forming reaction (Scheme 1.21) 
requires that B(C6F5)3 abstracts a hydride from the substrate while overcoming undesirable catalyst 
deactivation through the formation of stable acid base adducts with the amine unit as well as other 
Lewis acid-sensitive functional groups.41-42 Furthermore, for the proposed transformation to be 
catalytic, we must find a way to let the in situ-generated [H B(C6F5)3]  release a hydride, thereby 
regenerating B(C6F5)3; thus, an appropriate hydride acceptor must be identified.46  
Scheme 1.22. Stoichiometric Activation of H2 and CO2 by FLP 
 
Our subsequent aim was to develop enantioselective organoborane-catalyzed D- and/or E-
amino C H functionalization reactions (Scheme 1.21B and C). The first transformation we 
envisioned to achieve was to use a chiral organoborane catalyst to promote enantioselective union 
of N-alkylamines and silicone enolates (Scheme 1.21B). This process requires that in situ-
                                                          
41 Welch, G. C.; San Juan, R. R.; Masuda, J. D.; Stephan, D. W. Science, 2006, 314, 1124 1126. 
42 Mömming, C. M.; Otten, E.; Kehr, G.; Fröhlich, R.; Grimme, S.; Stephan, D. W.; Erker, G. Angew. Chem., Int. Ed. 
2009, 48, 6643 6646. 
43 Dobrovetsky, R.; Stephan, D. W. J. Am. Chem. Soc. 2013, 135, 49744977. 
44 Otten, E.; Neu, R. C.; Stephan, D. W. J. Am. Chem. Soc. 2009, 131, 99189919. 
45 Dureen, M. A.; Stephan, D. W. J. Am. Chem. Soc. 2009, 131, 83968397. 
46 Ilic, S.; Alherz, A.; Musgrave, C. B.; Glusac, K. D. Chem. Soc. Rev. 2018, 47, 2809 2836. 
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generated chiral borohydride, which is ionically bond to the iminium, controls enantioselectivity 
in the C C bond forming step (XLVI 1.61).47 
Another approach to achieve highly enantioselective D-amino C H functionalization 
would be to implement a catalyst system consisting of an achiral organoborane and a chiral Lewis 
acid co-catalyst (Scheme 1.21C). Specifically, the B-based catalyst promotes the formation of 
iminiums while the chiral co-catalyst activates an appropriate pronucleophile (e.g., 1.62); ensuing 
enantiodetermining C C bond formation could afford the desired D-functionalized amines (e.g., 
1.63). Significant advantages of employing the cooperative Lewis acid/Lewis acid co-catalyst 
system are the following: 
1) enables the generation of both nucleophilic and electrophilic partners from otherwise unreactive 
substrates. 
2) either one or both of the catalysts can be chiral; various potential catalyst combinations are 
available for improving stereoselectivity. 
3) both the reaction efficiency and stereoselectivity can be easily optimized by efficient evaluation 
of readily accessible Lewis acids and chiral ligands. 
4) the enantioselective processes may be highly atom-economical as they generate no waste (vs 
the reactions in Scheme 1.21A and 1.21B that produce TMSH as a byproduct). 
Despite these desirable attributes of cooperative Lewis acid/Lewis acid catalysis, a 
fundamental challenge has to do with the difficulty in achieving highly enantioselective reactions 
by letting the achiral organoborane and chiral organometallic catalysts that may have potential 
overlapping functions play their independent roles.48 In addition, functional group tolerance could 
                                                          
47 Brak, K.; Jacobsen, E. N. Angew. Chem., Int. Ed. 2013, 52, 534 561. 
48 Romiti, F.; del Pozo, J.; Paioti, P. H. S.; Gonsales, S. A.; Li, X.; Hartrampf, F. W. W.; Hoveyda, A. H. J. Am. Chem. 
Soc. 2019, 141, 1795217961. 
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be diminished in case the organometallic co-catalyst is not sterically and electronica  f a ed  
against the Lewis basic moieties. 
Should we find that the enantioselective D-amino C H functionalization can be promoted 
by the cooperative functions of two Lewis acids, our next aim would be to achieve transformations 
of E-amino C H bonds (Scheme 1.21C). Inspired by (F5C6)3B/NEt2Ph-mediated enamine forming 
reactions from NEt2Ph reported by the Santini group (e.g., Scheme 1.5b, VI VII),21 we 
postulated that the N-alkylamine can be converted into an enamine intermediate (O-TBS 
ralo ifene XLVIII) by deprotonation of the in situ-generated iminium (XLVII) by an 
appropriate Brønsted base catalyst. Ensuing stereoselective reaction of the enamine and an 
electrophile (e.g., D,E-unsaturated compound 1.64), which is activated by the chiral Lewis acid, 
could deliver -substituted amines (e.g., 1.65). 
Through the development of the cooperative catalyst systems, the main aim of this 
dissertation research is to address the critical unresolved problems of stereoselective amino C H 
functionalization; that is to discover a highly functional group tolerant, efficient and stereoselective 
catalyst system that can be used to produce an array of structurally complex and synthetically 
valuable N-alkylamines that cannot be readily accessed by the conventional methods. 
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Chapter Two 
Enantioselective D-Amino CH Functionalization through Cooperative Action of Chiral 
and Achiral Lewis Acid Catalysts 
 
2.1 Introduction 
Amines that possess a stereogenic center at the D-position of the nitrogen atom are 
commonly found in pharmaceuticals, natural products, and catalysts used in enantioselective 
synthesis (Scheme 2.1).1 Therefore, the development of catalytic processes for the preparation of 
enantiomerically enriched D-substituted amines is a crucial and widely investigated topic of 
research in chemical catalysis.2 Particularly, direct functionalization of D-amino CH bond has 
gained attention for its potential to be applied in the late-stage modification of various N-based 
molecules, which could provide rapid access to a library of structurally complex N-alkylamines 
that are difficult to prepare through conventional synthetic methods.3-4 
Scheme 2.1. Enantio-enriched D-Substituted N-Alkylamines 
 
                                                          
1 (a) Linghu, X.; Kennedy-Smith, J. J.; Toste, F. D. Angew. Chem., Int. Ed. 2007, 46, 7671-7673. (b) Marino, J. P.; 
Rubio, M. B.; Cao, G.; de Dios, A. J. Am. Chem. Soc. 2002, 124, 13398-13399. 
2 Yin, Q.; Shi, Y.; Wang, J.; Zhang, X. Chem. Soc. Rev. 2020, 49, 61416153. 
3 Campos, K. Chem. Soc. Rev. 2007, 36, 10691084. 
4 Borgel, J.; Ritter, T. Chem 2020, 6, 18771887. 
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However, as discussed in Chapter 1, catalyst systems that could promote efficient, regio- 
and enantio-selective transformations of D-amino C H bonds in N-alkylamines remain 
underdeveloped. The paucity of effective and broadly applicable catalyst systems originates from 
the following fundamental challenges:  
1) unreactive nature of the D-amino CH bonds. 
2) the requirement for external oxidants and harsh reaction conditions. 
3) the demand for directing groups; and their installation/removal for the molecule that does not 
contain a moiety to serve as a directing group.  
In this chapter, we describe our studies aimed at overcoming the difficulties listed above 
and developing a broadly applicable and sustainable element-based catalyst system for 
enantioselective functionalization of otherwise unreactiveD-amino CH bond. 
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2.2 Background 
Despite the difficulties associated with transformation of D-amino CH bonds discussed 
above, synthesis of enantio-enriched D-substituted N-alkylamines through activation of amino 
CH bond has been investigated by a number of groups. The previously reported protocols for D-
CH functionalization of N-alkylamines typically involve the formation of an iminium,5 an D-
amino radical,6 or a metallacycle intermediate.7 An alternative method for the activation and 
conversion of D-amino CH bond was developed by the group of Davies (Scheme 2.2).8 Through 
metal-carbenoid insertion into amino CH bond of N-Boc pyrrolidine 2.1, the E-amino carbonyl 
compound 2.3 was obtained. Although this method enabled highly selective transformation of 
amino CH bonds, its application to late-stage modification could not be achieved due to the low 
functional group tolerance. 
Scheme 2.2.  D-Amino CH Functionalization through Carbene Insertion 
 
Campos and co-workers reported an enantioselective lithiation of N-Boc pyrrolidine and 
consecutive Negishi coupling for the synthesis of D-arylated amine (Scheme 2.3).9 The reaction of 
N-Boc pyrrolidine 2.1 with s-BuLi and ()-sparteine generates the enantio-enriched D-lithiated 
intermediate, which could be converted to organozinc halide (II) by ZnI2. Ensuing Negishi 
                                                          
5 Beatty, J. W.; Stephenson, C. R. J. Acc. Chem. Res. 2015, 48, 14741484. 
6 Nakajima, K.; Miyake, Y.; Nishibayashi, Y. Acc. Chem. Res. 2016, 49, 19461956. 
7 He, C.; Whitehurst, W. G.; Gaunt, M. J. Chem 2019, 5, 10311058. 
8 Davies, H. M. L.; Venkataramani, C.; Hansen, T.; Hopper, D. W. J. Am. Chem. Soc. 2003, 125, 64626468. 
9 Campos, K. R.; Klapars, A.; Waldman, J. H.; Dormer, P. G.; Chen, C.-Y. J. Am. Chem. Soc. 2006, 128, 35383539. 
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coupling with phenyl bromide affords the desired product 2.4. As this method requires a 
stoichiometric amount of s-BuLi, amines that contain base-sensitive functional group cannot be 
tolerated in this catalyst system. 
Scheme 2.3. Enantioselective Lithiation of N-Boc-Pyrrolidine and Negishi Coupling 
 
An enantioselective D-amino CH functionalization of tetrahydroisoquinoline derivatives  
promoted by a combination of photoredox and N-heterocyclic carbene (NHC) catalysts was 
developed by the Rovis group (Scheme 2.4).10 The Ru-based photocatalyst generates an iminium 
ion from N-alkylamine 2.5 while NHC catalyst promotes the formation of Breslow intermediate 
with an aldehyde (III). Ensuing stereoselective CC bond forming reaction provides the D-
substituted amine 2.7. Major limitation of this method are the use of precious Ru-based catalyst as 
well as external oxidant. 
Scheme 2.4. Cooperative N-Heterocyclic Carbene and Photoredox Catalysis 
 
The group of Yu demonstrated the sulfur-directed CH arylation of pyrrolidines promoted 
by a chiral Pd-based catalyst (Scheme 2.5).11 This transformation is proposed to proceed via a five-
                                                          
10 DiRocco, D. A.; Rovis, T. J. Am. Chem. Soc. 2012, 132, 80948097. 
11 Jain, P.; Verma, P. Xia, G.; Yu, J.-Q. Nat. Chem. 2017, 9, 140144. 
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membered palladacycle upon directed D-amino CH activation (IV), which undergoes cross-
coupling with PhB(OH)2 affording D-arylated pyrrolidines 2.9. In addition to the installation and 
removal of directing thionyl group, the use of stoichiometric oxidant and Pd-based catalyst are the 
limitation of this protocol. 
Scheme 2.5. Directed D-Amino CH Bond Functionalization Promoted by a Pd-Based Catalyst 
 
Despite the advances made in the field of enantioselective D-amino CH functionalization, 
fundamental challenges still remain to be addressed for practical applications of the 
aforementioned methods. Therefore, we envisaged the development of a highly efficient, regio- 
and enantio-selective functionalizations of D-amino CH bonds promoted by sustainable element-
based catalysts. 
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2.3 Our Approach 
 As we contemplated ways to achieve D-amino CH functionalization, we were inspired by 
the unique capability of frustrated Lewis pairs (FLPs) that could activate otherwise inert 
molecules.12 As discussed in Chapter 1, it was demonstrated that hindered and strongly Lewis 
acidic organoborane could disfavor the formation of stable acidbase adduct with sterically 
encumbered amine and promote hydride abstraction from D-CH bond, generating an ion pair of 
iminium and borohydride (e.g., 2.10 V, Scheme 2.6).13   
Based on the literature precedents, we envisioned the use of Lewis acidic organoborane to 
generate electrophilic iminium ion in situ, which can be trapped by an appropriate nucleophilic 
species such as silicon enolate (Scheme 2.6). Specifically, the organoborane catalyst could abstract 
hydride from amine 2.10 to form iminium ion and borohydride (V). The nucleophilic silicon 
enolate 2.11 could react with the iminium intermediate to forge a new D-amino CC bond (VI). 
The -amino carbonyl compound 2.12 can be obtained upon the release of environmentally benign 
Me3SiH as a single byproduct. 
Scheme 2.6. Proposed Catalytic Cycle for Lewis Acid-Catalyzed Hydride Abstraction. 
 
                                                          
12 Stephan, D. W.; Erker, G. Angew. Chem., Int. Ed. 2015, 54, 64006441. 
13  (a) Millot, N.; Santini, C. C.; Fenet, B.; Basset, J. M. Eur. J. Inorg. Chem. 2002, 2002, 3328 3335. (b) 
Schwendemann, S.; Frohlich, R.; Kehr, G.; Erker, G. Chem. Sci. 2011, 2, 18421849. 
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When we started our investigation, the use of an iminium ion in situ generated through 
borane-catalyzed hydride abstraction from N-alkylamines was confined to transfer hydrogenation 
of imines14 and dehydrogenation of N-heterocycles.15 The engagement of the versatile iminium 
intermediate in the context of amino CH functionalization promoted by organoborane catalyst 
remained to be developed. 
  
                                                          
14 Farrell, J. M.; Heiden, Z. M.; Stephan, D. W. Organometallics 2011, 30, 44974500. 
15 (a) Maier, A. F. G.; Tussing, S.; Schneider, T.; Flörke, U.; Qu, Z.-W.; Grimme, S.; Paradies, J. Angew. Chem., Int. 
Ed. 2016, 55, 1221912223. (b) Kojima, M.; Kanai, M. Angew. Chem., Int. Ed. 2016, 55, 1222412227. 
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2.4 (F5C6)3B-Catalyzed D-Alkylation of N-Alkylamines Using Silicon Enolates 
 To first demonstrate the proof of concept that an organoborane can promote hydride 
abstraction from amines and the resulting iminium ion can react with silicon enolate, we evaluated 
various combinations of Lewis acid catalysts and N-alkylamine substrates. Based on the literature 
precedents,10-11 we considered utilizing strongly Lewis acidic and hindered B(C6F5)3 as a catalyst 
and examined its ability to convert N,N-dimethylanilines into corresponding E-amino carbonyl 
compounds via iminium ion (Table 2.1). The reaction of N,N-dimethylaniline (2.13a) and 1-
methoxy-2-methyl-1-(trimethylsiloxy)propene (2.11a) in the presence of 20 mol% B(C6F5)3 
provided 2.14a in 31% yield (C2H4Cl2, 22 °C). We hypothesized that electron-donating 
substituents on the N-aryl group may enhance the reaction efficiency by increasing the hydride 
donor ability of the D-amino CH bond as well as generating more stable iminium intermediate. 
While the reaction of electron-donating para-methoxy-substituted 2.13b afforded 2.14b in 25%  
Table 2.1. Evaluation of N-Aryl Substituentsa,b 
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yield, none of the desired product was observed with electron-deficient para-
trifluoromethylphenyl-substituted 2.13c. With 3,5-di-tert-butyl-substituents, D-alkylation product 
2.14d was obtained in 38% yield. 
To test whether more hindered amines could further disfavor the acid-base complexation 
and facilitate the hydride abstraction, we evaluated an array of ortho-disubstituted anilines. 
Whereas 2,6-difluoro-N,N-dimethylaniline (2.13e) gave none of the Mannich-type product, larger 
and more electron-rich N,N,2,6-tetramethylaniline (2.13f) resulted in the drastic improvement of 
reaction efficiency, providing 2.14f in 78% yield. Encouraged by this result, we studied the 
reaction with 4-methoxy-N,N,2,6-tetramethylaniline (2.13g), which contains the N-aryl substituent 
that could be removed under oxidative conditions,16 afforded the desired product 2.14g in 56% 
yield. Through the use of less hindered and more electron-deficient 2,6-difluoro-4-
methoxyphenyl-substituted 2.13h, the corresponding E-amino carbonyl compound 2.14h was 
obtained in 51% yield. 
To further improve the reaction efficiency, we evaluated various reaction conditions using 
2.14g and 2.11a as a model substrate (Table 2.2). In the absence of B(C6F5)3, no desired product 
was obtained (entry 2). In some cases (entries 1 and 3 9), secondary amine 2.15g was also 
obtained, likely through the cleavage of the C N bond upon the reaction of in situ generated 
iminium ion with water. Among the N,N-dimethylanilines evaluated, only ortho- dimethyl-
substituted 2.13f and 2.13g afforded the CN cleaved byproducts. At lower catalyst loading of 10 
mol%, 2.14g was formed more selectively over 2.15g in 71% and 22% yield, respectively (entry 
3). Since the Mannich reaction involves ionic intermediates, we hypothesized more polar solvents 
could facilitate the reaction and evaluated the effect of ethereal solvents. In Et2O with 10 mol% 
                                                          
16 Jurberg, I. D.; Peng, B.; Wöstefeld, E.; Wasserloos, M.; Maulide, N. Angew. Chem., Int. Ed. 2012, 51, 19501953. 
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Table 2.2. Optimization of Reaction Conditionsa,b 
catalyst loading, 2.14g was formed in an increased yield of 83%, but with 5.0 mol% B(C6F5)3, the 
product yield diminished considerably (22% yield, entries 4 5). When THF was used as the 
solvent, 2.14g was obtained in 38% yield (entry 6). Use of less polar aromatic hydrocarbons such 
as benzene and toluene as the solvent, 2.14g was obtained in 81% and 75% yield, respectively 
(entries 7 8). When catalyst loading was lowered to 5.0 mol% in benzene, 2.14g was obtained 
with high selectivity (<5% of 2.15g) and in >95% yield (entry 9). The unique reactivity of B(C6F5)3 
has been demonstrated by the control experiments where less hindered BF3 OE 2 or less acidic 
BPh3 proved to be ineffective (entries 10 11). These results are in line with our hypothesis that 
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strongly Lewis acidic and hindered B(C6F5)3, along with sterically demanding and electron-rich 
N-alkylamines, represent the most effective catalyst/substrate combination. 
 With the optimal reaction conditions, we evaluated various N-alkylamines in the reaction 
with siliconenolate 2.11 (Table 2.3). With 5.0 mol% B(C6F5)3, N,N-dimethyl-substituted 2.13g 
afforded 2.14g in 80% yield. N-Benzyl and N-cyclopropylmethyl-substituted anilines, 2.13i and 
2.13j, gave the corresponding products in 64% and 56% yield, respectively. In these instances, D-
amino methylene CH bonds remained intact. D-Amino C H bond of N-arylpyrrolidine 2.13k was 
converted to a C C bond by the use of 10 mol% B(C6F5)3, affording 2.14k in 90% yield. An 
Table 2.3. Evaluation of N-Alkylaminesa,b 
 
 40  
unprotected hydroxyl group was tolerated in this reaction as 1-(4-Methoxy-2,6-
dimethylphenyl)pyrrolidin-3-ol (2.13l), provided the D-alkylated products in their O-silylated 
forms of 2.14l (31% yield, 4.0:1 trans:cis) and 2.14m (23% yield, >20:1 trans:cis).17 Reaction of 
D-methyl-substituted pyrrolidine furnished 2.14n in 70% yield with trans:cis of 7.0:1. N-
arylpiperidine 2.13o was also a suitable substrate and 2.14o was isolated in 38% yield with the 
elevated reaction temperature of 50 °C. N-aryl group was not a requirement as an array of 
trialkylamines were efficiently coupled with ((1-methoxyprop-1-en-1-yl)oxy)trimethylsilane 
(2.11b), leading to the formation of 2.16a2.16d (88% 95% yield). Reaction of methyl (S)-3-
(bis((S)-1-phenylethyl)amino)-2-methylpropanoate with 2.11b delivered 2.16d as a 1.6:1 mixture 
of diastereomers, which were separated after flash silica gel column chromatography, providing 
the enantiomerically pure D-amino esters. 
 Then we moved on to the evaluation of various silicon enolates in the reaction with aniline 
(Table 2.4). Cyclopentyl- and cyclohexyl-substituted substrates reacted with 2.13g to afford 2.14p 
and 2.14q in 73% and 79% yield, respectively. The less sterically hindered ketene acetal 2.11b 
furnished 2.14r in 66% yield. A broader range of ketene acetals proved to be applicable to reactions 
with N-arylpyrrolidine 2.13k. D-Cycloalkylesters and methyl propionate could be incorporated, 
furnishing the corresponding 2-substituted pyrrolidine products 2.14s2.14u in 60% to >95% 
yield. Nucleophilic species derived from 3-methyldihydrofuran-2(3H)-one was found to be 
compatible and provided 2.14v in 70% yield with 1.3:1 dr. In addition to silyl ketene acetals, 
trimethyl((1-(methylthio)vinyl)oxy)silane can give E-amino thioester 2.14w (52% yield). 
 
                                                          
17 After isolation by silica gel column chromatography, 2.14l and 2.14m were treated with an aqueous solution of 4.0 
N HCl and characterized as their corresponding non-silylated compounds. See Section 2.7 for details. 
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Table 2.4. Evaluation of Various Silicon Enolatesa,b 
 
The catalytic protocol is scalable, as shown by the reaction of 2.13k performed on a 1.0 
mmol scale (Scheme 2.7). The D-alkylated product 2.14k was obtained in 95% yield by the use of 
5.0 mol% B(C6F5)3. The 4-methoxy-2,6-dimethylphenyl group of 2.14k could be readily removed 
under oxidative conditions to provide 2.19 in 97% yield. 
Scheme 2.7. Scale-up Synthesis and Removal of N-Aryl Group 
 
The utility of this method was demonstrated through the late-stage modification of 
bioactive N-alkylamines such as citalopram (antidepressant), atomoxetine (treatment for ADHD), 
and fluoxetine (antidepressant) (Table 2.5). N-Methyl C H bonds of these drug compounds were 
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selectively functionalized to C C bonds to afford synthetically useful amount of E-amino carbonyl 
compounds 2.18a (23% yield, 0.30 g), 2.18b (25% yield, 92 mg), and 2.18c (27% yield, 113 mg). 
Table 2.5. Late-Stage Functionalization of Bioactive Amines. 
 
In summary, we have developed a catalytic protocol for the Mannich-type reaction of N-
alkylamines catalyzed by B(C6F5)3 in order to generate various E-amino carbonyl compounds. This 
method is applicable to the late-stage functionalization of various N-containing pharmaceuticals 
that contain D-CH bonds. On the basis of our mechanistic hypotheses, development of an 
enantioselective variant of this transformation should be possible through the design of chiral 
Lewis acid catalysts. 
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2.5. Union of N-Alkylamines and DE-Unsaturated Compounds Through Cooperative Action 
of Chiral and Achiral Lewis Acid Catalysts 
Having demonstrated that B(C6F5)3 can promote D-CH alkylation of N-alkylamines via 
iminium ion through hydride abstraction, we envisioned the development of an enantioselective 
transformation based on this study. We first hypothesized that a chiral organoborane might be able 
to catalyze hydride abstraction from amine and the subsequent enantioselective CC bond 
formation. However, when we prepared and evaluated chiral borane catalysts18 for the union of 
2.13k and 2.11a, no desired product (2.14k) was obtained (Scheme 2.8). 
Scheme 2.8. Evaluation of chiral borane catalyst 
 
We postulated that the chiral organoboranes we evaluated were either not potent enough to 
abstract hydride from amine 2.13k, or not sufficiently hindered to overcome acidbase 
complexation with the amine substrate. Furthermore, even if hydride abstraction from 2.13k could 
take place to generate intermediate VII, it would be challenging to control the enantioselectivity 
by the in situ generated chiral borohydride, which is ionically bond to the iminium.19 
                                                          
18 (a) Corey, E. J.; Helal, C. J. Angew. Chem., Int. Ed. 1998, 37, 19862012. (b) Meng, W.; Feng, X.; Du, H. Acc. 
Chem. Res. 2018, 51, 191201. 
19 Brak, K.; Jacobsen, E. N. Angew. Chem., Int. Ed. 2013, 52, 534 561. 
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Since the approach utilizing chiral organoboranes for promoting the D-alkylation of amines 
was not successful, we envisioned the use of a chiral Lewis acid co-catalyst in combination with 
B(C6F5)3. The cooperative catalyst system could enable the activation of both coupling partners 
and in situ generate the electrophilic and nucleophilic species, thus circumventing the wasteful 
pre-activation step. Furthermore, cooperative catalysts could enhance the reaction rate by bringing 
both nucleophilic and electrophilic coupling partners in close proximity. However, there are 
fundamental challenges that need to be overcome. Specifically, mutual quenching between acidic 
and basic components in an electrophile, a nucleophile, and catalysts might be problematic. To 
circumvent the acid base complexation, a combination that exhibits high affinity (i.e., hard hard 
or soft soft pairing) are often avoided. Therefore, the existing cooperative catalyst systems have 
been limited to transformations involving weakly to moderately acidic and/or basic promoters, 
which confines the substrate scope to highly acid- or base-sensitive molecules. Development of 
potent cooperative two-catalyst systems that could overcome mutual quenching and facilitate 
reactions between otherwise inert substrates is an important unresolved problem in 
enantioselective catalysis. 
To develop a catalytic protocol for enantioselective union of N-alkylamines and carbon-
based nucleophiles, we envisioned the use of two independent Lewis acid catalysts for 
accomplishing separate tasks (Scheme 2.9). We premised that B(C6F5)3 could abstract a hydride 
from amine 2.13 to generate an ion pair of borohydride and an iminium ion (VIII). Meanwhile, a 
chiral Lewis acid co-catalyst could activate the DE-unsaturated compound (2.20 IX) to facilitate 
the borohydride reduction (X), furnishing the chiral enolate (XI). An ensuing stereoselective CC 
bond forming reaction between the iminium ion and the enantio-enriched enolate would afford a 
E-amino carbonyl product (2.21).  
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Scheme 2.9. Proposed Catalytic Cycle for Cooperative Catalyst System  
 
A major advantage of the proposed approach is that by evaluating various combinations of 
Lewis acids and chiral ligands, the reaction efficiency and stereoselectivity may be easily 
optimized (vs bifunctional catalysts that require tethering of different catalytic sites). To achieve 
this, the untethered Lewis acid catalysts must perform independently to activate each coupling 
partner without overlapping functions, as otherwise, stereoselectivity would suffer from the 
racemic background reaction.20 The functionally similar B(C6F5)3 and a chiral Lewis acid co-
catalyst promoted enantioselective union of N-alkylamines and various DE-unsaturated 
compounds is presented herein. 
We first investigated whether a single Lewis acid B(C6F5)3 can activate both coupling 
partners (Scheme 2.9, M L* = B(C6F5)3) to promote the Mannich-type reaction between N-
                                                          
20 Manville, N.; Alite, H.; Haeffner, F.; Hoveyda, A. H.; Snapper, M. L. Nat. Chem. 2013, 5, 768774. 
 46  
alkylamines and the DE-unsaturated compounds (Table 2.6). The reaction between 2.13k and 
2.20a in the presence of 5.0 mol% B(C6F5)3 afforded 2.21a in >95% yield as a separable mixture 
of diastereomers (entry 1, anti:syn = 2.3:1, Table 2.6). The di-substituted product 2.22 was 
obtained in less than 5% yield. In ethereal solvents, Et2O and THF, 2.21a was formed in 94% and 
26% yield, respectively (entries 2 3). When the reaction was carried out in a relatively non-polar 
aromatic hydrocarbon, such as toluene and benzene, 2.21a was obtained in 81% and >95% yield 
(entries 4 5); notably, 2.21a was isolated in >95% yield in benzene in just 30 minutes (entry 6). 
When the catalyst loading was lowered to 2.5 mol%, longer reaction time was needed (48 h, 2.21a 
in 84% yield; entry 7).21 None of the desired product was formed in the absence of B(C6F5)3 (entry  
Table 2.6. Evaluation of Reaction Parameters 
 
                                                          
21 The significant difference in reaction rate observed when the loading of B(C6F5)3 is lowered from 5.0 mol% to 2.5 
mol% suggests that the mechanism of the reaction proposed in Scheme 2.9 is not the complete picture. Formations of 
aggregates or other pre-organized states requiring multiple equivalents of B(C6F5)3 or substrate may be involved.  
Kinetic and spectroscopic studies exhibited higher order dependence with respect to B(C6F5)3 (see Section 2.7 for 
details).  
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8), or when the less hindered BF3 OE 2 or the less acidic BPh3 were used (entries 9 10). These 
results are consistent with our hypothesis that hindered and highly acidic B(C6F5)3 and sterically 
demanding and electron-rich N-alkylamines represent the most effective catalyst and substrate 
combination. 
With the optimal reaction conditions, we evaluated the scope of the pronucleophiles using 
2.13k as the amine substrate to generate the corresponding E-amino carbonyl compounds 
(2.21a2.21h, Table 2.7). The reaction with methyl acrylate (2.20a) and benzyl acrylate (2.20b) 
afforded 2.21a and 2.21b in 97% and 91% yield, respectively. Isopropyl acrylate (2.20c) gave 
2.21c in 78% yield, while a more hindered tert-butyl acrylate did not afford the desired product. 
This result suggests that B(C6F5)3 may not be capable of coordinating to more sterically 
encumbered acrylates. The less electrophilic thioacrylate (2.20d) was also suitable substrate, 
affording 2.21d in 53% yield, and the use of acrylonitrile (2.20e) furnished 2.21e in 50% yield. 
An D-quaternary carbon center-containing 2.21f was obtained in 97% yield using methyl 
methacrylate (2.20f). With dimethyl acetylenedicarboxylate (2.20g), which can be converted to an 
allenolate nucleophile in situ, 2.21g was furnished in 52% yield as a separable mixture of E and Z 
isomers (1:1.6). The use of N-phenylmaleimide (2.20h) furnished 2.21h in >95% yield. 
We then evaluated an array of cyclic and acyclic N-alkylamines. It was found that 3,3-
dimethyl, 3-((tert-butyldimethylsilyl)oxy)-substituted N-aryl pyrrolidines (2.13t and 2.13u), N-
aryl piperidine (2.13o) and N-aryl azepane (2.13v) gave the corresponding products (2.21i 2.21l) 
in 63% to 95% yield. An acyclic 4-methoxy-N,N,2,6-tetramethylaniline (2.13g) can react with N-
phenylmaleimide to provide 2.21m in 62% yield. Trialkyl-substituted amines that lack the fused 
N-aryl group also underwent efficient transformation and were coupled with acrylates, leading to 
the formation of 2.21n 2.21p (91% yield). The use of (R)-N-methyl-1-phenyl-N-((R)-1-  
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Table 2.7. Coupling of N-alkylamines and DE-unsaturated compounds through B(C6F5)3-
catalyzed hydride abstraction 
 
phenylethyl)ethan-1-amine (2.13w) with benzyl acrylate (2.20b) delivered 2.21p as a 1.5:1 
mixture of diastereomers which were separated through flash silica gel column chromatography 
to afford enantiomerically pure isomers. 
Having demonstrated that B(C6F5)3 is capable of generating both electrophilic and 
nucleophilic species in situ, we envisioned the incorporation of a chiral Lewis acid co-catalyst for 
 49  
enantioselective transformation. With N-arylpyrrolidine 2.13k and 3-acryloyloxazolidin-2-one 
2.23a as model substrates, we evaluated various combinations of Lewis acid and chiral ligands to 
find out that 10 mol% of B(C6F5)3 and (TfO)2Mg L1 can promote the coupling reaction affording 
2.24a in >95% yield with modest er of 80:20 and 68:32 for anti (major) and syn isomers, 
respectively (Scheme 2.10a). Control experiments with 10 mol% B(C6F5)3 as the only catalyst 
demonstrated that B(C6F5)3 not only promotes the desired hydride abstraction from amine 2.13k 
but also activates the DE-unsaturated N-acyloxazolidinone 2.23a (XIII), providing rac-2.24a in 
35% yield. To discourage carbonyl activation by the achiral co-catalyst B(C6F5)3 (XIII), favoring  
Scheme 2.10. Effect of Chiral Lewis Acid Co-catalysts on Enantioselective Coupling of an N-
Alkylamine and N-Acryloyloxazolidinones  
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the involvement of XII, dimethyl oxazolidinone containing Michael acceptor 2.23b was used in 
order to minimize the extent to which intermediates such as XV are formed (Scheme 2.10b). 
Indeed, the racemic background reaction was suppressed as rac-2.24b was produced in <5% yield 
with 10 mol% B(C6F5)3 as the only catalyst, and 2.24b was obtained in 88% yield with significantly 
improved enantioselectivity of up to 98:2 er. 
Having identified that the use of a dimethyl oxazolidinone can suppress (F5C6)3B-
activation of DE-unsaturated compound (Scheme 2.10b), other alkyl or aryl substituted 
oxazolidinones were evaluated with B(C6F5)3 and Mg(OTf)2/L1 as the optimal catalyst 
combination (Table 2.8). Compared to dihydrogen- or dimethyl-substituted oxazolidinone-
containing product, cyclohexyl-substituted 2.24c was obtained with improved anti:syn ratio of 
5.6:1. The enantiomerically pure N-acryloyloxazolidinones containing benzyl (2.23d) or phenyl  
Table 2.8. Evaluation of Different Oxazolidinone Substrates 
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(2.23e-(S), 2.23e-(R)) moieties also underwent efficient reaction. (R)-3-Acryloyl-4-
phenyloxazolidin-2-one (2.23e-(R)) e e e  he a ched  e a i e  i h Mg(OTf)2/L1 
combination to afford 2.24e-(R) in >95% yield and 6.8:1:0:0 dr. When mismatching 2.23e-(S) was 
used, 2.24e-(S) was obtained in diminished yield and diastereoselectivity (61% yield, 3.7:1:0:2.1 
dr). The use of the chiral co-catalyst in the diastereoselective reactions was important for both 
efficiency and stereoselectivity, as 2.24e-(R) was produced in just 14% yield and 2.5:2.5:1:1 dr in 
its absence. When catalyst loadings of B(C6F5)3 and Mg(OTf)2/L1 were reduced to 5.0 mol%, 
2.24e-(R) was obtained in comparable yield of 93% with retained diastereoselectivity. 
This catalytic process is scalable; for instance, 5.0 mmol of 2.13k was converted to 2.24e-
(R) in 6.7:1:0:0 dr (>95% conv.; Scheme 2.11a). The enantio-enriched diastereomers were isolated 
by flash silica gel column chromatography to afford the major isomer in 1.47 g (70% yield; minor 
diastereomer: 0.16 g, 8% yield). The major diastereomer was then converted to corresponding E-  
Scheme 2.11. Synthesis of Enantio-enriched D-Substituted Amines 
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amino ester (2.25), E-amino acid (2.26), and E-amino alcohol (2.27) in 64 91% yield without 
erosion of er (Scheme 2.11b). Furthermore, by treating the major diastereomer of 2.24e-(R) with 
NaOMe in methanol, 2.28 was obtained in 97% yield, which was analyzed by X-ray 
crystallography to reveal its absolute configuration to be (R,R,R).22 
We applied this method for the synthesis of various enantiomerically enriched N-
alkylamines (Table 2.9). Upon flash silica gel column chromatography, the diastereomers were 
converted into the corresponding benzyl ester (2.29), and HPLC analysis revealed that 2.24f2.24h 
were enantiopure isomers (>99:1 er). N-Substituted pyrrolidines were reacted with 3-acryloyl-4,4- 
Table 2.9. Evaluation of N-Alkylamines 
 
                                                          
22 The absolute configuration of the minor diastereomer was determined as (R)-N-((R)-2-hydroxy-1-phenylethyl)-2-
((S)-1-(4-methoxy-2,6-dimethylphenyl)pyrrolidin-2-yl)propanamide. See Section 2.7 for further details. 
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dimethyloxazolidin-2-one (2.23b) in the presence of catalytic amounts of B(C6F5)3 and 
Mg(OTf)2/L1 to give E-amino carbonyl product 2.24i and 2.24j in 71% and 70% overall yield, 
respectively. An increase in enantioselectivity for both diastereomers was observed with more 
sterically hindered para-t-Bu-substituted 2.24j (98:2 er (2.24j-anti) and 99:1 er (2.24j-syn)) 
compared to para-H-substituted 2.24i (95:5 er (2.24i-anti) and 97:3 er (2.24i-syn)). Sterically 
congested trialkylamines such as 2.13r also reacted with 2.23b to afford 2.24k in 46% yield with 
95:5 er. 
A stereochemical model for reaction of the in situ generated iminium ion with the L1 Mg
enolate complex was developed by density functional theory (DFT) studies (Figure 2.1).23  
Figure 2.1. Stereochemical models to account for the observed sense of stereoselectivity.   
 
                                                          
23 Stereochemical model for reaction of L3Mgenolate complex with iminium ion; DFT studies were performed at 
the PBE0-D3BJ/def2TZVPP//M06L/DF-def2SVP level of theory in CH2Cl2 (SMD solvation model). See Section 2.7 
for details. Abbreviations: L3, PyBOX ligand; SMD, solvation model based on density; ''Edisp = ''E(PBE0-D3BJ) 
 ''E(PBE0). 
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These investigations suggest that the enantiomers of the major diastereomer are generated 
via XVI and XVII ('G = 18.1 and 18.8 kcal/mol, respectively), while the enantiomers of the minor 
diastereomer are probably formed via XVIII and XIX ('G = 20.6 and 21.1 kcal/mol respectively). 
High enantioselectivity for the major as well as the minor diastereomer is due to effective blocking 
of the re face of the Mgenolate by steric repulsion (XVII and XIX). Nonetheless, we should note 
that highly accurate modeling of diastereoselectivity is difficult, and depends strongly on 
attenuation of dispersion interactions in solution.24,25 It is possible that modes other than XVI and 
XVIII might similarly contribute to formation of the minor diastereomer (see Section 2.7 for 
details). 
  
                                                          
24  Yang, L.; Adam, C.; Nichol, G. S.; Cockroft, S. L. Nat. Chem. 2013, 5, 10061010. 
25 Pollice, R.; Bot, M.; Kobylianskii, I. J.; Shenderovich, I.; Chen, P. J. Am. Chem. Soc. 2017, 139, 1312613140. 
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2.6. Conclusions and Future Outlook 
To summarize, we have developed a catalytic protocol for efficient and stereoselective 
Mannich-type reaction through the cooperative action of seemingly competitive Lewis acid 
catalysts, B(C6F5)3 and a chiral MgPyBOX complex. We discovered that by proper tuning of 
structurally and electronically different Lewis acids and substrates, the ability of chiral and achiral 
Lewis acid catalysts to serve as a hydride acceptor from amines, or an activator of DE-unsaturated 
compounds, can be adjusted. Therefore, enantioselective Mannich-type reactions between amines 
and D,E-unsaturated compounds were achieved without loss in enantioselectivity arising from any 
undesirable mode of activation by the achiral Lewis acid B(C6F5)3.  
The principles established in this work served as a conceptual framework for the 
development of transformations that demand independently operational Lewis acidic co-catalysts 
that may have overlapping functions. Based on this study, our group recently developed a catalytic 
protocol for enantioselective synthesis of N-propargylamines through D-amino CH 
functionalization (Scheme 2.12). 26  This process is promoted through the concerted action of 
seemingly competitive Lewis acids, B(C6F5)3 and a chiral organocopper complex. The reaction of 
N-alkylamine 2.13k and trimethylsilylacetylene 2.29 with 10 mol% of B(C6F5)3, a chiral Cu-based 
complex, and 1.0 equivalent of Ph3COH afforded 2.30 in 75% yield with 95:5 er. Studies aimed at 
expanding the scope of hydride donors and pro-nucleophiles to achieve the late-stage regio- and 
stereo-selective D-amino CH functionalization of bioactive compounds are currently ongoing in 
our laboratory. 
  
                                                          
26 Chan, J. Z.; Yesilcimen, A.; Cao, M.; Zhang, Y.; Zhang, B.; Wasa, M. J. Am. Chem. Soc. 2020, 142, 1649316505. 
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Scheme 2.12. Enantioselective D-Amino C H Functionalization by B(C6F5)3 and Cu PyBOX  
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Chapter Three 
E-CH Functionalization of N-Alkylamines through Cooperative Action of Lewis Acid and 
Brønsted Base Catalysts 
 
3.1. Introduction 
 Despite the recent advances in activation of CH bonds in N-alkylamines (3.1), catalytic 
strategies to functionalize E-amino CH bonds remain underdeveloped, particularly in an 
enantioselective manner (Scheme 3.1).1-2 One of the reason for this is that N-directed LnPd-
catalyzed E-amino CH activation requires the formation of a strained four-membered  
Scheme 3.1. Challenges Associated with E-Amino CH Functionalization 
 
                                                          
1 (a) He, C.; Whitehurst, W. G.; Gaunt, M. J. Chem. 2019, 5, 1031 1058. (b) Trowbridge, A.; Walton, S. M.; Gaunt, 
M. J. Chem. Rev. 2020, 120, 2613 2692.  
2 Ohno, S.; Miyoshi, M.; Murai, K.; Arisawa, M. Synthesis 2021, doi: 10.1055/a-1483-4575. 
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palladacycle I (vs a more favorable five-membered palladacycle IV formed by J-amino CH 
activation).1 Moreover, the radical II or cationic intermediates III generated through activating E-
amino CH bonds are not stabilized by hyperconjugation (vs D-amino radical VI or carbocation 
VII generated by D-amino CH activation) and thus are not readily accessible. Accordingly, the 
development of a general and broadly applicable catalyst system for regio- and enantio-selective 
transformations of E-amino CH bonds that is applicable to late-stage functionalization of 
complex bioactive compounds represents an important research objective. 
As described in Chapter 2, we have demonstrated that Lewis acidic B(C6F5)3 abstracts a 
hydride from D-position of amines, thereby generating an iminium ion (VIII), which can be 
trapped by an appropriate nucleophile to provide D-substituted amines (Scheme 3.2). Based on the 
literature precedent,3 we postulated that the iminium generated in situ can be deprotonated by a 
Brønsted base, furnishing an enamine intermediate (IX). Through the reaction between enamine 
and electrophilic species, activated by a chiral Lewis acid co-catalyst, we hypothesized that regio- 
and enantio-selective functionalization of E-amino CH bonds can be achieved. 
Scheme 3.2. Regioselective CH Functionalization of N-Alkylamines 
 
                                                          
3 Millot, N.; Santini, C. C.; Fenet, B.; Basset, J. M. Eur. J. Inorg. Chem. 2002, 2002, 3328 3335. 
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3.2. Catalytic Deuterium Incorporation within Metabolically Stable E-Amino CH Bonds 
of Drug Molecules 
Isotope labeling of bioactive compounds is a widely-applied strategy used in drug 
discovery.4 It allows incorporation of additional mass or radioactive tag into a molecule without 
drastically changing its chemical structure or biological functions; these labeled compounds are 
applied to in vitro quantification of metabolites, which could assist elucidating metabolic pathway 
of drug molecules.5 Furthermore, isotopically enriched molecules can be utilized in radioligand, 
ei  a d c a e  bi di g a a   gai  a be e  de a di g f he ha ace ica  
bioavailability and toxicity in vivo.4 
Among various isotopes, hydrogen isotopes (deuterium and tritium) are often preferred as 
tracer nuclides. This is because: (i) hydrogens are ubiquitous in bioactive compounds, (ii) 
hydrogen isotope labeling reagents are readily available and (iii) hydrogen isotope can be detected 
with high sensitivity.3-4 The hydrogen isotope incorporation into complex pharmaceuticals can be 
achieved through either a multistep synthesis, starting from commercially available isotope-
enriched precursors, 6  or direct hydrogen isotope exchange (HIE) of CH bonds in the drug 
molecules.7-8 Although advances in CH activation promoted by precious metal-based catalysts 
                                                          
4 (a) Atzrodt, J.; Derdau, V.; Fey, T.; Zimmermann, J. Angew. Chem., Int. Ed. 2007, 46, 77447765. (b) Harbeson, S. 
L.; Tung, R. D. MedChem News 2014, 2, 822. (c) Atzrodt, J.; Derdau, V.; Kerr, W. J.; Reid, M. Angew. Chem., Int. 
Ed. 2018, 57, 17581784. (d) Atzrodt, J.; Derdau, V.; Kerr, W. J.; Reid, M. Angew. Chem., Int. Ed. 2018, 57, 
30223047. (e) Pirali, T.; Serafini, M.; Cargnin, S.; Genazzani, A. A. J. Med. Chem. 2019, 62, 52765297. 
5 (a) Penner, N.; Klunk, L. J.; Prakash, C. Biopharm. Drug Dispos. 2009, 30, 185203. (b) Miyoshi, S.; Mitsuoka, K.; 
Nishimura, S. A. in Radioisotopes Applications in Bio-Medical Science, Singh, N., Ed.; InTech Open Access 
Publisher, 2011; Chapter 5. (c) Iglesias, J.; Sleno, L.; Volmer, D. A. Current Drug Metabolism 2012, 13, 12131225. 
6 (a) Maltais, F.; Jung, Y. C.; Chen, M.; Tanoury, J.; Perni, R. B.; Mani, N.; Laitinen, L.; Huang, H.; Liao, S.; Gao, 
H.; Tsao, H.; Block, E.; Ma, C.; Shawgo, R. S.; Town, C.; Brummel, C. L.; Howe, D.; Pazhanisamy, S.; Raybuck, S.; 
Namchuk, M.; Bennani, Y. L. J. Med. Chem. 2009, 52, 79938001. (b) Allen, P. H.; Hickey, M. J.; Kingston, L. P.; 
Wilkinson, D. J. J. Labelled Comp. Radiopharm. 2010, 53, 731738. (c) Lockey, W. J. S.; McEwen, A.; Cooke, R. J. 
Labelled Comp. Radiopharm. 2012, 55, 235257. (d) Elmore, C. S.; Bragg, R. A. Bioorg. Med. Chem. Lett. 2015, 25, 
167171. 
7 Kang, Q.-K.; Shi, H. Synlett 2021, 32, doi: 10.1055/a-1354-0367. 
8 (a) Pieters, G.; Taglang, C.; Bonnefille, E.; Gutmann, T.; Puente, C.; Berthet, J.-C.; Dugave, C.; Chaudret, B.; 
Rousseau, B. Angew. Chem., Int. Ed. 2014, 53, 230234. (b) Taglang, C.; Martinez-Prieto, L. M.; del Rosal, I.; Maron, 
L.; Poteau, R.; Philippot, K.; Chaudret, B.; Perato, S.; Lone, A. S.; Puente, C.; Dugave, C.; Rousseau, B.; Pieters, G. 
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enabled HIE involving aromatic C(sp2)H bonds, the HIE of C(sp3)H bonds remains as a difficult 
problem.6-7 Furthermore, for identification and detection of drug metabolites, isotopes should be 
incorporated at a metabolically stable position in order to minimize the loss of the label.3-4 
However, metabolically stable CH bonds are also often difficult to convert into CD or CT 
bonds using small-molecule catalysts. 
As N-alkylamine moiety is prevalent in bioactive compounds,9 there has been an increasing 
demand for the development of catalytic HIE process targeting amino CH bonds.10 Such methods 
would enable rapid access to a library of labeled N-containing drug analogues.9 Particularly, 
catalytic HIE protocols involving D-amino CH bonds have been developed by many groups 
including the work by the MacMillan group where the Ir-based photocatalyst promotes deuterium 
incorporation into bioactive amines (Scheme 3.3).9d However, as D-amino CH bonds are labile  
Scheme 3.3. Regioselective HIE of Amino CH Bonds in Bioactive Compounds 
 
                                                          
Angew. Chem., Int. Ed. 2015, 54, 1047410477. (c) Yu, R. P.; Hesk, D.; Rivera, N.; Pelczer, I.; Chirik, P. J. Nature 
2016, 529, 195199. (d) Kerr, W. J.; Lindsay, D. M.; Reid, M.; Atzrodt, J.; Derdau, V.; Rojahn, P.; Weck, R. Chem. 
Commun. 2016, 52, 66696672. (e) Valero, M.; Weck, R.; Gussregen, S.; Atzrodt, J.; Derdau, Volker. Angew. Chem., 
Int. Ed. 2018, 57, 8159 8163. (f) Kerr, W. J.; Mudd, R. J.; Reid, M.; Atzrodt, J.; Derdau, V. ACS. Catal. 2018, 8, 
1089510900. (g)  Sawama, Y.; Nakano, A.; Matsuda, T.; Kawajiri, T.; Yamada, T.; Sajiki, H. Org. Process Res. 
Dev. 2019, 23, 648653. 
9 McGrath, N. A.; Brichacek, M.; Njardarson, J. T. J. Chem. Educ. 2010, 53, 13481349. 
10 (a) Neubert, L.; Michalik, D.; Bahn, S.; Imm, S.; Neumann, H.; Atzrodt, J.; Derdau, V.; Holla, W.; Beller, M. J. Am. 
Chem. Soc. 2012, 134, 1223912244. (b) Chatterjee, B.; Krishnakumar, V.; Gunanathan, C. Org. Lett. 2016, 18, 
58925895. (c) Hale, L. V. A.; Szymczak, N. K. J. Am. Chem. Soc. 2016, 138, 1348913492. (d) Loh, Y. Y.; Nagao, 
K.; Hoover, A. J.; Hesk, D.; Rivera, N. R.; Colletti, S. L.; Davies, I. W.; MacMillan, D. W. C. Science 2017, 358, 
11821187 
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under physiological conditions,11 D-labeled amine molecules may lose the isotope label during 
metabolic processes. Therefore, the development of methods for regioselective deuterium 
incorporation within metabolically stable E-amino CH bonds (vs more reactive D- amino CH 
bonds) contained in bioactive compounds would be highly desirable.   
                                                          
11 (a) Markey, S. P. in Principles of Clinical Pharmacology, second ed., Atkinson, A.J.; Abernethy, D. R.; Daniels, 
C.E.; Dedrick, R.L.; Markey, S.P. Eds.; Academic Press, Burlington, 2007; Chapter 11. (b) Trager, W. F. in 
Comprehensive Medicinal Chemistry II, Taylor, J. B.; Triggle, D. J. Eds.; Elsevier, 2007; Volume 5. 
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3.2.1. Background 
A great effort has been made to develop efficient catalytic methods for incorporation of 
hydrogen isotopes into amino CH bonds over the last decade. The state-of-the-art examples of 
HIE of D-amino CH bonds will be presented in this section. 
The group of Beller developed a protocol for DE-deuteration of tertiary amines utilizing a 
Ru-ba ed Sh  ca a  a d ic de e a ed e  ch a  D2O (Scheme 3.4).9a Upon heating 
b  ic a e i  he e e ce f 10 % Sh  ca a , a i e c ai i g d g ec e  
including metoclopramide (3.2), underwent DE-deuteration via enamine intermediate. Although 
selective deuterium incorporation into amino CH bonds was achieved, the method required large 
excess of deuterium source and the substrate scope was limited to tertiary amines. 
Scheme 3.4. D,E-Deuteration of Bioactive Amines Promoted by Ru-Based Catalyst 
 
D-Deuteration of primary and secondary amines promoted by Ru-based catalyst was 
demonstrated by Gunanathan and coworkers (Scheme 3.5).9b A series of primary and secondary 
amines, such as sertraline (3.4), were reacted with 0.52.0 mol% of C2 and D2O to afford D-
deuterated amines. The reaction proceeds through NH activation by a cationic Ru complex to 
generate imine, followed by 1,3-de e ide a fe . U ike Sh  ca a  (C1, Scheme 2.1), C2 
did not promote deuteration of tertiary amines and the E-deuteration was only observed on linear 
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acyclic primary amines with <10% d-incorporation. In addition to amines, the potassium salt of 
amino acids also underwent D-deuteration selectively. 
Scheme 3.5. D-Deuteration of Amines and Amino Acids Promoted by Ru-Based Catalyst 
 
The MacMillan group has demonstrated that through a photoredox-mediated hydrogen 
atom transfer, selective installation of deuterium or tritium at D-amino CH bonds of 
pharmaceuticals (3.6) can be achieved using isotopically labeled water (Scheme 3.6).9d Although 
this method uses an Ir-based catalyst, it is scalable and the functional group tolerance is high as 
shown by total 18 examples of N-containing bioactive compounds undergoing deuteration and 
tritiation. 
Scheme 3.6. D-Deuteration of Bioactive Amines Promoted by Ir-Based Photoredox Catalyst 
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Current catalytic HIE protocols for bioactive amines developed by the groups of Beller, 
Gunanathan, and MacMillan involve isotope incorporation at D-amino CH bond. We surmised 
that there still remains demand for a complimentary method where deuterium can be selectively 
installed at the metabolically stable E-amino position, as it could minimize the loss of isotope label. 
Therefore, we envisioned the development of a catalyst system that could selectively incorporate 
deuterium into E-CH bonds in N-based pharmaceuticals using easily accessible deuterium source 
while circumventing the use of precious metal-based catalysts. 
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3.2.2. Our Approach 
  While contemplating ways to develop a protocol for selective E-amino CH deuteration, 
we envisioned the use of cooperative catalyst system consisting of B(C6F5)3 and a Brønsted base 
catalyst (Scheme 3.7). Based on previous stoichiometric reaction reported by Santini,3 we 
hypothesized that (F5C6)3B-catalyzed hydride abstraction from N-alkylamine would generate 
iminium ion in situ, which could be deprotonated by a Brønsted base co-catalyst furnishing 
enamine intermediate (3.1 X XI). Concurrently, from Lewis acid-activated deuterium source, 
the base co-catalyst can promote dedeuteration (3.8 XI) to generate an electrophilic deuterating 
reagent [Dbase]+. The nucleophilic enamine then reacts with electrophilic deuterating reagent to 
forge a new CD bond and the resultant iminium ion could undergo borohydride reduction 
affording the E-deuterated amine (3.9) while regenerating both acid and base catalysts. 
Scheme 3.7. Proposed Catalytic Cycle for Deuterium Incorporation into E-Amino CH Bonds 
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3.2.3. Results and Discussion 
 To begin our investigation, we set out to study whether B(C6F5)3 can promote the E-
selective deuteration of N-alkylamines (3.1) using D2O since it is a commonly used d-source and 
its activation by B(C6F5)3 has been demonstrated in the literature (Scheme 3.8).12 When we treated 
N-aryl piperidine 3.1b and D2O with 10 mol% B(C6F5)3, we were able to observe selective 
deuterium incorporation of 50% at the E-position of aniline (Scheme 3.8a). In this reaction, N-
alkylamine substrate and/or product could serve as a Brønsted base and thus no external base 
catalyst was necessary. However, when trialkylamine substrates such as 3.1c were evaluated, we 
did not observe any deuterium incorporation (Scheme 3.8b). We hypothesized that due to the 
higher basicity of trialkylamines (e.g., 3.1c) relative to that of anilines (e.g., 3.1b), B(C6F5)3 may 
tend to form the borate and ammonium ion pair (3.10) in the presence of excess D2O and the amine  
Scheme 3.8. Deuteration of E-Amino CH Bonds Using D2O 
 
                                                          
12 For the use of D2O and B(C6F5)3, see: Li. W.; Wang, M.-M.; Hu, Y.; Werner, T. Org. Lett. 2017, 19, 57685771. 
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(Scheme 3.8c).13 The formation of 3.10 could inhibit the (F5C6)3B-catalyzed hydride abstraction 
and subsequent deprotonation, preventing the in situ generation of enamine intermediate. To 
overcome this issue, either less basic N-alkylamines such as 3.1a or less base-sensitive d-source 
may be used. As our aim was to develop a general and broadly applicable deuteration method for 
bioactive amines, which often involve basic trialkylamine moiety, we decided to evaluate less 
acidic deuterium sources rather than compromising with the substrate scope. 
 Various d-alcohols, which contain less acidic deuteron than D2O, were evaluated as 
deuterating reagent for HIE of E-amino CH bonds using verapamil (3.1a, calcium channel 
blocker) as a representative substrate (Table 3.1). Similar to the discussion above, when 3.1a was 
reacted with 6.8 equivalent of D2O in the presence of 10 mol% B(C6F5)3, no labeling was observed  
Table 3.1. Evaluation of Alcohols as d-Source for E-Amino CH Deuteration of Verapamil 
 
                                                          
13 Sa e i , A. D.; F ca e, F.; Ca a i, I; Re c i, L.; Be i ghe i, T.; D A f , G.; D ghi, D.; Maggi i, D.; 
Mercandelli, P.; Sironi, A. Inorg. Chem. 2005, 44, 50305041. 
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(entry 1). On the other hand, when d-labeled alcohols were used as d-source, we observed the 
conversion of E-amino CH bonds into CD bonds, consistent with our hypothesis (14-63% d-
incorporation; entries 24). It should be noted that by using more sterically hindered t-BuOD, d-
incorporation level drastically improved to 63% (vs 17% d-incorporation using (CD3)2CDOD). 
However, the use of larger equivalence (40.8 equivalent) of t-BuOD to further facilitate the 
labeling led to complete loss of reactivity (entry 5). We reasoned that the (F5C6)3B-catalyzed 
hydride abstraction is outcompeted by B(C6F5)3 interacting with large excess of Lewis basic 
alcohol and the deuteration process cannot take place. These results suggest that the ideal d-source 
that could prevent undesired acidbase complexation with B(C6F5)3 should: (i) be less base-
sensitive than D2O or d-alcohol (ii) contain multiple accessible D atom per molecule so that large 
excess of d-source is not required. 
 Our group has previously demonstrated that cooperative Lewis acid and base catalysts can 
promote Mannich-type reaction of monocarbonyl compounds (e.g., 3.11a) by activating less acidic 
D-carbonyl CH bonds to in situ generate enolate and ammonium (XII; Scheme 3.9a).14 Based on  
Scheme 3.9. Deuteration of E-Amino CH Bonds Using D2O 
 
                                                          
14 Chan, J. Z.; Yao, W.; Hastings, B. T.; Lok, C. K.; Wasa, M. Angew. Chem., Int. Ed. 2016, 55, 1387713881. 
 69  
this study, we hypothesized that we could utilize D-deuterated monocarbonyl compounds 3.11 as 
d-source, which can contain multiple D-carbonyl CD bonds with higher pKa value compared to 
that of D2O or alcohols (Scheme 3.9b). Through cooperative action of B(C6F5)3 and Brønsted basic 
N- alkylamine, [R3ND]+ can be generated in situ and serve as an electrophilic deuterating reagent 
(XIII). 
 Various D-deuterated ketones were prepared and evaluated as d-source for E-amino CH 
deuteration of verapamil (3.1a; Table 3.2). Consistent with our hypothesis, when 3.1a was treated 
with 6.8 equivalent of acetophenone-d3 and 10 mol% B(C6F5)3, we observed improved d-
incorporation level of up to 79% (entry 1). We also tested cyclohexanone-d4 but obtained 3.9a 
with lower deuterium incorporation, probably due to its higher pKa compared to acetophenone 
(entry 2). Finally, by using acetone-d6, a readily accessible reagent that contains 6 D/molecule, we  
Table 3.2. Evaluation of Ketones as d-Source for E-Amino CH Deuteration of Verapamil 
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were able to obtain the product with >90% of d-incorporation (entry 3). 
 With acetone-d6 as the optimal d-source, we then evaluated various reaction conditions in 
order to further improve the reaction efficiency (Table 3.3). It was found that only after 1 hour, we  
can observe similar level of reaction efficiency (entry 1). Although the d-incorporation level 
diminished, 5.0 mol% of B(C6F5)3 was able to promote the E-selective deuteration of 3.1a (entry 
2). Deuterium incorporation drastically decreased to <35% at lower reaction temperature of 125 
°C and 100 °C (entry 34).  However, by reacting 3.1a with two batches of 5.0 mol% of B(C6F5)3  
Table 3.3. Evaluation of Reaction Parametersa,b,c 
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and acetone-d6 (6.8 equivalent), we were able to obtain 3.9a with >95% labeling (entry 5). Without 
B(C6F5)3 or when the less hindered BF3 or the less Lewis acidic BPh3 were used, no conversion of 
CH bonds to CD bonds was observed (entries 6 8). These findings are in line with our 
hypothesis that strongly acidic B(C6F5)3 together with sterically demanding and electron-rich N-
alkylamine constitute the most effective combination.  
An array of acyclic bioactive compounds that containE-amino C H bonds (3.1a 3.1j) 
underwent efficient deuteration (Table 3.4).  This catalytic method was found to be compatible 
with N-containing pharmaceuticals that contain Lewis acid-sensitive functional groups. In addition 
to the basic N-alkylamine moiety (3.1a, 3.1d 3.1l), cyano (3.1a), ether (3.1a, 3.1d), ester (3.1e), 
amide (3.1f, 3.1g, 3.1j) and ketone (3.1l) were tolerated to afford the deuteration products 3.9a, 
3.9d 3.9l in 77 to >95% yield after isolation by flash column silica gel chromatography. 
Deuterium incorporation was achieved with high regioselectivity for E-amino C H bonds. In 
addition, acidic D-carbonyl C H bonds were converted to CD bonds under the standard reaction 
conditions (3.9g, 3.9j, 3.9l) based on 1H NMR spectra analysis of crude reaction mixtures. 
However, in case of 3.9j, D-carbonyl C D bonds underwent D H exchange during purification by 
silica gel column chromatography.  
For substrates that possess electronically and sterically disparate E-amino C H bonds 
(3.1a, 3.1d, 3.1e, 3.1h, 3.1i, 3.1j, 3.1l), different levels of deuterium labeling was observed. With 
verapamil 3.1a, deuteration of non-benzylic C4 H bonds was more efficient compared to benzylic 
C2 H (Table 3.3, entries 1-5). In case of clomiphene 3.1d and dicyclomine 3.1e, C2 H bonds of 
N-ethyl groups underwent more efficient deuteration (90%) than C1 H bonds (15 and 23%). 
Although this protocol is highly functional group tolerant, HIE was more efficient with substrates 
bearing a protecting group as shown by the examples of lidocaine (3.1f) and cinacalcet (3.1h).  
 72  
Table 3.4. Deuteration of Acyclic E-Amino CH Bondsa,b,c 
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While 80% of E-C H bonds of lidocaine 3.1f was converted to C D bonds to give 3.9f, deuteration 
of N-benzyl-protected lidocaine 3.1g proceeded more efficiently to afford 3.9g with 96% labeling. 
Cinacalcet 3.1h, which contains secondary amine moiety, afforded 3.9h (63% [C2] a d 8% [C2 ]) 
under the standard conditions, when N-benzyl-protected cinacalcet 3.1f was obtained with >98% 
of E-amino C2 H bonds labeled. With less sterically hindered secondary amine-containing 
nortriptyline 3.1k and propafenone 3.1l, N-benzhydryl group was installed to furnish 3.9k and 3.9l. 
Silyl protection of the secondary alcohol also improved the efficiency of deuteration in the case of  
propafenone 3.1l.  
Deuteration of E-C H bonds in various cyclic bioactive amines was successful (Table 3.5; 
3.1m 3.1u). An array of heterocycles including piperidine (3.1m 3.1s), 1,4-diazepane (3.1t), 
piperazine (3.1u), thiophene (3.1m, 3.1n), indanone (3.1o), benzodioxole (3.1q, 3.1r), 
benzothiophene (3.1s), as well as benzoimidazole (3.1t) were tolerated to afford the corresponding 
labeled products in 85 to >95% yield. Enolizable D-carbonyl C H bonds in clopidogrel 3.1m, 
prasugrel 3.1n, and donepezil 3.1o underwent efficient deuteration, but acidic D-keto C D bond 
of 3.9n was converted to C H bond during purification by silica gel chromatography. Less acidic 
D-carbonyl C H bond in bupivacaine 3.1p was not deuterated. When both acyclic and cyclic E-
amino C H bonds were present (3.1p and 3.1s), labeling of the cyclic C H bond was more efficient 
(>90% vs d29% for the acyclic C H). For paroxetine, more hindered N-benzhydryl-protected 3.9r 
was obtained with higher d-incorporation level (92%) compared to N-benzyl-protected 3.9q 
(76%). Furthermore, the tertiary C3 H bond remained intact for both 3.9q and 3.9r. Deuteration 
of 1,4-diazepane-containing emedastine 3.1t took place at C2 H (33%) and C6 H (61%) bonds. 
All eight C H bonds of piperazine in O-TBS-dropropizine 3.1u underwent efficient deuteration 
providing 3.9u (>86%).  
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Table 3.5. Deuteration of Cyclic E-Amino CH Bondsa,b,c 
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The protocol is scalable as demonstrated by the gram scale reaction of verapamil 3.1a (1.4 
g, 3.0 mmol; Scheme 3.10). By treating 3.1a with 5.0 mol% B(C6F5)3, 20.4 mmol of acetone-d6, 
followed by filtration through a pad of silica gel and repeating the aforementioned procedure, 3.9a 
was obtained in 95% yield (2.9 mmol, 1.3 g) with >93% d-incorporation. 
Scheme 3.10. Scale-Up Experiment 
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3.2.4. Conclusions and Future Outlook 
In summary, we have developed an efficient and regioselective HIE protocol for E-amino 
C H bonds in various bioactive compounds through cooperative action of B(C6F5)3 and N-
alkylamine. We have demonstrated that N-containing pharmaceuticals can be converted to the 
corresponding enamine intermediate, which can react with an electrophilic deuterating agent that 
is in situ generated from readily accessible acetone-d6. 
The principles outlined above provide a new rational basis for the development of 
processes applicable to the late-stage stereoselective E-amino CH functionalization of bioactive 
amines.  
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3.3. Enantioselective E-Amino CH Functionalization through Cooperative Action of 
Chiral and Achiral Lewis Acid Catalysts 
 As discussed in Section 3.1, there is a paucity of catalyst systems that could promote the 
regio- and stereo-selective E-CH functionalization of N-alkylamines.1-2 This is mainly due to the 
poorly reactive nature of the E-amino CH bond, which would require the formation of the radical 
or cationic intermediates (II or III, Scheme 3.1) that cannot be stabilized by hyperconjugation, or 
a strained four-membered metallacycle (I, Scheme 3.1). Therefore, the development of an efficient 
and enantioselective catalyst system for the synthesis of E-substituted N-alkylamines through CH 
functionalization remains as an important unsolved problem. 
3.3.1. Background 
Despite the aforementioned challenges associated with E-amino CH functionalization, 
there exist few literature precedents for the synthesis of enantiomerically enriched E-substituted 
amines through activation of E-amino CH bond.15-16 The Gaunt group disclosed a Pd-catalyzed 
enantioselective CH activation protocol to afford enantio-enriched aziridines 3.15 using chiral 
phosphoric acid as a ligand (Scheme 3.11).11b This transformation is proposed to proceed via a 
four-membered cyclopalladation complex (XIV) through secondary amine-directed 
stereoselective CH activation. However, this method is limited to sterically hindered amines such 
as tetramethyl-morpholinone derivatives in order to overcome the undesired mutual quenching 
between acidic catalyst and basic amine moiety. Furthermore, the poor functional group tolerance 
                                                          
15 Ohno, S.; Miyoshi, M.; Murai, K.; Arisawa, M. Synthesis 2021, doi: 10.1055/a-1483-4575. 
16 (a) He, J.; Li, S.; Deng, Y.; Fu, H.; Laforteza, B. N.; Spangler, J. E.; Homs, A.; Yu, J.-Q. Science 2014, 343, 
12161220. (b) Smalley, A. P.; Cuthbertson, J. D.; Gaunt, M, J. J. Am. Chem. Soc. 2017, 139, 14121415. (c) Su, B.; 
Lee, T.; Hartwig, J. F. J. Am. Chem. Soc. 2018, 140, 1803218038. (d) Lin, W.; Zhang, K.-F.; Baudoin, O. Nat. Catal. 
2019, 2, 882888. 
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of this catalyst system due to the requirement for stoichiometric oxidant limits its application to 
the late-stage functionalization of complex molecules. 
Scheme 3.11. Enantioselective CH Activation of Aliphatic Amines Promoted by a Pd-Based 
Catalyst 
 
Hartwig and coworkers demonstrated enantioselective E-CH silylation of 
(silylmethyl)amine 3.16 for the synthesis of silicon-containing pyrrolidines derivatives 3.17 
promoted by an Ir-based catalyst (Scheme 3.12).11c The incorporation of a methylene linker 
between the silyl group and the nitrogen center prevents the activation of a weaker D-CH bond 
as it would lead to a strained four-membered azasiletidine; instead, a rare E-selective CH bond 
functionalization is achieved to generate a more stable five-membered metallacycle intermediate. 
The limitation of this method includes the use of precious Ir-based catalyst and cryogenic 
conditions. Moreover, the substrates that contain functional groups that are prone to reduction may 
not be tolerated in this catalyst system involving the use of silane-containing substrate and Ir-based 
catalyst. 
Scheme 3.12. E-Selective CH Silylation of Aliphatic Amines Promoted by an Ir-Based Catalyst 
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The group of Baudoin reported a regiodivergent enantioselective CH functionalization of 
Boc-1,3-oxazinanes 3.18 (Scheme 3.13).11d This one-pot reaction proceeds through sparteine-
mediated enantioselective lithiation of Boc-1,3-oxazinane 3.18 and transmetallation to zinc to 
afford 3.19. Following migratory Negishi coupling of organozinc species with an organic 
electrophile such as phenyl bromide furnishes E-substituted amine product 3.20, which can be 
converted to an enantio-enriched E-amino acid. However, due to the demand for stoichiometric 
amounts of s-BuLi and (+)-sparteine, this method is not functional group tolerant. Furthermore, 
this method has a confined substrate scope of sterically hindered Boc-1,3-oxazinanes to overcome 
the undesired acidbase complexation. 
Scheme 3.13. Enantioselective E-CH Functionalization of Boc-1,3-oxazinanes  
 
As summarized above, the literature precedents on enantioselective methods for E-amino 
CH functionalization require the use of precious Pd- or Ir-based catalysts. Moreover, the use of 
stoichiometric oxidant (AgOAc, I2, and/or IOAc) or base (s-BuLi) would be problematic with 
substrates that contain oxidant- and/or base-sensitive functional groups. As a consequence, 
application of these methods to the late stage modification of bioactive amines would be 
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challenging (Scheme 3.14a). To address these fundamental limitations, we envisioned the 
development of an enantioselective and sustainable element-based catalyst system that is 
applicable to the late-stage E-CH functionalization of bioactive amines under mild and redox-
neutral conditions (Scheme 3.14b). 
Scheme 3.14. Enantioselective E-amino CH Functionalization  
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3.3.2. Our Approach 
As described in Section 2.5, we have demonstrated that separate and independently 
operational Lewis acid co-catalysts whose functions might easily overlap and the simultaneous use 
of which might initially seem to have a negative impact on enantioselectivity can, in fact, promote 
highly enantioselective process. Furthermore, in Section 3.2, we disclosed that through cooperative 
function of Lewis acidic B(C6F5)3 and a Brønsted basic N-alkylamine, enamine can be generated 
in situ from the corresponding N-containing pharmaceuticals. It was also shown that the resultant 
enamine intermediate can react with an appropriate electrophilic species to regioselectively modify 
E-CH bond contained in structurally complex bioactive amines.  
Based on these previous studies, we envisioned the development of a catalytic protocol for 
the late-stage stereoselective E-amino CH functionalization of N-based drug molecules through 
the use of a cooperative catalyst system consisting of B(C6F5)3, a Brønsted base catalyst, and a 
chiral Lewis acid co-catalyst (M L*, Scheme 3.15). We propose that B(C6F5)3 could abstract 
hydride from N-alkylamine 3.21 to give an ion pair consisting of an iminium and a borohydride 
(XVI). The iminium ion could be deprotonated by a Brønsted base to afford enamine XVII. The 
reaction between the nucleophilic enamine (XVII) and the chiral Lewis acid-activated D,E-
unsaturated compound (XVIII) would forge a new CC bond in a stereoselective manner to 
furnish zwitterionic intermediate XIX. Ensuing protonation and reduction of XIX would provide 
E-alkylation product 3.23. 
By using the untethered and independently operational catalyst system, we could easily 
optimize the reaction efficiency and stereoselectivity through evaluation of Lewis acids, chiral 
ligands and base co-catalysts. Nonetheless, the major challenge we need to overcome is the 
potential mutual quenching between the acidic and basic components of catalysts, substrates, and 
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the product. Moreover, the achiral Lewis acid B(C6F5)3 could have overlapping function with the 
chiral Lewis acid and promote racemic background reaction by activating the electrophile 3.22 
(ML*= B(C6F5)3; XVIII). Therefore, we need to develop a potent cooperative catalyst system 
that could overcome these fundamental challenges and promote the enantioselective E-amino CH 
functionalization of N-alkylamines. 
Scheme 3.15. Direct Enantioselective E-CH Functionalization of Amines through Cooperative 
Actions of B(C6F5)3 and Chiral Lewis Acid Co-catalyst 
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3.3.3. Results and Discussion  Method Development 
 We began our investigation by examining if B(C6F5)3 could activate both N,N-
dibenzylethanamine (3.21a) and diisopropyl fumarate (3.22a) to promote the E-amino CH 
alkylation affording 3.23a (Table 3.6). When 3.21a was reacted with 3.22a under the presence of 
10 mol% B(C6F5)3 and 10 mol% triethylamine, 2,2,6,6-tetramethylpiperidine (TMP) or 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU), 3.23a was obtained in 50%, 25%, and <5% yield, 
respectively (entries 1 3). When the reaction was conducted without any external base catalyst, 
the desired product 3.23a was furnished in 73% yield (entry 4); suggesting Brønsted basic 3.21a 
and/or 3.23a could mediate the deprotonation of iminium intermediate for generation of enamine 
(XVI XVII, Scheme 3.15). It should be noted that the formation of 3.24 was also observed 
(entried 16), probably through the reaction between enolate (XIX, Scheme 3.15) and 3.22a, 
followed by intramolecular cyclization. To improve the selectivity and suppress formation of 3.24,  
Table 3.6. Evaluation of Various Reaction Parametersa,b,c 
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we carried out the transformation in lower concentration (entries 56). Although we were able to 
observe 3.24 in only 5% yield, the overall reaction efficiency decreased and the desired 3.23a was 
also obtained in lower yield of 54% (vs 73% in entry 4). When the reaction was run for 12 hours, 
3.23a was furnished in 91% yield. None of the product was formed without B(C6F5)3, or when less 
hindered BCl3 or less acidic BPh3 were used (entries 79). These results point to the fact that 
strongly Lewis acidic and hindered B(C6F5)3 together with sterically demanding and electron-rich 
N-alkylamines represent the most effective catalyst substrate combination. 
With the optimal reaction conditions, we went on to evaluate various N-alkylamines using 
diisopropyl fumarate 3.22a (Table 3.7). An array of acyclic amines was found to be suitable for 
this transformation, providing corresponding E-substituted amines (3.23a3.23h). While reaction 
of N,N-dibenzylethanamine and 3.22a afforded 3.23a in 88% yield, N,N-dibenzylpropan-1-amine 
afforded 3.23b and 3.23c in 58% and 33% yield, respectively. Compound 3.23c is likely generated 
through intramolecular Mannich-type reaction between an iminium ion and enolate (XIX, Scheme 
3.15). With the more sizeable N,N-dibenzyl-2-methylpropan-1-amine, 3.23d was obtained as the 
only product (69% yield), which may be due to acceleration of the Mannich-process by the Thorpe-
Ingold effect.  
N-Benzhydryl-substituted secondary amines containing an N H group were suitable 
substrates, giving 3.23e3.23g in 66 93% yield. However, when a secondary amine that bears a 
more hindered trityl group (e.g., N-tritylethanamine), none of the desired product was obtained; 
this may be attributed to rapid substrate decomposition. Furthermore, with less hindered N-
benzylethanamine, the formation of (F5C6)3B amine adduct likely competes with Lewis acid-
catalyzed hydride abstraction, affording the desired E-alkylation product in <5% yield. From the 
reaction of enantio-enriched 3.21xx, 3.23h was furnished in 90% yield as a 1.4:1 mixture of  
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Table 3.7. E-Alkylation of Different N-Alkylaminesa,b,c 
 
chromatographically separable diastereomers, allowing us to secure the amino ester in 
enantiomerically pure form.  
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A range of compounds that contain a 4-substituted piperidine moiety, which is prevalent 
in pharmaceuticals, proved to be compatible pro-nucleophiles. The union of N-benzyl-4-(((tert-
butyldimethylsilyl)oxy)methyl)piperidine and 3.22a afforded a mixture of 3.23i and enamine 3.23j 
in 74% and 26% yield, respectively. The reaction of N,N-dibenzyl-1-(1-benzylpiperidin-4-
yl)methanamine and 3.22a gave 3.23k and 3.23l in 51% and 47% yield, respectively. The enamine 
product (e.g., 3.23j) may be produced through intramolecular deprotonation of iminium ion by the  
enolate moiety within the zwitterionic intermediate (XIX, Scheme 3.15). Alternatively, 
protonation of enolate in XIX by the ammonium ion, followed by deprotonation of the resulting 
iminium intermediate by the amine may provide enamine product. In both pathways, regeneration 
of reactive catalysts from borohydride and ammonium ion likely proceeds through reduction of 
3.22a; indeed, the formation of diisopropyl succinate was observed. 
As indicated by synthesis of 3.23m and 3.23n, chiral pyrrolidines may be used as starting 
materials. While the reaction involving less hindered 1-(4-methoxy-2,6-dimethylphenyl) 
piperidine provided 3.23o as the only product in 89% yield, with the bulkier 4,4-dimethyl-
substituted piperidine, enamine 3.23p was obtained in 93% yield.24 
 The functional group tolerance of this protocol was demonstrated by the late-stage 
modification of bioactive amines, which afforded corresponding E-functionalized amines (3.23q
3.23t; Table 3.8). The piperidine moiety in raloxifine (antidepressant), risperidone (anti-psychotic) 
and paroxetine (anti-Alzheimer) was readily altered, showing that not only the basic N-alkylamine 
moieties but also a ketone (3.23q), a benzothiophene (3.23q), an ether (3.23q, 3.23s), a 
pyrimidinone (3.23r) and benzoisoxazole (3.23s) can be tolerated in our catalyst system.  
Risperidone, possessing more sterically hindered E-amino C H bonds furnished enamine 3.23r in 
32% yield and only <5% of the product derived from alkylation of acyclic E-amino C H bond (H  
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Table 3.8. E-Alkylation of Various N-Containing Pharmaceuticalsa,b,c 
 
labelled in red) was be observed (1H NMR analysis). The process involving N-benzyl paroxetine 
afforded 3.23s and 3.23t in 39% and 14% yield, respectively. 
Mono- and di-carbonyl-substituted alkenes proved to be suitable substrates (Table 3.9). 
Using dibenzyl fumarate, we were able to isolate 3.23u in 79% yield; <10% cyclobutane product 
was observed (vs 3.23b and 3.23c, 58% and 33% yield, respectively; Table 3.7). Methyl-4,4,4-
trifluorobut-2-enoate was converted to 3.23v in 74% yield as a single diastereomer. The reaction 
of N,N-dibenzylpropan-1-amine with benzyl acrylate gave 3.23w exclusively in 75% yield. 
Finally, N-phenylmaleimide afforded the corresponding product 3.23x in 49% yield. 
Having demonstrated that B(C6F5)3 can promote union of N-alkylamines and DE-
unsaturated compounds, we aimed to develop a catalytic protocol for highly stereoselective E- 
amino C H functionalization. We first chose the prolinol derivative 3.21k and (S,E)-4-phenyl-3-
(4,4,4-trifluorobut-2-enoyl)oxazolidin-2-one 3.25a as model substrates for diastereoselective 
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Table 3.9. E-Alkylation of Amines with Different Electrophilesa,b 
 
transformation (Scheme 3.16). We hypothesized that the use of enantio-enriched electrophile may 
provide the product with diastereoselectivity and reacted 3.21k and 3.25a in the presence of 
B(C6F5)3, however, the product 3.26a was formed in <5% yield (Scheme 3.16a). This could be 
because B(C6F5)3 does not sufficiently activate 3.25a as it was shown to facilitate the in situ 
generation enamine intermediate (E-alkylation product 3.23n was obtained from (F5C6)3B-
catalyzed reaction of 3.21k and 3.22a). We wondered if a Lewis acid co-catalyst could activate 
3.25a and promote diastereoselective E-amino alkylation. After evaluation of various Lewis acids, 
it was found that the use of 10 mol% ZnI2 as a co-catalyst can afford 3.26a in 82% yield as a single 
diastereomer. The presence of HBPin as an additive affected the diastereoselectivity, as 3.26a was 
produced in 67% yield and 10:1 dr without HBPin.  
We then started our investigation on enantioselective E-amino C H alkylation reaction 
using achiral substrates 3.21q and 3.25b, through cooperative function of B(C6F5)3 and a chiral 
organometallic co-catalyst (Scheme 3.16b). After extensive evaluation of metal-ligand complex, 
we found out that a complex of L1Mg(ClO4)2 can promote E-amino C H alkylation of 3.21q  
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Scheme 3.16. Stereoselective E-CH Functionalization of N-Alkylamines through Cooperative 
Actions of B(C6F5)3 and a Lewis Acid Co-catalyst 
 
affording 3.26b in 67% yield (1.6:1 dr, 90:10 er). However, it was the highest efficiency or 
enantioselectivity we could obtain for the reaction between 3.21q and 3.25b. 
In an effort to achieve highly enantioselective E-CH functionalization of N-alkylamines, 
we evaluated various combinations of chiral Lewis acid co-catalysts and DE-unsaturated 
compounds possessing different auxiliaries (Table 3.10). It was found that 1-(4-
methoxyphenyl)pyrrolidine 3.21r can be coupled with 2-acryloylpyrazolidinone derivative 3.25c 
in the presence of 10 mol% of B(C6F5)3 and chiral bisoxazoline ligandSc(OTf)3 complex. When 
Ph BOX, Ph DBFOX and Ph PyBOX ligands (e.g., L2 L4) were tested, 3.26c was obtained with 
low enantioselectivity (58:42 50:50 er). However, after evaluation of alkyl-substituted PyBOX 
ligands (e.g., L5 L8), 3.26c was obtained in 72% yield, 2.7:1 dr and up to 98:2 er, using (S)-i-Bu  
PyBOX (L8). Yield of 3.26c was improved to 85% when L9 and L10 were used, however, L10 
was a superior ligand as 3.26c was obtained with higher enantioselectivity of up to 98:2 er. 
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Table 3.10. Evaluation of Chiral Ligandsa,b 
 
Having found the optimal combination of LSc(OTf)3 complex and auxiliary, we explored 
the scope of DE-unsaturated compounds and N-alkylamines for the enantioselective 
transformation (Table 3.11). Electrophiles possessing ester, ketone, or CF3 substituent underwent 
efficient reaction with 1-(4-methoxyphenyl)pyrrolidine (3.21r) to furnish corresponding E-
alkylated products (3.26c3.26f) in 62 83% yield with 95:5 98:2 er. N-Substituents of the 
pyrazolidinone unit were found to affect stereoselectivity as the reaction of 3.21r with 3.25c and 
3.25d afforded 3.26c (2.0:1 dr, up to 98:2 er) and 3.26d (3.0:1, up to 95:5 er), respectively.  
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Table 3.11. Enantioselective E-Functionalization of N-Alkylamines a,b 
 
When acyclic N-ethyl-4-methoxy-N,2,6-trimethylaniline 3.21s was treated with F3C-
substituted 3.25f (Scheme 3.17), N-arylpiperidine derivative 3.26g was obtained in 67% yield 
(>20:1 dr, 95:5 er). The plausible mechanism for generation of 3.26g involves E-amino C H 
alkylation of 3.21s by 3.25f furnishing a zwitterionic intermediate containing an iminium and an 
enolate (XX), which could isomerize to XXI; ensuing intramolecular Mannich-type reaction 
would afford 3.26g.  
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Scheme 3.17. Sequential E-alkylation and Mannich-type reaction for synthesis of piperidine 
derivative 3.26g 
 
The E-alkylation of N-arylpiperidines or N-arylazapene using 3.25f provided products as 
enamines 3.26h 3.26j in 74 95% yield and 93:7 96:4 er (Table 3.11). The reaction of N-
arylpiperidine-3,3,5,5-d4 3.21l-d (0.10 mmol) and 3.25f (0.20 mmol) afforded 3.26h-d (84% yield, 
95:5 er) and 3.27f-d (0.08 mmol; Scheme 3.18). The D/H exchange at C5 position of 3.26h-d 
(>95% in 3.21l-d o 81% in 3.26h-d) and incorporation of deuterium at enolizableD-carbonyl 
positions in 3.26h-d and 3.27f-d was observed by the 1H NMR analyses, indicating that [(F5C6)3B
H]  [base D]+ formed in situ reacts with 3.25f to produce 3.27f-d, to regenerate B(C6F5)3 (vs 
through the release of H D). 
Scheme 3.18. Incorporation Deuterium into Enolizable Positions of 3.26h-d 
 
This protocol is highly functional group tolerant as shown by the conversion of E-Amino 
C H bonds in bioactive trialkylamines such as cloperastine 3.21u and raloxifene derivative 3.21n, 
which afforded enamines 3.26k and 3.26l in 53% yield (90:10 er) and 57% yield (95:5 er), 
respectively (Table 3.11).  
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The scalability of this method was demonstrated by the reaction of 4.0 mmol of N-
arylpiperidine 3.21l and 3.25f with 10 mol% B(C6F5)3 and L10 Sc(OTf)3, which delivered the 
corresponding product 3.26h in 95% yield (1.9 g; Scheme 3.19). 
Scheme 3.19. Scalability of Enantioselective E-Amino CH Alkylation 
 
By treating 3.26f with LiSEt followed by reduction of the resulting thioester, alcohol 3.28 
was obtained in 95% yield (Scheme 3.20a). After the conversion of 3.28 into the corresponding 
carbamate 3.29, absolute configuration was determined through the X-ray crystallographic 
analysis (see Section 3.4 for details). Enamine product 3.26h, obtained by enantioselective E-
alkylation, could serve as versatile intermediates (Scheme 3.20b) as hydrogenation of 3.26h by a 
chiral Ir-based complex afforded 3.30 in 83% yield with 5.0:1 dr,26 while fluorocyanation of 3.26h 
using NFSI and TMSCN furnished 3.31 in 88% yield with 4.0:1 dr.27 
Scheme 3.20. Modification of E-Alkylated Amine Products 
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3.3.4. Results and Discussion  Mechanistic Investigations 
Having demonstrated that cooperative catalyst system consisting of B(C6F5)3, chiral Lewis 
acid, and Brønsted base can promote the functionalization of E-amino CH bonds, we designed 
and carried out investigations to shed light on the mechanism of the catalytic process. The 
mechanistic studies include: (i) determination of reaction orders (Figure 3.1), (ii) kinetic isotope 
effect (KIE) studies (Scheme 3.21), and (iii) determination of Hammett U values (Scheme 3.24). 
Based on the results obtained from mechanistic investigations, we propose a revised catalytic cycle 
for catalytic E-C H alkylation reaction (Scheme 3.22). 
We began our investigation by performing the initial kinetic experiments for the reaction 
of N-arylpyrrolidine 3.21r and DE-unsaturated compound 3.25g to determine the reaction order 
of each species (Figure 3.1). The reaction rate was found to have: (i) a second-order dependence 
on B(C6F5)3 concentration (Figure 3.1a), (ii) a zero-order dependence on the concentration of L6
Sc(OTf)3 complex (Figure 3.1b), (iii) a first-order dependence on concentration of amine 3.21r 
(Figure 3.1c), and (iv) a reverse first-order dependence on the concentration of electrophile 3.25g 
(Figure 3.1d). The independence of the reaction rate on the initial concentration of L6 Sc(OTf)3 
implies that turnover-limiting step is prior to the enantioselective C C bond formation between in 
situ generated enamine and [L6 Sc(OTf)3]-activated 3.25g (Scheme  3.15, XXVI o XXVII); thus, 
either the hydride abstraction or the deprotonation step is likely turnover-limiting.  
To determine whether the cleavage of D- or E-amino CH bond is involved in the turnover-
limiting step, we carried out independent KIE experiments (Scheme 3.21). From the independent 
rate measurements involving 3.21rand 3.21r-dD (Scheme 3.21a), kH/kD = 1.28 ± 0.07 was observed. 
On the other hand, the reaction rate comparison between 3.21r and 3.21r-dE (Scheme 3.21b) 
disclosed that 3.21r reacts 2.5 times faster than 3.21r-dE (kH/kD = 2.50 ± 0.13). These results 
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suggest that the turnover-limiting step is the deprotonation step involving cleavage of D-imino 
CH or CD bonds (Scheme 3.15, XVIoXVII) and that (F5C6)3B-catalyzed hydride abstraction 
is reversible.  
We hypothesized that the reverse first-order dependence on the concentration of 3.25g is 
due to the catalyst resting state consisting of 3.25g and B(C6F5)3. Indeed, the 19F NMR analysis of 
the reaction mixture supports the formation of [3.25g B(C6F5)3] (XXII, Scheme 3.22). 
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Scheme 3.21. Kinetic Isotope Effect Studies 
 
Meanwhile, the second-order dependence on B(C6F5)3 concentration indicates that there 
are two B(C6F5)3 involved in the turnover-limiting step; thus, second-order dependence on the 
concentration of electrophile 3.25g is expected. However, the reverse first-order dependence we 
observed suggests that one electrophile 3.25g is involved in the turnover-limiting step. 
Furthermore, the first-order dependence on the concentration of amine 3.21r implies that the  
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Scheme 3.22. A Revised Catalytic Cycle Consistent with the Results of Mechanistic Investigations 
 
deprotonation of iminium (Scheme 3.15, XVIoXVII) is not mediated by the N-alkylamine 
substrate. 
Based on the results discussed above, we propose a revised catalytic cycle that is consistent 
with the kinetic data we obtained from the mechanistic studies (Scheme 3.22). The reaction is 
proposed to proceed through the release of B(C6F5)3 from the catalyst resting state (XXII), 
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followed by hydride abstraction from 3.21 to generate an ion pair consisting of an iminium and a 
borohydride (XXIII). Borohydride could then reduce (F5C6)3B-activated 3.25 to furnish a 
(F5C6)3B enolate (XXIIIoXXIV).17 Ensuing isomerization of the iminium into an enammonium 
(XXIVoXXV) is likely the turnover-limiting step (see the Hammett studies, and Section 3.4).18 
Protonation of (F5C6)3B enolate would release B(C6F5)3, 3.27, and the enamine intermediate 
(XXVoXXVI). The reaction between the nucleophilic enamine and [L Sc(OTf)3]-activated 
electrophile 3.25 would forge a new CC bond in an enantioselective manner affording a 
zwitterionic intermediate XXVII. To close the catalytic cycle, proton transfer within XXVII 
delivers 3.26-enamine and regenerates L Sc(OTf)3. Alternatively, borohydride reduction of the 
iminium and protonation of the enolate in XXVII could furnish 3.26-alkylamine. 
As shown in Tables 3.7, 3.8, and 3.11, the E-alkylated amine products were obtained either 
as an enamine, an N-alkylamine, or a mixture of the two (e.g., 3.23i and 3.23j, Table 3.7). 
Therefore, we wanted to study the origin of enamine and N-alkylamine products. Specifically, 
whether the N-alkylamine product was formed by transfer hydrogenation of XXVII 
(XXVIIo3.26-alkylamine, Scheme 3.22), or through reduction of enamines (3.26-
enamineo3.26-alkylamine). The progress of (F5C6)3B-catalyzed reaction between N-
arylpiperidine 3.21l and 3.22a was monitored (Scheme 3.23a), which gives a mixture of N-
alkylamine 3.23o (57% yield) and enamine 3.32 (29% yield) under the concentration of 1.0 M (vs 
the process in 0.25 M, which selectively affords 3.23o; Table 3.7). There was minimal 
transformation of 3.32 into 3.23o as the concentration of 3.32 mostly unchanged once the reaction 
                                                          
17 Chen, G. Q.; Kehr, G.; Daniliuc, C. G.; Bursch, M.; Grimme, S.; Erker, G. Chem. Eur. J. 2017, 23, 47234729. 
18 (a) Sorgi, K. L.; Maryanoff, C. A.; McComsey, D. F.; Graden, D. W.; Maryanoff, B. E. J. Am. Chem. Soc. 1990, 
112, 35673579. (b) Han, J.; Lu, Z.; Flach, A. L.; Paton, R. S.; Hammond, G. B.; Xu, B. Chem. Eur. J. 2015, 21, 
1168711691. (c) Ashley, M. A.; Hirschi, J. S.; Izzo, J. A.; Vetticatt, M. J. J. Am. Chem. Soc. 2016, 138, 17561759.  
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was complete (2 h; Scheme 3.23b). These results are consistent with our hypothesis that 3.26-
alkylamine (Scheme 3.22) is formed by transfer hydrogenation of XXVII without the 
intermediacy of 3.26-enamine. However, the source of proton and hydride has not yet been 
identified. 
Scheme 3.23. Origin of Enamine and N-Alkylamine Products 
 
To probe further if, and under precisely what conditions 3.32 can be converted to 3.23o, 
we investigated the transformation of 3.32 in the presence of 20 mol% B(C6F5)3 (C6H6, 12 h; 
Scheme 3.23c). We were able to observe 30% conversion of 3.32 to 3.23o as well as 15% of 
[pyridinium]+[C6F5]  (3.34). Furthermore, by treating 3.32 with N-arylpiperidine-3,3,5,5-d4 3.21l-
d, 3.23o-d was obtained in 50% yield; there was significant D/H exchange in both 3.23o-d (at C3 
and C5 positions, 71% and 67%, respectively) and recovered 3.21l-d. These data suggest that 
B(C6F5)3 can catalyze transfer hydrogenation of 3.32 in the presence of another molecule of 3.32 
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and/or 3.21l-d serving as sources of H+ (or D+) and hydride. Nonetheless, under the standard 
conditions for (F5C6)3B-catalyzed E-C H alkylation reaction (Schemes 3.22 and 3.23a), in situ 
generated [(F5C6)3B H] [base H]+ (derived from the reaction of B(C6F5)3 and N-alkylamine 3.21) 
reacts with either a highly reactive zwitterionic intermediate (XXVIIo3.26-alkylamine) or 
(F5C6)3B-activated DE-unsaturated compounds  (XXIIIoXXIVoXXVo3.27). Therefore, 
transfer hydrogenation of the relatively unreactive enamine 3.32 to give 3.23o is likely 
outcompeted by these more facile processes.   
We carried out Hammett studies to gain further insight regarding the turnover-limiting step 
of this catalytic transformation (Scheme 3.24). It was found that the reaction rate has a strong 
dependence on the electronic properties of the N-alkylamines; N-arylpyrrolidine derivatives (3.21) 
possessing electron-donating substituents reacted with higher efficiency (U = 4.9, Schemes 3.24a 
and 3.24c). The large negative U value supports the proposed mechanism (Scheme 3.22) where 
B(C6F5)3 abstracts a hydride from N-arylpyrrolidine 3.21 into an N-aryl iminium cation 
(3.21oXXIII), and its isomerization into an enammonium species (XXIIIoXXIVoXXV); these 
processes take place at or prior to the turnover-limiting step.  
Meanwhile, the reaction rate was less dependent of the electronic properties of DE-
unsaturated compounds 3.25 and those involving electron-withdrawing groups reacted more 
rapidly (U = 0.92, Schemes 3.24b and 3.24d). This result is consistent with the proposed catalytic 
cycle that borohydride reduction of 3.25 furnishes a boron enolate intermediate (Scheme 3.22; 
XXIIIoXXIV), which also occurs at or prior to the turnover-limiting step.  
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Scheme 3.24. Hammett Studies 
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3.3.5. Conclusions and Future Outlook 
We have demonstrated that the cooperative actions of B(C6F5)3 and an appropriate 
Brønsted base can convert a broad array of N-based pharmaceuticals into enamines. We have 
successfully developed the reaction of in situ generated enamines with D+ as well as Michael 
acceptors.19-20 By incorporation of a chiral organometallic catalyst, enantioselective E-amino CH 
alkylation was also achieved. 
Despite the advances we have achieved, these work also unveiled key shortcomings of our 
approach.  
1) scope of compatible transformations is narrow 
2) functional group tolerance remains to be modest; less hindered basic moieties (e.g., alcohols, 
primary amines) needed appropriate protections. 
3) modest reaction efficiency and enantioselectivity (e.g., 3.26k, Table 3.11). 
These problems originate from the fact that our organoborane/chiral Lewis acid co-catalyst system 
is not generally applicable enough to promote efficient and enantioselective union of otherwise 
poorly reactive pronucleophiles and electrophiles. 
 In the future work, our group will continue to investigate novel catalyst systems capable of 
converting various molecules into electrophilic and/or nucleophilic intermediates through Lewis 
acid-catalyzed hydride abstraction (Scheme 3.25). Some of the representative processes include 
the activation of ethers 3.36, thioethers 3.37 and alkenes 3.38 into the corresponding carbocations 
(XXX, XXXII, and XXXIV); trapping of these carbocations with different nucleophiles may 
allow access to a broad array of D-substituted compounds. Alternatively, nucleophilic 
                                                          
19 Chang, Y.; Yesilcimen, A.; Cao, M.; Zhang, Y.; Zhang, B.; Chan, J. Z.; Wasa, M. J. Am. Chem. Soc. 2019, 141, 
14570 14575. 
20 Chang, Y.; Cao, M.; Chan, J. Z.; Zhao, C.; Wang, Y.; Yang, R.; Wasa, M. J. Am. Chem. Soc. 2021, 143, 2441
2455. 
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intermediates (XXXI, XXXIII, and XXXV) generated through deprotonation of the carbocations 
can be used to produce a wide range of E-substituted molecules. To address the issue of functional 
group tolerance, further investigation must be performed to discover Lewis acid and base catalysts 
ha  a e e e ica  a d e ec ica  f a ed  agai  he acidic a d ba ic ie ie . O  
studies (c.f., Schemes 2.12 and 3.24) indicate that various metal ligand complexes (e.g., LnSc
PyBoX, LnCu bisphosphine) are moderately tolerant of acid-sensitive functional groups; 
identification of other organometallic complexes that promote more efficient hydride abstraction 
and/or activation of coupling partners could lead to drastic expansion in the substrate scope as well 
as functional group tolerance. Furthermore, the in-situ generated intermediates generated by 
hydride abstraction from amines, ethers, thioethers and alkenes (e.g., XXVIIIXXXV, Scheme 
3.25AD) can be trapped by nucleophilic and/or electrophilic partners that are generated by 
organometallic catalysis (Scheme 3.25E), 21 - 22  photocatalysis (Scheme 3.25E), 23 - 24  and 
electrocatalysis (Scheme 3.25G). 25 - 26  Through these future work, our aim is to address the 
fundamental limitations associated with enantioselective late-stage CH functionalization 
reactions. 
  
                                                          
21 He, J.; Wasa, M.; Chan, K. S. L.; Shao, Q.; Yu, J.-Q. Chem. Rev. 2017, 117, 8754 8786. 
22 Ozawa, F.; Kubo, A.; Hayashi, T. J. Am. Chem. Soc. 1991, 113, 14171419. 
23 (a) Romero, N. A.; Nicewicz, D. A. Chem. Rev. 2016, 116, 10075 10166. (b) Shaw, M. H.; Twilton, J.; MacMillan, 
D. W. C. J. Org. Chem. 2016, 81, 6898 6926. 
24 Nagib, D. A.; Scott, M. E.; MacMillan, D. W. C. J. Am. Chem. Soc. 2009, 131, 1087510877. 
25 Yan, M.; Kawamata, Y.; Baran, P. S. Chem. Rev. 2017, 117, 13230 13319. (b) Liu, J.; Lu, L.; Wood, D.; Lin, S. 
ACS Cent. Sci. 2020, 6, 1317 1340. 
26 Song, L.; Fu, N.; Ernst, B. G.; Lee, W. H.; Frederick, M. O.; DiStasio Jr., R. A.; Lin, S. Nat. Chem. 2020, 12, 
747754. 
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Appendix A. Experimental for Chapter 2 
General e perimental procedures 
A  eac i  e e e f ed i  a da d, d  g a a e fi ed i h bbe  e a de  a  i e  
a he e f i ge  e  he i e de c ibed. S ai e  ee  i ge   ca ae e e ed 
 a fe  ai - a d i e- e i i e i id . Re ed c ce a i  efe   i  e  
a   e e a e. E a a i  a d c ce a i   ac  e e e f ed i g h e ac  
(ca. 40  Hg). C  ch a g a h  a  e f ed i h Si iaF a h  60 (40 63 ic ) 
i ica ge  f  Si ic c e. Thi  a e  ch a g a h  (TLC) a  ed f  eac i  i i g a d 
d c  de ec i  i g e-c a ed g a  a e  c e ed i h 0.20  i ica ge  i h f e ce  
i dica ; i a i a i  b  UV igh  (Oex = 254 )  KM O4 ai . 
Materials 
Reage  e e cha ed i  eage  g ade f  c e cia  ie  a d ed i h  f he  
ifica i , e  he i e de c ibed. A i e  a d i ic  e a e  e e e a ed acc di g  
he ced e  e ed e i .1-22 T i ( e af he )b a e a d ((1- e h -2-
e h -1-e -1- ) ) i e h i a e e e cha ed f  TCI a d ed i h  f he  
ifica i . H2O, i  he ic ced e , efe   di i ed a e . 
Instrumentation 
Proton nuclear magnetic resonance (1H NMR) spectra and proton-decoupled carbon nuclear 
magnetic resonance (13C {1H} NMR) spectra were recorded at 25 °C (unless stated otherwise) on 
Inova 600 (600 MHz), Varian Unity/Inova 500 (500 MHz) or Oxford AS400 (400 MHz) 
spectrometers at the Boston College nuclear magnetic resonance facility. Chemical shifts for 
protons are reported in parts per million downfield from tetramethylsilane and are referenced to 0 
ppm. Chemical shifts for carbon are reported in parts per million downfield from tetramethylsilane 
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and are referenced to the carbon resonances of the solvent. The solvent peak was referenced to 
77.0 ppm for 13C for CDCl3. Benzotrifluoride was used as an external standard for 19F NMR and 
referenced to 63.7 ppm. Data are represented as follows: chemical shift, integration, multiplicity 
(br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constants in 
Hertz (Hz).   
Infrared spectra were recorded on a Bruker FT-IR Alpha (ATR mode) spectrophotometer. Data 
are represented as follows: frequency of absorption (cm 1).  
High-resolution mass spectrometry was performed on a JEOL AccuTOF-DART (positive mode) 
at the Mass Spectrometry Facility, Boston College.  
Abbreviations used 
Bn = benzyl, Boc = tert-butoxycarbonyl, DART = direct analysis in real time, DCE = 1,2-
dichloroethane, DCM = dichloromethane, DIPEA = diisopropylethylamine, DMF = N,N-
dimethylformamide, dr = diastereomeric ratio, er = enantiomeric ratio, ESI = electrospray 
ionization, Et2O = diethyl ether, EtOAc = ethyl acetate, HR = high-resolution, KOH = potassium 
hydroxide, LC = liquid chromatography, MgSO4 = magnesium sulfate, MS = mass spectrometry, 
NA = not applicable, PTLC = preparatory thin-layer chromatography, TBME = tert-butyl methyl 
ether, TBS = tert-butyldimethylsilyl, Tf = trifluromethanesulfonate, THF = tetrahydrofuran, TLC 
= thin-layer chromatography, TMS = trimethylsilane, TOF = time-of-flight. 
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A1. Substrate Preparation 
Preparation of Amine Substrates 
Table S2.1A. List of Amine Substrates 
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Table S2.1B. List of Amine Substrates 
 
 
Amines 2.13a, 2.13p and 2.13q were obtained from commercial sources and used without further 
purification. Substrates 2.13b-2.13f,1 2.13g,2-7 2.13h1, 2.13i,7 2.13j,8 2.13k,9 2.13l,10-12 2.13n,13 
2.13o,9 2.13r,14-16 and 2.13s,17-18 were prepared accordingly to the literature procedures. Amine 
2.17a was obtained commercially as the HBr salt and was treated with NaOH (1.0 M aqueous 
solution) before use. Amines 2.17b1 and 2.17c1 were prepared accordingly to the literature 
procedures. The spectroscopic data for the newly synthesized molecules (2.13e, 2.13g, 2.13h, 2.13i, 
2.13j, 2.13k, 2.13l, 2.13n, 2.13o, 2.13r, 2.13s, 2.17b, and 2.17c) are described as the following. 
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General Procedure for the Methylation of Amines 
 
Amines 2.13b-2.13f, 2.13h, 2.17b and 2.17c were prepared following a known procedure.1 A 
solution of amine and formaldehyde (37% aq. solution, 6.0 equiv.) was cooled to 0 °C. To the 
reaction mixture, formic acid (10 equiv.) was added dropwise. The reaction mixture was then 
warmed to 90 °C for 2 hours. Upon completion, NaOH (1M aq. solution) was added at 0 °C until 
the pH of the aqueous layer was 12. The organic material was then extracted with Et2O (3 x 15 
mL). The combined organic layers were dried (MgSO4), filtered, and concentrated in vacuo. The 
unpurified product mixture was subjected to silica gel chromatography. 
 
 
2,6-Difluoro-N,N-dimethylaniline (2.13e)  
2,6-Difluoro-N,N-dimethylaniline was prepared on a 5.0 mmol scale using the General Procedure 
for the Methylation of Amines to afford a colorless liquid (560 mg, 71%). 1H NMR (500 MHz, 






 111  
 
tert-Butyl (4-hydroxy-2,6-dimethylphenyl)carbamate (S2): tert-Butyl (4-hydroxy-2,6-
dimethylphenyl)carbamate was prepared following a known procedure.2 To a solution of 4-amino-
3,5-dimethylphenol (S1, 10.0 g, 72.9 mmol) in THF (200 mL), was added di-tert-butyl dicarbonate 
(16.7 mL, 72.9 mmol) in a dropwise manner. The reaction mixture was allowed to stir at 22 °C for 
12 hours. Upon completion, the reaction mixture was concentrated and used without further 
purification. The spectroscopic data of S2 matched those reported by Nam.3  
tert-Butyl (4-methoxy-2,6-dimethylphenyl)carbamate (S3): tert-Butyl (4-methoxy-2,6-
dimethylphenyl)carbamate was prepared following a known procedure.4 Carbamate S2 (8.6 g, 36.4 
mmol) was dissolved in acetone (50 mL). To the solution was added potassium carbonate (6.1 g, 
54.6 mmol) and iodomethane (2.3 mL, 36.4 mmol), dropwise. The reaction mixture was heated to 
reflux and allowed to stir for 12 hours. Upon completion (monitored by TLC), the reaction was 
quenched with a saturated aqueous solution of KOH (50 mL), extracted with Et2O (3 x 50 mL), 
dried (MgSO4), and concentrated in vacuo. The unpurified product mixture was subjected to silica 
gel chromatography to afford a colorless solid (5.9 g, 65% yield). 1H NMR (400 MH , CDC 3)  
6.60 ( , 2H), 3.76 ( , 3H), 2.24 ( , 6H), 1.49 ( , 9H). 
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tert-Butyl (4-methoxy-2,6-dimethylphenyl)(methyl)carbamate (S4): tert-Butyl (4-methoxy-
2,6-dimethylphenyl)(methyl)carbamate was prepared following a known procedure.5 Carbamate 
S3 (8.5 g, 33.9 mmol) was dissolved in THF (30 mL). The solution was cooled to 0 °C, sodium 
hydride (60% oil dispersion, 1.6 g, 40.7 mmol) was added and allowed to stir for 10 minutes. 
Subsequently, iodomethane (2.5 mL, 40.7 mmol) was added dropwise at 0 °C. The reaction 
mixture was allowed to stir at 22 °C for 2 hours. Upon completion of the reaction (monitored by 
TLC), water was slowly added to the reaction mixture, extracted with EtOAc (3 x 20 mL), dried 
(MgSO4) and concentrated in vacuo. The unpurified product mixture was subjected to silica gel 
chromatography (5% EtOAc/hexanes) to give the product as a colorless solid (8.5 g, 95%). 1H 
NMR (400 MH , CDC 3)  6.596.57 (m, 2H), 3.773.75 (m, 3H), 3.04 (s, 3H), 2.17 2.15 (m, 
6H), 1.32 ( , 9H). 
 
General Procedure for the Removal of N-Boc Protection Group5 
 
To a solution of carbamate S3 or S4 in DCM (0.3 M), CF3COOH (5.0 equiv.) was added dropwise 
at 22 °C. The reaction mixture was allowed to stir for 1 hour. Upon completion of the reaction 
(monitored by TLC), aqueous NaHCO3 was added until the solution was alkaline, extracted with 
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DCM, dried (MgSO4), filtered, and concentrated. The unpurified product mixture was subjected 
to silica gel chromatography (5% EtOAc/hexanes) to give the product as a yellow liquid. The 
spectroscopic data of S5 matched those reported by Organ.6  
4-Methoxy-N,2,6-trimethylaniline (S6): 1H NMR (500 MHz, CDCl3)  6.58 ( , 2H), 3.74 ( , 
3H), 2.72 (s, 1H), 2.68 (s, 3H), 2.29 (s, 6H).  
 
General Procedure A for the Alkylation of Amine S6 
 
Amines 2.13g and 2.13i were prepared following a known procedure.7 To a solution of 4-methoxy-
N,2,6-trimethylaniline (S6) in THF (0.5 M) at 78 °C, was added n-BuLi (2.5 M, 1.0 equiv.), 
dropwise. The reaction mixture was allowed to stir for 10 minutes, whereupon the respective 
alkylhalide (1.0 equiv.) was added dropwise at 78 °C. The reaction mixture was then allowed to 
warm to 0 C. Upon completion of the reaction (monitored by TLC), the unpurified product 
mixture was concentrated in vacuo and purified by silica gel chromatography (2% EtOAc/hexanes).  
 
General Procedure B for the Alkylation of Amine S6 
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Amine 2.13j was prepared following a known procedure.8 To a solution of 4-methoxy-N,2,6-
trimethylaniline (S6) in DMF (1 M) at 0 C, was added sodium hydride (1.2 equiv.). The mixture 
was warmed to 60 C to stir for 15 minutes then allowed to cool to 0 C, whereupon the alkylhalide 
(1.2 equiv.) was added dropwise. The reaction mixture was warmed to 60 C and stirred for 12 
hours. The unpurified product mixture was then cooled to 0 C, water was added slowly, extracted 
with EtOAc, dried (MgSO4), concentrated in vacuo, and was purified by silica gel chromatography 




4-Methoxy-N,N,2,6-tetramethylaniline was synthesized using General Procedure A on a 10.0 
mmol scale to afford a colorless liquid (765 mg, 43%). 1H NMR (400 MHz, CDCl3)  6.54 ( , 




2,6-Difluoro-4-methoxy-N,N-dimethylaniline was prepared on a 5.0 mmol scale following the 
General Procedure for the Methylation of Amines to afford a colorless liquid (860 mg, 92%). 1H 
NMR (400 MHz, CDCl3)  6.46  6.37 (m, 2H), 3.74 (s, 3H), 2.81 (t, J = 1.3 Hz, 6H). 
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N-Benzyl-4-methoxy-N,2,6-trimethylaniline (2.13i) 
N-Benzyl-4-methoxy-N,2,6-trimethylaniline was synthesized using General Procedure A on a 3.1 
mmol scale to afford a colorless oil (408 mg, 52%). 1H NMR (500 MHz, CDCl3)  7.41  7.37 
(m, 2H), 7.33 (t, J = 7.5 Hz, 2H), 7.25 (m, 1H), 6.56 (s, 2H), 4.14 (s, 3H), 3.76 (s, 3H), 2.65 (s, 




N-(Cyclopropylmethyl)-4-methoxy-N,2,6-trimethylaniline was synthesized using General 
Procedure B on a 3.0 mmol scale to give the product as a colorless liquid (346 mg, 53%). 1H NMR 
(400 MHz, CDCl3)  6.54 ( , 2H), 3.75 ( , 3H), 2.81 ( , 5H), 2.27 ( , 6H), 0.95  0.82 (m, 1H), 
0.45  0.39 (m, 2H), 0.11  0.02 (m, 2H). 
 
Procedure for Synthesizing Amine 2.13k and 2.13o 
 
 116  
1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidine (2.13k) 
1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidine was prepared using a known procedure.9 A mixture 
of aniline S5 (1.0 g, 6.6 mmol), K2CO3 (2.7 g, 19.8 mmol), and 1,4-dibromobutane (1.2 mL, 9.9 
mmol) in acetonitrile (10 mL) was heated to reflux for 12 hours. Upon completion, the reaction 
mixture was quenched with H2O, extracted with EtOAc (3 x 25 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. The unpurified product mixture was subjected to silica gel chromatography 
(3% EtOAc/hexanes) to give the product as a yellow liquid (1.1 g, 82%). 1H NMR (500 MHz, 




1-(4-Methoxy-2,6-dimethylphenyl)-3-(methoxymethoxy)pyrrolidine was synthesized using a 
known procedure.10 1,4-dibromo-2-(methoxymethoxy)butane was prepared following the 
literature procedure using chloromethyl methyl ether.11 To a solution of aniline S5 (500 mg, 3.3 
mmol) in n-butanol (5 mL) was added 1,4-dibromo-2-(methoxymethoxy)butane (1.0 g, 3.63 mmol) 
and triethylamine (1.4 mL, 9.9 mmol). The solution was then allowed to heat at 80 °C for 14 hours. 
The reaction mixture was diluted with H2O (10 mL) and extracted with EtOAc (3 x 10 mL). The 
combined organic layer was washed with brine (1 x 20 mL), dried (MgSO4), and concentrated in 
vacuo. The unpurified product mixture was subjected to silica gel chromatography to afford S7 as 
a colorless liquid (263 mg, 30%). 1H NMR (500 MHz, CDCl3)  6.57 ( , 2H), 4.75  4.69 (m, 2H), 
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4.44  4.36 (m, 1H), 3.75 (s, 3H), 3.47  3.39 (m, 2H), 3.39 (s, 3H), 3.21  3.09 (m, 2H), 2.25 (s, 
6H), 2.24  2.12 (m, 1H), 2.11  2.00 (m, 1H).  
 
1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidin-3-ol (2.13l) 
1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidin-3-ol was obtained by the deprotection of the MOM 
protecting group of S7 following the literature procedure.12 To a solution of amine S7 (100 mg, 
0.4 mmol) in MeOH (1 mL) at 0 °C was added 10 M HCl (0.8 mL), dropwise. The reaction was 
allowed to stir for 12 hours at room temperature, whereupon the reaction mixture was concentrated 
in vacuo. The resulting residue was basified with saturated aqueous solution of K2CO3 until 
alkaline. The solution was then extracted with EtOAc (3 x 15 mL) and the combined organic layers 
were dried (MgSO4), filtered, and concentrated in vacuo. The unpurified product mixture was 
subjected to silica gel chromatography (15% EtOAc/hexanes) to afford the product as a colorless 
liquid (70 mg, 78%). 1H NMR (500 MHz, CDCl3)  6.52 ( , 2H), 4.45 ( , 1H), 3.70 ( , 3H), 3.43 
 3.39 (m, 1H), 3.11  3.06 (m, 1H), 3.01  2.97 (m, 1H), 2.20 (s, 6H), 2.18  2.10 (m, 1H), 1.94 




1-(4-Methoxy-2,6-dimethylphenyl)-2-methylpyrrolidine was prepared using a known procedure.13 
To a solution of aniline S5 (650 mg, 4.3 mmol) in DMF (5 mL) was added K2CO3 (654 mg, 4.7 
mmol) and 1,4-dibromopentane (0.6 mL, 4.7 mmol). The reaction mixture was stirred under reflux 
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for 12 hours. After cooling the reaction mixture to room temperature, the mixture was quenched 
with H2O (10 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were dried 
(MgSO4), filtered, and concentrated in vacuo. The unpurified product mixture was subjected to 
silica gel chromatography (2% EtOAc/hexanes) to afford 2.13n as a colorless liquid (593 mg, 
63%). 1H NMR (500 MHz, CDCl3)  6.57 ( , 2H), 3.75 ( , 3H), 3.59  3.51 (m, 1H), 3.27 (td, J = 
7.9, 5.0 Hz, 1H), 3.05 (td, J = 8.1, 6.2 Hz, 1H), 2.24 (s, 6H), 2.14  2.03 (m, 1H), 2.02  1.81 (m, 
2H), 1.59  1.46 (m, 1H), 0.91 (d, J = 6.0 Hz, 3H). 
 
 
1-(4-Methoxy-2,6-dimethylphenyl)piperidine (2.13o)  
1-(4-Methoxy-2,6-dimethylphenyl)piperidine was prepared using a known procedure9 on 1.0 
mmol scale, using 1,5-dibromopentane. The product was obtained as a white solid (165 mg, 75%). 
1H NMR (500 MHz, CDCl3)  6.52 ( , 2H), 3.74 ( , 3H), 2.98 ( , J = 5.1 Hz, 4H), 2.29 (s, 6H), 




Butyldimethylsilyl)oxy)-N-isopropyl-2-methylpropan-2-amine was prepared following a known 
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procedure.14 To a solution of 2-(isopropylamino)-2-methylpropan-1-ol15 (20 mmol), and 
triethylamine (26 mmol) in DCM (50 mL) at 0 °C was added tert-butyldimethylsilyl 
trifluoromethanesulfonate (26 mmol) dropwise. The reaction mixture was allowed to stir at 22 °C 
for 24 hours. Upon completion, the reaction was quenched with H2O (20 mL), the organic phase 
was separated and the aqueous phase was extracted with DCM (3 × 50 mL). The combined organic 
phases were dried (MgSO4), filtered, and concentrated in vacuo. The unpurified product mixture 
was subjected to silica gel chromatography (5% Et3N/hexanes) to afford S9 as a colorless oil (4.68 
g, 19.08 mmol, 95%). 1H NMR (400 MHz, CDCl3)  3.32 ( , 2H), 2.87 ( , 1H), 1.04 (d, J = 6.3 
Hz, 6H), 1.01 (s, 6H), 0.89 (s, 9H), 0.04 (s, 6H). 
1-((tert-Butyldimethylsilyl)oxy)-N-isopropyl-N,2-dimethylpropan-2-amine (2.13r)  
1-((tert-Butyldimethylsilyl)oxy)-N-isopropyl-N,2-dimethylpropan-2-amine was prepared 
following a known procedure.16 A 37% aq. solution of formaldehyde (1.6 g, 22 mmol) was added 
to a mixture of 1-((tert-butyldimethylsilyl)oxy)-N-isopropyl-2-methylpropan-2-amine S9 (4.43 g, 
18.1 mmol) and 88% formic acid (1.8 g, 39 mmol) at 0 °C. The reaction mixture was kept at 55 °C 
for 2 hours. Upon completion (monitored by TLC), the reaction was quenched with 8.0 M KOH 
(10 mL), extracted with Et2O (3 x 50 mL), dried (MgSO4), and concentrated in vacuo. The 
unpurified product mixture was subjected to silica gel chromatography (2% Et3N/hexanes) to 
afford 2.13r as a colorless oil (3.2 g, 68% yield). 1H NMR (600 MHz, CDCl3)  3.43 ( , 2H), 3.31 
(hept, J = 6.6 Hz, 1H), 2.21 (s, 3H), 1.05 (s, 6H), 1.00 (d, J = 6.8 Hz, 6H), 0.89 (s, 9H), 0.03 (s, 
6H). 
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(S)-N-Methyl-1-phenyl-N-((S)-1-phenylethyl)ethan-1-amine (2.13s)  
(S)-N-Methyl-1-phenyl-N-((S)-1-phenylethyl)ethan-1-amine was prepared following a known 
procedure.17 A 37% aq. solution of formaldehyde (17.6 mmol) was added to a mixture of (S)-
bis((S)-1-phenylethyl)amine S10 (1.0 g, 4.4 mmol) and 88% formic acid (8.8 mmol) at 0 °C. The 
reaction mixture was kept at 70 °C for 10 hours. Upon completion (monitored by TLC), the 
reaction was basified with 1 M NaOH, extracted with EtOAc (3 x 40 mL), dried (MgSO4), and 
concentrated in vacuo. The unpurified product mixture was subjected to silica gel chromatography 
(2% Et3N/hexanes) to afford 2.13s as a colorless oil (0.9 g, 94% yield). 1H NMR (500 MHz, CDCl3) 





1-(4-Methoxy-2,6-dimethylphenyl)-3,3-dimethylpyrrolidine was synthesized using the General 
Procedure for Cyclic Amine Substrates on a 5.9 mmol scale, using 1,4-dibromo-2,2-
dimethylbutane. The product was obtained as a colorless liquid (1.2 g, 88%). 1H NMR (600 MHz, 
CDCl3)  6.57 ( , 2H), 3.75 ( , 3H), 3.25 ( , J = 6.9 Hz, 2H), 2.90 (s, 2H), 2.24 (s, 6H), 1.73 (t, J 
= 6.9 Hz, 2H), 1.18 (s, 6H). 
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3-((tert-Butyldimethylsilyl)oxy)-1-(4-methoxy-2,6-dimethylphenyl)pyrrolidine (2.13u)  
3-((tert-Butyldimethylsilyl)oxy)-1-(4-methoxy-2,6-dimethylphenyl)pyrrolidine was synthesized 
using the General Procedure for Cyclic Amine Substrates on a 16.5 mmol scale, using tert-
butyl((1,4-dibromobutan-2-yl)oxy)dimethylsilane. The product was obtained as a colorless liquid 
(4.9 g, 89%). 1H NMR (500 MHz, CDCl3)  6.57 ( , 2H), 4.48 ( , J = 5.2, 3.5 Hz, 1H), 3.75 (s, 
3H), 3.41  3.35 (m, 2H), 3.08 (td, J = 7.8, 4.1 Hz, 1H), 3.02 (dd, J = 8.9, 3.1 Hz, 1H), 2.25 (s, 
6H), 2.12  2.04 (m, 1H), 1.92  1.85 (m, 1H), 0.90 (s, 9H), 0.09 (s, 3H), 0.07 (s, 3H). 
 
 
1-(4-Methoxy-2,6-dimethylphenyl)azepane (2.13v)  
1-(4-Methoxy-2,6-dimethylphenyl)azepane was prepared using the General Procedure for Cyclic 
Amine Substrates on 4.7 mmol scale, using 1,6-dibromohexane. The product was obtained as a 
colorless oil (371 mg, 34%). 1H NMR (500 MHz, CDCl3)  6.56 ( , 2H), 3.75 ( , 3H), 3.09  3.01 
(m, 4H), 2.29 (s, 6H), 1.70 (s, 8H). 
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(R)-N-Methyl-1-phenyl-N-((R)-1-phenylethyl)ethan-1-amine (2.13w) 
(R)-N-Methyl-1-phenyl-N-((R)-1-phenylethyl)ethan-1-amine (2.13w) was prepared following a 
known procedure.7 A 37% aq. solution of formaldehyde (4.4 mmol) was added to a mixture of (R)-
bis((R)-1-phenylethyl)amine S11 (0.54 g, 2.2 mmol) and 88% formic acid (8.8 mmol) at 0 °C. The 
reaction mixture was kept at 70 °C for 10 hours. Upon completion (monitored by TLC), the 
reaction was basified with 1 M NaOH, extracted with EtOAc (3 x 40 mL), dried (MgSO4), and 
concentrated in vacuo. The crude reaction mixture was purified by silica gel chromatography 
(hexanes/Et3N = 50:1) to afford a colorless oil (440 mg, 84% yield). 1H NMR (500 MHz, CDCl3) 





(R)-N,N-Dimethyl-3-phenyl-3-(o-tolyloxy)propan-1-amine was prepared following the General 
Procedure for Methylation of Amines on a 8.8 mmol scale. The unpurified product mixture was 
subjected to silica gel chromatography (4% MeOH/DCM) and was obtained as a colorless liquid 
(2.3 g, 97% yield). 1H NMR (500 MHz, CDCl3)  7.41  7.28 (m, 4H), 7.28  7.19 (m, 1H), 7.13 
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 7.06 (m, 1H), 6.99  6.90 (m, 1H), 6.76 (td, J = 7.4, 1.1 Hz, 1H), 6.62 (d, J = 8.2 Hz, 1H), 5.22 
(dd, J = 8.2, 4.7 Hz, 1H), 2.45 (t, J = 7.3 Hz, 2H), 2.31 (s, 3H), 2.23 (s, 6H), 2.21  2.12 (m, 1H), 




N,N-Dimethyl-3-phenyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine was prepared following 
the General Procedure for Methylation of Amines on a 7.3 mmol scale. The unpurified product 
mixture was subjected to silica gel chromatography (2% MeOH/DCM) and was obtained as a 
colorless liquid (2.2 g, 95% yield). 1H NMR (500 MHz, CDCl3)  7.42 (d, J = 8.6 Hz, 2H), 7.37 
 7.30 (m, 4H), 7.29  7.25 (m, 1H), 6.91 (d, J = 8.6 Hz, 2H), 5.28 (dd, J = 8.2, 5.0 Hz, 1H), 2.50 
 2.37 (m, 2H), 2.24 (s, 6H), 2.22  2.14 (m, 1H), 1.98 (tt, J = 13.9, 5.7 Hz, 1H).  
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Preparation of Silicon Enolate Substrates 
Table S2.2. Silicon Enolate Substrates  
 
Silicon enolate molecule 2.11a was obtained from commercial sources. Substrates 2.11b,19 
2.11c,20 2.11d,20 2.11e,20 2.11f,21 and 2.11g22 were prepared accordingly to the procedures 
previously reported in the literatures.  
 
General Procedure for Preparation of Silicon Enolates 
 
T  a i  f dii a i e (1.25 e i .) i  THF, -B Li (2.5 M i  he a e , 1.2 e i .) a  
added d i e a  78 °C and the solution was stirred for 15 minutes. A solution of ester in THF 
a  added d i e a  78 °C and the solution was stirred for 1 hour. Subsequently, TMSCl (1.2 
e i .) a  added  a  78 °C, the reaction mixture was warmed up to 22 °C a d a  i ed 
i  he c e i  f he eac i  ( i ed b  1H NMR). The eac i  i e a  di ed 
i h ice-c d e a e a d he e i g e i  a  fi e ed h gh a ad f Ce i e. The fi a e 
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a  c ce a ed de  ac  a d he e i g c de i e a  ified b  di i a i  de  
ed ced e e  gi e he c e di g i ic  e a e. 
 
 
((1-Metho prop-1-en-1- l)o )trimeth lsilane (2.11b)  
((1-Me h -1-e -1- ) ) i e h i a e a  he i ed f i g he ge e a  ced e 
a  20.0  ca e a d a  ke  a  78 °C until the reaction was c e e. The d c  a  
b ai ed a  c e  i id (E/Z = 7:1). The NMR ec c ic da a e e i  ag ee e  i h h e 
e ed i  he i e a e.19 
 
 
(C clopent lidene(metho )metho )trimeth lsilane (2.11c)  
(C c e ide e( e h ) e h ) i e h i a e a  he i ed f i g he ge e a  
ced e  7.7  ca e. The d c  a  b ai ed a  c e  i id. The NMR 
ec c ic da a e e i  ag ee e  i h h e e ed i  he i e a e.20  
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(C clohe lidene(metho )metho )trimeth lsilane (2.11d) 
(C c he ide e( e h ) e h ) i e h i a e a  he i ed f i g he ge e a  
ced e a  10.0  ca e. The d c  a  b ai ed a  c e  i id. The NMR 
ec c ic da a e e i  ag ee e  i h h e e ed i  he i e a e.20 
 
 
(C clobut lidene(metho )metho )trimeth lsilane (2.11e)  
(C c b ide e( e h ) e h ) i e h i a e a  he i ed f i g he ge e a  
ced e a  8.7  ca e. The d c  a  b ai ed a  c e  i id (OSi/CSi=6:1). The 
NMR ec c ic da a e e i  ag ee e  i h h e e ed i  he i e a e.20 
 
 
Trimeth l((3-meth l-4,5-dih drofuran-2- l)o )silane (2.11f) 
T i e h ((3- e h -4,5-dih d f a -2- ) ) i a e a  he i ed f i g he ge e a  
ced e a  10.0  ca e. The d c  a  b ai ed a  c e  i id. The NMR 
ec c ic da a e e i  ag ee e  i h h e e ed i  he i e a e.22 
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Trimeth l((1-(meth lthio)vin l)o )silane (2.11g) 
T i e h ((1-( e h hi ) i ) ) i a e a  he i ed f i g he ge e a  ced e a  
10.0  ca e a d a  ke  a  78 °C until the reaction was complete (1 hour). The filtrate was 
c ce a ed de  ac  a d he e i g c de i  a  ified b  di i a i  de  ed ced 
e e (40 C, 40 Hg),  gi e i e h ((1-( e h hi ) i ) ) i a e a  c e  i id. 
1H NMR (400 MH , CDC 3)  4.39 (d, J = 2.2 H , 1H), 4.22 (d, J = 2.2 H , 1H), 2.22 ( , 3H), 
0.26 ( , 9H). 
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Preparation of D,E-Unsaturated Substrates 
Table S2.3. D,E-Unsaturated Substrates. 
 
D,E-Unsaturated molecules 2.20a, 2.20b, and 2.20e2.20h were obtained from commercial 
sources. Substrates 2.20c,14 2.20d,15 2.23a,16 2.23b,17 2.23c,17 2.23d,16 2.23e-(S),16 and 2.23e-(R)16 
were prepared accordingly to the procedures previously reported in the literatures.  
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A2. Optimization Studies 
B(C6F5)3-Catalyzed Mannich-type Reaction 
Experimental Procedure for the Optimization of Solvent (Table S2.4) 
To a 15 mL oven-dried sealed tube equipped with a magnetic stir bar was added amine 2.13k (0.1 
mmol), B(C6F5)3 (0.01 mmol), ((1-methoxy-2-methylprop-1-en-1-yl)oxy)trimethylsilane 2.11a 
(0.2 mmol), and solvent (0.25 mL) under a nitrogen atmosphere. The reaction mixture was stirred 
for 12 hours at 22 °C. Upon completion, the reaction mixture was concentrated in vacuo. The 
product yield was determined by the 1H NMR analysis of the unpurified product mixtures using 
mesitylene as the internal standard. The unpurified product mixture was subjected to PTLC using 
20% EtOAc in hexanes as the eluent to give 2.14k.  
 
Table S2.4. Evaluation of Solvents for Cyclic Amine Substrate 2.14k 
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Reaction of Different N,N-Dialkylanilines with Silicon Enolate 2.11a (Table S2.5) 
To a 15 mL oven-dried sealed tube equipped with a magnetic stir bar was added N,N-dialkylaniline 
(0.2 mmol), B(C6F5)3 (0.02 mmol), ((1-methoxy-2-methylprop-1-en-1-yl)oxy)trimethylsilane 
2.11a (0.4 mmol), and DCE (0.5 mL) under a nitrogen atmosphere. The reaction mixture was 
allowed to stir for 12 hours at 22 °C. Upon completion, the reaction mixture was concentrated in 
vacuo. The 1H NMR analysis of the unpurified product mixtures revealed that there was no product 
formation and >90% of the starting amine was observed using mesitylene as the internal standard.  
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Reaction of N,N-Dimethylaniline with Different Silicon Enolates (Table S2.6) 
To a 15 mL oven-dried sealed tube equipped with a magnetic stir bar was added N,N-methylaniline 
(0.2 mmol), B(C6F5)3 (0.02 mmol), silicon enolate 2 (0.4 mmol), and benzene (0.5 mL) under a 
nitrogen atmosphere. The reaction mixture was allowed to stir for 12 hours at 22 °C. Upon 
completion, the reaction mixture was concentrated in vacuo. The 1H NMR analysis of the 
unpurified product mixtures revealed that there was no product formation and >90% of 2.13g was 
observed using mesitylene as the internal standard. 
 
Table S2.6. Evaluation of Silicon Enolates 
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Experimental Procedure for the Optimization of the Amine Protecting Group (Table S2.7) 
An oven-dried sealed tube equipped with a magnetic stir bar was used. Amine 2.13 (0.20 mmol), 
methyl acrylate 2.20a (0.24 mmol), B(C6F5)3 (0.01 mmol), and benzene (0.2 mL) were added to 
the reaction vessel under nitrogen atmosphere. The reaction mixture was stirred at 22 °C for 12 h. 
Upon completion, the reaction mixture was concentrated in vacuo. The product yield was 
determined by the 1H NMR analysis of the unpurified product mixture using mesitylene as the 
internal standard. 
Table S2.7. Evaluation of Amine Protecting Group. 
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Experimental Procedure for the Optimization of the 1,2,2,6,6-Pentamethylpiperidine 
Substrate (Table S2.8) 
An oven-dried sealed tube equipped with a magnetic stir bar was used. Amine 2.13p (0.20 mmol), 
benzyl acrylate 2.20b (0.24 mmol), B(C6F5)3, and solvent (0.4 mL) were added to the reaction 
vessel under nitrogen atmosphere. The reaction mixture was stirred under nitrogen atmosphere for 
12 h. Upon completion, the reaction mixture was concentrated in vacuo. The product yield was 
determined by the 1H NMR analysis of the unpurified product mixture using mesitylene as the 
internal standard. 
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Experimental Procedure for the Optimization of the Lewis Acid Co-Catalyst (Table S2.9) 
An oven-dried sealed tube equipped with a magnetic stir bar was used. 1-(4-Methoxy-2,6-
dimethylphenyl)pyrrolidine 2.13k (0.10 mmol), 3-acryloyloxazolidin-2-one 2.23a (0.12 mmol), 
B(C6F5)3 (0.01 mmol), Lewis acid co-catalyst (0.01 mmol) and DCM (0.3 mL) were added to the 
reaction vessel under nitrogen atmosphere. The reaction mixture was stirred at 22 °C for 12 h. 
Upon completion, the reaction mixture was filtered through silica gel and concentrated in vacuo. 
The product yield was determined by the 1H NMR analysis of the unpurified product mixture using 
mesitylene as the internal standard. 
Table S2.9. Evaluation of Co-Catalyst. 
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Experimental Procedure for the Optimization of the Metal with L3 (Table S2.10) 
An oven-dried sealed tube equipped with a magnetic stir bar was used. To this tube were added 
Lewis acid co-catalyst (0.01 mmol), 2,6-bis((R)-4-phenyl-4,5-dihydrooxazol-2-yl)pyridine L3 
(0.012 mmol), and DCM (0.2 mL) under nitrogen atmosphere. The mixture was stirred for 20 min 
at 22 °C. Subsequently, 3-acryloyloxazolidin-2-one 2.23a (0.12 mmol), 1-(4-methoxy-2,6-
dimethylphenyl)pyrrolidine 2.13k (0.10 mmol), B(C6F5)3 (0.01 mmol) and DCM (0.1 mL) were 
added to the reaction vessel, and the resulting mixture was stirred at 22 °C for 12 h. Upon 
completion, the reaction mixture was filtered through a plug of silica gel and concentrated in vacuo. 
The product yield and anti:syn ratio were determined by the 1H NMR analysis of the unpurified 
product mixture using mesitylene as the internal standard. The Mannich product was purified and 
isolated by preparative TLC (4:1 hexanes/EtOAc). The er value of each diastereomer was 
determined by HPLC analysis of the isolated product.  
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Table S2.10. Evaluation of Metal with L3. 
 
 137  
Experimental Procedure for the Optimization of PyBOX Ligand (Table S2.11) 
An oven-dried sealed tube equipped with a magnetic stir bar was used. To this tube were added 
Mg(OTf)2 (0.01 mmol), ligand (0.012 mmol), DCM (0.2 mL) under nitrogen atmosphere. The 
mixture was stirred for 20 min at 22 °C. Subsequently, 3-acryloyl-4,4-dimethyloxazolidin-2-one 
2r (0.12 mmol), 1-(4-methoxy-2,6-dimethylphenyl)pyrrolidine 1a (0.10 mmol), B(C6F5)3 (0.01 
mmol), and DCM (0.1 mL) were added to the reaction vessel, and the resulting mixture was stirred 
at 22 °C for 12 h. Upon completion, the reaction mixture was filtered through a pad of silica gel 
and concentrated in vacuo. The product yield and anti:syn ratio were determined by the 1H NMR 
analysis of the unpurified product mixture using mesitylene as the internal standard. The Mannich 
product was purified and isolated by preparative TLC (4:1 hexanes/EtOAc). The er values of each 
diastereomer was determined by HPLC analysis of the isolated product.  
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Table S2.11. Evaluation of Chiral Ligand. 
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A3. General Procedures 
General Procedure for the (F5C6)3B-Catalyzed Mannich Reaction Using Silicon Enolate 
(Tables 2.2-2.5) 
 
An oven-dried sealed tube equipped with a magnetic stir bar was used. To this tube were added 
amine (0.2 mmol), B(C6F5)3 (0.01 mmol or 0.02 mmol), silicon enolate 2.11 (0.4 mmol), and 
solvent (0.5 mL) under nitrogen atmosphere. The reaction mixture was allowed to stir for 12 hours 
at 22 °C. Upon completion, the reaction mixture was diluted with DCM, concentrated in vacuo 
and purified by silica gel column chromatography, typically using ethyl ether in hexanes as the 
eluent. 
 
Procedure for a 1.0 mmol Scale Reaction (Scheme 2.7) 
An oven-dried sealed tube equipped with a magnetic stir bar was used. To this tube were added 
amine 2.13k (0.2 g, 1.0 mmol), B(C6F5)3 (26 mg, 0.05 mmol), ((1-methoxy-2-methylprop-1-en-1-
yl)oxy)trimethylsilane 2.11a (0.3 g, 2.0 mmol), and THF (2.5 mL) under nitrogen atmosphere. The 
reaction mixture was allowed to stir for 12 hours at 22 °C. The unpurified product mixture was 
subjected to silica gel chromatography (3% Et2O/hexanes) to afford 2.14k as a colorless liquid 
(0.3 g, 97%). 
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Procedure for Deprotection of N-Aryl Group 
 
The deprotection of N-aryl group was performed following the literature procedure.23 To a solution 
of 2.14k (61 mg, 0.2 mmol) in MeCN (2.0 mL) at 0 °C was added a solution of ceric ammonium 
nitrate (548 mg, 1.0 mmol) in H2O (3.3 mL), dropwise. The reaction mixture was allowed to stir 
at 0 °C for 1 hour, whereupon the mixture was cooled to 22 °C and stirred for 3 hours. Upon 
completion (monitored by TLC), the reaction mixture was quenched with 1.0 M NaOH until the 
pH of the solution was 10; and the crude product was extracted with DCM (3 x 15 mL). The 
combined organic layers were concentrated in vacuo, whereupon the resulting oil was acidified 
with 4.0 N HCl (4 mL) and extracted again with DCM (3 x 5 mL). The aqueous layer was then 
concentrated in vacuo to obtain a solid residue. To the unpurified product mixture was added 
DCM, and the resulting suspension was filtered through Celite and concentrated to afford a brown 
residue which was characterized as the HCl salt of 2.19 (40 mg, 97%). Upon treatment of the salt 
with K2CO3 (aqueous) and extraction with DCM (3 x 10 mL), the free base 2.19 was obtained as 
a brown oil (27 mg, 79% yield from 2.19 HCl). The spectroscopic data of 2.19 matched those 
reported by Sekiya.24    
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General Procedures for the Stereoselective Coupling of N-Alkylamines and DE-Unsaturated 
Molecules 
General Procedure for (F5C6)3B-Catalyzed Racemic Mannich Reactions  
 
To a 15 mL oven-dried sealed tube was added amine 2.13 (0.2 mmol, 1 equiv.), D,E-unsaturated 
compound 2.20 (0.24 mmol, 1.2 equiv.), a catalytic amount of B(C6F5)3 and solvent under nitrogen 
atmosphere. The reaction mixture was stirred at either 22 °C or 70 °C for 12 to 48 hours. Upon 
completion, the reaction mixture was diluted with EtOAc, concentrated in vacuo and purified by 
silica gel column chromatography. 
 
General Procedure for Stereoselective Mannich Reactions  
 
An oven-dried sealed tube equipped with a magnetic stir bar was used. To this tube were added 
Mg(OTf)2 (0.02 mmol), ligand L4 (0.024 mmol), DCM (0.2 mL) under nitrogen atmosphere. The 
mixture was stirred for 20 min at 22 °C, then oxazolidinone substrate 2.23 (0.30 mmol), 1-(4-
methoxy-2,6-dimethylphenyl)pyrrolidine 2.13k (0.20 mmol), B(C6F5)3 (0.02 mmol), and DCM 
(0.1 mL) were added to the vessel. The reaction mixture was stirred at 22 °C for 12 h. Upon 
completion, the crude mixture was filtered through a pad of silica gel and concentrated in vacuo. 
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The Mannich product was purified and isolated by silica gel column chromatography. The anti:syn 
ratio was determined by 1H NMR analysis of the crude reaction mixture. The er values of each 
diastereomer was determined by HPLC analysis of the isolated product.  
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Procedure for Large Scale Reaction 
We carried out the following studies in order to determine the absolute configuration of 
enantioenriched products 2.24a2.24d, 2.24e-(S), and 2.24e-(R) and the relative configuration of 
products 2.21a to 2.21p and 2.24a to 2.24l. We first obtained product 2.24e-(R) in 1.68 g by the 
following procedure. 
 
To a 35 mL oven-dried sealed tube was added Mg(OTf)2 (0.25 mmol), ligand L4 (0.30 mmol), 
DCM (10 mL) under nitrogen atmosphere. The mixture was stirred for 30 min at 22 °C, then (R)-
3-acryloyl-4-phenyloxazolidin-2-one 2.24e-(R) (1.3 g, 6.0 mmol), 1-(4-methoxy-2,6-
dimethylphenyl)pyrrolidine 2.13k (1.02 g, 5.0 mmol), B(C6F5)3 (0.25 mmol), and DCM (5.0 mL) 
were added to the vessel. The reaction mixture was stirred at 22 °C for 48 h. Upon completion, the 
solvent was removed in vacuo. The anti:syn ratio was determined to be 87:13 by 1H NMR analysis 
of the crude reaction mixture. Purification by silica gel column chromatography using 4:1 
hexanes:Et2O gave the product as a colorless solid as a mixture of diastereomers (1.68 g, 78% 
yield). Further purification was carried out by silica gel column chromatography using 4:1 
hexanes:Et2O to obtain the major diastereomer in 1.41 g as a colorless oil. 
We then subjected 2.24e-(R) to the following derivatization studies which yielded 2.252.28. 
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Procedure for Determination of the Absolute Configuration 





yl)propanamide (2.28) was synthesized following a known procedure.21 A solution of 2.24e-(R)-
anti (590 mg, 1.4 mmol) in MeOH (3.5 mL) was chilled to 0 °C, whereupon NaOMe (827 mg, 
15.3 mmol) was added portionwise. The reaction was allowed to stir for 1 h, whereupon the 
reaction was quenched with aq. NH4Cl (3 mL). The aqueous layer was extracted with EtOAc (3 x 
5 mL). The combined organic layers were dried (MgSO4), filtered, and concentrated in vacuo. The 
crude product was purified by silica gel chromatography (3:1 hexanes:EtOAc) to afford 2.28 as a 
crystalline solid (393 mg, 97% yield). The solid material was recrystallized in 19:1 
hexanes:isopropanol to obtain a crystal for X-ray crystallography. The X-ray crystallographic 
analysis revealed that the absolute configuration of 2.28 is (R,R,R), see SI Section 7. The Mannich 
product 2.24e-(R)-syn was also subjected to these reaction conditions, but was obtained as a 
colorless oil. 
 
1H NMR (600 MHz, CDCl3)  7.32 (t, J = 7.5 Hz, 2H), 7.29  7.25 (m, 1H), 7.20  7.17 (m, 2H), 
6.59 (d, J = 3.0 Hz, 1H), 6.56 (d, J = 3.1 Hz, 1H), 5.89 (d, J = 6.3 Hz, 1H), 4.74 (td, J = 6.0, 3.6 
Hz, 1H), 3.92 (dt, J = 7.1, 5.4 Hz, 1H), 3.75 (s, 3H), 3.63 (tdd, J = 10.7, 8.9, 7.2, 3.6 Hz, 2H), 3.26 
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(dt, J = 8.4, 5.9 Hz, 1H), 2.98 (q, J = 7.6 Hz, 1H), 2.89 (d, J = 6.1 Hz, 1H), 2.29 (s, 3H), 2.25 (s, 
3H), 2.17 (qd, J = 6.9, 5.1 Hz, 1H), 2.07 (dq, J = 11.7, 7.5, 7.1 Hz, 1H), 1.93  1.83 (m, 3H), 1.13 
(d, J = 7.0 Hz, 3H); 13C NMR (151 MHz, CDCl3)  178.9, 159.4, 142.8, 141.8, 141.6, 140.4, 131.5, 
130.5, 129.3, 117.3, 115.7, 69.5, 65.5, 59.2, 57.9, 55.3, 49.1, 31.6, 27.8, 22.3, 22.2, 16.7; IR (neat) 
3383, 3305, 2952, 1644, 1602, 1601, 1512, 1492, 1466, 1261, 1154,1068, 700 cm-1; HRMS 
(DART) m/z Calcd for C26H33N2O4 (MH+): 274.1596; found: 274.1588. 
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Procedures for the Derivatization of Enantioenriched Mannich Products 
Compounds 2.24e-(R)-anti, 2.24e-(R)-syn, and 2.24b could be converted into the corresponding 
methyl esters (2.25-anti or 2.25-syn).  
 
 
(R)-2-((R)-1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidin-2-yl)propanoic acid (S12) 
(R)-2-((R)-1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidin-2-yl)propanoic acid was prepared by 
following a known procedure.19 To a solution of Mannich product 2.24b-(R)-anti (169 mg, 0.4 
mmol) in THF:H2O (3:1, 4.8 mL) at 0 °C was added H2O2 (30% v/v, 0.16 mL, 1.6 mmol) and 2.0 
M LiOH (0.28 mL, 0.56 mmol), dropwise. The mixture was stirred at 22 °C for 5 h, whereupon 
the reaction was quenched with NaHSO3. The crude mixture was then concentrated in vacuo, then 
diluted with EtOAc (10 mL), H2O (10 mL), and 1.0 M NaOH (5 mL). The organic layer was 
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separated and the aqueous layer was extracted with EtOAc (3 x 15 mL). Subsequently, the aqueous 
layer was acidified with 6.0 M HCl (3 mL) and extracted with EtOAc (3 x 15 mL). The combined 
organic layers were washed with brine (20 mL), dried (MgSO4), filtered. and concentrated in vacuo 
to afford S12 as a colorless solid (102 mg, 92%) which was used without further purification. 1H 
NMR (600 MHz, CDCl3)  6.66  6.40 (m, 1H), 3.92 (dt, J = 9.0, 4.9 Hz, 1H), 3.71 (s, 3H), 3.34 
(td, J = 7.9, 3.9 Hz, 1H), 3.02 (q, J = 8.1 Hz, 1H), 2.39 (m, 1H), 2.29 (s, 3H), 2.25 (s, 3H), 2.16  
2.06 (m, 1H), 2.02  1.89 (m, 1H), 1.87  1.78 (m, 1H), 1.12 (d, J = 7.1 Hz, 3H). 
 
Methyl (R)-2-((R)-1-(4-methoxy-2,6-dimethylphenyl)pyrrolidin-2-yl)propanoate (2.25-anti) 
Methyl (R)-2-((R)-1-(4-methoxy-2,6-dimethylphenyl)pyrrolidin-2-yl)propanoate was prepared by 
following a known procedure.22 Acetyl chloride (0.14 mL, 2.0 mmol) was added dropwise to a 
solution of propanoic acid S12 (111 mg, 0.4 mmol) in MeOH (1.8 mL). The reaction mixture was 
heated at reflux for 12 h. The reaction mixture was concentrated in vacuo, then saturated K2CO3 
(6 mL) was added at 0 °C. The aqueous layer was extracted with DCM (3 x 10 mL) and the 
combined organic layers were washed with brine (15 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. The crude product was purified by silica gel column chromatography (50:1 
Hexanes: Et2O) to afford 2.25 as a colorless oil (110 mg, 94% yield). HPLC (Chiralpak IC then 
Chiralcel OJ-H; 1%/ 99% hexane/isopropanol, 0.5 mL/min; 2.25-anti: tr = 33.1 min (major), 42.1 
min (minor); >99:1 er. 
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2.24e-(R)-syn and 2.24b were subjected to analogous conditions to afford 2.25-syn and 2.25-
anti.23  
2.24b was carried through as a mixture of diastereomers. 
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2.25-syn from 2.24e-(R)-syn: HPLC (Chiralpak IC then Chiralcel OJ-H; 1%/ 99% 
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Product 2.25, derived from 2.24b, was isolated as a mixture of diastereomers. The following is the 
HPLC trace for the mixture of 2.25-anti and 2.25-syn. 
 
2.25-anti (from 2.24b): HPLC (Chiralpak IC then Chiralcel OJ-H; 1%/ 99% hexanes/isopropanol, 
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2.25-syn (from 2.24b): HPLC (Chiralpak IC then Chiralcel OJ-H; 1%/ 99% hexanes/isopropanol, 











By comparing the HPLC traces of 2.25-anti and 2.25-syn prepared as above, we determined that 
the absolute configuration of 2.24b-anti is (R,R). 
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Procedure for the Removal of the Chiral Auxiliary to obtain Amino Alcohol 2.27 
 
(R)-2-((R)-1-(4-Mmethoxy-2,6-dimethylphenyl)pyrrolidin-2-yl)propan-1-ol (2.27) 
(R)-2-((R)-1-(4-Mmethoxy-2,6-dimethylphenyl)pyrrolidin-2-yl)propan-1-ol (2.27) was prepared 
using a known procedure.24 A solution of LiBH4 in THF (2M, 0.15 mL, 0.3 mmol) was added to a 
solution of imide 2.24e-(R)-anti (85 mg, 0.2 mmol) in Et2O (2.0 mL) under N2 atmosphere at 20 
°C. Subsequently, MeOH (0.3 mmol) was added dropwise at 20 °C. The reaction mixture was 
then allowed to stir at 0 °C for 1 h. Upon completion of the reaction (monitored by TLC), aq. 
NaHCO3 (2 mL) was added slowly and was extracted with EtOAc (3 x 5 mL). The combined 
organic layers were dried (MgSO4), filtered, and concentrated in vacuo. The crude product was 
purified by silica gel column chromatography (3:1 Hexanes: Et2O) to afford 2.27as a colorless 
solid (48 mg, 91% yield).  
 
1H NMR (600 MHz, CDCl3)  6.58 ( , 1H), 6.53 ( , 1H), 3.74 ( , 3H), 3.70  3.59 (m, 1H), 3.49 
 3.33 (m, 2H), 3.27 (ddd, J = 11.7, 5.7, 3.6 Hz, 1H), 2.98 (q, J = 7.8 Hz, 1H), 2.30 (s, 3H), 2.24 
(s, 3H), 2.01  1.84 (m, 3H), 1.82  1.67 (m, 1H), 1.57 (dt, J = 6.5, 3.3 Hz, 1H), 1.30 (s, 1H), 0.90 
(dd, J = 6.9, 1.1 Hz, 3H); 13C NMR (151 MHz, CDCl3)  156.4, 140.3, 138.6, 137.7, 114.7, 113.2, 
66.7, 62.1, 55.1, 52.4, 40.2, 27.3, 25.5, 19.6, 19.3, 12.2; HPLC (Chiralpak AD-H; 2.5%/ 98.5% 
hexane/isopropanol, 0.5 mL/min; 2.27: tr = 29.6 min (minor), 33.4 min (major); >99:1 er. 







Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
  10  15.410 BB    0.3000 1.07135e4   548.13867  20.7717
  11  28.438 BV E  0.5751 1102.76941   29.03877   2.1381
  12  29.632 VV R  0.6526 1.87236e4   439.88187  36.3019
  13  31.593 VV E  0.6780 1028.70410   23.53091   1.9945
  14  33.382 VB    0.7419 1.84833e4   383.79434  35.8361
Totals :                  5.15774e4  1498.56132
Signal 2: DAD1 B, Sig=210,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  29.632 VV R  0.6872 1.14651e5  2246.79272  52.9755
   2  33.383 VB    0.7791 1.01772e5  2008.70105  47.0245
Totals :                  2.16424e5  4255.49377
Signal 3: DAD1 C, Sig=214,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  29.632 MM    0.7036 8.18790e4  1939.54919  49.4199
   2  33.383 MM    0.8083 8.38011e4  1727.90881  50.5801
Totals :                  1.65680e5  3667.45801
Signal 4: DAD1 D, Sig=230,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  29.632 MM    0.7208 3.81312e4   881.72113  50.6034
   2  33.383 MM    0.8097 3.72217e4   766.20929  49.3966
Totals :                  7.53529e4  1647.93042
Signal 5: DAD1 E, Sig=260,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   5.798 BV    0.1588   41.64840    3.83184   0.0921
   2   6.120 VB    0.1819   42.12455    3.36954   0.0932
   3   6.758 BB    0.2791  557.22943   27.64653   1.2328
Data File C:\Chem32\1\Data\JOE 2018-01-09 19-25-54\003-0201.D
Sample Name: pyrrolidine_AlcoholDeriv_Rac_AD-H
Wasa_LC1 1/26/2018 10:29:17 AM SYSTEM Page 3 of 4
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
  18  49.443 BB    0.8697  258.37952    3.77879   0.3936
  19  52.797 BB    0.4895   89.17640    2.50419   0.1358
  20  54.045 BB    0.3999   54.88164    2.07983   0.0836
  21  55.766 BB    0.5186  128.90715    3.66269   0.1964
  22  57.527 BB    0.9116  372.85184    5.57969   0.5679
Totals :                  6.56503e4  1539.41300
Signal 4: DAD1 D, Sig=230,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  33.561 MM    0.8663 1.88582e4   362.82062 100.0000
Totals :                  1.88582e4   362.82062
Signal 5: DAD1 E, Sig=260,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   5.721 BV    0.5201  403.45050    9.68353   3.7994
   2   6.140 VV    0.1566  174.48851   15.83574   1.6432
   3   6.541 VB    0.3923 1330.09717   45.07400  12.5259
   4  10.630 BB    0.2922  225.53136   11.23590   2.1239
   5  33.561 BB    0.7965 8485.21387  164.86253  79.9076
Totals :                  1.06188e4   246.69170
=====================================================================
                          *** End of Report ***
Data File C:\Chem32\1\Data\JOE 2018-01-10 10-23-59\051-0101.D
Sample Name: pyrrolidine_AlcoholDeriv_ee_AD-H
Wasa_LC1 1/26/2018 10:31:22 AM SYSTEM Page 4 of 4
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Procedure for the Removal of the para-Methoxyphenyl Group 
 
(R)-2-((R)-Pyrrolidin-2-yl)propanoic acid (2.26) 
(R)-2-((R)-Pyrrolidin-2-yl)propanoic acid (2.26) was prepared using a known procedure.25 A 
solution of ceric ammonium nitrate (CAN, 548 mg, 1.0 mmol) in H2O (3.3 mL, 0.30 M to CAN) 
was added to a solution of propanoic acid S13 (55.5 mg, 0.20 mmol) in MeCN (2.0 mL) at 0 °C 
under N2 atmosphere. The mixture was stirred at 0 °C for 1 h, whereupon the reaction was diluted 
with EtOAc (2.0 mL) then concentrated in vacuo to remove volatile side products and solvent 
(H2O was evaporated by azeotropic distillation with toluene). The solid residue was then filtered 
over a pad of Celite using EtOAc as the eluent. The filtrate was concentrated to afford 2.26 as a 
solid (19.9 mg, 70% yield). 1H NMR (500 MHz, D2O)  3.75 ( , J = 9.1 Hz, 1H), 3.36 (dt, J = 
19.6, 11.4 Hz, 2H), 2.90 (ddt, J = 13.5, 8.5, 4.1 Hz, 1H), 2.33 (td, J = 7.6, 7.1, 3.8 Hz, 1H), 2.17  
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Experimental Procedure for the Control Experiments with (R)-3-acryloyl-4-
phenyloxazolidin-2-one 
An oven-dried sealed tube equipped with a magnetic stir bar was used. Amine 2.13k (0.20 mmol), 
(R)-3-acryloyl-4-phenyloxazolidin-2-one 2.23e-(R) (0.24 mmol), B(C6F5)3 (0.02 mmol), and 
DCM (0.3 mL) were added under nitrogen atmosphere. The reaction mixture was stirred at 22 °C 
for 12 h. Upon completion, the reaction mixture was concentrated in vacuo. The product yield was 
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A4. Density Functional Theory (DFT) Calculations 
DFT computations26 were performed with the Gaussian 09 suite of programs.27 Geometries were 
optimized with the M06L28 functional and the def2-SVP basis set29 in conjunction with the 
corresponding Coulomb fitting basis set to speed up calculations (denoted DF; density fitting).30 
An ultrafine integration grid was applied. The effect of a polar reaction medium (dichloromethane, 
DCM) was approximated by means of an integral equation formalism variant of the polarizable 
continuum model (IEFPCM).31 Stationary points were probed through vibrational analysis and 
Gibbs free energy corrections were performed under standard conditions (298.15 K, 1.0 atm). 
Additionally, we probed the performance of various density functionals through single-point 
energy calculations at the geometries optimized with the level described above by means of the 
SMD32 solvation model with DCM as solvent and the larger def2-TZVPP basis set.29 Since the 
correct density functional is not known we tested several state of the art approaches that have been 
developed over the past decade, all of which are have been designed to account for dispersion:26,33 
M06L,28 M06,28 MN15,26i ZB97XD34 and PBE0-D3BJ.26b,35 Additionally, results with the 
corresponding parent functionals ZB97X and PBE026b are included. In the manuscript we only 
report the M06L/def2-TZVPPDCM(SMD)//M06L/DF-def2-SVPDCM(IEFPCM) energies and the 
comparison of other density functionals is provided in Figures S4-S12. Images of computed 
geometries are shown in Figures S1S3 and a file for convenient viewing of computed geometries 
i h he g a  Me c  3.3 i  a e ded a  e a a e c di a e .  file.36 
 
Challenges and simplifications 
(a) All transition state calculations have been carried out in absence of the triflate counterions, 
rendering the overall charge of the transition state structures +2 (Figure S1). Furthermore, 
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the solvent has been approximated by a contiuum and it is assumed that the M06L/DF-
def2-SVPDCM(IEFPCM) optimized structures are an appropriate reflection of the geometry in 
solution. Nonetheless, the exact solution geometry is likely unknown. 
(b) Initial scans of the potential energy surface have revealed a very flat region for CC 
distances between 2.2 and 2.6 Å and attempts to locate a transition state were unsuccessful 
in most instances. We hence decided to perform a number of constrained optimizations in 
0.030.10 Å intervals (Figures S4S8), including the assessment of thermal corrections to 
the free energy (Gcorr; see Figure S4c). The largest energy values from Figures S4S8 have 
been used in the comparsion of various density functionals (Figures S9S12). 
(c) The stereochemical model under investigation resembles molecular balance experiments 
designed to assess the contribution of dispersion interactions in solution.37,38 The challenge 
here lies in the accurate comparison of two kinds of molecular assemblies: that is, in some 
structures dispersion is a dominant contributor to the interaction energy (for example,  
and ; Figure S1), whereas dispersion interactions are much less pronounced in alternative 
geometries (for example, XI and XII; Figure S1). 
(d) Accurate electronic energies are likely not sufficient in assessing the relative energies of 
IXXII. Equally important are thermal/entropic contributions (Gcorr = 'G  'E; see Figure 
S4c). The large Gcorr-values for  and  (2223 kcal/mol) are expected and are likely 
the result from significantly reduced vibrational freedom due to the close alignment 
between the aryl ring of the substrate and the ligand.  It is, however, much less clear why 
the Gcorr-values for structures IX, X, XI and XII fluctuate between 1720 kcal/mol. We 
assume an error bar of 12 kcal/mol, particularly since Gcorr-values for the immediate 
sphere of solvent molecules, which has not been explicitly modeled, are unknown. 
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(e) To assess the error due to basis set incompleteness associated with the def2-TZVPP basis 
set we performed additional single point calculations with M06L/DF-def2-
QZVPPDCM(SMD). The energies relative to the separate iminium ion and Z-enolate complex 
increased by less than 0.3 kcal/mol, suggesting that the def2-TZVPP basis set is of 
sufficient quality. 
 
The stereochemical model 
An extended stereochemical model (than the one provided in the manuscript) for reaction of 
L3Mg-enolate complex with the in situ generated iminium ion is shown in Figure S1 and the 
computed electronic ('E) and free energies ('E) at the M06L/DF-def2-
TZVPPDCM(SMD)//M06L/DF-def2-SVPDCM(IEFPCM) level of theory are provided in Figure S2. In 
addition to the four modes shown in the manuscript (IXXII), we considered two additional modes 
that lead to the minor diastereomer (i.e.,  and ), wherein the iminium ion is approaching the 
enolate nucleophile with its aryl ring pointing up. It appears that accurate determination of free 
energy values is challenging and will strongly depend on the attenuation of dispersion interactions 
in solution.37,38 For instance, we find that functionals accounting for dispersion (e.g., M06L) 
clearly favor pathway  over XI electronically ('E values), particularly with the small def2-
SVP basis set applied during geometry optimization (8.8 vs 5.0 kcal/mol; grey curve in Figure 
S2). While correcting for basis set incompleteness reduces the energy difference to 2.0 kcal/mol 
(3.3 vs 1.3 kcal/mol; red curve in Figure S2), it is only after addition of thermal corrections ('G 
= 'E + Gcorr) when XI becomes the most favorable mode of addition (19.1 vs 18.1 kcal/mol; blue 
curve in Figure S2). 
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Steric influence of the para-substituent on the substrate on diastereoselectivity 
Based on these large fluctuations in the relative energy between pathways  and XI we decided 
to test experimentally the influence of substituent R on diastereoselectivity (Figure S3a). We 
hypothesized that increasing the size of R would lead to destabilization of mode  and result in 
an increase in d.r. We indeed observed a minor effect when R is altered from H to tert-butyl 
(3.8:1.0 vs 4.6:1.0 d.r.), although this change is likely too small to render  the major pathway 
for generation of the minor diastereomer. In addition to these experimental trends we investigated 
the effect of a more sizable tert-butyl group on the relative energy between  and XI 
computationally (labeled as t-Bu and XIt-Bu; Figure S3b). While the electronic energy ('E) of 
 is 2.0 kcal/mol lower than for XI (R = OMe), t-Bu is destabilized by 0.8 kcal/mol relative 
to XIt-Bu. A side view of the corresponding transition state structures for  and t-Bu illustrates 
the significantly increased steric demand in the latter structure. This is reflected in the longer 
distance between C2 on the substrate and C1 on the ligand in t-Bu (3.65 Å; Figure S2), as opposed 
to  (3.15 Å).  
On the basis of these results we propose that the minor diastereomer is generated through a 
combination of pathways  and IX, with IX likely being favored, otherwise a much more 
pronounced effect on diastereoselectivity would be expected. 
 
Comparison of results with various density functionals 
A comparison of electronic energies ('E) with a range of density functionals is provided in 
Figures S9S10, the corresponding free energy values are shown in Figures S11S12. Various 
state of the art methods (M06L, M06, MN15, ZB97XD and PBE0-D3BJ) yield similar electronic 
energies relative to the separate iminium ion and Z-enolate complex (Figure S9S10), while 'E-
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values are significantly larger with density functionals that do not properly account for dispersion 
(ZB97X and PBE0). It is worth mentioning that the electronic energy of  is predicted to be 
lower than that of XI by approximately 3 kcal/mol with functionals M06L, M06, MN15, ZB97XD 
and PBE0-D3BJ (Figure S10), whereas  is destabilized relative to XI by approximately 3 
kcal/mol with ZB97X and PBE0 (Figure S9). These data indicate that dispersion terms (D) 
contribute about 6 kcal/mol to the stabilization of  relative to XI. After addition of thermal 
contributions (Gcorr; cf. Figure S4c) the energy values for  and XI are of similar magnitude with 
functionals M06L, M06, MN15, ZB97XD and PBE0-D3BJ (Figure S12). Based on these results 
and considering the expected error bar associated with densitiy functionals (>12 kcal/mol),26 we 
chose to report the single point energies with M06-L, which is also the method used during 
geometry optimization. 
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Figure S1. Geometries of computed structures [M06L/DF-def2-SVPDCM(IEFPCM)] including free energy values obtained 
at the M06L/DF-def2-TZVPPDCM(SMD)//M06L/DF-def2-SVPDCM(IEFPCM) level of theory; the CC distance between the 

























































































































DG = 0.0 kcal/mol DG = 6.4 kcal/mol
DG = 19.1 kcal/mol DG = 26.5 kcal/mol
DG = 20.6 kcal/mol DG = 21.1 kcal/mol
DG = 18.1 kcal/mol DG = 18.8 kcal/mol
 166  
 
Figure S2. Comparison of electronic and free energies for transition states IX XII obtained at the M06L/DF-def2-
TZVPPDCM(SMD)//M06L/DF-def2-SVPDCM(IEFPCM) level of theory. 
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Figure S3. Influence of the para-substituent on the substrate on the relative energy between IX  and XI; electronic 
and free energies have been assessed at the M06L/DF-def2-TZVPPDCM(SMD)//M06L/DF-def2-SVPDCM(IEFPCM) level of 
theory; the CC distance between the electrophilic carbon on the iminium and the nucleophilic carbon on the enolate 

















a  structure of IX’  (R = OMe) b  structure of IX’t-Bu  (R = tert-butyl)
front view front view
side view side view
side
view
energy relative to XI
DE: - 2.0 kcal/mol 
DG: 1.0 kcal/mol
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DE: 0.8 kcal/mol 
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C1 carbon atom on oxazole ring between O and N
C2 carbon atom in para position of the aryl group
     on the substrate

































a  Experimentally observed influcence of the size of the para substituent on the substrate on diastereoselectivity
minor increase in d.r.
b  Computationally investigated influcence of a tert-butyl group in para position of the substrate on diastereoselectivity
IX’  R = OMe
IX’t-Bu  R = tert-butyl
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Figure S4. (a) Electronic energies ('E), (b) free energies ('G) and (c) thermal corrections to the free energy (Gcorr) 
at the level of optimization [M06L/DF-def2-SVPDCM(IEFPCM)] as a function of the CC distance [Å] and (d,e) single 
point energies with the SMD solvation model [M06L/DF-def2-SVPDCM(SMD)]; 'G = 'E + Gcorr. 
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Figure S5. (a,b) Single point electronic energies ('E) and free energies ('G) at the M06L/DF-def2-TZVPPDCM(SMD) 
level as a function of the CC distance [Å]; (c,d) single point electronic energies ('E) and free energies ('G) at the 
M06/def2-TZVPPDCM(SMD) level as a function of the CC distance [Å]; 'G = 'E + Gcorr. 
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Figure S6. (a,b) Single point electronic energies ('E) and free energies ('G) at the M06L/DF-def2-TZVPPDCM(SMD) 
level as a function of the CC distance [Å]; (c,d) single point electronic energies ('E) and free energies ('G) at the 
MN15/def2-TZVPPDCM(SMD) level as a function of the CC distance [Å]; 'G = 'E + Gcorr. 
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Figure S7. (a,b) Single point electronic energies ('E) and free energies ('G) at the ZB97XD/DF-def2-TZVPPDCM(SMD) 
level as a function of the CC distance [Å]; (c,d) single point electronic energies ('E) and free energies ('G) at the 
ZB97X/def2-TZVPPDCM(SMD) level as a function of the CC distance [Å]; 'G = 'E + Gcorr. 
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Figure S8. (a,b) Single point electronic energies ('E) and free energies ('G) at the PBE0-D3BJ/DF-def2-
TZVPPDCM(SMD) level as a function of the CC distance [Å]; (c,d) single point electronic energies ('E) and free 
energies ('G) at the PBE0/def2-TZVPPDCM(SMD) level as a function of the CC distance [Å]; 'G = 'E + Gcorr. 
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Figure S9. Comparison of electronic energies ('E in kcal/mol) for IX XII obtained with several density functionals; 
the maximum values from the corresponding graphs in Figures S4S8 have been used. 
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Figure S10. Comparison of electronic energies ('E in kcal/mol) for IX XII obtained with several density functionals; 
expansion of the energy range between 7 and 8 kcal/mol in Figure S9. 
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Figure S11. Comparison of free energies ('G in kcal/mol) for IX XII obtained with several density functionals; the 
maximum values from the corresponding graphs in Figures S4S8 have been used. 
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Figure S12. Comparison of free energies ('G in kcal/mol) for IX XII obtained with several density functionals; 
expansion of the energy range between 15 and 30 kcal/mol in Figure S11. 
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A5. Analytical Data 
 
Methyl 3-((4-methoxy-2,6-dimethylphenyl)(methyl)amino)-2,2-dimethylpropanoate (2.14g)  
Substrate 2.13g was reacted with ((1-methoxy-2-methylprop-1-en-1-yl)oxy)trimethylsilane 2.11a 
following the general procedure using benzene as the solvent and 5 mol% B(C6F5)3. After 
purification by column chromatography (3% ethyl ether in hexanes), 2.14g was obtained as a 
colorless liquid (44.7 mg, 80%). 1H NMR (600 MHz, CDCl3)  6.53 ( , 2H), 3.73 ( , 3H), 3.52 ( , 
3H), 3.17 (s, 2H), 2.69 (s, 3H), 2.26 (s, 6H), 1.16 (s, 6H); 13C NMR (151 MHz, CDCl3)  178.1, 
156.2, 144.2, 137.5, 113.7, 67.2, 55.2, 51.4, 45.3, 43.9, 23.7, 19.3; IR (neat)Q 2948, 2837, 2790, 
1729, 1602, 1484, 1468, 1433, 1286, 1192, 1154, 1140, 1063, 983, 855 cm-1; HRMS (DART) 
Calcd for C16H26NO3 (MH+): 280.1913; found: 280.1902. 
 
 
Methyl 3-((4-methoxy-2,6-dimethylphenyl)amino)-2,2-dimethylpropanoate (2.15g) 
1H NMR (400 MHz, CDCl3)  6.45 ( , 2H), 4.39 ( , 1H), 3.52 ( , 3H), 3.16 ( , 2H), 2.69 ( , 3H), 
2.23 (s, 6H), 1.16 (s, 6H); 13C NMR (126 MHz, CDCl3)  178.2, 152.1, 144.2, 137.8, 115.1, 67.2, 
51.4, 45.4, 43.9, 23.7, 19.1; IR (neat)Q 3402, 2949, 2927, 2792, 1707, 1609, 1592, 1467, 1390, 
1289, 1239, 1196, 1163, 1095, 1026, 856 cm-1; HRMS (DART) Calcd for C15H24NO3 (MH+): 
266.1756; found: 266.1744. 
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Methyl 3-(benzyl(4-methoxy-2,6-dimethylphenyl)amino)-2,2-dimethylpropanoate (2.14i)  
Substrate 2.13i was reacted with ((1-methoxy-2-methylprop-1-en-1-yl)oxy)trimethylsilane 2.11a 
following the general procedure using benzene as the solvent. After purification by column 
chromatography (2% ethyl ether in hexanes), 2.14i was obtained as a colorless liquid (45.5 mg, 
64%). 1H NMR (500 MHz, CDCl3)  7.23  7.19 (m, 3H), 7.06  7.00 (m, 2H), 6.48 (s, 2H), 4.00 
(s, 2H), 3.73 (s, 3H), 3.42 (s, 3H), 3.25 (s, 2H), 2.05 (s, 6H), 1.12 (s, 6H); 13C NMR (126 MHz, 
CDCl3) G 177.9, 156.1, 141.1, 138.7, 138.1, 129.9, 127.9, 127.0, 113.8, 63.3, 60.4, 55.1, 51.3, 44.9, 
23.9, 19.8; IR (neat)Q 3027, 2948, 2837, 1732, 1602, 1470, 1455, 1314, 1261, 1194, 1152, 1069, 
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Methyl 3-((cyclopropylmethyl)(4-methoxy-2,6-dimethylphenyl)amino)-2,2-
dimethylpropanoate (2.14j)  
Substrate 2.13j was reacted with ((1-methoxy-2-methylprop-1-en-1-yl)oxy)trimethylsilane 2.11a 
following the general procedure using benzene as the solvent. After purification by column 
chromatography (3% ethyl ether in hexanes), 2.14j was obtained as a colorless liquid (35.8 mg, 
56%). 1H NMR (600 MHz, CDCl3)  6.52 (s, 2H), 3.73 (s, 3H), 3.42 (s, 3H), 3.27 (s, 2H), 2.79 
(d, J = 6.9 Hz, 2H), 2.31 (s, 6H), 1.15 (s, 6H), 0.85  0.77 (m, 1H), 0.35  0.31 (m, 2H), -0.06  -
0.10 (m, 2H); 13C NMR (151 MHz, CDCl3) G178.0, 156.1, 142.2, 138.1, 113.7, 65.1, 62.0, 55.1, 
51.3, 45.1, 23.8, 23.7, 19.9, 10.5, 3.7; IR (neat)Q 2947, 2837, 1730, 1602, 1468, 1389, 1314, 1259, 
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Methyl 2-(1-(4-methoxy-2,6-dimethylphenyl)pyrrolidin-2-yl)-2-methylpropanoate (2.14k)  
Substrate 2.13k was reacted with ((1-methoxy-2-methylprop-1-en-1-yl)oxy)trimethylsilane 2.11a 
following the general procedure, using THF as the solvent. After purification by column 
chromatography (5% ethyl ether in hexanes) 2.14k was obtained as a colorless liquid (55.0 mg, 
90%). 1H NMR (600 MHz, CDCl3)  6.56  6.51 (m, 2H), 4.05 (dd, J1 = 9.4 Hz, J2 = 2.0 Hz, 1H), 
3.73 (s, 3H), 3.30  3.28 (m, 1H), 3.07 (s, 3H), 2.92  2.88 (m, 1H), 2.29 (s, 3H), 2.25 (s, 3H), 
2.13  2.05 (m, 1H), 1.91  1.81 (m, 3H), 1.11 (s, 3H), 1.08 (s, 3H); 13C NMR (151 MHz, CDCl3) 
 177.8, 156.1, 139.9, 139.8, 136.8, 114.6, 112.9, 66.8, 55.1, 54.5, 50.9, 47.7, 27.6, 25.6, 23.2, 
19.7, 19.6, 19.4; IR (neat)Q 2948, 2836, 1732, 1603, 1466, 1315, 1253, 1192, 1129, 1070, 839 










 181  
  
Methyl 2-(hydroxy-1-(4-methoxy-2,6-dimethylphenyl)pyrrolidin-2-yl)-2-methylpropanoate 
(2.14l-OH, 2.14m-OH)  
Substrate 2.13l was reacted with ((1-methoxy-2-methylprop-1-en-1-yl)oxy)trimethylsilane 2.11a 
following the general procedure using THF as the solvent. 1H NMR analysis of the unpurified 
reaction mixture revealed that 2.14l and 2.14m were obtained in the ratio of 2.5:1. The 
diastereomeric ratio (dr) of 2.14l was 4:1 and the dr of 2.14m was >20:1. After purification by 
column chromatography (3% ethyl ether in hexanes), 2.14l and 2.14m were separated to give pure 
2.14l (24.2 mg, 31% yield) and 2.14m (18.3 mg, 23% yield). The isolated and purified products 
were treated with 4.0 N HCl for 24 hours to give the desilylated products that are characterized as 
below. The relative configuration of the pyrrolidine substituents for 2.14l-OH and 2.14m-OH was 
assigned anti based on NOESY experiments (See SI Section 5 for NOE spectra). 
Major regioisomer (2.14l-OH): 1H NMR (500 MHz, CDCl3)  6.57  6.48 (m, 2H), 4.55  4.35 
(m, 1H), 4.34  4.05 (m, 1H), 3.77  3.68 (m, 3H), 3.64  3.57 (m, 1H), 3.28  3.01 (m, 3H), 2.88 
 2.80 (m, 1H), 2.40  2.19 (m, 6H), 2.14  1.93 (m, 2H), 1.70  1.54 (m, 1H), 1.13  0.93 (m, 
6H); 13C NMR (126 MHz, CDCl3)  177.8, 177.3, 156.5, 156.3, 139.9, 139.6, 138.4, 138.4, 137.3, 
136.9, 114.9, 114.7, 113.2, 113.0, 70.7, 70.5, 66.8, 65.9, 63.3, 62.0, 55.2, 51.4, 51.1, 46.9, 46.7, 
36.7, 36.6, 24.2, 23.5, 21.0, 20.0, 19.50, 19.46; IR (neat) Q 3418, 2947, 2837, 1730, 1602, 1469, 
1315, 1267, 1193, 1134, 1069, 990, 854 cm-1; HRMS (DART) Calcd for C18H28NO4 (MH+): 
322.2018; found: 322.2024. 
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Minor regioisomer (2.14m-OH): 1H NMR (500 MHz, CDCl3)  6.57  6.49 (m, 2H), 4.31 (d, J 
= 5.1 Hz, 1H), 4.05 (s, 1H), 3.73 (s, 3H), 3.32  3.20 (m, 2H), 3.14 (s, 3H), 2.40 (s, 3H), 2.29 (s, 
3H), 2.06  1.97 (m, 1H), 1.81 (dd, J = 13.2, 5.5 Hz, 1H), 1.69 (br, 1H), 1.18 (s, 3H), 1.05 (s, 3H); 
13C NMR (151 MHz, CDCl3) 177.4, 156.3, 139.8, 138.1, 137.4, 114.7, 113.1, 75.8, 75.3, 55.2, 
52.2, 51.2, 46.1, 34.0, 22.6, 20.8, 19.7, 19.5; IR (neat)Q 3485, 2948, 2835, 1732, 1603, 1469, 
1314, 1256, 1192, 1154, 1131, 1071, 991, 856 cm-1; HRMS (DART) Calcd for C18H28NO4 (MH+): 
322.2018; found: 322.2016. 
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Methyl 2-(-1-(4-methoxy-2,6-dimethylphenyl)-5-methylpyrrolidin-2-yl)-2-
methylpropanoate (2.14n)  
Substrate 2.13n was reacted with ((1-methoxy-2-methylprop-1-en-1-yl)oxy)trimethylsilane 2.11a 
following the general procedure, using THF as the solvent. 1H NMR analysis of the crude material 
revealed that the diastereomeric ratio was 7:1. After purification by column chromatography (4% 
ethyl ether in hexanes) 2.14n was obtained as a colorless liquid (44.7 mg, 70%) as a mixture of 
diastereomers. The relative configuration of the pyrrolidine substituents was assigned anti based 
on NOESY experiments. 
1H NMR (500 MHz, CDCl3)  6.51 (d, J = 6.1 Hz, 2H), 4.20  4.14 (m, 1H), 3.76  3.70 (m, 4H), 
3.05 (s, 3H), 2.26 (s, 3H), 2.24 (s, 3H), 2.16  2.05 (m, 2H), 1.80  1.70 (m, 1H), 1.55  1.46 (m, 
1H), 1.09 (s, 3H), 1.04 (s, 3H), 0.71 (d, J = 6.4 Hz, 3H); 13C NMR (126 MHz, CDCl3)  177.7, 
155.6, 139.4, 137.8, 136.8, 113.9, 112.9, 67.3, 57.5, 55.1, 51.0, 47.8, 33.8, 25.5, 23.3, 20.6, 20.0, 
19.7, 19.5; IR (neat)Q 2956, 2873, 2836, 1731, 1602, 1467, 1371, 1303, 1256, 1192, 1155, 1131, 
1070, 854 cm-1; HRMS (DART) Calcd for C19H30NO3 (MH+): 320.2226; found: 320.2236. 
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Methyl -2-(1-(4-methoxy-2,6-dimethylphenyl)piperidin-2-yl)-2-methylpropanoate (2.14o)  
Substrate 2.13o was reacted with ((1-methoxy-2-methylprop-1-en-1-yl)oxy)trimethylsilane 2.11a 
following the general procedure using benzene as the solvent; the reaction mixture was heated at 
50 °C. After purification by column chromatography (5% ethyl ether in hexanes), 2.14o was 
obtained as a colorless liquid (24.3 mg, 38%). 1H NMR (600 MHz, CDCl3)  6.55 (d, J = 3.1 Hz, 
1H), 6.44 (d, J = 3.1 Hz, 1H), 3.81  3.76 (m, 1H), 3.73 (s, 3H), 3.23 (s, 3H), 3.07  2.99 (m, 1H), 
2.99  2.91 (m, 1H), 2.35 (s, 3H), 2.32 (s, 3H), 1.82  1.72 (m, 2H), 1.59  1.47 (m, 4H), 1.06 (m, 
6H); 13C NMR (151 MHz, CDCl3)  177.9, 155.9, 142.4, 138.6, 137.9, 114.5, 113.4, 61.4, 55.1, 
52.2, 51.3, 48.3, 26.2, 25.7, 24.4, 22.9, 20.9, 20.6, 19.7; IR (neat)Q 2934, 2854, 2836, 1731, 1601, 
1466, 1388, 1255, 1233, 1171, 1133, 1069, 917, 854 cm-1; HRMS (ESI) Calcd for C19H30NO3 
(MH+): 320.2226; found: 320.2228. 
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Meth l 2-meth l-3-(2,2,6,6-tetrameth lpiperidin-1- l)propanoate (2.16a) 
Substrate 2.13p was reacted with ((1-methoxyprop-1-en-1-yl)oxy)trimethylsilane 2.11b following 
the general procedure using THF as the solvent at 70 °C. After purification by column 
chromatography (2.5% triethylamine in hexanes), 2.16a was obtained as a colorless liquid (45.8 
mg, 95%). 1H NMR (600 MHz, CDCl3)  3.65 ( , 3H), 2.86 (dd, J = 15.4, 7.4 Hz, 1H), 2.57 (h, J 
= 7.1 Hz, 1H), 2.45 (dd, J = 15.5, 5.4 Hz, 1H), 1.52 (br, 2H), 1.44  1.36 (m, 4H), 1.11 (d, J = 7.3 
Hz, 3H), 1.01 (s, 6H), 0.95 (s, 6H); 13C NMR (151 MHz, CDCl3)  177.8, 54.6, 51.2, 48.9, 44.2, 
41.3, 17.8, 16.1; IR (neat)Q 2966, 2927, 2874, 1736, 1464, 1434, 1379, 1365, 1256, 1168 cm-1; 
HRMS (ESI) Calcd for C14H28NO2 (MH+): 242.2042; found: 242.2117.   
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Meth l 3-( e -but l(isoprop l)amino)-2-meth lpropanoate (2.16b) 
Substrate 2.13q was reacted with ((1-methoxyprop-1-en-1-yl)oxy)trimethylsilane 2.11b following 
the general procedure using THF as the solvent at 70 °C. After purification by column 
chromatography (2.5% triethylamine in hexanes), 2.16b was obtained as a colorless liquid (40.1 
mg, 93%). 1H NMR (600 MHz, CDCl3)  3.66 ( , 3H), 3.29  3.19 (m, 1H), 2.84 (dd, J = 14.5, 
7.7 Hz, 1H), 2.65  2.52 (m, 1H), 2.49 (dd, J = 14.4, 6.8 Hz, 1H), 1.10 (d, J = 6.9 Hz, 3H), 1.07 
(s, 9H), 1.01 (d, J = 6.7 Hz, 3H), 0.94 (d, J = 6.8 Hz, 3H); 13C NMR (151 MHz, CDCl3)  177.4, 
55.6, 51.2, 47.0, 46.6, 43.0, 28.6, 22.7, 15.2; IR (neat)Q 2959, 2928, 2864, 2178, 1738, 1707, 
1457, 1387, 1376, 1249, 1168, 1138, 1112 cm-1; HRMS (ESI) Calcd for C12H26NO2 (MH+): 
216.1885; found: 216.1961.   
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Meth l 3-((1-(( e -but ldimeth lsil l)o )-2-meth lpropan-2- l)(isoprop l)amino)-2-
meth lpropanoate (2.16c) 
Substrate 2.13r was reacted with ((1-methoxyprop-1-en-1-yl)oxy)trimethylsilane 2.11b following 
the general procedure using THF as the solvent at 70 °C. After purification by column 
chromatography (2% triethylamine in hexanes), 2.16c was obtained as a colorless liquid (64.9 mg, 
94%). 1H NMR (600 MHz, CDCl3)  3.65 ( , 3H), 3.40  3.34 (m, 2H), 3.26 (dt, J = 12.8, 7.0 Hz, 
1H), 2.96 (dd, J = 14.6, 7.8 Hz, 1H), 2.65 (dd, J = 15.0, 7.2 Hz, 1H), 2.57 (h, J = 7.0 Hz, 1H), 1.08 
(d, J = 7.0 Hz, 3H), 1.05 (s, 6H), 1.02 (d, J = 6.8 Hz, 3H), 0.96 (d, J = 6.7 Hz, 3H), 0.89 (s, 9H), 
0.03 (s, 6H); 13C NMR (151 MHz, CDCl3)  177.3, 69.6, 59.3, 51.1, 47.3, 46.4, 42.9, 25.8, 24.3, 
22.8, 18.2, 15.1, -5.6; IR (neat)Q 2954, 2929, 2884, 2857, 1737, 1462, 1360, 1250, 1197, 1165, 
1086, 835, 774 cm-1; HRMS (ESI) Calcd for C18H40NO3Si (MH+): 346.2699; found: 346.2778.   
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Meth l 3-(bis((S)-1-phen leth l)amino)-2-meth lpropanoate (2.16d) 
Substrate 2.13s was reacted with ((1-methoxyprop-1-en-1-yl)oxy)trimethylsilane 2.11b following 
the general procedure using THF as the solvent at 70 °C. By 1H NMR analysis of the unpurified 
reaction mixture, the diastereomeric ratio was determined to be 1.6:1. After purification by column 
chromatography (2% triethylamine in hexanes), 2.16d was obtained as a colorless liquid (57.3 mg, 
88%). Diastereomers were separated chromatographically: 2.16d-(S,S,R) (35.3 mg, 54%) and 
2.16d-(S,S,S) (22.0 mg, 34%).25 
 
2.16d-(S, S, R): 
1H NMR (500 MHz, CDCl3)  7.35  7.24 (m, 8H), 7.24  7.18 (m, 2H), 3.86 (q, J = 6.9 Hz, 2H), 
3.68 (s, 3H), 3.06 (ddd, J = 13.9, 8.2, 1.4 Hz, 1H), 2.53  2.41 (m, 1H), 2.36 (ddd, J = 13.8, 6.4, 
1.5 Hz, 1H), 1.35 (dd, J = 6.9, 1.5 Hz, 6H), 0.87 (dd, J = 6.9, 1.5 Hz, 3H); 13C NMR (151 MHz, 
CDCl3)  176.9, 144.4, 128.0, 127.9, 126.6, 58.4, 51.3, 50.1, 41.4, 18.8, 15.1; IR (neat)Q 2969, 
2934, 1736, 1452, 1371, 1196, 1177, 1150, 758, 700 cm-1; HRMS (ESI) Calcd for C21H28NO2 
(MH+): 326.4240; found: 326.2121; [ ]25D = 33.5° (c = 0.4, EtOH).   
  
2.16d-(S, S, S): 
1H NMR (500 MHz, CDCl3)  7.32  7.23 (m, 8H), 7.23  7.17 (m, 2H), 3.95 (q, J = 6.9 Hz, 2H), 
3.46 (s, 3H), 2.76 (dd, J = 7.5, 2.4 Hz, 2H), 2.59 (q, J = 7.1 Hz, 1H), 1.44  1.33 (m, 6H), 1.11 
(dd, J = 6.9, 0.8 Hz, 3H); 13C NMR (151 MHz, CDCl3)  176.3, 144.4, 127.9, 127.9, 126.5, 57.5, 
51.3, 49.5, 40.5, 17.8, 15.4; IR (neat)Q 2968, 2946, 1735, 1493, 1451, 1196, 1180, 1152, 699 cm-
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1; HRMS (ESI) Calcd for C21H28NO2 (MH+): 326.4240; found: 326.2120; [ ]25D = 2.1° (c = 0.3, 
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Methyl 1-(((4-methoxy-2,6-dimethylphenyl)(methyl)amino)methyl)cyclopentane-1-
carboxylate (2.14p)  
Substrate 2.13g was reacted with (cyclopentylidene(methoxy)methoxy)trimethylsilane 2.11c 
following the general procedure using benzene as the solvent. After purification by column 
chromatography (3% ethyl ether in hexanes), 2.14p was obtained as a colorless liquid (44.6 mg, 
73%). 1H NMR (500 MHz, CDCl3)  6.52 ( , 2H), 3.73 ( , 3H), 3.55 ( , 3H), 3.26 ( , 2H), 2.69 ( , 
3H), 2.25 (s, 6H), 2.16  2.04 (m, 2H), 1.67  1.46 (m, 6H); 13C NMR (151 MHz, CDCl3)  178.0, 
156.2, 143.8, 137.8, 113.7, 65.1, 56.7, 55.2, 51.4, 43.2, 34.4, 25.0, 19.3; IR (neat)Q 2948, 2870, 
2837, 2794, 1729, 1602, 1484, 1434, 1272, 1192, 1154, 1063, 854 cm-1; HRMS (DART) Calcd 
for C18H28NO3 (MH+): 306.2069; found: 306.2076. 
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Methyl 1-(((4-methoxy-2,6-dimethylphenyl)(methyl)amino)methyl)cyclohexane-1-
carboxylate (2.14q)  
Substrate 2.13g was reacted with (cyclohexylidene(methoxy)methoxy)trimethylsilane 2.11d 
following the general procedure using benzene as the solvent. After purification by column 
chromatography (4% ethyl ether in hexanes), 2.14q was obtained as a colorless liquid (50.5 mg, 
79%). 1H NMR (500 MHz, CDCl3)  6.52 ( , 2H), 3.73 ( , 3H), 3.55 ( , 3H), 3.17 ( , 2H), 2.65 ( , 
3H), 2.27 (s, 6H), 2.13  2.04 (m, 2H), 1.59  1.49 (m, 3H), 1.40  1.28 (m, 2H), 1.24  1.15 (m, 
3H); 13C NMR (126 MHz, CDCl3)  176.9, 156.1, 144.4, 137.4, 113.7, 67.7, 55.1, 51.2, 49.9, 43.8, 
32.6, 26.0, 23.0, 19.4; IR (neat)Q 2934, 2853, 2792, 1730, 1602, 1451, 1372, 1298, 1156, 1133, 
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Methyl 3-((4-methoxy-2,6-dimethylphenyl)(methyl)amino)-2-methylpropanoate (2.14r)  
Substrate 2.13g was reacted with ((1-methoxyprop-1-en-1-yl)oxy)trimethylsilane 2.11b following 
the general procedure using benzene as the solvent. After purification by column chromatography 
(5% ethyl acetate in hexanes), 2.14r was obtained as a colorless liquid (35.0 mg, 66%). 1H NMR 
(600 MHz, CDCl3)  6.52 ( , 2H), 3.74 ( , 3H), 3.65 ( , 3H), 3.32  3.25 (m, 1H), 3.07  3.00 (m, 
1H), 2.74  2.65 (m, 4H), 2.25 (s, 3H), 2.21 (s, 3H), 1.13 (d, J = 7.0 Hz, 3H); 13C NMR (151 MHz, 
CDCl3)  176.7, 156.4, 142.5, 138.3, 138.2, 113.8, 113.6, 60.1, 55.2, 51.5, 41.0, 40.3, 19.4, 19.1, 
15.4; IR (neat)Q 2949, 2838, 2799, 1736, 1602, 1485, 1458, 1435, 1379, 1304, 1254, 1194, 1155, 

















Substrate 2.13k was reacted with (cyclobutylidene(methoxy)methoxy)trimethylsilane 2.11e 
following the general procedure using THF as the solvent.  After purification by column 
chromatography (5% ethyl ether in hexanes), 2.14s was obtained as a colorless liquid (48.9 mg, 
77%). 1H NMR (500 MHz, CDCl3)  6.56  6.50 (m, 2H), 4.07 (dd, J1 = 8.6 Hz, J2 = 3.8 Hz, 1H), 
3.73 (s, 3H), 3.33  3.24 (m, 4H), 2.94 (q, J = 7.8 Hz, 1H), 2.41  2.29 (m, 1H), 2.26 (s, 3H), 2.24 
(s, 3H), 2.21  1.98 (m, 5H), 1.93  1.67 (m, 4H); 13C NMR (151 MHz, CDCl3)  177.2, 156.4, 
140.8, 139.0, 137.4, 114.4, 112.8, 64.8, 55.1, 54.1, 52.4, 51.3, 28.4, 28.1, 25.6, 25.2, 19.5, 19.0, 
15.7; IR (neat)Q 2947, 2836, 1727, 1602, 1481, 1464, 1434, 1316, 1266, 1209, 1193, 1153, 1116, 












Substrate 2.13k was reacted with (cyclopentylidene(methoxy)methoxy)trimethylsilane 2.11c 
following the general procedure using THF as the solvent. After purification by column 
chromatography (5% ethyl ether in hexanes), 2.14t was obtained as a colorless liquid (66.0 mg, 
>95%). 1H NMR (600 MHz, CDCl3)  6.58  6.50 (m, 2H), 4.13 (dd, J1 = 9.2 Hz, J2 = 2.6 Hz, 
1H), 3.73 (s, 3H), 3.32  3.18 (m, 4H), 2.90 (q, J = 7.4 Hz, 1H), 2.29 (s, 3H), 2.23 (s, 3H), 2.19  
2.09 (m, 2H), 1.93  1.81 (m, 4H), 1.60  1.48 (m, 6H); 13C NMR (151 MHz, CDCl3)  177.6, 
156.2, 140.2, 139.5, 137.0, 114.5, 112.8, 66.0, 60.5, 55.1, 54.4, 51.2, 34.1, 31.4, 28.8, 25.3, 25.2, 
25.1, 19.6, 19.1; IR (neat)Q 2947, 2872, 2835, 1726, 1602, 1463, 1433, 1370, 1316, 1255, 1228, 
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Methyl 2-(1-(4-methoxy-2,6-dimethylphenyl)pyrrolidin-2-yl)propanoate (2.14u) 
Substrate 2.13k was reacted with ((1-methoxyprop-1-en-1-yl)oxy)trimethylsilane 2.11b following 
the general procedure using THF as the solvent. 1H NMR analysis of the unpurified reaction 
mixture revealed that the diastereomeric ratio was 2.5:1. After purification by column 
chromatography (5% ethyl ether in hexanes), 2.14u was obtained as a colorless liquid (34.9 mg, 
60%) as a mixture of diastereomers. The diastereomers were isolated by PTLC (10% ether in 
hexanes): major diastereomer (16.0 mg, 27% yield), minor diastereomer (12.2 mg, 21% yield).25 
 
2.14u-major: 1H NMR (400 MHz, CDCl3)  6.59  6.50 (m, 2H), 3.92  3.84 (m, 1H), 3.74 (s, 
3H), 3.34  3.24 (m, 4H), 3.02  2.94 (m, 1H), 2.40  2.31 (m, 1H), 2.27 (s, 3H), 2.24 (s, 3H), 2.12 
 2.02 (m, 1H), 1.97  1.86 (m, 2H), 1.82  1.72 (m, 1H), 1.11 (d, J = 7.0 Hz, 3H); 13C NMR (151 
MHz, CDCl3)  176.1, 156.6, 140.7, 138.5, 137.4, 114.4, 112.9, 62.7, 55.2, 52.7, 51.1, 45.2, 29.0, 
25.0, 19.5, 19.2, 13.5; IR (neat) Q 2948, 2838, 1733, 1602, 1484, 1465, 1374, 1318, 1273, 1194, 
1154, 1117, 1067, 855 cm-1; HRMS (ESI) Calcd for C17H26NO3 (MH+): 292.1912; found: 
292.1908.  
 
2.14u-minor: 1H NMR (500 MHz, CDCl3)  6.59  6.52 (m, 2H), 3.87  3.81 (m, 1H), 3.74 (s, 
3H), 3.44 (s, 3H), 3.30  3.24 (m, 1H), 2.96  2.88 (m, 1H), 2.49  2.41 (m, 1H), 2.29 (s, 3H), 2.23 
(s, 3H), 2.17  2.08 (m, 1H), 1.96  1.84 (m, 3H), 1.01 (d, J = 7.0 Hz, 3H); 13C NMR (151 MHz, 
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CDCl3)  175.9, 156.4, 140.3, 138.8, 137.2, 114.5, 113.0, 63.6, 55.2, 53.4, 51.1, 45.9, 29.8, 25.1, 













Substrate 2.13k was reacted with trimethyl((3-methyl-4,5-dihydrofuran-2-yl)oxy)silane 2.11f 
following the general procedure using THF as the solvent. 1H NMR analysis of the unpurified 
reaction mixture revealed that the diastereomeric ratio was 1.3:1. After purification by column 
chromatography (10% ethyl ether in hexanes), 2.14v was obtained as a colorless liquid (42.8 mg, 
70%). Diastereomers were separated chromatographically; major diastereomer (23.9 mg, 39%) 
and minor diastereomer (18.9 mg, 31%). 
 
2.14v-major: 1H NMR (400 MHz, CDCl3)  6.55 ( , 2H), 4.12  4.04 (m, 2H), 3.87 (t, J = 6.1 Hz, 
1H), 3.74 (s, 3H), 3.39  3.31 (m, 1H), 3.00  2.91 (m, 1H), 2.38  2.27 (m, 4H), 2.25 (s, 3H), 2.20 
 2.13 (m, 2H), 2.00  1.88 (m, 2H), 1.78  1.69 (m, 1H), 1.26 (s, 3H); 13C NMR (151 MHz, 
CDCl3)  180.8, 156.5, 139.9, 139.2, 136.5, 114.9, 113.3, 64.7, 64.0, 55.1, 54.5, 48.2, 32.1, 27.6, 
25.8, 19.5, 19.3, 19.1; IR (neat)Q 2962, 2912, 2836, 1767, 1603, 1482, 1466, 1371, 1317, 1255, 
1193, 1154, 1070, 1031, 854 cm-1; HRMS (DART) Calcd for C18H26NO3 (MH+): 304.1913; found: 
304.1924. 
 
2.14v-minor: 1H NMR (600 MHz, CDCl3)  6.60  6.53 (m, 2H), 4.27  4.16 (m, 2H), 3.94 (dd, 
J1 = 8.8 Hz, J2 = 3.9 Hz, 1H), 3.75 (s, 3H), 3.37  3.32 (m, 1H), 2.99  2.93 (m, 1H), 2.55  2.48 
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(m, 1H), 2.30 (s, 3H), 2.29  2.22 (m, 4H), 2.00  1.89 (m, 3H), 1.79  1.73 (m, 1H), 0.94 (s, 3H); 
13C NMR (126 MHz, CDCl3)  181.2, 156.5, 140.4, 139.1, 136.4, 114.8, 113.4, 65.5, 65.2, 55.1, 
54.7, 48.9, 31.2, 29.5, 25.6, 22.6, 19.8, 19.2; HRMS (ESI) Calcd for C18H26NO3 (MH+): 304.1913; 
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S-Methyl 2-(1-(4-methoxy-2,6-dimethylphenyl)pyrrolidin-2-yl)ethanethioate (2.14w) 
Substrate 2.13k was reacted with trimethyl((1-(methylthio)vinyl)oxy)silane 2.11g following the 
general procedure using THF as the solvent. After purification by column chromatography (5% 
ethyl acetate in hexanes), 2.14w was obtained as a colorless liquid (30.5 mg, 52%). 1H NMR (400 
MHz, CDCl3)  6.57 (b , 2H), 3.95  3.88 (m, 1H), 3.75 (s, 3H), 3.28  3.22 (m, 1H), 3.06  2.99 
(m, 1H), 2.58 (dd, J1 = 14.3 Hz, J2 = 4.4 Hz, 1H), 2.48 (dd, J1 = 14.3, J2 = 9.2 Hz, 1H), 2.24 (s, 
6H), 2.23  2.13 (m, 4H), 2.03  1.86 (m, 2H), 1.79  1.70 (m, 1H); 13C NMR (151 MHz, CDCl3) 
 198.4, 156.8, 140.7, 138.9, 136.4, 114.3, 113.0, 58.7, 55.2, 51.4, 50.6, 31.9, 24.5, 19.2, 11.5; IR 
(neat)Q 2953, 2872, 2836, 1685, 1603, 1483, 1370, 1319, 1269, 1193, 1154, 1069, 1018, 855 cm-
1; HRMS (ESI) Calcd for C16H24NO2S (MH+): 294.1527; found: 294.1530.   




Substrate 2.17a was reacted with ((1-methoxy-2-methylprop-1-en-1-yl)oxy)trimethylsilane 2.11a  
following the general procedure on a 3.0 mmol scale using benzene as the solvent at 70 °C. After 
purification by column chromatography (20% ethyl acetate in hexanes), 2.18a was obtained as a 
colorless liquid (301.9 mg, 23%).  
1H NMR (500 MHz, CDCl3)  7.63  7.56 (m, 1H), 7.50 (s, 1H), 7.46  7.34 (m, 3H), 7.01 (t, J = 
8.7 Hz, 2H), 5.17 (q, J = 12.9 Hz, 2H), 3.59 (s, 3H), 2.44 (s, 2H), 2.34 (t, J = 7.0 Hz, 2H), 2.18 
(ddd, J = 14.2, 11.4, 4.7 Hz, 1H), 2.08 (s, 4H), 1.45  1.32 (m, 1H), 1.29  1.18 (m, 1H), 1.12 (s, 
6H); 13C NMR (126 MHz, CDCl3)  178.1, 162.0 (d, JC-F = 246.1 Hz), 149.6, 140.3, 139.7 (d, JC-
F = 3.1 Hz), 131.8, 126.7 (d, JC-F = 8.0 Hz), 125.2, 122.7, 118.6, 115.3 (d, JC-F = 21.1 Hz), 111.6, 
91.2, 71.3, 67.4, 59.5, 51.5, 44.1, 43.6, 38.7, 23.9, 23.8, 22.0; 19F NMR (470 MHz, CDCl3)  -
116.48 (tt, J = 8.4, 5.0 Hz); IR (neat)Q 2950, 2847, 2788, 2229, 1725, 1506, 1460, 1271, 1224, 
1193, 1149, 1049, 1033, 834 cm-1; HRMS (ESI) Calcd for C25H30FN2O3 (MH+): 425.2235; found: 
425.2232.   
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Methyl (R)-2,2-dimethyl-3-(methyl(3-phenyl-3-(o-tolyloxy)propyl)amino)propanoate (2.18b) 
Substrate 2.17b was reacted with ((1-methoxy-2-methylprop-1-en-1-yl)oxy)trimethylsilane 2.11a  
following the general procedure on a 1.0 mmol scale using DCM as the solvent. After purification 
by column chromatography (15% ethyl acetate in hexanes), 2.18b was obtained as a colorless 
liquid (91.9 mg, 25%).  
1H NMR (500 MHz, CDCl3)  7.36  7.26 (m, 4H), 7.26  7.19 (m, 1H), 7.09 (d, J = 7.3 Hz, 1H), 
6.94 (t, J = 7.9 Hz, 1H), 6.75 (t, J = 7.4 Hz, 1H), 6.59 (d, J = 8.2 Hz, 1H), 5.19 (dd, J = 8.5, 4.3 
Hz, 1H), 3.58 (s, 3H), 2.59 (t, J = 7.3 Hz, 2H), 2.51 (t, J = 1.8 Hz, 2H), 2.31 (s, 3H), 2.21 (s, 3H), 
2.11 (dq, J = 14.4, 7.2 Hz, 1H), 2.00  1.88 (m, 1H), 1.18  1.07 (m, 6H); 13C NMR (151 MHz, 
CDCl3)  180.8, 158.7, 145.0, 133.1, 131.2, 130.0, 129.6, 129.1, 128.4, 122.7, 115.4, 80.4, 69.7, 
58.9, 54.2, 54.2, 46.6, 39.5, 26.6, 26.5, 19.2; IR (neat)Q 2949, 2847, 1727, 1601, 1491, 1453, 
1305, 1270, 1237, 1192, 1149, 1119, 1047, 747, 700 cm-1; HRMS (ESI) Calcd for C23H32NO3 
(MH+): 370.2383; found: 370.2372; [ ]25D = 4.6° (c = 1.0, CHCl3).   




Substrate 2.17c was reacted with ((1-methoxy-2-methylprop-1-en-1-yl)oxy)trimethylsilane 2.11a 
following the general procedure on 1.0 mmol scale using DCM as the solvent. After purification 
by column chromatography (15% ethyl acetate in hexanes), 2.18c was obtained as a colorless 
liquid (113 mg, 27%).  
1H NMR (500 MHz, CDCl3)  7.42 (d, J = 8.5 Hz, 2H), 7.32 (d, J = 4.3 Hz, 4H), 7.25 (d, J = 3.4 
Hz, 1H), 6.89 (d, J = 8.5 Hz, 2H), 5.25 (dd, J = 8.5, 4.4 Hz, 1H), 3.59 (d, J = 1.1 Hz, 3H), 2.67  
2.45 (m, 4H), 2.21 (s, 3H), 2.16  2.01 (m, 1H), 2.01  1.86 (m, 1H), 1.12 (d, J = 7.4 Hz, 6H); 13C 
NMR (151 MHz, CDCl3)  178.1, 160.7, 141.4, 128.7, 127.7, 125.8, 126.7 (q, JC-F = 3.8 Hz), 
124.4 (q, JC-F = 271.1 Hz), 122.6 (q, JC-F = 32.7 Hz), 115.7, 78.3, 67.1, 55.8, 51.6, 43.92, 43.91, 
36.9, 24.0, 23.8; 19F NMR (470 MHz, CDCl3)  -62.53; IR (neat)Q 2970, 1727, 1614, 1517, 1455, 
1325, 1250, 1177, 1158, 1110, 1067, 1044, 835, 701 cm-1; HRMS (ESI) Calcd for C23H29F3NO3 
(MH+): 424.2100; found: 424.2092.   
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Methyl 2-(1-(4-methoxy-2,6-dimethylphenyl)pyrrolidin-2-yl)propanoate (2.21a) 
1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidine 2.13k (0.2 mmol, 1 equiv.) was reacted with 
methyl acrylate 2.20a (0.24 mmol, 1.2 equiv.) following the General Procedure using B(C6F5)3 
(5.0 mol%), benzene (0.2 mL) as the solvent and was carried out for 12 h at 22 °C. 1H NMR 
analysis of the crude material revealed that 2.21a-anti and 2.21a-syn were obtained in the ratio of 
2.3:1. After purification by column chromatography (hexanes: EtOAc = 20:1), 2.21a was obtained 
as a mixture of diastereomers (56 mg, 97%). Further purification was carried out by PTLC using 
hexanes: DCM = 5:1 as the eluent to separate 2.21a-anti and 2.21a-syn.  
 
2.21a-anti: 1H NMR (600 MHz, CDCl3)  6.56 (d, J = 3.0 Hz, 1H), 6.53 (d, J = 3.0 Hz, 1H), 3.88 
(q, J = 6.4 Hz, 1H), 3.74 (s, 3H), 3.31  3.28 (m, 4H), 2.98 (q, J = 7.7 Hz, 1H), 2.36 (p, J = 6.8 Hz, 
1H), 2.27 (s, 3H), 2.24 (s, 3H), 2.07 (dq, J = 12.4, 7.5 Hz, 1H), 1.96  1.87 (m, 2H), 1.77 (dq, J = 
12.8, 6.1 Hz, 1H), 1.11 (d, J = 7.0 Hz, 3H); 13C NMR (151 MHz, CDCl3) 176.2, 156.6, 140.7, 
138.5, 137.5, 114.4, 112.9, 62.8, 55.2, 52.7, 51.1, 45.2, 29.1, 25.0, 19.5, 19.3, 13.5; IR (neat) 2947, 
1733, 1061, 1484, 1464, 1434, 1319, 1260, 1194, 1154, 1066 cm-1; HRMS (DART) m/z Calcd for 
C17H26NO3 (MH+): 292.1913; found: 292.1921. 
 
2.21a-syn: 1H NMR (600 MHz, CDCl3)  6.57 (d, J = 3.1 Hz, 1H), 6.54 (d, J = 2.8 Hz, 1H), 3.88 
 3.81 (m, 1H), 3.74 (s, 3H), 3.44 (s, 3H), 3.27 (td, J = 8.1, 7.5, 2.8 Hz, 1H), 2.92 (td, J = 8.5, 6.6 
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Hz, 1H), 2.45 (ddd, J = 7.0, 5.6, 1.4 Hz, 1H), 2.29 (s, 3H), 2.23 (s, 3H), 2.15  2.08 (m, 1H), 1.97 
 1.84 (m, 3H), 1.01 (dd, J = 7.0, 1.4 Hz, 3H); 13C NMR (151 MHz, CDCl3)  175.9, 156.4, 140.3, 
138.9, 137.2, 114.5, 113.0, 63.6, 55.2, 53.4, 51.1, 45.9, 29.8, 25.1, 19.4, 19.1, 13.8; IR (neat) 2948, 
1733, 1602, 1483, 1463, 1318, 1257, 1193, 1154, 1068cm-1; HRMS (DART) m/z Calcd for 
C17H26NO3 (MH+): 292.1913; found: 292.1919. 
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Benzyl 2-(1-(4-methoxy-2,6-dimethylphenyl)pyrrolidin-2-yl)propanoate (2.21b)  
1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidine 2.13k (0.1 mmol, 1.0 equiv.) was reacted with 
benzyl acrylate 2.20b (0.24 mmol, 1.2 equiv.) following the General Procedure using B(C6F5)3 
(5.0 mol%), benzene (0.2 mL) as the solvent and was carried out for 12 h at 22 °C.  1H NMR 
analysis of the crude material revealed that 2.21b-anti and 2.21b-syn were obtained in the ratio of 
2.5:1. After purification by column chromatography (hexanes: EtOAc = 30:1), 3c was obtained as 
a mixture of diastereomers (67 mg, 91%). Further purification was carried out by PTLC using 
hexanes: DCM = 5:1 as the eluent to separate 2.21b-anti and 2.21b-syn.  
 
2.21b-anti: 1H NMR (600 MHz, CDCl3)  7.34  7.28 (m, 3H), 7.24  7.19 (m, 2H), 6.54 (d, J = 
3.1 Hz, 1H), 6.51 (d, J = 3.1 Hz, 1H), 4.77  4.62 (m, 2H), 3.95  3.91 (m, 1H), 3.72 (s, 3H), 3.30 
(ddd, J = 8.4, 7.0, 4.8 Hz, 1H), 2.98 (dt, J = 8.4, 7.4 Hz, 1H), 2.42 (p, J = 6.8 Hz, 1H), 2.26 (s, 3H), 
2.21 (s, 3H), 2.09  2.02 (m, 1H) 1.96  1.85 (m, 2H), 1.80  1.74 (m, 1H), 1.14 (d, J = 7.0 Hz, 
3H); 13C NMR (151 MHz, CDCl3) 178.2, 159.2, 143.3, 141.2, 140.1, 138.9, 131.0, 130.5, 130.5, 
117.1, 115.6, 68.4, 65.4, 57.8, 55.3, 47.9, 31.6, 27.7, 22.1, 22.0, 16.1; IR (neat) 2944, 2878, 2837, 
1731, 1602, 1483, 1464, 1318, 1263, 1192, 1154, 1068, 697 cm-1; HRMS (DART) m/z Calcd for 
C23H30NO3 (MH+): 368.2226; found: 368.2237. 
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2.21b-syn:  1H NMR (600 MHz, CDCl3)  7.37  7.27 (m, 5H), 6.56 (d, J = 3.1 Hz, 1H), 6.51 (d, 
J = 3.1 Hz, 1H), 4.95 (d, J = 12.3 Hz, 1H), 4.71 (d, J = 12.3 Hz, 1H), 3.88 (ddd, J = 8.2, 5.5, 2.8 
Hz, 1H), 3.73 (s, 3H), 3.33  3.20 (m, 1H), 2.91 (td, J = 8.6, 6.6 Hz, 1H), 2.50 (qd, J = 7.0, 5.5 Hz, 
1H), 2.27 (s, 3H), 2.20 (s, 3H), 2.16  2.07 (m, 1H), 1.94  1.84 (m, 3H), 1.04 (d, J = 7.0 Hz, 3H); 
13C NMR (151 MHz, CDCl3)  175.3, 156.4, 140.4, 139.0, 137.2, 136.1, 128.4, 128.2, 128.0, 
114.5, 113.1, 65.9, 63.7, 55.2, 53.5, 46.1, 29.9, 25.2, 19.4, 19.2, 13.7; IR (neat) 2940, 1731, 1602, 
1483, 1463, 1256, 1192, 1154, 1068, 698 cm-1; HRMS (DART) m/z Calcd for C23H30NO3 (MH+): 
368.2226; found: 368.2239. 
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Isopropyl 2-(1-(4-methoxy-2,6-dimethylphenyl)pyrrolidin-2-yl)propanoate (2.21c) 
1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidine 2.13k (0.2 mmol, 1.0 equiv.) was reacted with 
isopropyl acrylate 2.20c (0.24 mmol, 1.2 equiv.) following the General Procedure using B(C6F5)3 
(5.0 mol%), benzene (0.2 mL) as the solvent and was carried out for 12 h at 22 °C. 1H NMR 
analysis of the crude material revealed that 2.21c-anti and 2.21c-syn were obtained in the ratio of 
2.1:1. After purification by column chromatography (hexanes: Et2O = 32:1), 2.21c was obtained 
as a mixture of diastereomers (50 mg, 78%). Further purification was carried out by PTLC using 
hexanes: Et2O = 9:1 as the eluent to separate 2.21c-anti and 2.21c-syn. 
 
2.21c-anti: 1H NMR (500 MHz, CDCl3)  6.57  6.55 (m, 1H), 6.54 (d, J = 2.8 Hz, 1H), 4.65 (hept, 
J = 6.2 Hz, 1H), 3.91 (dt, J = 7.7, 5.4 Hz, 1H), 3.74 (s, 3H), 3.29 (ddd, J = 8.4, 6.8, 4.6 Hz, 1H), 
2.98 (q, J = 7.6 Hz, 1H), 2.35  2.29 (m, 1H), 2.27 (s, 3H), 2.25 (s, 3H), 2.07  1.99 (m, 1H), 1.96 
 1.88 (m, 2H), 1.83  1.77 (m, 1H), 1.11 (dd, J = 7.1, 0.6 Hz, 3H), 1.08 (d, J = 6.3 Hz, 3H), 1.05 
(d, J = 6.2 Hz, 3H); 13C NMR (126 MHz, CDCl3) 175.2, 156.6, 140.5, 138.5, 137.6, 114.5, 113.0, 
67.1, 62.4, 55.1, 52.6, 44.8, 28.4, 25.1, 21.6, 21.5, 19.5, 19.3, 12.8; IR (neat) 2973, 1731, 1602, 
1481, 1464, 1371, 1317, 1260, 1153, 1105, 1067, 854, 698 cm-1; HRMS (DART) m/z Calcd for 
C19H30NO3 (MH+): 320.2226; found: 320.2221. 
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2.21c-syn: 1H NMR (600 MHz, CDCl3)  6.57 (d, J = 3.0 Hz, 1H), 6.53 (d, J = 3.0 Hz, 1H), 4.82 
(hept, J = 6.3 Hz, 1H), 3.78 (ddd, J = 8.6, 6.0, 2.9 Hz, 1H), 3.74 (s, 3H), 3.27 (td, J = 7.9, 2.6 Hz, 
1H), 2.92 (td, J = 8.6, 6.5 Hz, 1H), 2.43  2.36 (m, 1H), 2.32 (s, 3H), 2.23 (s, 3H), 2.17  2.09 (m, 
1H), 1.98  1.91 (m, 1H), 1.91  1.85 (m, 2H), 1.16 (d, J = 6.3 Hz, 3H), 1.08 (d, J = 6.3 Hz, 3H), 
0.97 (d, J = 6.9 Hz, 3H); 13C NMR (151 MHz, CDCl3)  175.1, 156.4, 140.3, 139.3, 137.2, 114.5, 
113.0, 67.1, 63.8, 55.1, 53.5, 46.7, 30.1, 25.2, 21.8, 21.5, 19.3, 19.3, 14.2; IR (neat) 2974, 1723, 
1603, 1464, 1317, 1255, 1153, 1107, 1068, 854 cm-1; HRMS (DART) m/z Calcd for C19H30NO3 
(MH+): 320.2226; found: 320.2216. 
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S-Phenyl 2-(1-(4-methoxy-2,6-dimethylphenyl)pyrrolidin-2-yl)propanethioate (2.21d) 
1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidine 2.13k (0.2 mmol, 1.0 equiv.) was reacted with S-
phenyl prop-2-enethioate 2.20d (0.24 mmol, 1.2 equiv.) following the General Procedure using 
B(C6F5)3 (5.0 mol%), benzene (0.2 mL) as the solvent and was carried out for 12 h at 22 °C. 1H 
NMR analysis of the crude material revealed that 2.21d-anti and 2.21d-syn were obtained in the 
ratio of 1.8:1. After purification by column chromatography (hexanes: Et2O = 30:1), 2.21d was 
obtained as a mixture of diastereomers (39 mg, 53%). 1H NMR (500 MHz, CDCl3)  7.36  7.29 
(m, 3H), 7.16  7.11 (m, 2H), 6.59 (s, 1H), 6.55 (s, 1H), 4.06 (dt, J = 7.3, 5.7 Hz, 1H), 3.76 (s, 3H), 
3.33 (ddd, J = 8.4, 6.9, 4.9 Hz, 1H), 3.00 (q, J = 7.6 Hz, 1H), 2.70  2.62 (m, 1H), 2.32 (s, 3H), 
2.25 (s, 3H), 2.11  1.98 (m, 1H), 1.97  1.88 (m, 2H), 1.86  1.80 (m, 1H), 1.22 (d, J = 7.0 Hz, 
3H); 13C NMR (151 MHz, CDCl3) 200.0, 156.8, 140.6, 138.8, 137.2, 134.5, 129.1, 129.0, 128.8, 
114.5, 113.2, 62.6, 55.1, 53.5, 52.5, 28.9, 25.0, 19.6, 19.5, 13.74; HRMS (DART) m/z Calcd for 
C22H27NO2S (MH+): 370.1835; found: 370.1833. 
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2-(1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidin-2-yl)propanenitrile (2.21e) 
1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidine 2.13k (0.2 mmol, 1.0 equiv.) was reacted with 
acrylonitrile 2.20e (0.5 mmol, 2.5 equiv.) following the General Procedure using B(C6F5)3 (10 
mol%), benzene (0.4 mL) as the solvent and was carried out for 48 h at 70 °C. 1H NMR analysis 
of the crude material revealed that 2.21e-anti and 2.21e-syn were obtained in the ratio of 1.3:1. 
After purification by column chromatography (hexanes: Et2O = 10:1), 2.21e was obtained as a 
mixture of diastereomers (25.9 mg, 50%). Further purification was carried out by PTLC using 
hexanes: Et2O = 20:1 as the eluent to separate 2.21e-anti and 2.21e-syn.  
 
2.21e-anti: 1H NMR (600 MHz, CDCl3)  6.60 (d, J = 3.0 Hz, 1H), 6.56 (d, J = 3.0 Hz, 1H), 3.80 
 3.72 (m, 4H), 3.36 (td, J = 8.0, 2.5 Hz, 1H), 3.02 (td, J = 8.9, 6.6 Hz, 1H), 2.53 (qd, J = 7.2, 3.5 
Hz, 1H), 2.34 (s, 3H), 2.28  2.23 (m, 1H), 2.22 (s, 3H), 2.14  2.09 (m, 1H), 2.01  1.90 (m, 2H), 
1.18 (d, J = 7.3 Hz, 3H); 13C NMR (151 MHz, CDCl3)  156.9, 140.3, 137.8, 137.2, 122.7, 114.8, 
113.3, 63.3, 55.2, 53.6, 32.3, 29.7, 25.3, 19.4, 19.2, 14.0; IR (neat) 2951, 2242, 2228, 1603, 1483, 
1464, 1318, 1262, 1192, 1154, 1068, 837 cm-1; HRMS (DART) m/z Calcd for C16H23N2O (MH+): 
259.1810; found: 259.1807. 
 
2.21e-syn: 1H NMR (600 MHz, CDCl3)  6.62 (d, J = 3.0 Hz, 1H), 6.56 (d, J = 3.0 Hz, 1H), 3.76 
(s, 3H), 3.46 (dt, J = 8.0, 3.9 Hz, 1H), 3.35 (td, J = 7.8, 3.2 Hz, 1H), 3.10  3.02 (m, 1H), 2.56 (qd, 
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J = 7.3, 3.7 Hz, 1H), 2.39 (s, 3H), 2.30  2.24 (m, 1H), 2.23  2.17 (m, 4H), 2.04 (td, J = 8.3, 3.9 
Hz, 1H), 1.97 (dq, J = 11.2, 3.7 Hz, 1H), 1.15 (d, J = 7.3 Hz, 3H); 13C NMR (151 MHz, CDCl3)  
157.1, 141.3, 138.0, 136.3, 122.8, 114.8, 113.2, 64.7, 55.2, 52.5, 31.7, 28.3, 24.7, 19.2, 19.1, 15.6; 
IR (neat) 2951, 2837, 2239, 1602, 1544, 1483, 1464, 1318, 1267, 1192, 1155, 1067, 858 cm-1; 
HRMS (DART) m/z Calcd for C16H23N2O (MH+): 259.1810; found: 259.1816. 
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Methyl 2-(1-(4-methoxy-2,6-dimethylphenyl)pyrrolidin-2-yl)-2-methylpropanoate (2.21f) 
1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidine 2.13k (0.2 mmol, 1.0 equiv.) was reacted with 
methyl methacrylate 2.20f (0.24 mmol, 1.2 equiv.) following the General Procedure using 
B(C6F5)3 (10 mol%), benzene (0.4 mL) as the solvent and was carried out for 24 h at 70 °C. 
After purification by column chromatography (hexanes: Et2O = 40:1), 2.21f was obtained as a 
colorless oil (59.1 mg, 97%).  
 
1H NMR (600 MHz, CDCl3)  6.54 (q, J = 3.1 Hz, 2H), 4.05 (dd, J = 9.4, 2.2 Hz, 1H), 3.73 (s, 
3H), 3.29 (ddd, J = 9.1, 6.9, 2.5 Hz, 1H), 3.07 (s, 3H), 2.90 (td, J = 8.9, 6.8 Hz, 1H), 2.29 (s, 3H), 
2.25 (s, 3H), 2.13  2.05 (m, 1H), 1.92  1.80 (m, 3H), 1.11 (s, 3H), 1.08 (s, 3H); 13C NMR (151 
MHz, CDCl3)  177.8, 156.1, 139.9, 139.8, 136.8, 114.6, 112.9, 66.8, 55.1, 54.5, 50.9, 47.7, 27.6, 
25.6, 23.2, 19.7, 19.6, 19.4; IR (neat) 2947, 2836, 1731, 1602, 1466, 1315, 1253, 1191, 1128, 1069, 
839 cm-1; HRMS (DART) Calcd for C18H28NO3 (MH+): 306.2069; found: 306.2067. 
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Dimethyl 2-(1-(4-methoxy-2,6-dimethylphenyl)pyrrolidin-2-yl)fumarate (2.21g) 
1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidine 2.13k (0.2 mmol, 1.0 equiv.) was reacted with 
dimethyl but-2-ynedioate 2.20g (0.24 mmol, 1.2 equiv.) following the General Procedure using 
B(C6F5)3 (10 mol%), benzene (0.4 mL) as the solvent and was carried out for 24 h at 70 °C. 1H 
NMR analysis of the crude material revealed that (E)-2.21g and (Z)-2.21g were obtained in the 
ratio of 1:1.6. After purification by column chromatography (hexanes: Et2O = 5:1), (E)-2.21g was 
obtained as yellow liquid (29.8 mg, 21%) and (Z)-2.21g was obtained as colorless liquid (42.5 mg, 
31%). The relative configuration was assigned based on NOESY experiments (see SI Section 7 
for NOE spectra). 
 
(E)-2.21g: 1H NMR (600 MHz, CDCl3)  6.51 (s, 2H), 6.27 (s, 1H), 5.50 (dd, J = 9.6, 4.2 Hz, 1H), 
3.77 (s, 3H), 3.72 (s, 3H), 3.61 (s, 3H), 3.44  3.39 (m, 1H), 3.06  3.00 (m, 1H), 2.47  2.41 (m, 
1H), 2.35  2.09 (m, 8H), 2.06  1.95 (m, 1H); 13C NMR (126 MHz, CDCl3) 167.8, 165.8, 156.5, 
152.4, 138.0, 124.8, 114.5, 113.0, 58.6, 55.1, 53.9, 51.9, 51.6, 32.0, 25.9, 19.1; IR (neat) 2951, 
2848, 1729, 1603, 1434, 1256, 1206, 1154, 1114, 1069, 855 cm-1; HRMS (DART) m/z Calcd for 
C19H26NO5 (MH+): 348.1811; found: 348.1822. 
 
(Z)-2.21g: 1H NMR (600 MHz, CDCl3)  6.55 (s, 2H), 5.99 (d, J = 1.1 Hz, 1H), 4.35  4.28 (m, 
1H), 3.77 (d, J = 1.7 Hz, 3H), 3.74 (d, J = 1.7 Hz, 3H), 3.67 (d, J = 1.8 Hz, 3H), 3.41  3.37 (m, 
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1H), 3.01 (dt, J = 10.2, 7.8 Hz, 1H), 2.32  2.28 (m, 7H), 2.16  2.09 (m, 1H), 2.04  1.95 (m, 
1H)；13C NMR (151 MHz, CDCl3) 1168.7, 165.7, 156.7, 153.8, 137.3, 119.0, 114.1, 113.5, 64.3, 
55.1, 53.0, 52.2, 51.7, 31.9, 24.7, 19.6; IR (neat) 2950, 2838, 1724, 1602, 1434, 1316, 1255, 1193, 
1153, 1067, 854 cm-1; HRMS (DART) m/z Calcd for C19H26NO5 (MH+): 348.1811; found: 
348.1810. 
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1-(4-Methoxy-2,6-dimethylphenyl)-1'-phenyl-[2,3'-bipyrrolidine]-2',5'-dione (2.21h) 
1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidine 2.13k (0.2 mmol, 1.0 equiv.) was reacted with 1-
phenyl-1H-pyrrole-2,5-dione 2.20h (0.24 mmol, 1.2 equiv.) following the General Procedure 
using B(C6F5)3 (5.0 mol%), benzene (0.2 mL) as the solvent and was carried out for 12 h at 22 °C. 
1H NMR analysis of the crude material revealed that 2.21h-anti and 2.21h-syn were obtained in 
the ratio of 4.5:1. After purification by column chromatography (hexanes: EtOAc = 5:1), 2.21h 
was obtained as a mixture of diastereomers (75 mg, 99%). Further purification was carried out by 
PTLC to separate 2.21h-anti and 2.21h-syn.  
 
2.21h-anti: 1H NMR (500 MHz, CDCl3)  7.46 (t, J = 7.7 Hz, 2H), 7.41  7.35 (m, 1H), 7.27  
7.22 (m, 2H), 6.62  6.56 (m, 2H), 4.31 (td, J = 6.8, 4.0 Hz, 1H), 3.76 (s, 3H), 3.38  3.30 (m, 1H), 
3.16  3.07 (m, 1H), 2.98  2.93 (m, 1H), 2.89 (dd, J = 18.8, 4.0 Hz, 1H), 2.71 (dd, J = 18.8, 9.2 
Hz, 1H), 2.32 (s, 3H), 2.26 (s, 3H), 2.14  1.98 (m, 3H), 1.64 (dt, J = 11.2, 6.6 Hz, 1H); 13C NMR 
(101 MHz, CDCl3)  177.8, 176.4, 157.0, 139.8, 138.3, 135.6, 131.9, 129.1, 128.6, 126.4, 114.9, 
113.4, 60.8, 55.2, 51.8, 43.2, 30.7, 26.3, 24.6, 19.8, 18.9; IR (neat) 2946, 1711, 1599, 1498, 1384, 
1181, 1154, 692 cm-1; HRMS (DART) m/z Calcd for C23H27N2O3 (MH+): 379.2022; found: 
379.2039. 
 
 216  
2.21h-syn: 1H NMR (500 MHz, CDCl3)  7.34  7.27 (m, 3H), 6.79  6.74 (m, 2H), 6.55  6.49 
(m, 2H), 4.53 (td, J = 7.0, 2.9 Hz, 1H), 3.72 (s, 3H), 3.44 (dt, J = 8.8, 6.2 Hz, 1H), 3.12 (dd, J = 
18.1, 4.8 Hz, 1H), 3.07  2.96 (m, 2H), 2.78 (dd, J = 18.1, 9.5 Hz, 1H), 2.35  2.27 (m, 4H), 2.25 
(s, 3H), 2.04  1.95 (m, 2H), 1.89  1.80 (m, 1H); 13C NMR (126 MHz, CDCl3)  177.4, 176.3, 
156.9, 139.0, 138.2, 137.0, 131.7, 128.7, 128.2, 126.3, 115.2, 113.4, 59.4, 55.1, 54.1, 45.6, 31.7, 
29.9, 24.7, 20.3, 18.8; IR (neat) 2951, 1709, 1600, 1499, 1382, 1180, 1068, 694 cm-1; HRMS 
(DART) m/z Calcd for C23H27N2O3 (MH+): 379.2022; found: 379.2036. 
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Methyl 2-(1-(4-methoxy-2,6-dimethylphenyl)-4,4-dimethylpyrrolidin-2-yl)propanoate (2.21i) 
1-(4-Methoxy-2,6-dimethylphenyl)-3,3-dimethylpyrrolidine 2.13t (0.2 mmol, 1.0 equiv.) was 
reacted with methyl acrylate 2.20a (0.24 mmol, 1.2 equiv.) following the General Procedure using 
B(C6F5)3 (5.0 mol%), benzene (0.2 mL) as the solvent and was carried out for 12 h at 22 °C. 1H 
NMR analysis of the crude material revealed that 2.21i-anti and 2.21i-syn were obtained in the 
ratio of 3.0:1. After purification by column chromatography (hexanes: Et2O = 65:1), 2.21i-anti 
was obtained as a white solid (44.9 mg, 70%), 2.21i-syn was obtained as a colorless oil (15.6 mg, 
24%).  
 
2.21i-anti: 1H NMR (600 MHz, CDCl3)  6.55 (d, J = 3.0 Hz, 1H), 6.48 (d, J = 3.0 Hz, 1H), 4.05 
(q, J = 7.9, 7.4 Hz, 1H), 3.73 (d, J = 1.0 Hz, 3H), 3.11 (s, 3H), 3.08 (d, J = 8.3 Hz, 1H), 2.82 (d, J 
= 8.3 Hz, 1H), 2.36 (p, J = 6.9 Hz, 1H), 2.29 (s, 3H), 2.29 (s, 3H), 1.81 (dd, J = 12.2, 6.8 Hz, 1H), 
1.52 (dd, J = 12.2, 8.0 Hz, 1H), 1.20 (s, 3H), 1.15 (s, 3H), 1.02 (d, J = 7.0 Hz, 3H). 13C NMR (151 
MHz, CDCl3)  176.1, 156.5, 140.5, 139.3, 135.7, 114.1, 113.0, 66.0, 61.9, 55.1, 51.0, 45.3, 44.7, 
36.3, 29.4, 28.6, 19.7, 19.4, 14.7; IR (neat) 2950, 1734, 1602, 1482, 1465, 1269, 1193, 1154, 854 
cm-1; HRMS (DART) m/z Calcd for C19H30NO3 (MH+): 320.2226; found: 320.2241. 
 
2.21i-syn: 1H NMR (600 MHz, CDCl3)  6.57 (d, J = 3.0 Hz, 1H), 6.50 (d, J = 3.0 Hz, 1H), 3.90 
(q, J = 7.1 Hz, 1H), 3.75 (s, 3H), 3.57 (s, 3H), 3.03 (d, J = 8.4 Hz, 1H), 2.82 (d, J = 8.4 Hz, 1H), 
 218  
2.54 (p, J = 7.0 Hz, 1H), 2.28 (s, 3H), 2.27 (s, 3H), 1.88 (dd, J = 12.6, 7.7 Hz, 1H), 1.67 (dd, J = 
12.6, 6.3 Hz, 1H), 1.22 (s, 3H), 1.12 (s, 3H), 0.87 (dd, J = 6.9, 0.8 Hz, 3H); 13C NMR (151 MHz, 
CDCl3)  176.0, 156.4, 139.8, 137.8, 137.3, 114.4, 113.3, 66.5, 63.1, 55.1, 51.2, 46.0, 44.7, 36.8, 
29.2, 28.4, 19.8, 19.4, 15.4; IR (neat) 2951, 1735, 1603, 1483, 1465, 1256, 1192, 1155, 1069, 855 
cm-1; HRMS (DART) m/z Calcd for C19H30NO3 (MH+): 320.2226; found: 320.2240. 




3-((tert-Butyldimethylsilyl)oxy)-1-(4-methoxy-2,6-dimethylphenyl)pyrrolidine 2.13u (0.2 mmol, 
1.0 equiv.) was reacted with methyl acrylate 2.20a (0.24 mmol, 1.2 equiv.) following the General 
Procedure using B(C6F5)3 (5.0 mol%), benzene (0.2 mL) as the solvent and was carried out for 12 
h at 22 °C. 1H NMR analysis of the crude material revealed that 2.21j-anti, 2.21j-a  and 2.21j-
syn, 2.21j-  were obtained in the ratio of 6.9:5.9:3.0:1. After purification by column 
chromatography (hexanes: Et2O = 13:1), 2.21j was obtained as a mixture of diastereomers (69 mg, 
82%). Further purification was carried out by PTLC to separate 2.21j-anti and 2.21j-syn. The 
relative configuration of the pyrrolidine substituents was assigned anti based on NOESY 
experiments. 
 
2.21j-anti: 1H NMR (600 MHz, CDCl3)  6.56 (d, J = 3.0 Hz, 1H), 6.53 (d, J = 3.1 Hz, 1H), 4.41 
(t, J = 4.7 Hz, 1H), 4.09  4.04 (m, 1H), 3.74 (s, 3H), 3.55 (dd, J = 9.2, 5.2 Hz, 1H), 3.47 (s, 3H), 
2.81 (dd, J = 9.2, 3.6 Hz, 1H), 2.42 (qd, J = 6.9, 5.1 Hz, 1H), 2.33 (s, 3H), 2.23 (s, 3H), 2.06 (ddd, 
J = 12.6, 7.0, 5.6 Hz, 1H), 1.98 (ddd, J = 12.1, 7.1, 4.3 Hz, 1H), 0.97 (d, J = 7.0 Hz, 3H), 0.89 (s, 
9H), 0.08 (s, 3H), 0.04 (s, 3H); 13C NMR (151 MHz, CDCl3)  175.7, 156.5, 140.1, 138.0, 137.6, 
114.4, 112.9, 70.9, 62.0, 61.8, 55.1, 51.1, 44.5, 39.1, 25.8, 19.3, 19.1, 18.1, 14.1, -4.75, -4.81.; IR 
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(neat) 2951, 2929, 2856, 1735, 1603, 1464, 1318, 1253, 1154, 1068, 1024, 832, 774 cm-1; HRMS 
(DART) m/z Calcd for C23H40NO4Si (MH+): 422.2727; found: 422.2724. 
 
2.21j-syn: 1H NMR (600 MHz, CDCl3)  6.54 ( , 1H), 6.52 ( , 1H), 4.38 (d , J = 5.1, 2.6 Hz, 1H), 
4.14 (q, J = 7.3 Hz, 1H), 3.73 (s, 3H), 3.60 (dd, J = 9.5, 4.9 Hz, 1H), 3.18 (s, 3H), 2.83 (d, J = 9.5 
Hz, 1H), 2.34 (s, 3H), 2.32  2.27 (m, 1H), 2.25 (s, 3H), 1.97 (ddd, J = 12.6, 6.3, 2.8 Hz, 1H), 1.78 
 1.72 (m, 1H), 1.06 (d, J = 7.0 Hz, 3H), 0.89 (s, 9H), 0.08 (s, 3H), 0.04 (s, 3H); 13C NMR (151 
MHz, CDCl3)  176.0, 156.6, 140.6, 139.6, 136.2, 114.2, 112.7, 70.8, 62.0, 60.9, 55.1, 51.0, 45.3, 
39.7, 25.8, 19.2, 19.0, 18.0, 14.2, -4.77, -4.81; IR (neat) 2952, 2928, 2856, 1737, 1604, 1465, 1319, 
1258, 1155, 1069, 1028, 853, 775 cm-1; HRMS (DART) m/z Calcd for C23H40NO4Si (MH+): 
422.2727; found: 422.2741. 
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Methyl 2-(1-(4-methoxy-2,6-dimethylphenyl)piperidin-2-yl)propanoate (2.21k) 
1-(4-Methoxy-2,6-dimethylphenyl)piperidine 2.13o (0.2 mmol, 1.0 equiv.) was reacted with 
methyl acrylate 2.20a (0.24 mmol, 1.2 equiv.) following the General Procedure using B(C6F5)3 
(5.0 mol%), benzene (0.2 mL) as the solvent and was carried out for 12 h at 22 °C. 1H NMR 
analysis of the crude material revealed that 2.21k-anti and 2.21k-syn were obtained in the ratio of 
10:1.0. After purification by column chromatography (hexanes: Et2O = 19:1), 2.21k was obtained 
as a mixture of diastereomers (39 mg, 63%). Further purification was carried out by PTLC using 
DCM: hexanes = 3:2 as the eluent to separate 2.21k-anti and 2.21k-syn.  
 
2.21k-anti: 1H NMR (600 MHz, CDCl3)  6.60 (d, J = 3.0 Hz, 1H), 6.43 (d, J = 3.0 Hz, 1H), 3.73 
(s, 3H), 3.67 (dt, J = 9.7, 3.3 Hz, 1H), 3.60 (s, 3H), 3.10  3.04 (m, 1H), 2.84  2.79 (m, 1H), 2.44 
(qd, J = 7.0, 3.6 Hz, 1H), 2.37 (s, 3H), 2.30 (s, 3H), 1.89  1.83 (m, 1H), 1.62  1.56 (m, 2H), 1.48 
 1.34 (m, 3H), 0.86 (d, J = 7.0 Hz, 3H); 13C NMR (151 MHz, CDCl3)  175.8, 156.4, 139.4, 139.2, 
138.4, 114.3, 113.5, 59.6, 55.0, 52.4, 51.5, 41.1, 27.3, 26.7, 24.9, 20.0, 19.1, 9.7; IR (neat) 2922, 
2851, 1736, 1602, 1481, 1464, 1211, 1169, 1151, 1111, 1069, 855 cm-1; HRMS (DART) m/z 
Calcd for C18H28NO3 (MH+): 306.2069; found: 306.2078. 
 
2.21k-syn: 1H NMR (600 MHz, CDCl3)  6.60 (d, J = 3.0 Hz, 1H), 6.44 (d, J = 3.0 Hz, 1H), 3.75 
(s, 3H), 3.49 (s, 3H), 3.23 (dt, J = 10.6, 2.9 Hz, 1H), 3.00 (td, J = 11.7, 3.1 Hz, 1H), 2.84 (dd, J = 
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11.9, 3.8 Hz, 1H), 2.53 (qd, J = 7.3, 3.3 Hz, 1H), 2.26 (s, 3H), 2.22 (s, 3H), 1.89 (dt, J = 12.8, 4.1 
Hz, 1H), 1.84  1.79 (m, 1H), 1.66  1.50 (m, 3H), 1.33 (tdt, J = 12.8, 9.0, 3.9 Hz, 1H), 1.08 (d, J 
= 7.2 Hz, 3H); 13C NMR (151 MHz, CDCl3) 175.2, 156.4, 140.3, 140.1, 137.6, 113.8, 113.4, 62.8, 
55.1, 52.7, 51.0, 40.5, 27.9, 26.7, 25.2, 20.0, 19.3, 15.7; HRMS (DART) m/z Calcd for C18H28NO3 
(MH+): 306.2069; found: 306.207. 
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Methyl 2-(1-(4-methoxy-2,6-dimethylphenyl)azepan-2-yl)propanoate (2.21l) 
1-(4-Methoxy-2,6-dimethylphenyl)azepane 2.13v (0.2 mmol, 1.0 equiv.) was reacted with methyl 
acrylate 2.20a (0.24 mmol, 1.2 equiv.) following the General Procedure using B(C6F5)3 (5.0 mol%), 
benzene (0.2 mL) as the solvent and was carried out for 12 h at 22 °C. 1H NMR analysis of the 
crude material revealed that 2.21l-anti and 2.21l-syn were obtained in the ratio of 2.0:1.0. After 
purification by column chromatography (hexanes: Et2O = 32:1), 2.21l was obtained as a mixture 
of diastereomers (42 mg, 66%). Further purification was carried out by PTLC using DCM: hexanes 
= 3:2 as the eluent to seperate 2.21l-anti and 2.21l-syn.  
 
2.21l-anti: 1H NMR (500 MHz, CDCl3)  6.59  6.55 (m, 2H), 3.79 (dt, J = 10.0, 4.3 Hz, 1H), 
3.74 (s, 3H), 3.46 (s, 3H), 3.31 (ddd, J = 14.8, 9.9, 1.4 Hz, 1H), 3.15  3.07 (m, 1H), 2.45 (qd, J = 
7.0, 4.1 Hz, 1H), 2.39 (s, 3H), 2.26 (s, 3H), 1.94  1.86 (m, 1H), 1.84  1.61 (m, 5H), 1.51 (dtt, J 
= 13.8, 9.2, 2.1 Hz, 1H), 1.44  1.33 (m, 1H), 1.13 (d, J = 7.0 Hz, 3H); 13C NMR (126 MHz, 
CDCl3)  176.2, 155.9, 141.4, 138.7, 137.9, 114.3, 113.8, 62.1, 55.2, 53.1, 51.3, 43.9, 32.3, 30.0, 
29.3, 26.3, 20.4, 20.0, 12.1; IR (neat) 2923, 2849, 1731, 1602, 1481, 1433, 1309, 1253, 1196, 1162, 
1069, 853 cm-1; HRMS (DART) m/z Calcd for C19H30NO3 (MH+): 320.2226; found: 320.2231. 
 
2.21l-syn: 1H NMR (600 MHz, CDCl3)  6.57 (dd, J = 22.4, 3.1 Hz, 2H), 3.74 (s, 3H), 3.50 (s, 
3H), 3.46  3.38 (m, 2H), 3.01 (dd, J = 15.1, 5.6 Hz, 1H), 2.50 (qd, J = 7.1, 3.2 Hz, 1H), 2.38 (s, 
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3H), 2.29 (s, 3H), 2.01  1.91 (m, 2H), 1.86  1.68 (m, 3H), 1.58 (dt, J = 13.9, 4.7 Hz, 1H), 1.48  
1.40 (m, 1H), 1.33 (qt, J = 12.1, 3.9 Hz, 1H), 0.99 (d, J = 7.1 Hz, 3H); 13C NMR (151 MHz, CDCl3) 
 176.0, 155.6, 141.6, 138.8, 137.0, 114.1, 114.0, 64.7, 55.1, 52.1, 51.0, 44.3, 32.5, 30.8, 30.1, 
26.6, 20.6, 19.8, 14.9; IR (neat) 2925, 2851, 1732, 1602, 1482, 1411, 1308, 1254, 1196, 1164, 
1070, 853 cm-1; HRMS (DART) m/z Calcd for C19H30NO3 (MH+): 320.2226; found: 320.2211. 




4-Methoxy-N,N,2,6-tetramethylaniline 2.13g (0.2 mmol, 1.0 equiv.) was reacted with 1-phenyl-
1H-pyrrole-2,5-dione 2.20h (0.24 mmol, 1.2 equiv.) following the General Procedure using 
B(C6F5)3 (10 mol%), benzene (0.2 mL) as the solvent and was carried out for 24 h at 70 °C. After 
purification by column chromatography (hexanes: EtOAc = 4:1), 2.21m was obtained as a white 
solid (44 mg, 62%), 2.21m-di was obtained as a white solid (14 mg, 27%).  
 
2.21m: 1H NMR (600 MHz, CDCl3)  7.46 (t, J = 7.7 Hz, 2H), 7.40  7.36 (m, 1H), 7.26  7.23 
(m, 2H), 6.56 (s, 2H), 3.75 (s, 3H), 3.69 (dd, J = 13.2, 4.1 Hz, 1H), 3.36 (dd, J = 13.2, 8.4 Hz, 1H), 
3.09 (tt, J = 8.8, 4.5 Hz, 1H), 2.94  2.81 (m, 2H), 2.78 (s, 3H), 2.31 (s, 3H), 2.29 (s, 3H); 13C 
NMR (151 MHz, CDCl3)  180.6, 178.7, 159.4, 144.3, 140.7, 140.5, 134.6, 131.8, 131.2, 129.0, 
116.8, 116.7, 60.0, 57.9, 44.6, 44.0, 36.3, 22.1, 22.0; IR (neat) 2929, 2849, 1710, 1599, 1499, 1384, 




dione (2.21m-di): 1H NMR (600 MHz, CDCl3)  7.48  7.44 (m, 2H), 7.40  7.36 (m, 1H), 7.22 
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(dt, J = 8.4, 1.2 Hz, 2H), 6.51 (d, J = 3.0 Hz, 2H), 6.48 (d, J = 3.0 Hz, 2H), 3.73 (s, 6H), 3.56 (dd, 
J = 13.5, 5.3 Hz, 2H), 3.40 (dd, J = 13.5, 3.5 Hz, 2H), 3.01 (t, J = 4.1 Hz, 2H), 2.64 (s, 6H), 2.24 
(s, 6H), 2.21 (s, 6H); 13C NMR (151 MHz, CDCl3)  181.0, 159.3, 145.1, 140.3, 139.9, 134.8, 
131.8, 131.1, 129.0, 117.0, 116.5, 59.5, 57.8, 48.3, 45.0, 22.2, 21.9; IR (neat) 2960, 2921, 1710, 
1600, 1485, 1368, 1315, 1191, 1154, 1063 cm-1; HRMS (DART) m/z Calcd for C32H40N3O4 
(MH+): 530.3019; found: 530.3021. 
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Benzyl 2-methyl-3-(2,2,6,6-tetramethylpiperidin-1-yl)propanoate (2.21n) 
1,2,2,6,6-Pentamethylpiperidine 2.13p (0.2 mmol, 1.0 equiv.) was reacted with benzyl acrylate 2c 
(0.24 mmol, 1.2 equiv.) following the General Procedure using B(C6F5)3 (10 mol%), benzene (0.4 
mL) as the solvent and was carried out for 12 h at 70 °C. After purification by column 
chromatography (hexanes: EtOAc = 10:1), 2.21n was obtained as a colorless oil (57.8 mg, 91%).  
 
1H NMR (600 MHz, CDCl3)  7.40  7.28 (m, 5H), 5.16  5.04 (m, 2H), 2.89 (dd, J = 15.4, 7.5 
Hz, 1H), 2.64 (td, J = 7.5, 5.8 Hz, 1H), 2.48 (dd, J = 15.4, 5.6 Hz, 1H), 1.51 (s, 2H), 1.38 (dd, J = 
6.7, 4.4 Hz, 4H), 1.13 (d, J = 7.1 Hz, 3H), 1.01 (s, 6H), 0.95 (s, 6H); 13C NMR (126 MHz, CDCl3) 
177.1, 136.3, 128.4, 128.0, 128.0, 65.8, 54.6, 48.9, 44.2, 41.3, 17.8, 16.1; IR (neat) 2965, 2927, 
1733, 1456, 1379, 1364, 1256, 1164, 696 cm-1; HRMS (DART) m/z Calcd for C20H32NO2 (MH+): 
318.2433; found: 318.2443. 




1-((tert-Butyldimethylsilyl)oxy)-N-isopropyl-N,2-dimethylpropan-2-amine 2.13r (0.2 mmol, 1.0 
equiv.) was reacted with benzyl acrylate 2.20b (0.24 mmol, 1.2 equiv.) following the General 
Procedure using B(C6F5)3 (10 mol%) and 0.2 mL benzene as the solvent and was carried out for 
12 h at 22 °C.. After purification by column chromatography (hexanes: Et3N = 49:1), 2.21o was 
obtained as a colorless oil (76.6 mg, 91%).  
 
1H NMR (500 MHz, CDCl3)  7.37  7.26 (m, 5H), 5.14  5.05 (m, 2H), 3.39  3.33 (m, 2H), 3.25 
(qd, J = 8.2, 7.5, 5.3 Hz, 1H), 3.04  2.97 (m, 1H), 2.70  2.59 (m, 2H), 1.09 (dt, J = 6.7, 1.6 Hz, 
3H), 1.01 (d, J = 9.7 Hz, 9H), 0.95 (dt, J = 6.7, 1.5 Hz, 3H), 0.87 (t, J = 1.5 Hz, 9H); 13C NMR 
(126 MHz, CDCl3) 176.7, 136.4, 128.4, 128.0, 127.9, 69.6, 65.7, 59.3, 47.4, 46.4, 42.9, 25.9, 
24.32, 24.28, 18.2, 15.2, -5.6; IR (neat) 2956, 2929, 2856, 1734, 1461, 1250, 1156, 1085, 834, 
773, 667 cm-1; HRMS (DART) m/z Calcd for C24H44NO3Si (MH+): 422.309; found: 422.3102. 
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Benzyl 3-(bis((R)-1-phenylethyl)amino)-2-methylpropanoate (2.21p) 
(R)-N-Methyl-1-phenyl-N-((R)-1-phenylethyl)ethan-1-amine 2.13w (0.2 mmol, 1 equiv.) was 
reacted with benzyl acrylate 2.20b (0.24 mmol, 1.2 equiv.) following the General Procedure using 
B(C6F5)3 (10 mol%), DCM (0.4 mL) as the solvent and was carried out for 12 h at 70 °C. 1H NMR 
analysis of the crude material revealed that 2.21p-(R,S) and 2.21p-(R,R) were obtained in the ratio 
of 1.5:1.0.  After purification by column chromatography (hexanes: Et2O = 30:1), 2.21p was 
obtained as a colorless oil (72.5 mg, 91%). Further purification was carried out by PTLC using 
Et2O: hexanes = 1:9 as the eluent to separate 2.21p-(R,S) and 2.21p-(R,R).  
 
2.21p-(R,S): 1H NMR (500 MHz, CDCl3)  7.41  7.31 (m, 4H), 7.28  7.18 (m, 6H), 5.19  5.07 
(m, 2H), 3.84 (q, J = 6.9 Hz, 2H), 3.10 (dd, J = 14.0, 8.3 Hz, 1H), 2.52 (q, J = 7.1 Hz, 1H), 2.36 
(dd, J = 14.0, 6.2 Hz, 1H), 1.33 (d, J = 6.9 Hz, 6H), 0.90 (d, J = 6.9 Hz, 3H); 13C NMR (126 MHz, 
CDCl3) 176.4, 144.4, 136.2, 128.5, 128.14, 128.06, 128.0, 127.9, 126.6, 66.0, 58.4, 50.1, 41.6, 
18.9, 15.2; IR (neat) 2971, 1731, 1492, 1452, 1174, 1144, 748, 695 cm-1; HRMS (DART) m/z 
Calcd for C27H32NO2 (MH+): 402.2433; found: 402.2451. 
 
2.21p-(R,R): 1H NMR (500 MHz, CDCl3)  7.33 (dd, J = 12.7, 6.9 Hz, 2H), 7.28  7.23 (m, 6H), 
7.19 (q, J = 4.9, 4.5 Hz, 2H), 4.97 (d, J = 12.5 Hz, 1H), 4.83 (d, J = 12.5 Hz,1H), 3.94 (q, J = 6.9 
Hz, 2H), 2.80 (qd, J = 13.8, 7.2 Hz, 2H), 2.62 (h, J = 7.0 Hz, 1H), 1.37 (d, J = 6.8 Hz, 6H), 1.13 
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(d, J = 6.9 Hz, 3H); 13C NMR (126 MHz, CDCl3)  175.8, 144.4, 136.3, 128.4, 127.94, 127.92, 
126.6, 65.8, 57.7, 49.7, 40.7, 18.0, 15.4; IR (neat) 2970, 1732, 1492, 1452, 1356, 1218, 1177, 751, 
698 cm-1; HRMS (DART) m/z Calcd for C27H32NO2 (MH+): 402.2433; found: 402.2442. 
 
 
The minor diastereomer was obtained from three reactions following the General Procedure using 
B(C6F5)3 (10 mol%), DCM (0.6 mL) as the solvent and was carried out for 12 h at 70 °C on 0.6 
mmol scale. The derivatization of the minor diastereomer was performed based on the literature 
previously reported.18 The minor diastereomer (190 mg, 0.47 mmol) was dissolved in a solution 
of 4.4% formic acid in MeOH (9.4 mL), whereupon Pd-C (10 mol%, 162 mg) was added. The 
reaction mixture was then heated at 40 °C for 2 h. Upon cooling, the suspension was filtered 
through a pad of Celite and the mixture was concentrated to remove the solvent and volatile side 
products to obtain the product as a colorless oil (48 mg, >95% yield). [ ]25D = 4.8° (c = 1.0, H2O). 
Based on the observed optical rotation value, the absolute configuration of the minor diastereomer 
was assigned as 2.21p-(R,R). 
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3-(2-(1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidin-2-yl)propanoyl)oxazolidin-2-one (2.24a) 
1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidine 2.13k was reacted with 3-acryloyloxazolidin-2-one 
2.23a following the General Procedure for Stereoselective Mannich Reactions. The 1H NMR 
analysis of the crude material revealed 2.24a was obtained in >95% yield as a mixture of 
diastereomers; the ratio of 2.24a-anti and 2.24a-syn was determined to be 1.6:1. [ ]25D = 18.2° 
(c = 1.0, EtOH). The absolute configuration of 2.24a-anti was assigned in analogy (see SI Section 
4). 
 
1H NMR (600 MHz, CDCl3)  6.55 (d, J = 2.9 Hz, 1H), 6.49 (d, J = 3.0 Hz, 1H), 4.20 (td, J = 9.0, 
4.8 Hz, 1H), 4.04  3.99 (m, 2H), 3.73 (s, 3H), 3.68 (dd, J = 8.0, 6.7 Hz, 1H), 3.60 (dt, J = 10.5, 
9.1 Hz, 1H), 3.32 (q, J = 7.5 Hz, 1H), 3.13 (ddd, J = 10.4, 9.2, 4.8 Hz, 1H), 2.99 (td, J = 8.4, 4.6 
Hz, 1H), 2.27 (s, 3H), 2.22 (s, 3H), 2.14  2.08 (m, 1H), 2.01  1.94 (m, 1H), 1.93  1.86 (m, 1H), 
1.77  1.71 (m, 1H), 1.12 (d, J = 6.9 Hz, 3H); 13C NMR (151 MHz, CDCl3) 176.4, 156.7, 153.0, 
141.1, 140.8, 136.8, 113.7, 112.4, 62.8, 61.7, 55.2, 51.7, 42.9, 42.6, 30.8, 24.4, 19.4, 19.1, 15.6; 
IR (neat) 2962, 2837, 1775, 1695, 1601, 1478, 1384, 1267, 1221, 1194, 1154, 1066 cm-1; HRMS 
(DART) m/z Calcd for C19H27N2O4 (MH+): 347.1971; found: 347.1964. HPLC (Chiralpak IA; 
10%/ 90% hexane/ isopropanol, 1.0 mL/min; 2.24a-anti: tr = 6.8 min (major), 6.2 min (minor); 
80:20 er; 2.24a-syn: 8.4 min (major), 7.6 min (minor) 68:32 er). 

























1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidine 2.13k was reacted with 3-acryloyl-4,4-
dimethyloxazolidin-2-one 2.23b following the General Procedure for Stereoselective Mannich 
Reactions. The 1H NMR analysis of the crude material revealed 2.24b was obtained in 88% yield 
as a mixture of diastereomers; the ratio of 2.24b-anti and 2.24b-syn was determined to be 4.3:1. 
[ ]25D = 31.1° (c = 1.0, EtOH). 
 
1H NMR (500 MHz, CDCl3)  6.53  6.50 (m, 2H), 4.02 (q, J = 6.7 Hz, 1H), 3.84 (d, J = 8.3 Hz, 
1H), 3.74 (d, J = 8.4 Hz, 1H), 3,73  3.71 (m, 4H), 3.30 (ddd, J = 8.4, 7.2, 5.6 Hz, 1H), 2.97 (td, J 
= 7.9, 6.1 Hz, 1H), 2.26 (s, 3H), 2.24 (s, 3H), 2.10 (dtd, J = 11.8, 7.0, 5.9 Hz, 1H), 2.01  1.88 (m, 
2H), 1.87  1.80 (m, 1H), 1.37 (s, 3H), 1.12 (d, J = 7.0 Hz, 3H), 1.10 (s, 3H); 13C NMR (126 MHz, 
CDCl3)  177.1, 156.7, 153.5, 140.6, 139.5, 137.6, 114.4, 112.8, 74.7, 61.8, 55.1, 54.0, 52.5, 44.2, 
29.9, 25.1, 24.4, 24.1, 19.4, 15.0; IR (neat) 2963, 2836, 1773, 1698, 1602, 1481, 1376, 1303, 1176, 
1154, 1071, 765 cm-1; HRMS (DART) m/z Calcd for C21H31N2O4 (MH+): 375.2284; found: 
375.2292. HPLC (Chiralpak IC; 2.5%/ 97.5% hexane/ isopropanol, 0.5 mL/min; 2.24b-anti: tr = 
25.1 min (major), 19.3 min (minor); 97:3 er; 2.24b-syn: 22.1 min (major), 20.9 min (minor) 98:2 
er). 






















1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidine 2.13k was reacted with 1-acryloyl-3-oxa-1-
azaspiro[4.5]decan-2-one 2.23c following the General Procedure for Stereoselective Mannich 
Reactions. The 1H NMR analysis of the crude material revealed 2.24c was obtained in 79% yield 
as a mixture of diastereomers; the ratio of 2.24c-anti and 2.24c-syn was determined to be 5.6:1. 
[ ]25D = 47.5° (c = 1.0, EtOH). The absolute configuration of 2.24c-anti was assigned in analogy  
 
1H NMR (600 MHz, CDCl3) 6.52 (t, J = 2.8 Hz, 2H), 4.07 (d, J = 8.5 Hz, 1H), 3.99 (q, J = 6.6 
Hz, 1H), 3.87 (dd, J = 8.5, 1.1 Hz, 1H), 3.75 (t, J = 6.8 Hz, 1H), 3.71 (s, 3H), 3.29 (td, J = 7.8, 5.5 
Hz, 1H), 2.97 (td, J = 8.0, 6.5 Hz, 1H), 2.25 (s, 3H), 2.24 (s, 3H), 2.17  2.06 (m, 2H), 1.97  1.89 
(m, 2H), 1.85 (ddd, J = 11.3, 7.4, 5.7 Hz, 1H), 1.76  1.69 (m, 1H), 1.66  1.62 (m, 1H), 1.57  
1.53 (m, 1H), 1.49  1.45 (m, 1H), 1.18  1.08 (m, 7H), 1.07  1.01 (m, 1H); 13C NMR (151 MHz, 
CDCl3)  177.6, 156.7, 154.0, 140.5, 139.3, 137.6, 114.3, 112.9, 71.3, 63.9, 61.9, 55.1, 52.6, 44.3, 
31.9, 31.2, 29.7, 25.2, 24.0, 22.9, 22.8, 19.4, 19.2, 14.8; IR (neat) 2929, 2860, 1771, 1698, 1602, 
1482, 1456, 1375, 1318, 1262, 1224, 1157, 1071 cm-1; HRMS (DART) m/z Calcd for C24H35N2O4 
(MH+): 415.2597; found: 415.2594. HPLC (Chiralcel IA; 2.5%/ 97.5% hexane/ isopropanol, 0.5 
mL/min; 3s-anti: tr = 12.6 min (major), 14.7 min (minor); 95:5 er; 3s-syn: 13.4 min (major), 16.9 
min (minor) 98:2 er). 






















1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidine 2.13k was reacted with (R)-3-acryloyl-4-
benzyloxazolidin-2-one 2.23d following the General Procedure for Stereoselective Mannich 
Reactions. The 1H NMR analysis of the crude material revealed 2.24d was obtained in 66% yield 
as a mixture of diastereomers; the ratio of diastereomers was determined to be 12:2:1:0.  
 
1H NMR (500 MHz, CDCl3)  7.32  7.22 (m, 3H), 7.10  7.04 (m, 2H), 6.50 (s, 2H), 4.05 (td, J 
= 8.2, 5.9 Hz, 1H), 3.93 (dd, J = 8.3, 1.5 Hz, 1H), 3.85  3.75 (m, 2H), 3.68 (s, 3H), 3.66  3.59 
(m,1H), 3.32 (q, J = 7.5 Hz, 1H), 3.03  2.97 (m, 2H), 2.62 (dd, J = 13.5, 8.7 Hz, 1H), 2.26 (s, 3H), 
2.24 (s, 3H), 2.16  2.09 (m, 1H), 2.01  1.89 (m, 2H), 1.74 (dq, J = 11.0, 8.4 Hz, 1H), 1.17 (d, J 
= 6.9 Hz, 3H); 13C NMR (151 MHz, CDCl3)  178.7, 159.4, 155.5, 143.80, 143.76, 139.4, 138.0, 
132.0, 131.4, 129.8, 116.3, 115.2, 68.5, 65.2, 57.8, 54.2, 45.6, 40.3, 33.6, 27.1, 22.1, 21.8, 18.5; 
IR (neat) 2959, 2923, 2852, 1776, 1692, 1601, 1481, 1383, 1210, 1154, 1067, 703 cm-1; HRMS 
(DART) m/z Calcd for C26H33N2O4 (MH+): 437.244; found: 437.2436. 
 




1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidine 2.13k was reacted with (S)-3-acryloyl-4-
phenyloxazolidin-2-one 2.23e-(S) following the General Procedure for Stereoselective Mannich 
Reactions. The 1H NMR analysis of the crude material revealed 2.24e-(S) was obtained in 61% 
yield as a mixture of diastereomers; the ratio of diaseteromers was determined to be 3.6:2.1:1:0.  
 
1H NMR (600 MHz, CDCl3)  7.38  7.29 (m, 3H), 7.21  7.17 (m, 2H), 6.53 (s, 2H), 5.31 (dd, J 
= 8.8, 3.8 Hz, 1H), 4.57 (t, J = 8.8 Hz, 1H), 4.18 (dd, J = 8.9, 3.9 Hz, 1H), 3.87 (dt, J = 7.1, 4.5 
Hz, 1H), 3.75 (s, 3H), 3.70  3.65 (m, 1H), 3.23 (ddd, J = 8.5, 6.9, 3.4 Hz, 1H), 2.97 (q, J = 8.1 
Hz, 1H), 2.24 (s, 3H), 2.19 (s, 3H), 1.85  1.79 (m, 2H), 1.76  1.72 (m, 2H), 1.19 (d, J = 6.9 Hz, 
3H); 13C NMR (151 MHz, CDCl3) 175.6, 156.5, 153.0, 140.3, 139.2, 138.2, 137.5, 129.0, 128.5, 
126.0, 114.6, 113.0, 69.6, 61.8, 57.7, 55.0, 52.8, 42.8, 27.2, 25.7, 19.30, 19.25, 11.4; IR (neat) 
2955, 2835, 1777, 1699, 1602, 1480, 1457, 1382, 1316, 1262, 1194, 1153, 699 cm-1; HRMS 








1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidine 2.13k was reacted with (R)-3-acryloyl-4-
phenyloxazolidin-2-one 2.23e-(R) following the General Procedure for Stereoselective Mannich 
Reactions. The 1H NMR analysis of the crude material revealed 2.24e-(R) was obtained in >95% 
yield as a mixture of diastereomers; the ratio of 2.24e-(R)-anti and 2.24e-(R)-syn was determined 
to be 87:13. [ ]25D = 160.8° (c = 1.0, EtOH). The absolute configurations of 2.24e-(R)-anti and 
2.24e-(R)-syn were assigned as described in SI Section 4. 
 
2.24e-(R)-anti: 1H NMR (600 MHz, CDCl3)  7.29 (t, J = 7.4 Hz, 2H), 7.26  7.23 (m, 1H), 7.06 
(d, J = 7.5 Hz,2H), 6.60 (d, J = 3.0 Hz, 1H), 6.54 (d, J = 3.0 Hz, 1H), 4.56 (dd, J = 8.4, 2.4 Hz, 
1H), 4.27 (t, J = 8.4 Hz, 1H), 4.03  3.94 (m, 2H), 3.77 (s, 3H), 3.71 (q, J = 7.3 Hz, 1H), 3.33 (q, 
J = 7.5 Hz, 1H), 3.01 (td, J = 8.4, 4.6 Hz, 1H), 2.31 (s, 3H), 2.21 (s, 3H), 2.13  2.04 (m, 1H), 2.10 
 2.05 (m, 1H), 1.92  1.86 (m, 1H), 1.74  1.68 (m, 1H), 1.07 (d, J = 6.9 Hz, 3H); 13C NMR (151 
MHz, CDCl3)  175.2, 156.8, 153.2, 141.3, 141.2, 139.5, 136.7, 129.0, 128.2, 125.1, 113.8, 112.4, 
69.8, 62.4, 57.4, 55.2, 51.5, 42.7, 30.7, 24.4, 19.4, 19.2, 15.6; IR (neat) 2962, 2836, 1776, 1698, 
1600, 1479, 1456, 1380, 1193, 1153, 699 cm-1; HRMS (DART) m/z Calcd for C25H31N2O4 (MH+): 
423.2284; found: 423.2282. 
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2.24e-(R)-syn: 1H NMR (600 MHz, CDCl3)  7.33  7.29 (m, 2H), 7.28  7.24 (m, 1H), 7.16  
7.12 (m, 2H), 6.59 (d, J = 3.1 Hz, 1H), 6.54 (d, J = 3.1 Hz, 1H), 4.70 (dd, J = 8.4, 2.9 Hz, 1H), 
4.37 (t, J = 8.5 Hz, 1H), 4.13  4.03 (m, 2H), 3.81  3.70 (m, 4H), 3.35  3.26 (m, 1H), 2.95  2.85 
(m, 1H), 2.31 (s, 3H), 2.28  2.19 (m, 4H), 2.03  1.94 (m, 1H), 1.91  1.85 (m, 1H), 1.84  1.80 
(m, 1H), 1.00 (d, J = 6.8 Hz, 3H); 13C NMR (126 MHz, CDCl3)  175.0, 156.4, 153.5, 140.7, 139.5, 
139.4, 137.0, 129.0, 128.4, 125.5, 114.4, 113.0, 70.0, 62.5, 57.9, 55.2, 53.6, 44.6, 30.9, 25.3, 19.4, 
19.3, 12.6; IR (neat) 2957, 2835, 1774, 1701, 1602, 1479, 1457, 1380, 1317, 1193, 1042, 698 cm-
1; HRMS (DART) m/z Calcd for C25H31N2O4 (MH+): 423.2284; found: 423.2291. 
 
 




1-(4-Methoxy-2,6-dimethylphenyl)-3,3-dimethylpyrrolidine 2.13t was reacted with (R)-3-
acryloyl-4-phenyloxazolidin-2-one 2.23e-(R) following the General Procedure for Stereoselective 
Mannich Reactions. 1H NMR analysis of the crude material revealed that 2.24f-major and 2.24f-
minor were obtained in the ratio of 58:17:0:0. After purification by column chromatography 
(hexanes: Et2O = 17:3 then 15:5), 2.24f-major (52 mg, 58%) and 2.24f-minor (15 mg, 17%) were 
obtained as single diastereomers. The absolute configurations of 2.24f-major and 2.24f-minor 
were assigned as described in SI Section 4. 
 
2.24f-major: 1H NMR (500 MHz, CDCl3) 7.34  7.20 (m, 3H), 7.08  7.02 (m, 2H), 6.60 (d, J 
= 3.0 Hz, 1H), 6.53 (d, J = 3.0 Hz, 1H), 4.45 (dd, J = 8.4, 2.2 Hz, 1H), 4.23  4.11 (m, 2H), 4.01 
 3.93 (m, 1H), 3.81  3.71 (m, 4H), 3.17 (d, J = 7.9 Hz, 1H), 2.80 (d, J = 7.9 Hz, 1H), 2.33 (s, 
3H), 2.24 (s, 3H), 1.78 (dd, J = 11.6, 5.5 Hz, 1H), 1.56 (dd, J = 11.7, 9.7 Hz, 1H), 1.19 (s, 3H), 
1.17 (s, 3H), 1.00 (d, J = 6.9 Hz, 3H); 13C NMR (126 MHz, CDCl3) 175.0, 156.8, 153.2, 142.5, 
141.5, 139.6, 135.7, 129.0, 128.2, 125.1, 113.7, 112.5, 69.7, 65.1, 61.9, 57.4, 55.3, 46.2, 42.6, 36.7, 
29.2, 28.4, 19.7, 19.3, 16.1; IR (neat) 2953, 2863, 2836, 1780, 1698, 1600, 1481, 1380, 1196, 1154, 
702 cm-1; HRMS (DART) m/z Calcd for C27H35N2O4 (MH+): 451.2597; found: 451.2612; [ ]25D 
= 152.7° (c = 1.0, EtOH). 
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2.24f-minor: 1H NMR (500 MHz, CDCl3) 7.41  7.30 (m, 3H), 7.16  7.11 (m, 2H), 6.48 (d, J 
= 3.1 Hz, 1H), 6.40 (d, J = 3.0 Hz, 1H), 5.27 (dd, J = 8.8, 4.0 Hz, 1H), 4.57 (t, J = 8.8 Hz, 1H), 
4.18 (ddd, J = 12.5, 8.8, 5.2 Hz, 2H), 3.81 (t, J = 6.6 Hz, 1H), 3.73 (s, 3H), 3.03 (d, J = 8.4 Hz, 
1H), 2.76 (d, J = 8.4 Hz, 1H), 2.25 (s, 6H), 1.50 (dd, J = 12.3, 8.6 Hz, 1H), 1.24  1.18 (m, 1H), 
1.12 (s, 3H), 1.05 (s, 3H), 1.01 (d, J = 6.9 Hz, 3H); 13C NMR (151 MHz, CDCl3) 175.6, 156.3, 
153.1, 139.4, 139.04, 139.01, 135.5, 129.0, 128.5, 126.1, 114.4, 113.3, 69.6, 65.9, 60.1, 57.9, 55.0, 
42.7, 41.1, 36.0, 29.5, 28.8, 19.7, 19.4, 12.7; IR (neat) 2952, 2920, 2850, 1779, 1702, 1481, 1381, 




2.24f-major was transformed into the corresponding benzyl ester 2.29-major following 
previously reported literatures.19,20  
(R)-2-((R)-1-(4-Methoxy-2,6-dimethylphenyl)-4,4-dimethylpyrrolidin-2-yl)propanoic acid 
(R)-2-((R)-1-(4-Methoxy-2,6-dimethylphenyl)-4,4-dimethylpyrrolidin-2-yl)propanoic acid was 
prepared by following a known procedure.19 To a solution of Mannich product 2.24f-major (90 
mg, 0.2 mmol) in THF:H2O (3:1, 2.4 mL) at 0 °C was added H2O2 (30% v/v, 0.02 mL, 0.8 mmol) 
and 2.0 M LiOH (0.14 mL, 0.28 mmol), dropwise. The mixture was stirred at 22 °C for 5 h, 
whereupon the reaction was quenched with NaHSO3. The crude mixture was then concentrated in 
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vacuo, then diluted with EtOAc (2 mL), H2O (2 mL), and 1 M NaOH (2 mL). The organic layer 
was separated and the aqueous layer was extracted with EtOAc (3 x 5 mL). Subsequently, the 
aqueous layer was acidified with 6 M HCl (2 mL) and extracted with EtOAc (3 x 5 mL). The 
combined organic layers were washed with brine (10 mL), dried (MgSO4), filtered. and 
concentrated in vacuo to afford (R)-2-((R)-1-(4-Methoxy-2,6-dimethylphenyl)-4,4-
dimethylpyrrolidin-2-yl)propanoic acid as a yellow solid (60 mg, 98%) which was used without 





was prepared by following a known procedure.20 Benzyl bromide (0.12 mL, 1.0 mmol) was added 
dropwise to a mixture of (R)-2-((R)-1-(4-Methoxy-2,6-dimethylphenyl)-4,4-dimethylpyrrolidin-2-
yl)propanoic acid (61 mg, 0.2 mmol) and K2CO3 (28 mg, 0.2 mmol) in acetone (1.0 mL). The 
reaction mixture was heated at reflux for 12 h. The reaction mixture was filtered through a pad of 
celite and the solvent was evaporated by rotary evaporation. The crude product was purified by 
silica gel column chromatography (19:1 Hexanes: Et2O) to afford 2.29-major as a colorless oil 
(74 mg, 93% yield).  
 
1H NMR (500 MHz, CDCl3) 7.31 (qd, J = 7.7, 4.0 Hz, 3H), 7.20 (d, J = 7.2 Hz, 2H), 6.51 (d, J = 
3.0 Hz, 1H), 6.47 (d, J = 3.1 Hz, 1H), 4.61  4.38 (m, 2H), 4.10 (q, J = 7.6 Hz, 1H), 3.70 (s, 3H), 
3.12  3.02 (m, 1H), 2.87  2.77 (m, 1H), 2.48  2.38 (m, 1H), 2.29 (s, 3H), 2.27 (s, 3H), 1.82  
1.75 (m, 1H), 1.52 (dd, J = 12.2, 8.1 Hz, 1H), 1.21  1.18 (m, 3H), 1.14 (d, J = 1.3 Hz, 3H), 1.05 
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(dd, J = 7.0, 1.4 Hz, 3H); 13C NMR (151 MHz, CDCl3) 175.5, 156.5, 140.5, 139.4, 136.2, 135.7, 
128.3, 127.80, 127.75, 114.2, 113.0, 66.0, 65.7, 61.9, 55.1, 45.3, 44.6, 36.3, 29.4, 28.6, 19.7, 19.5, 
14.7; HPLC (Chiralpak AD-H; 1%/ 99% hexane/isopropanol, 0.5 mL/min; 5v-major: tr = 11.4 







Signal 2: DAD1 B, Sig=210,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  11.372 BV    0.3234 6.31420e4  3076.77075  50.4308
   2  12.077 VB    0.3114 6.20631e4  3129.58765  49.5692
Totals :                  1.25205e5  6206.35840
Signal 3: DAD1 C, Sig=214,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  11.372 BV    0.2906 5.01685e4  2676.98486  50.3099
   2  12.077 VB    0.2768 4.95505e4  2768.60571  49.6901
Totals :                  9.97190e4  5445.59058
Signal 4: DAD1 D, Sig=230,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  11.372 BV    0.2759 1.84011e4  1022.80670  50.2007
   2  12.077 VB    0.2610 1.82540e4  1070.08130  49.7993
Totals :                  3.66551e4  2092.88800
Signal 5: DAD1 E, Sig=260,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  11.372 BV    0.2746 7922.97559  443.02206  50.3373
   2  12.077 VB    0.2575 7816.78369  461.69904  49.6627
Totals :                  1.57398e4   904.72110
=====================================================================
                          *** End of Report ***
Data File C:\Chem32\1\Data\JOE 2018-01-09 17-17-31\001-0201.D
Sample Name: diMe_OBnEster_MAJOR_RacStd_AD-H
Wasa_LC1 1/26/2018 10:49:08 AM SYSTEM Page 3 of 3








Signal 2: DAD1 B, Sig=210,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  12.109 MM    0.2945 2.61223e4  1478.15210 100.0000
Totals :                  2.61223e4  1478.15210
Signal 3: DAD1 C, Sig=214,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   6.120 BV R  0.1796 1080.61401   84.28934   5.1415
   2   6.656 VB E  0.2155   40.93517    2.99348   0.1948
   3   7.524 BV    0.1419   27.83509    3.00991   0.1324
   4   8.281 BB    0.4060  250.94867    8.92516   1.1940
   5   9.353 BB    0.3078   89.15699    3.97368   0.4242
   6  12.109 BB    0.2672 1.91140e4  1086.95911  90.9433
   7  16.174 BB    0.4157  414.01382   14.47365   1.9699
Totals :                  2.10175e4  1204.62433
Signal 4: DAD1 D, Sig=230,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   6.120 BB    0.1851  355.88660   26.76414   4.8008
   2   8.219 BB    0.3339  103.23051    4.59941   1.3925
   3   9.364 BB    0.3299   56.32647    2.33087   0.7598
   4  12.109 BB    0.2654 6736.99219  386.40054  90.8792
   5  16.172 BB    0.4617  160.69478    4.93688   2.1677
Totals :                  7413.13054  425.03185
Signal 5: DAD1 E, Sig=260,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   6.126 BB    0.1898   28.92779    2.16595   0.9767
   2  12.109 BB    0.2622 2859.26172  164.94635  96.5424
   3  16.177 BB    0.3831   73.47362    2.80999   2.4808
Totals :                  2961.66312  169.92229
=====================================================================
Data File C:\Chem32\1\Data\JOE 2018-01-19 12-09-44\002-0301.D
Sample Name: diMePyrolidine_JZC1052_ee_OD-H
Wasa_LC1 1/26/2018 10:49:44 AM SYSTEM Page 3 of 4




1,2,2,6,6-Pentamethylpiperidine 2.13p was reacted with (R)-3-acryloyl-4-phenyloxazolidin-2-one 
2.23e-(R) following the General Procedure for Stereoselective Mannich Reactions at 60 °C. 1H 
NMR analysis of the crude material revealed that 2.24g-major and 2.24g-minor were obtained in 
the ratio of 2.0:1. After purification by PTLC (hexanes: EtOAc: Et3N = 16:4:1), 2.24g-major (35 
mg, 47%) and 2.24g-minor (28 mg, 24%) were obtained as single diastereomers. 
 
2.24g-major: 1H NMR (500 MHz, CDCl3) 7.37 (t, J = 7.0 Hz, 2H), 7.33 (d, J = 6.8 Hz, 1H), 
7.29  7.25 (m, 2H), 5.44  5.36 (m, 1H), 4.69  4.60 (m, 1H), 4.23 (ddd, J = 8.9, 3.4, 1.6 Hz, 1H), 
4.03 (p, J = 6.8 Hz, 1H), 2.95 (dd, J = 15.5, 6.5 Hz, 1H), 2.49 (dd, J = 15.5, 5.8 Hz, 1H), 1.51 (d, 
J = 5.9 Hz, 2H), 1.39 (dd, J = 8.5, 4.6 Hz,4H), 1.10 (d, J = 7.1 Hz,3H), 1.03 (s, 6H), 0.97 (s, 6H); 
13C NMR (126 MHz, CDCl3) 177.6, 153.3, 139.4, 129.1, 128.5, 125.6, 69.6, 57.8, 54.6, 47.8, 
41.4, 41.3, 17.8, 16.4; IR (neat) 2963, 2926, 1780, 1699, 1381, 1320, 1242, 1197, 1042, 761 cm-
1; HRMS (DART) m/z Calcd for C22H33N2O3 (MH+): 373.2491; found: 373.2504; [ ]25D = 107.9° 
(c = 0.3, EtOH). 
 
2.24g-minor: 1H NMR (500 MHz, CDCl3) 7.40  7.30 (m, 5H), 5.45 (dd, J = 8.9, 4.0 Hz, 1H), 
4.67 (dd, J = 9.6, 8.2 Hz, 1H), 4.31  4.24 (m, 1H), 3.97 (q, J = 6.8 Hz, 1H), 2.90 (dd, J = 15.4, 
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6.3 Hz, 1H), 2.37 (dd, J = 15.4, 6.3 Hz, 1H), 1.47 (s, 2H), 1.32 (t, J = 6.0 Hz, 4H), 1.16 (dd, J = 
7.1, 1.3 Hz, 3H), 0.96 (s, 6H), 0.78 (s, 6H); 13C NMR (151 MHz, CDCl3) 177.7, 153.4, 139.3, 
129.0, 128.6, 126.3, 69.5, 57.9, 54.6, 47.5, 41.6, 41.4, 17.8, 16.4; IR (neat) 2964, 2925, 2872, 1777, 
1700, 1457, 1380, 1319, 1196, 1044, 949, 699 cm-1; HRMS (DART) m/z Calcd for C22H33N2O3 
(MH+): 373.2491; found: 373.2474. 
 
 
2.24g-major was transformed into the corresponding benzyl ester 2.30 following previously 
reported literatures.19,20 HPLC (Chiralcel OD-H; 2.5%/ 97.5% hexane/ isopropanol, 0.3 mL/min; 











Signal 2: DAD1 B, Sig=210,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   9.617 BV E  0.4102   85.66731    3.26378   0.0729
   2   9.998 VB R  0.1884 1737.17468  134.73553   1.4790
   3  11.157 BB    0.3700  140.25397    5.38239   0.1194
   4  12.553 BV    0.3174 5.11232e4  2450.86841  43.5242
   5  13.338 VB    0.3458 5.31715e4  2333.48706  45.2681
   6  15.166 BV    0.3114 2012.29797  100.57347   1.7132
   7  15.794 VB    0.3757 2970.09277  119.59342   2.5286
   8  18.859 BV    0.4646  374.99554   11.93493   0.3193
   9  19.726 VV    0.4023  330.21573   12.18028   0.2811
  10  20.201 VB    0.5049  386.08643   10.85573   0.3287
  11  32.157 BB    1.3847 4158.10645   44.15428   3.5400
  12  39.660 BBA   0.8390  969.58582   19.26030   0.8255
Totals :                  1.17459e5  5246.28959
Signal 3: DAD1 C, Sig=214,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  12.553 BV    0.3105 3.89884e4  1891.08167  49.0918
   2  13.338 VB    0.3420 4.04311e4  1786.66699  50.9082
Totals :                  7.94195e4  3677.74866
Signal 4: DAD1 D, Sig=230,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  12.553 BV    0.2982 7523.91992  374.85226  49.2105
   2  13.338 VB    0.3294 7765.33203  351.95917  50.7895
Totals :                  1.52893e4   726.81143
Signal 5: DAD1 E, Sig=260,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   9.998 BB    0.1850   73.74391    5.85267   3.1714
   2  12.553 BV    0.2947  998.59540   50.48923  42.9451
   3  13.338 VB    0.3247 1025.46667   47.33791  44.1007
   4  15.775 BB    0.3492   55.16742    2.42693   2.3725
   5  19.723 BB    0.4426  172.30855    6.15475   7.4102
Data File C:\Chem32\1\Data\JOE 2018-01-24 11-57-03\051-0301.D
Sample Name: PMP_OBn_Rac_OD-H
Wasa_LC1 1/26/2018 10:14:54 AM SYSTEM Page 3 of 4
Signal : DAD1 B, Sig=210,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   9.885 BV R  0.2503 5218.80078  289.56799   9.5940
   2  10.498 VB E  0.1543  137.35313   14.01525   0.2525
   3  10.946 BB    0.2198  137.73628    9.13990   0.2532
   4  12.401 BV E  0.3925 3775.58936  140.94868   6.9409
   5  12.888 VV R  0.3636 4.35171e4  1815.74707  79.9999
   6  14.014 VB E  0.2820 1327.97534   70.41232   2.4413
   7  15.099 BB    0.4059  281.89401    9.79071   0.5182
Totals :                  5.43964e4  2349.62193
Signal 3: DAD1 C, Sig=214,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   9.884 BV R  0.2557 5210.86230  281.80453  12.1739
   2  10.500 VV E  0.2037  170.51910   12.15090   0.3984
   3  10.950 VB E  0.3192  250.60991   11.73183   0.5855
   4  12.396 BV E  0.3877 3026.10913  113.25787   7.0698
   5  12.888 VV R  0.3609 3.27945e4  1371.69690  76.6163
   6  14.015 VB E  0.2834 1158.26392   61.03849   2.7060
   7  15.094 BB    0.4065  192.67404    6.68107   0.4501
Totals :                  4.28035e4  1858.36158
Signal 4: DAD1 D, Sig=230,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  12.886 MM    0.3695 5700.90869  257.16043 100.0000
Totals :                  5700.90869  257.16043
Signal 5: DAD1 E, Sig=260,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   9.883 BB    0.2000  164.74242   12.01617  14.0560
   2  10.959 BB    0.3059   57.11954    2.84859   4.8735
   3  12.380 BV E  0.4363  106.49444    3.44858   9.0862
   4  12.888 VB R  0.3470  813.12915   35.52960  69.3770
   5  14.015 BB    0.2648   30.55952    1.79329   2.6074
Data File C:\Chem32\1\Data\JOE 2018-01-25 17-02-55\052-0201.D
Sampl  Nam : PMP_OBn_ee_OD-H
Wasa_LC1 1/26/2018 10:46:08 AM SYSTEM Page 3 of 4




1-((tert-Butyldimethylsilyl)oxy)-N-ethyl-N-isopropyl-2-methylpropan-2-amine 2.13r was reacted 
with (R)-3-acryloyl-4-phenyloxazolidin-2-one 2.23e-(R) following the General Procedure for 
Stereoselective Mannich Reactions. 1H NMR analysis of the crude material revealed that 2.24h-
major and 2.24h-minor were obtained in the ratio of 7.4:1. After purification by silica gel column 
chromatography (hexanes: Et3N = 50:1 then 19:1), 2.24h-major (71 mg, 70%) and 2.24h-minor 
(9 mg, 10%) were obtained as single diastereomers.  
 
2.24h-major: 1H NMR (600 MHz, CDCl3)  7.37 (dd, J = 8.2, 6.7 Hz, 2H), 7.33 (d, J = 7.1 Hz, 
1H), 7.29  7.27 (m, 2H), 5.42 (dd, J = 8.5, 3.2 Hz, 1H), 4.64 (t, J = 8.7 Hz, 1H), 4.23 (dd, J = 8.8, 
3.3 Hz, 1H), 3.99 (h, J = 7.0 Hz, 1H), 3.43  3.34 (m, 2H), 3.27 (p, J = 6.7 Hz, 1H), 3.03 (dd, J = 
14.8, 7.3 Hz, 1H), 2.68 (dd, J = 14.8, 6.6 Hz, 1H), 1.06 (d, J = 7.2 Hz, 9H), 1.01 (d, J = 6.7 Hz, 
3H), 0.98 (d, J = 6.7 Hz, 3H), 0.89 (s, 9H), 0.02 (d, J = 1.3 Hz, 6H); 13C NMR (151 MHz, CDCl3) 
179.8, 156.0, 142.1, 131.8, 131.2, 128.3, 72.3, 72.2, 62.1, 60.4, 49.2, 49.0, 42.8, 28.5, 26.8, 26.8, 
20.8, 18.1, -2.9; IR (neat) 2956, 2925, 2854, 1781, 1702, 1459, 1381, 1195, 1086, 1044, 836, 774 
cm-1; HRMS (DART) m/z Calcd for C26H45N2O4Si (MH+): 477.3147; found: 477.3171; [ ]25D = 
60.9° (c = 0.8, EtOH). 
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2.24h-major was transformed into the corresponding benzyl ester 2.31 following previously 
reported literatures.19,20 HPLC (Chiralcel OD-H; 0.5%/ 99.5% hexane/ isopropanol, 1.0 mL/min; 











Signal 2: DAD1 B, Sig=210,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   9.553 MM    0.3346 1.11078e4   553.30640 100.0000
Totals :                  1.11078e4   553.30640
Signal 3: DAD1 C, Sig=214,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   3.191 BB    0.0777   26.96137    5.45439   0.2836
   2   4.776 BV    0.0914    8.54738    1.43678   0.0899
   3   5.759 BB    0.2971   32.72557    1.63773   0.3442
   4   6.494 BV    0.1551   16.43309    1.60946   0.1729
   5   6.873 VB    0.2515   75.61379    4.55815   0.7954
   6   7.719 BB    0.3177   42.63292    2.00832   0.4484
   7   8.865 BB    0.3653  118.62687    5.25660   1.2478
   8   9.553 BB    0.2932 8338.38574  417.24231  87.7103
   9  11.474 BB    0.6601  302.60452    7.29213   3.1831
  10  17.072 BB    0.8197  219.57695    3.73573   2.3097
  11  22.048 BB    0.7366  324.62189    6.90368   3.4147
Totals :                  9506.73009  457.13529
Signal 4: DAD1 D, Sig=230,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   3.190 BB    0.0767    5.41841    1.11530   0.3666
   2   6.875 BB    0.2439   20.34101    1.29054   1.3763
   3   9.553 BB    0.2923 1452.13831   72.92982  98.2570
Totals :                  1477.89773   75.33566
Signal 5: DAD1 E, Sig=260,4 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   9.553 BB    0.2921  222.08055   11.16121 100.0000
Totals :                   222.08055   11.16121
=====================================================================
Data File C:\Chem32\1\Data\JOE 2018-01-22 17-26-19\032-0101.D
Sample Name: OTBS_OBn_ee_OD-H
Wasa_LC1 1/26/2018 10:17:29 AM SYSTEM Page 3 of 4
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3-(2-(1-(2,6-dimethylphenyl)pyrrolidin-2-yl)propanoyl)-4,4-dimethyloxazolidin-2-one (2.24i)  
1-(2,6-dimethylphenyl)pyrrolidine 2.13y was reacted with 3-acryloyl-4,4-dimethyloxazolidin-2- 
one 2.23b following the General Procedure for Stereoselective Mannich Reactions. The 1H NMR 
analysis of the crude material revealed that 2.24i-anti and 2.24i-syn were obtained in the ratio of 
3.8:1. After purification by column chromatography (hexanes: Et2O = 19:1 then 9:1), 2.24i-anti 
(39 mg, 56%) and 2.24i-syn (10 mg, 15%) were obtained as single diastereomers. The absolute 
configurations of 2.24i-anti and 2.24i-syn were assigned in analogy.  
 
2.24i-anti: 1H NMR (600 MHz, CDCl3)  6.98  6.89 (m, 3H), 4.09 (q, J = 6.7 Hz, 1H), 3.83 (d, 
J = 8.2 Hz, 1H), 3.78  3.70 (m, 2H), 3.34 (ddd, J = 8.2, 7.0, 5.4 Hz, 1H), 2.96 (td, J = 7.9, 6.2 Hz, 
1H), 2.27 (d, J = 1.9 Hz, 6H), 2.13 (dq, J = 12.0, 6.7 Hz, 1H), 2.02  1.82 (m, 3H), 1.35 (s, 3H), 
1.12 (d, J = 6.9 Hz, 3H), 1.04 (s, 3H); 13C NMR (151 MHz, CDCl3)  177.0, 153.6, 144.8, 139.1, 
138.0, 129.4, 127.9, 125.2, 74.7, 61.7, 60.3, 52.5, 44.5, 29.8, 25.3, 24.4, 24.1, 19.3, 19.0, 15.0; IR 
(neat) 2965, 2874, 1774, 1699, 1466, 1374, 1304, 1219, 1176, 1085, 1035, 766 cm-1 ; HRMS 
(DART) m/z Calcd for C20H28N2O3 (MH+): 345.2172; f d: 345.2181; [ ]25D = 36.2° (c = 0.8, 
EtOH); HPLC (Chiralcel IC; 5.0%/ 95.0% n-butanol/ hexanes, 0.2 mL/min; tr = 27.3 min (minor), 
30.4 min (major); 89:11 er.  
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2.24i-syn: 1H NMR (500 MHz, CDCl3)  6.98 ( , J = 8.1 H , 2H), 6.92 ( , J = 7.4 H , 1H), 4.04 
(ddd, J = 8.9, 6.5, 2.7 Hz, 1H), 3.90 (d, J = 8.3 Hz, 1H), 3.82 (d, J = 8.3 Hz, 1H), 3.75 (q, J = 6.7 
Hz, 1H), 3.36 (td, J = 7.9, 2.8 Hz, 1H), 2.89 (td, J = 8.9, 6.7 Hz, 1H), 2.35 (s, 3H), 2.27 (s, 1H), 
2.25 (s, 3H), 2.09  1.96 (m, 1H), 1.95  1.84 (m, 1H), 1.75 (ddt, J = 12.9, 6.7, 2.9 Hz, 1H), 1.45 
(s, 3H), 1.17 (s, 3H), 1.00 (d, J = 6.7 Hz, 3H); 13C NMR (151 MHz, CDCl3)  177.1, 153.9, 146.9, 
139.0, 135.5, 129.6, 128.3, 124.8, 74.9, 63.3, 60.5, 53.7, 46.5, 31.7, 25.5, 24.6, 23.9, 19.3, 19.1, 
13.6; IR (neat) 2965, 2874, 1774, 1699, 1466, 1374, 1304, 1219, 1176, 1085, 1035, 766 cm-1; 
HRMS (DART) m/z Calcd for C20H28N2O3 (MH+): 345.2172; found: 345.2181; HPLC (Chiralcel 
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3-(2-(1-(4-(tert-Butyl)-2,6-dimethylphenyl)pyrrolidin-2-yl)propanoyl)-4,4- 
dimethyloxazolidin-2-one (2.24j)  
1-(4-(tert-Butyl)-2,6-dimethylphenyl)pyrrolidine 2.13z was reacted with 3-acryloyl-4,4- 
dimethyloxazolidin-2-one 2.23b following the General Procedure for Stereoselective Mannich 
Reactions. The 1H NMR analysis of the crude material revealed that 2.24j-anti and 2.24j-syn were 
obtained in the ratio of 4.4:1. After purification by column chromatography (hexanes: Et2O = 19:1 
then 9:1), 2.24j-anti (46 mg, 57%) and 2.24j-syn (10 mg, 13%) were obtained as single 
diastereomers. The absolute configurations of 2.24j-anti and 2.24j-syn were assigned in analogy.  
 
2.24j-anti: 1H NMR (500 MHz, CDCl3)  6.99  6.91 (m, 2H), 4.10 (q, J = 6.8 Hz, 1H), 3.83 (dd, 
J = 8.2, 1.0 Hz, 1H), 3.77  3.67 (m, 2H), 3.38  3.26 (m, 1H), 2.99  2.89 (m, 1H), 2.26 (d, J = 
3.0 Hz, 6H), 2.17  2.08 (m, 1H), 1.90 (dddd, J = 27.8, 23.7, 12.1, 6.6 Hz, 3H), 1.34 (s, 3H), 1.25 
(d, J = 1.0 Hz, 9H), 1.12 (dd, J = 7.0, 1.0 Hz, 3H), 0.98 (s, 3H); 13C NMR (126 MHz, CDCl3)  
177.1, 153.6, 147.4, 142.1, 138.2, 137.1, 126.3, 124.9, 74.7, 61.7, 60.2, 52.8, 44.7, 34.0, 31.5, 30.2, 
25.2, 24.4, 24.2, 19.6, 19.2, 15.34; IR (neat) 2963, 2871, 1774, 1700, 1483, 1459, 1373, 1305, 
1221, 1176, 1084, 766 cm-1 ; HRMS (DART) m/z Calcd for C24H36N2O3 (MH+): 401.2799; found: 
401.2789; [ ]25D = 40.6° (c = 1.0, EtOH).  
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2.24j-syn: 1H NMR (500 MHz, CDCl3)  7.05  6.87 (m, 2H), 4.06 (ddd, J = 8.4, 5.4, 2.4 Hz, 1H), 
3.87 (d, J = 8.3 Hz, 1H), 3.73 (dd, J = 12.8, 7.4 Hz, 2H), 3.41  3.28 (m, 1H), 2.89 (ddd, J = 9.5, 
8.5, 6.5 Hz, 1H), 2.34 (s, 3H), 2.32  2.25 (m, 1H), 2.22 (s, 3H), 2.09  1.94 (m, 1H), 1.94  1.84 
(m, 1H), 1.78 (ddt, J = 12.6, 7.2, 2.7 Hz, 1H), 1.42 (s, 3H), 1.25 (s, 9H), 1.06 (d, J= 6.7 Hz, 3H), 
1.00 (s, 3H); 13C NMR (151 MHz, CDCl3)  176.8, 154.0, 147.4, 144.0, 138.3, 134.5, 126.4, 125.3, 
74.9, 63.2, 60.5, 54.1, 46.4, 34.0, 31.6, 31.4, 25.5, 24.6, 24.4, 23.6, 19.5, 12.7; IR (neat) 2963, 
2871, 1774, 1700, 1483, 1459, 1373, 1305, 1221, 1176, 1084, 766 cm-1 ; HRMS (DART) m/z 
Calcd for C24H36N2O3 (MH+): 401.2799; found: 401.2789; HPLC (Chiralpak IA then OJ-H; 1.0%/ 
99.0% isopropanol/ hexanes, 0.1 mL/min; tr = 103.3 min (major), 108.1 min (minor); 98:2 er. 
 
2.24j-anti was transformed into the corresponding benzyl ester 2.32-anti following previously 
reported literatures.19,20  
1H NMR (500 MH , CDC 3)  7.34  7.27 (m, 3H), 7.21  7.18 (m, 2H), 7.00 (d, J = 2.4 Hz, 1H), 
6.96 (d, J = 2.4 Hz, 1H), 4.65 (d, J = 12.5 Hz, 1H), 4.54 (d, J = 12.5 Hz, 1H), 3.98 (td, J = 6.9, 5.3 
Hz, 1H), 3.39  3.29 (m, 1H), 3.00 (q, J = 7.7 Hz, 1H), 2.43 (p, J = 6.9 Hz, 1H), 2.29 (s, 3H), 2.24 
(s, 3H), 2.07 (dq, J = 12.1, 7.6 Hz, 1H), 1.98  1.85 (m, 2H), 1.84  1.73 (m, 1H), 1.25 (s, 9H), 
1.13 (d, J = 7.0 Hz, 3H); IR (neat) 2959, 2924, 2869, 2359, 2158, 1720, 1553, 1482, 1455, 1361, 
1222, 1151, 1109, 732, 696 cm-1 ; HRMS (DART) m/z Calcd for C26H36NO2 (MH+): 394.2741; 
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f d: 394.2733; [ ]25D = 38.9° (c = 0.5, EtOH); HPLC (Chiralpak OJ-H; 1.0%/ 99.0% 
isopropanol/ hexanes, 0.5 mL/min; tr = 7.3 min (minor), 8.3 min (major); 91:9 er. 
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3-(3-((1-((tert-Butyldimethylsilyl)oxy)-2-methylpropan-2-yl)(isopropyl)amino)-2- 
methylpropanoyl)-4,4-dimethyloxazolidin-2-one (2.24k)  
1-((tert-Butyldimethylsilyl)oxy)-N-ethyl-N-isopropyl-2-methylpropan-2-amine 2.13r was reacted 
with 3-acryloyl-4,4-dimethyloxazolidin-2-one 2.23b following the General Procedure for 
Stereoselective Mannich Reactions. After purification by silica gel column chromatography 
(hexanes: Et3N = 98.5 : 1.5), 2.24k (40 mg, 46%) was obtained as a colorless oil.  
 
1H NMR (400 MHz, CDCl3)  4.03  3.91 (m, 2H), 3.81 (h, J = 6.9 Hz, 1H), 3.37 (s, 2H), 3.26 (h, 
J = 6.7 Hz, 1H), 3.13 (dd, J = 14.4, 7.8 Hz, 1H), 2.64 (dd, J = 14.4, 6.6 Hz, 1H), 1.56 (d, J = 7.3 
Hz, 6H), 1.09 (d, J = 6.8 Hz, 3H), 1.07  0.99 (m, 12H), 0.88 (s, 9H), 0.01 (s, 6H); 13C NMR (151 
MHz, CDCl3)  178.8, 153.9, 75.0, 69.4, 60.6, 59.4, 46.9, 46.3, 41.1, 25.8, 24.8, 24.3, 24.2, 23.5, 
22.2, 18.2, 15.5, -5.6; IR (neat) 2958, 2930, 2888, 2857, 1780, 1705, 1467, 1387, 1362, 1304, 1252, 
1087, 837, 774 cm-1; HRMS (DART) m/z Calcd for C22H44N2O4Si (MH+): 429.3143; found: 
429.3133; [ ]25D = 7.3° (c = 1.0, EtOH). 
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2.24k was transformed into the corresponding benzyl ester 2.33 following previously reported 
literatures.19,20 HPLC (Chiralcel OD-H; 0.5%/ 99.5% n-butanol/ hexanes, 1.0 mL/min; 4c: tr = 
6.5 min (minor), 12.0 min (major); 96:4 er. 
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A8. X-Ray Crystallography Data of 2.28-major and 2.28-minor 
X-Ray Crystallography Data of 2.28-major 
 
Table S2.12.  Crystal data and structure refinement for C24H32N2O3. 
Identification code  C24H32N2O3 
Empirical formula  C24 H32 N2 O3 
Formula weight  396.51 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 9.6090(4) Å a= 90°. 
 374  
 b = 8.9512(4) Å b= 101.0730(10)°. 
 c = 12.4737(5) Å g = 90°. 
Volume 1052.92(8) Å3 
Z 2 
Density (calculated) 1.251 Mg/m3 
Absorption coefficient 0.653 mm-1 
F(000) 428 
Crystal size 0.560 x 0.460 x 0.280 mm3 
Theta range for data collection 3.611 to 66.644°. 
Index ranges -11<=h<=11, -10<=k<=10, -14<=l<=14 
Reflections collected 19999 
Independent reflections 3701 [R(int) = 0.0307] 
Completeness to theta = 66.644° 99.2 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7528 and 0.6460 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3701 / 3 / 274 
Goodness-of-fit on F2 1.062 
Final R indices [I>2sigma(I)] R1 = 0.0265, wR2 = 0.0684 
R indices (all data) R1 = 0.0265, wR2 = 0.0684 
Absolute structure parameter 0.00(4) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.202 and -0.152 e.Å-3 
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X-Ray Crystallography Data of 2.28-minor 
 
Table S2.13.  Crystal data and structure refinement for C24H32N2O3(CH3OH). 
Identification code  C24H32N2O3(CH3OH) 
Empirical formula  C25 H36 N2 O4 
Formula weight  428.56 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 7.8167(3) Å D= 90°. 
 b = 15.1723(5) Å E= 90°. 
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 c = 20.1325(7) Å J = 90°. 
Volume 2387.66(15) Å3 
Z 4 
Density (calculated) 1.192 Mg/m3 
Absorption coefficient 0.642 mm-1 
F(000) 928 
Crystal size 0.420 x 0.120 x 0.080 mm3 
Theta range for data collection 3.648 to 66.655°. 
Index ranges -9<=h<=9, -18<=k<=18, -23<=l<=23 
Reflections collected 16235 
Independent reflections 4210 [R(int) = 0.0707] 
Completeness to theta = 66.655° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7533 and 0.5967 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4210 / 3 / 291 
Goodness-of-fit on F2 1.026 
Final R indices [I>2sigma(I)] R1 = 0.0461, wR2 = 0.1154 
R indices (all data) R1 = 0.0574, wR2 = 0.1232 
Absolute structure parameter 0.4(2) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.329 and -0.277 e.Å-3 
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Appendi  B. E perimental for Section 3.2 
General E perimental Procedures 
A  eac i  e e e f ed i  a da d, e -d ied g a a e fi ed i h bbe  e a de  a  
i e  a he e f i ge  e  he i e de c ibed. S ai e  ee  i ge   ca a  e e 
ed  a fe  ai - a d i e- e i i e i id . Re ed c ce a i  efe   i  
e  a   e e a e. E a a i  a d c ce a i   ac  e e e f ed i g 
h e ac  (ca. 40  Hg). C  ch a g a h  a  e f ed i h Si iaF a h  60 (40
63 ic ) i ica ge  f  Si ic c e. Thi  a e  ch a g a h  (TLC) a  ed f  eac i  
i i g a d d c  de ec i  i g e-c a ed g a  a e  c e ed i h 0.25  i ica ge  
i h f e ce  i dica ; i a i a i  b  UV igh  (Oex = 254 )  KM O4 ai . 
Materials 
Reage  e e cha ed i  eage  g ade f  c e cia  ie  a d ed i h  f he  
ifica i , e  he i e de c ibed. A i e  e e e a ed acc di g  he ced e  
e ed e i 1-6. T i ( e af he )b a e a  cha ed f  TCI a d ed i h  
f he  ifica i . Ace e- 6 a  cha ed f  Ca b idge I e Lab a  a d ed 
i h  f he  ifica i . H2O, i  he ic ced e , efe   di i ed a e . 
Instrumentation 
P  c ea  ag e ic e a ce (1H NMR) ec a a d -dec ed ca b  c ea  
ag e ic e a ce (13C 1H  NMR) ec a e e ec ded a  25 C ( e  a ed he i e)  
I a 600 (600 MH )  Va ia  U i /I a 500 (500 MH )  O f d AS400 (400 MH ) 
ec e e  a  he B  C ege c ea  ag e ic e a ce faci i . Che ica  hif  f  
 a e e ed i  a  e  i i  d fie d f  e a e h i a e a d a e efe e ced  0 
. Che ica  hif  f  ca b  a e e ed i  a  e  i i  d fie d f  e a e h i a e 
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a d a e efe e ced  he ca b  e a ce  f he e . The eak i i  a e ed  e 
deci a  ace e  he  a e i di i g i hab e. The e  eak a  efe e ced  77.0  f  
13C f  CDC 3. Be if ide a  ed a  a  e e a  a da d f  19F NMR a d efe e ced  
-63.7 . Da a a e e e e ed a  f : che ica  hif , i eg a i , i ici  (b  = b ad,  
= i g e , d = d b e ,  = i e ,  = a e ,  = i e ), c i g c a  i  He  (H ).  
I f a ed ec a e e ec ded  a B ke  FT-IR A ha (ATR de) ec h e e . Da a a e 
e e e ed a  f : f e e c  f ab i  (c 1). 
O ica  a i  e e ea ed i g a 1 L ce  i h a 5 c  a h e g h  a R d h Re ea ch 
A a ica  A  IV P a i e e . I f a ed ec a e e ec ded  a B ke  FT-IR A ha (ATR 
de) ec h e e . Da a a e e e e ed a  f : f e e c  f ab i  (c 1). High-
e i  a  ec e  a  e f ed  a JEOL Acc TOF-DART ( i i e de) a  he 
Ma  S ec e  Faci i , B  C ege. 
Determination of Deuterium Content 
The a  f i c a ed de e i  i  a a e a  a ified b  a  ec e  a d b  
he dec ea e f 1H NMR i eg a  i e i ie  a  he ecified i i  c a ed  he a i g 
a e ia . I eg a  i e i ie  e e ca ib a ed agai  h d ge  ig a  ha  d   de g  H/D-
e cha ge. Ma  ec e  a ifica i  a  e f ed b  b ac i  f he ea  ec a  
a e  f he d c  a d b a e i g e c e  i  de   e i i a e he c ib i  f 
he a a  i e ab da ce  he a  a . The ea  ec a  a e  e e ca c a ed a  
he  f he e a i e ig a  i e i ie  f a gi e  i g e i ied i h he c e di g 
/  a e  de i ed f  he a  ec .  
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Abbreviations Used 
B  = be , B h= be h d , DART = di ec  a a i  i  ea  i e, DCM = dich e ha e, 
E 3N = i e h a i e, E 2O = die h  e he , E OAc = e h  ace a e, HR = high- e i , LC = 
i id ch a g a h , MS = a  ec e , PTLC = e a a i e hi  a e  ch a g a h , 
TBS = -b di e h i , Tf = if e ha e f a e, THF = e ah d f a , TOF = i e-
f-f igh . 
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B1. Substrate Preparation 
Preparation of Amine Substrates 
Table S3.1. List of Ac clic Amine Substrates 
 
A i e  3.1a, 3.1d, 3.1e, 3.1h a d 3.1j e e b ai ed f  f ee-ba i g c e cia  a ai ab e 
a i e a  a d ed i h  f he  ifica i .1 A i e 3.1f a  b ai ed f  c e cia  
ce a d ed i h  f he  ifica i . A i e  3.1g,2 3.1i,3 3.1k4 a d 3.1l5 e e e a ed 
acc di g  he i e a e ced e . The ec c ic da a a e ided be . 
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Table S3.2. List of C clic Amine Substrates 
 
A i e  3.1b, 3.1c, 3.1q,3 3.1r,4 3.1s,5 a d 3.1u6 e e e a ed acc di g  he i e a e 
ced e . The ec c ic da a a e ided be . A i e  3.1m-3.1p e e b ai ed f  
c e cia  ce a d ed i h  f he  ifica i . A i e 3.1t a  b ai ed f  f ee-
ba i g c e cia  a ai ab e a i e a  a d ed i h  f he  ifica i .1  
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General Procedure for the Free-Basing Amine Salts1 
T  a 250 L E e e e  f a k a  added a i e a  a d DCM. 2.0 M NaOH (a .) a  added 
d i e  he i ed i  i  H a e  i dica ed ha  he a e  a e  i  ba ic. The 
a e  a e  a  e ac ed i h DCM a d he c bi ed ga ic a e  e e d ied i h MgSO4, 
fi e ed, a d c ce a ed  ac . The e i g a i e a  ed i h  f he  ifica i . 
 
General Procedure A for the Alk lation of Amines3 
 
A i e  3.1i, 3.1k a d 3.1q e e e a ed b  he a k a i  f ec da  a i e . T  a i  f 
a i e (1.0 e i .) a d K2CO3 (5.0 e i .) i  MeCN a  added a k  ha ide (1.5 e i .). The 
eac i  i e a  he  a ed hea ed  100 C f  12 h . U  c e i  ( i ed b  
TLC), H2O a  added a d he ga ic a e ia  a  e ac ed i h E OAc. The c bi ed ga ic 
a e  e e d ied e  MgSO4, fi e ed, a d c ce a ed  ac . The ified d c  i e 
a  bjec ed  i ica ge  ch a g a h . 
 
General Procedure B for the Alk lation of Amines4 
 
A i e  3.1l a d 3.1r e e e a ed b  he a k a i  f ec da  a i e . T  a i  f a i e 
(1.0 e i .) a d a k  ha ide (1.1 e i .) i  MeCN, E 3N (3.0 e i .) a  added a  0 C. The 
eac i  i e a  he  a ed   22 C a d a ed  i  f  12 h . U  c e i  
( i ed b  TLC), H2O a  added a d he ga ic a e ia  a  e ac ed i h E OAc. The 
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c bi ed ga ic a e  e e d ied e  MgSO4, fi e ed, a d c ce a ed  ac . The 
ified d c  i e a  bjec ed  i ica ge  ch a g a h . 
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N-Bn lidocaine (3.1g)  
N-B  id cai e a  e a ed f i g a k  ced e.2 T  a i  f id cai e (3.0 g, 12.8 
) i  THF (45 L) a  added be  b ide (1.8 L, 15.4 ). T  he eac i  i e, 
KO -B  (2.9 g, 25.6 ) a  he  added i i e a d he eac i  i e a  a ed  
i  a  ef  f  48 h . The eac i  i e a  he  c ed a d c ce a ed  ac   
e e THF. T  he i e a  added H2O a d a  e ac ed i h E OAc. The c bi ed ga ic 
a e  e e he  d ied e  MgSO4, fi e ed, a d c ce a ed  ac . The ified d c  
i e a  he  bjec ed  i ica ge  c  ch a g a h  (MeOH:DCM = 1:99)  aff d 
3.1g a  a e  i id (2.5 g, 60%). 
1H NMR (600 MH , CDC 3)  7.25  7.16 ( , 5H), 7.12 (d, J = 7.5 H , 1H), 7.04 (d, J = 7.5 H , 
2H), 4.73 ( , 2H), 2.80 ( , 2H), 2.57 ( , J = 7.1 H , 4H), 1.87 ( , 6H), 0.91 ( , J = 7.1 H , 6H); 13C 
NMR (151 MHz, CDCl3)  170.6, 139.0, 137.1, 136.3, 128.9, 128.2, 128.0, 127.5, 54.6, 51.7, 47.4, 
17.8, 12.0; IR (neat) 2964, 2926, 1653, 1466, 1453, 1400, 1385, 1258, 1242, 1195, 1078, 773, 
743, 699 cm-1. 
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N-Bn cinacalcet (3.1i)  
N-B  ci aca ce  a  e a ed f i g a Ge e a  P ced e A f  he A k a i  f A i e  i g 
ci aca ce  h d ch ide (1.0 g, 2.5 ) a d be  b ide. The ified d c  i e 
a  he  bjec ed  i ica ge  c  ch a g a h  (E OAc:he a e  = 1:4)  aff d 3.1i a  
a c e  i id (0.9 g, 82%). 
1H NMR (600 MH , CDC 3)  8.26 (d, J = 8.0 H , 1H), 7.83 (d, J = 7.7 H , 1H), 7.74 (d, J = 8.1 
H , 1H), 7.56 (d, J = 7.1 H , 1H), 7.50  7.38 ( , 3H), 7.35 (d, J = 7.6 H , 1H), 7.24 ( , J = 7.8 
H , 6H), 7.12 ( , 1H), 6.96 (d, J = 7.4 H , 1H), 4.75  4.62 ( , 1H), 3.72 (d, J = 13.8 H , 1H), 
3.63 (d, J = 13.8 H , 1H), 2.60 ( , 2H), 2.33 (d, J = 14.0 H , 1H), 2.26 (d, J = 13.9 H , 1H), 1.53 
(d, J = 6.8 H , 5H); 13C NMR (126 MHz, CDCl3)  143.4, 140.6, 140.0, 134.0, 132.1, 131.6, 
130.5, 130.2, 129.0, 128.5, 128.4, 128.1, 127.6, 126.7, 125.33, 125.28, 125.0, 124.9, 124.6, 122.3, 
56.4, 55.8, 49.8, 33.2, 29.0, 14.3; 19F NMR (470 MH , CDC 3)  -62.40 (d, J = 3.0 H ); IR (neat) 
2968, 2939, 1492, 1327, 1160, 1120, 1072, 797, 778, 699 cm-1. 
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N-B h nortript line (3.1k)  
N-B h i i e a  e a ed f i g a Ge e a  P ced e A f  he A k a i  f A i e  
i g i i e h d ch ide (2.0 g, 6.7 ) a d (b e h e e)dibe e e. The 
ified d c  i e a  he  bjec ed  i ica ge  c  ch a g a h  (E 2O:he a e  
= 1:49)  aff d 3.1k a  a e  i id (2.2 g, 77%). 
1H NMR (500 MH , CDC 3)  7.35 (d, J = 7.6 H , 4H), 7.23 (dd, J = 8.3, 6.9 H , 5H), 7.20  7.09 
( , 7H), 7.09  7.05 ( , 1H), 7.02 (dd, J = 5.3, 3.8 H , 1H), 5.82 ( , J = 7.5 H , 1H), 4.31 ( , 1H), 
3.30 ( , 2H), 2.94 ( , 1H), 2.71 ( , 1H), 2.46 (d, J = 8.7 H , 2H), 2.32 (dd, J = 15.7, 8.4 H , 2H), 
2.07 ( , 3H); 13C NMR (126 MHz, CDCl3)  143.20, 143.17, 141.4, 140.1, 139.4, 137.0, 129.9, 
129.8, 129.0, 128.5, 128.3, 127.9, 127.3, 126.9, 126.7, 125.9, 125.7, 75.6, 55.0, 40.2, 33.7, 32.0, 
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O-TBS propafenone 
O-TBS afe e a  e a ed f i g he k  ced e.5 T  a i  f afe e 
HC  (2.0 g, 5.29 ) i  DCM a  0 C, i ida e (5.0 e i .) a  added, f ed b  he 
d i e addi i  f TBSC  (1.3 e i .). Af e  he addi i , he eac i  i e a  a ed  
a   22 C a d i ed f  12 h . U  c e i  ( i ed b  TLC), H2O a  added 
a d he ga ic a e ia  a  he  e ac ed i h DCM. The c bi ed ga ic a e  e e d ied 
e  MgSO4, fi e ed, a d c ce a ed  ac . The ified d c  i e a  bjec ed  
i ica ge  c  ch a g a h  (MeOH:DCM = 1:19)  aff d O-TBS afe e a  a 
c e  i id (2.0 g, 83%). 
 
N-B h, O-TBS propafenone (3.1l)  
N-B h, O-TBS afe e a  e a ed f i g he Ge e a  P ced e B f  he A k a i  
f A i e  i g O-TBS afe e (2.0 g, 4.4 ) a d (b e h e e)dibe e e. The 
ified d c  i e a  bjec ed  i ica ge  c  ch a g a h  (E 2O:he a e  = 
1:19)  aff d 3.1l a  a c e  i id (2.2 g, 81%). 
 
1H NMR (600 MH , CDC 3)  7.72 (d, J = 9.5 H , 1H), 7.47  7.40 ( , 1H), 7.25 (dd, J = 25.5, 
8.1 H , 6H), 7.14 (d , J = 15.4, 7.7 H , 9H), 7.03  6.92 ( , 2H), 4.82 ( , 1H), 4.18 (dd, J = 9.5, 
3.8 H , 1H), 4.10 (dd, J = 9.5, 3.3 H , 1H), 3.92 (d, J = 4.3 H , 1H), 3.36  3.16 ( , 1H), 3.08  
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2.99 ( , 1H), 2.98  2.84 ( , 2H), 2.79 (dd, J = 13.5, 9.0 H , 1H), 2.55 (dd, J = 13.5, 4.7 H , 1H), 
2.45 (d, J = 6.0 H , 2H), 1.43 (d, J = 7.4 H , 2H), 0.79 ( , 9H), 0.71 ( , J = 7.3 H , 3H), -0.06 ( , 
3H), -0.09 ( , 3H); 13C NMR (126 MHz, CDCl3)  201.2, 158.2, 142.1, 141.7, 141.5, 133.3, 130.5, 
128.8, 128.7, 128.4, 128.3, 128.2, 128.2, 128.1, 126.91, 126.88, 125.7, 120.5, 112.3, 71.2, 70.5, 
69.9, 54.2, 54.0, 45.4, 30.0, 25.7, 19.4, 17.9, 11.7, -4.7, -4.8; IR (neat) 2953, 2926, 1671, 1595, 
1578, 1469, 1248, 1110, 838, 752, 698 cm-1. 
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N-Bn paro etine (3.1q)  
N-B  a e i e a  e a ed f i g he Ge e a  P ced e A f  he A k a i  f A i e  
i g a e i e h d ch ide (3.0 g, 8.2 ) a d be  b ide. The ified d c  a  
bjec ed  i ica ge  c  ch a g a h  (E OAc:he a e  = 1:9)  aff d 3.1q a  a hi e 
id (2.9 g, 84%).  
1H NMR (500 MH , CDC 3)  7.40  7.30 ( , 4H), 7.25 ( , 1H), 7.16 (dd, J = 8.6, 5.5 H , 2H), 
6.96 ( , J = 8.7 H , 2H), 6.61 (d, J = 8.4 H , 1H), 6.31 (d, J = 2.5 H , 1H), 6.10 (dd, J = 8.5, 2.5 
H , 1H), 5.87 ( , 2H), 3.64 (d, J = 13.1 H , 1H), 3.59  3.50 ( , 2H), 3.44 (d, J = 6.9 H , 1H), 
3.04  2.96 ( , 1H), 2.55  2.42 ( , 1H), 2.27  2.14 ( , 1H), 2.12  2.01 ( , 2H), 1.90  1.73 
( , 2H); 13C NMR (126 MHz, CDCl3)  162.4, 160.5, 154.4, 148.1, 141.5, 139.9, 139.8, 138.3, 
129.2, 128.9, 128.8, 128.2, 127.0, 115.4, 115.2, 107.8, 105.6, 101.0, 98.0, 69.7, 63.4, 57.6, 53.8, 
44.1, 42.2, 34.4; 19F NMR (470 MH , CDC 3)  -116.71 (d, J = 7.5 H ); IR (neat) 2912, 1602, 
1506, 1485, 1221, 1181, 1132, 1036, 933, 831, 781, 738 cm-1. 
 
 390  
 
N-B h paro etine (3.1r) 
N-B h a e i e a  e a ed f i g he Ge e a  P ced e B f  he A k a i  f A i e  
i g a e i e h d ch ide (3.0 g, 8.2 ), (b e h e e)dibe e e. The ified 
d c  a  bjec ed  i ica ge  c  ch a g a h  (E 2O:he a e  = 1:9)  aff d 3.1r a  
a hi e id (3.5 g, 86%).  
1H NMR (500 MH , CDC 3)  7.52  7.35 ( , 4H), 7.28 ( , J = 7.5 H , 4H), 7.17 (d , J = 8.5, 6.4 
H , 5H), 6.96 ( , J = 8.6 H , 2H), 6.57 (d, J = 8.5 H , 1H), 6.21 (d, J = 2.5 H , 1H), 6.01 (dd, J = 
8.5, 2.5 H , 1H), 5.85 (d, J = 0.9 H , 2H), 4.37 ( , 1H), 3.50 (dd, J = 9.5, 2.9 H , 1H), 3.38 (dd, J 
= 9.5, 6.7 H , 1H), 3.23 (dd, J = 11.4, 2.9 H , 1H), 3.08  2.89 ( , 1H), 2.47 (dd, J = 11.6, 4.2 H , 
1H), 2.22 ( , 1H), 2.06  1.81 ( , 3H), 1.77 (d, J = 3.6 H , 1H); 13C NMR (126 MHz, CDCl3)  
162.5, 160.5, 154.3, 148.1, 142.81, 142.78, 141.5, 140.1, 140.0, 128.9, 128.8, 128.44, 128.43, 
128.1, 127.9, 126.9, 115.4, 115.2, 107.8, 105.7, 101.0, 98.1, 76.1, 69.6, 56.0, 52.5, 44.2, 42.5, 34.6; 
19F NMR (470 MH , CDC 3)  -116.74 (ddd, J = 14.0, 8.9, 5.3 H ); IR (neat) 2912, 1506, 1485, 
1466, 1336, 1268, 1222, 1037, 815, 705 cm-1. 
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O-TBS ralo ifene (3.1s)  
O-TBS a ife e a  e a ed f i g he k  ced e.5 T  a i  f a ife e HC  
(2.0 g, 3.9 ) i  DCM a  0 C, i ida e (5.0 e i .) a  added, f ed b  he d i e 
addi i  f TBSC  (2.6 e i .). Af e  he addi i , he eac i  i e a  a ed  a   22 
C a d i ed f  12 h . U  c e i  ( i ed b  TLC), H2O a  added a d he ga ic 
a e ia  a  he  e ac ed i h DCM. The c bi ed ga ic a e  e e d ied e  MgSO4, 
fi e ed, a d c ce a ed  ac . The ified d c  i e a  he  bjec ed  i ica 
ge  c  ch a g a h  (MeOH:DCM = 1:49)  aff d 3.1s a  a c e  i id (2.0 g, 73%). 
1H NMR (500 MH , CDC 3)  7.73 (d, J = 8.8 H , 2H), 7.56 ( , 1H), 7.32  7.22 ( , 3H), 6.89 ( , 
1H), 6.73 (d, J = 8.9 H , 2H), 6.66 (d, J = 8.6 H , 2H), 4.05 ( , J = 6.0 H , 2H), 2.72 ( , J = 6.0 H , 
2H), 2.47 ( , 4H), 1.58 ( , J = 5.6 H , 4H), 1.46  1.39 ( , 2H), 1.01 ( , 9H), 0.93 ( , 9H), 0.23 ( , 
6H), 0.12 ( , 6H); 13C NMR (126 MHz, CDCl3)  193.1, 162.9, 156.1, 153.5, 143.3, 139.9, 134.5, 
132.3, 130.6, 130.5, 130.3, 126.8, 124.0, 120.3, 119.2, 114.0, 112.1, 66.1, 57.7, 55.1, 25.9, 25.7, 
25.6, 24.1, 18.24, 18.19, -4.4, -4.5; IR (neat) 2927, 2891, 1596, 1464, 1255, 1164, 943, 909, 837, 
780 cm-1. 
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O-TBS dropropi ine (3.1u) 
O-TBS d i i e a  e a ed f i g he k  ced e.6 T  a i  f d i i e 
(1.2 g, 5.0 ) i  DCM a  0 C, E 3N (2.6 e i .) a  added, f ed b  he d i e addi i  
f TBSOTf (2.6 e i .). Af e  he addi i , he eac i  i e a  a ed  a   22 C a d 
i ed f  12 h . U  c e i  ( i ed b  TLC), H2O a  added a d he ga ic 
a e ia  a  he  e ac ed i h DCM. The c bi ed ga ic a e  e e d ied e  MgSO4, 
fi e ed, a d c ce a ed  ac . The ified d c  i e a  he  bjec ed  i ica 
ge  c  ch a g a h  (MeOH:DCM = 1:99)  aff d 3.1u a  a c e  i id (1.6 g, 69%). 
1H NMR (600 MH , CDC 3)  7.25 (dd, J = 8.8, 7.2 H , 2H), 6.95  6.88 ( , 2H), 6.83 (d, J = 7.3 
H , 1H), 3.80 (d, J = 5.1 H , 1H), 3.61 (dd, J = 10.0, 5.7 H , 1H), 3.53 (dd, J = 10.0, 5.6 H , 1H), 
3.17 ( , J = 5.0 H , 4H), 2.72  2.64 ( , 2H), 2.64  2.57 ( , 2H), 2.50 (dd, J = 13.0, 4.8 H , 1H), 
2.38 (dd, J = 13.0, 6.1 H , 1H), 0.90 (d, J = 5.1 H , 18H), 0.09 (d, J = 7.5 H , 6H), 0.06 (d, J = 
1.8 H , 6H); 13C NMR (126 MHz, CDCl3)  151.5, 129.0, 119.4, 115.9, 71.8, 66.2, 62.0, 54.3, 
49.2, 26.0, 25.9, 18.4, 18.2, -4.4, -4.5, -5.26, -5.34; IR (neat) 2925, 2853, 1598, 1500, 1460, 1229, 
1107, 1082, 989, 829, 772 cm-1. 
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Preparation of D-Deuterated Ketone Substrates 
 
Acetophenone-d3 
Ace he e- 3 a  he i ed f i g he k  ced e.7 Ace he e (5.8 g, 48 
), NaOH (0.16 g, 4.0 ) a d D2O (32 L) a  a ed  i  a  22 C f  24 h  de  
i ge . The eac i  i e a  di ed i h die h  e he . The a e  a e  a  e ac ed 
i h die h  e he . The c bi ed ga ic a e  a  d ied e  MgSO4, fi e ed a d c ce a ed 
 ac . The ified d c  i e a  bjec ed  i ica ge  c  ch a g a h  i g 
he a e  a  e e  aff d he ace he e- 3 a  c e  i id (4.9 g, 97%D, 84% ie d). The 
ec c ic da a a ched h e e ed b  Zh .7 
 
 
C clohe an-1-one-2,2,6,6-d4 
C c he a -1- e-2,2,6,6- 4 a  he i ed f i g he k  ced e.7 C c he a e 
(5.2 L, 50 ), NaOH (0.16 g, 1.0 ) a d D2O (32 L) a  a ed  i  a  22 C f  
24 h  de  i ge . The eac i  i e a  di ed i h die h  e he . The a e  a e  
a  e ac ed i h die h  e he . The c bi ed ga ic a e  a  d ied e  MgSO4, fi e ed a d 
c ce a ed  ac . The ified d c  i e a  di i ed (40 Hg, 40 C)  aff d 
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he c c he a -1- e-2,2,6,6- 4 a  c e  i id (4.0 g, 95%D, 78% ie d). The ec c ic 
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B2. Optimi ation Studies  
Evaluation of Reaction Conditions for B(C6F5)3-Catal ed E-Deuteration Involving 
Verapamil 
 
E perimental Procedure for the Evaluation of Reaction Parameters (see Table 3.3 in the 
Manuscript) 
T  a 15 L e -d ied e e e e  a  added e a a i  3.1a (0.1 ), Le i  acid (5.0 
%  10 %), B ed ba e (10 %), e e (0.4 L), a d ace e- 6 (0.68 ) de  
a i ge  a he e. The eac i  i e a  a ed  i  f  1 h  a  100 C, 125 C,  
150 C. U  c e i , he eac i  i e a  c ce a ed  ac . The d c  ie d a d 
de e i  i c a i  a e e e de e i ed b  he 1H NMR a a i  f he ified d c  
i e  i g e i e e a  he i e a  a da d.  
 
E perimental Procedure for the Evaluation of Solvents (see Table S3.3) 
T  a 15 L e -d ied e e e e  a  added e a a i  3.1a (0.1 ), B(C6F5)3 (10 %), 
e  (0.4 L), a d ace e- 6 (6.8 e i .) de  a i ge  a he e. The eac i  i e 
a  a ed  i  f  1 h  a  150 C. U  c e i , he eac i  i e a  c ce a ed 
 ac . The d c  ie d a d de e i  i c a i  a e e e de e i ed b  he 1H NMR 
a a i  f he ified d c  i e  i g e i e e a  he i e a  a da d.  
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E perimental Procedure for the Evaluation of Deuterium Sources (see Table S3.4) 
T  a 15 L e -d ied e e e e  a  added e a a i  3.1a (0.1 ), B(C6F5)3 (10 %), 
e e (0.4 L), a d - ce (6.8 e i .  40.8 e i .) de  a i ge  a he e. The 
eac i  i e a  a ed  i  f  12 h  a  150 C. U  c e i , he eac i  i e 
a  c ce a ed  ac . The d c  ie d a d de e i  i c a i  a e e e de e i ed 
b  he 1H NMR a a i  f he ified d c  i e  i g e i e e a  he i e a  
a da d.  
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Table S3.4. E a a i  f De e i  S ce  I i g Ve a a i  3.1a 
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E perimental Procedure for the Evaluation of Acetone-d6 Equivalence (see Table S3.5) 
T  a 15 L e -d ied e e e e  a  added e a a i  3.1a (0.3 ), B(C6F5)3 (2.5 
%), e e (1.2 L), a d ace e- 6 (2.010 equiv.) under a nitrogen atmosphere. The 
eac i  i e a  a ed  i  f  1 h  a  150 C. U  c e i , he eac i  i e 
a  c ce a ed  ac . The d c  ie d a d de e i  i c a i  a e e e de e i ed 
b  he 1H NMR a a i  f he ified d c  i e  i g e i e e a  he i e a  
a da d.  
 
Table S3.5. E a a i  f Ace e- 6 E i a e ce I i g Ve a a i  3.1a 
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B3. General Procedures for E-Deuteration of N-Alk lamines  
General Procedure A for the E-Deuteration of N-Alk lamines (See Tables 3.43.5 in the 
Manuscript) 
 
T  a 15 L e -d ied e e e e  a  added a i e 3.1 (0.2 ), B(C6F5)3 (10 %), 
e e (0.8 L), a d ace e- 6 (1.36 , 6.8 e i .) de  a i ge  a he e. The 
eac i  i e a  a ed  i  f  3 h  a  150 C. U  c e i , he eac i  i e 
a  c ce a ed  ac  a d ified b  i ica ge  c  ch a g a h .  
 
General Procedure B for the E-Deuteration of N-Alk lamines (See Tables 3.43.5 in the 
Manuscript) 
 
T  a 15 L e -d ied e e e e  a  added a i e 3.1 (0.2 ), B(C6F5)3 (5.0 %), 
e e (0.8 L), a d ace e- 6 (1.36 , 6.8 e i .) de  a i ge  a he e. The 
eac i  i e a  a ed  i  f  3 h  a  150 C. Af e  he ifica i  b  i ica ge  
c  ch a g a h  a d e a  f a i e , B(C6F5)3 (5.0 %), e e (0.8 L), a d 
ace e- 6 (1.36 , 6.8 e i .) e e added de  a i ge  a he e a d a  a ed  
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i  f  3 h  a  150 C. U  c e i , he eac i  i e a  c ce a ed  ac  a d 
ified b  i ica ge  c  ch a g a h .  
 
General Procedure C for the E-Deuteration of N-Alk lamines (See Tables 3.43.5 in the 
Manuscript) 
 
T  a 15 L e -d ied e e e e  a  added a i e 3.1 (0.2 ), B(C6F5)3 (10 %), 
e e (0.8 L), a d ace e- 6 (1.36 , 6.8 e i .) de  a i ge  a he e. The 
eac i  i e a  a ed  i  f  3 h  a  150 C. Af e  he ifica i  b  i ica ge  
c  ch a g a h  a d e a  f a i e , B(C6F5)3 (5.0 %), e e (0.8 L), a d 
ace e- 6 (1.36 , 6.8 e i .) e e added de  a i ge  a he e a d a  a ed  
i  f  3 h  a  150 C. U  c e i , he eac i  i e a  c ce a ed  ac  a d 
ified b  i ica ge  c  ch a g a h .  
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Procedure for Scale-Up Reaction (See Scheme 3.10 in the Manuscript) 
 
T  a 100 L e -d ied Sch e k f a k a  added a i e 3.1a (3.0 ), B(C6F5)3 (5.0 %), 
e e (12 L), a d ace e- 6 (20.4 , 6.8 e i .) de  a i ge  a he e. The eac i  
i e a  a ed  i  f  12 h  a  150 C. Af e  he ifica i  b  i ica ge  c  
ch a g a h  a d e a  f a i e , B(C6F5)3 (5.0 %), e e (12 L), a d ace e- 6 
(20.4 , 6.8 e i .) e e added de  a i ge  a he e a d a  a ed  i  f  12 
h  a  150 C. U  c e i , he eac i  i e a  c ce a ed  ac  a d ified 
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B4. Anal tical Data and Spectra 
 
Verapamil, 3.9a 
Ve a a i  3.1a a  eac ed i h ace e- 6 f i g he Ge e a  P ced e B. Af e  ifica i  
b  c  ch a g a h  (MeOH:DCM = 1:49), 3.9a a  b ai ed a  a e  i id (84 g, 
92%). 
De e i  i c a i : 3.86 D/ ec e (1H NMR), 4.11 D/ ec e [HRMS (DART)] 
1H NMR (600 MHz, CDCl3)  6.91 (dd, J = 8.4, 2.2 Hz, 1H), 6.88  6.81 (m, 2H), 6.79 (d, J = 7.9 
Hz, 1H), 6.69 (d, J = 7.8 Hz, 2H), 3.94  3.76 (m, 12H), 2.73  2.60 (m, 0.11H, 95%D), 2.56  
2.46 (m, 2H), 2.44  2.29 (m, 2H), 2.20 (s, 3H), 2.15  1.99 (m, 2H), 1.84 (d, J = 13.7 Hz, 1H), 
1.58  1.49 (m, 0.02H, 99%D), 0.79 (d, J = 6.7 Hz, 3.05H, 98%D); 13C NMR (151 MHz, CDCl3) 
 148.9, 148.7, 148.2, 147.2, 132.5, 130.5, 121.3, 120.4, 118.6, 111.9, 111.2, 111.0, 109.5, 59.0, 
56.5, 55.9, 55.8, 55.73, 55.71, 53.2, 41.7, 37.8, 35.2, 32.1, 22.3, 18.8, 18.5; IR (neat) 2933, 1512, 
1460, 1411, 1258, 1237, 1162, 1141, 1024, 804, 764 cm-1. 




 405  
 
 406  
 




C i he e 3.1d a  eac ed i h ace e- 6 f i g he Ge e a  P ced e A. Af e  
ifica i  b  c  ch a g a h  (MeOH:DCM = 1:19), 3.9d a  b ai ed a  a c e  
i id (78 g, 96%). 
De e i  i c a i : 5.70 D/ ec e (1H NMR), 6.89 D/ ec e [HRMS (DART)] 
1H NMR (600 MHz, CDCl3)  7.44  7.26 (m, 6H), 7.22  7.13 (m, 3H), 7.11  6.93 (m, 1H), 6.87 
(dd, J = 26.9, 8.7 Hz, 2H), 6.61 (d, J = 8.8 Hz, 2H), 4.16  3.93 (m, 1.71H, 15%D), 3.00  2.81 
(m, 2H), 2.67 (d, J = 34.3 Hz, 4H), 1.13  0.98 (m, 0.61H, 90%D); 13C NMR (151 MHz, CDCl3) 
 158.0, 157.6, 142.1, 141.3, 139.9, 139.8, 139.6, 134.3, 133.5, 132.5, 131.8, 131.2, 130.6, 130.0, 
129.9, 129.8, 129.7, 129.3, 129.0, 128.1, 128.0, 127.8, 127.4, 126.9, 113.9, 113.9, 66.9, 66.0, 60.3, 
51.6, 51.5, 51.4, 51.3, 47.62, 47.56, 10.8; IR (neat) 2940, 2806, 1603, 1505, 1244, 1174, 1153, 
1029, 758, 745, 695 cm-1. 
 
 408  
 
 
 409  
 
 410  
 411  
 
Dic clomine, 3.9e 
Dic c i e 3.1e a  eac ed i h ace e- 6 f i g he Ge e a  P ced e A. Af e  
ifica i  b  c  ch a g a h  (MeOH:DCM = 1:49), 3.9e a  b ai ed a  a c e  
i id (60 g, 97%).  
De e i  i c a i : 5.86 D/ ec e (1H NMR), 5.50 D/ ec e [HRMS (DART)] 
1H NMR (600 MHz, CDCl3)  4.17 ( , J = 6.3 Hz, 1.55H, 23%D), 2.73 (t, J = 6.5 Hz, 2H), 2.58 
(d, J = 7.0 Hz, 4H), 2.06 (d, J = 12.4 Hz, 2H), 1.75 (m, 2H), 1.69 (d, J = 12.9 Hz, 2H), 1.66  1.54 
(m, 4H), 1.37  1.24 (m, 3H), 1.23  1.06 (m, 6H), 1.06  1.02(m, 0.59H, 90%D), 1.02  0.93 (m, 
2H); 13C NMR (151 MHz, CDCl3)  176.2, 77.2, 77.0, 76.8, 62.0, 51.1, 50.7, 47.3, 46.8, 31.5, 
31.4, 27.8, 27.7, 27.0, 26.6, 26.04, 26.00, 23.75, 11.21; IR (neat) 2923, 2850, 1720, 1449, 1207, 
1194, 1171, 1156, 1125, 1101, 1049 cm-1. 
 412  
 
 413  
 
 414  
 
 415  
 
Lidocaine, 3.9f 
Lid cai e 3.1f a  eac ed i h ace e- 6 f i g he Ge e a  P ced e A. Af e  ifica i  
b  c  ch a g a h  (MeOH:DCM = 1:49), 3.9f a  b ai ed a  a hi e id (46 g, 
99%).  
De e i  i c a i : 4.80 D/ ec e (1H NMR), 4.78 D/ ec e [HRMS (DART)] 
1H NMR (500 MHz, CDCl3)  8.91 ( , 1H), 7.08 ( , 3H), 3.21 ( , 2H), 2.77  2.54 (m, 4H), 2.23 
(s, 6H), 1.23  1.01 (m, 1.23H, 80%D); 13C NMR (126 MHz, CDCl3)  170.1, 134.9, 133.9, 128.0, 
126.9, 57.4, 48.82, 48.76, 48.7, 48.6, 18.4, 11.9; IR (neat) 3265, 2936, 2818, 2219, 1684, 1491, 
1284, 1163, 1051, 767 cm-1. 
 416  
 
 417  
 
 418  
 
 419  
 
N-Bn lidocaine, 3.9g 
N-B  id cai e 3.1g a  eac ed i h ace e- 6 2 f i g he Ge e a  P ced e B. Af e  
ifica i  b  c  ch a g a h  (MeOH:DCM = 1:49), 3.9g a  b ai ed a  a e  
i id (62 g, 96%).  
De e i  i c a i : 6.18 D/ ec e (1H NMR), 6.26 D/ ec e [HRMS (DART)] 
1H NMR (500 MHz, CDCl3)  7.22 ( , 5H), 7.13 (dd, J = 8.0, 7.0 Hz, 1H), 7.04 (d, J = 7.6 Hz, 
2H), 4.73 (s, 1.82H, 9%D), 2.81 (s, 2H), 2.57 (s, 4H), 1.87 (s, 6H), 0.88 (s, 0.22H, 96%D); 13C 
NMR (126 MHz, CDCl3)  170.4, 138.9, 137.1, 136.3, 130.2, 129.0, 128.3, 128.1, 127.6, 54.6, 
51.8, 47.3, 17.9, 11.0; IR (neat) 2926, 1650, 1460, 1400, 1242, 1141, 1078, 773, 743, 700 cm-1. 
 420  
 
 421  
 
 422  
 
 423  
 
Cinacalcet, 3.9h 
Ci aca ce  3.1h a  eac ed i h ace e- 6 f i g he Ge e a  P ced e A. Af e  ifica i  
b  c  ch a g a h  (MeOH:DCM = 1:19), 3.9h a  b ai ed a  a e  i id (69 g, 
97%).  
De e i  i c a i : 1.50 D/ ec e (1H NMR), 1.52 D/ ec e [HRMS (DART)] 
1H NMR (500 MHz, CD3OD)  8.01 (d, J = 8.5 H , 1H), 7.72 (d, J = 8.1 H , 1H), 7.61 (d, J = 8.2 
H , 1H), 7.47 (d, J = 7.2 H , 1H), 7.40  7.26 ( , 5H), 7.20 (d , J = 16.2, 7.6 H , 2H), 4.54 ( , J 
= 6.5 H , 1H), 2.43 (ddd, J = 38.2, 16.0, 8.0 H , 4H), 1.75  1.57 (m, 0.75H, 63%D), 1.34 (d, J = 
6.7 H , 2.72H, 8%D); 13C NMR (126 MHz, CDCl3)  143.1, 141.1, 134.0, 131.79, 131.78, 131.4, 
131.0, 130.7, 130.5, 130.2, 129.04, 129.03, 128.7, 127.3, 125.8, 125.7, 125.41, 125.37, 125.11, 
125.08, 125.05, 125.0, 123.2, 122.9, 122.8, 122.71, 122.68, 122.65, 122.6, 53.8, 47.2, 33.3, 31.8, 
23.6; 19F NMR (470 MHz, CDCl3)  -62.47; IR (neat) 2923, 1448, 1326, 1198, 1160, 1119, 1072, 
798, 777, 701, 659 cm-1; [ ]25 D = +19.1  (c = 1.0, CH2C 2 abe ed), [ ]25 D = +28.3  (c = 1.0, 
CH2C 2 abe ed). 
 
 424  
 
 425  
 
 426  
 
 427  
 
N-Bn cinacalcet, 3.9i 
N-B  ci aca ce  3.1i a  eac ed i h ace e- 6 f i g he Ge e a  P ced e B. Af e  
ifica i  b  c  ch a g a h  (E 2O:he a e  = 1:9), 3.9i a  b ai ed a  a e  i id 
(88 g, 98%).  
De e i  i c a i : 1.99 D/ ec e (1H NMR), 2.28 D/ ec e [HRMS (DART)] 
1H NMR (600 MHz, CDCl3)  8.26 (d, J = 8.0 Hz, 1H), 7.83 (d, J = 7.7 Hz, 1H), 7.74 (d, J = 8.1 
Hz, 1H), 7.56 (d, J = 7.1 Hz, 1H), 7.50  7.38 (m, 3H), 7.35 (d, J = 7.6 Hz, 1H), 7.24 (t, J = 7.8 
Hz, 6H), 7.12 (s, 1H), 6.96 (d, J = 7.4 Hz, 1H), 4.75  4.62 (m, 1H), 3.72 (d, J = 13.8 Hz, 1H), 
3.63 (d, J = 13.8 Hz, 1H), 2.60 (s, 2H), 2.33 (d, J = 14.0 Hz, 1H), 2.26 (d, J = 13.9 Hz, 1H), 1.63 
(d, J = 6.3 Hz, 0.02H, >98%D), 1.53 (d, J = 6.8 Hz, 3H); 13C NMR (126 MHz, CDCl3)  143.4, 
140.6, 140.0, 134.0, 132.1, 131.59, 131.58, 130.5, 130.2, 129.0, 128.6, 128.4, 128.2, 128.1, 127.6, 
126.7, 125.4, 125.33, 125.28, 125.0, 124.89, 124.85, 124.83, 124.80, 124.6, 123.2, 122.4, 122.33, 
122.30, 122.27, 56.4, 55.8, 49.7, 33.1, 28.2, 14.4; 19F NMR (564 MHz, CDCl3)  -62.49; IR (neat) 
2858, 1449, 1331, 1197, 1159, 1118, 1097, 797, 778, 733, 699 cm-1; [ ]25 D = -28.5  (c = 1.0, 
CH2C 2 abe ed), [ ]25 D = -39.2  (c = 1.0, CH2C 2 abe ed). 
 
 
 428  
 
 
 429  
 
 430  
 
 431  
 
Ropinirole, 3.9j 
R i i e 3.1j a  eac ed i h ace e- 6 f i g he Ge e a  P ced e C. Af e  ifica i  
b  c  ch a g a h  (MeOH:DCM = 1:24), 3.9j a  b ai ed a  a hi e id (40 g, 
77%).  
De e i  i c a i : 4.70 D/ ec e (1H NMR), 5.24 D/ ec e [HRMS (DART)] 
1H NMR (500 MHz, CDCl3)  9.22 ( , 1H), 7.14 ( , J = 7.7 Hz, 1H), 6.84 (d, J = 7.8 Hz, 1H), 6.75 
(d, J = 7.7 Hz, 1H), 3.49 (s, 2H), 2.71 (d, J = 5.1 Hz, 2.74H, 63%D), 2.50 (s, 4H), 1.55  1.44 (m, 
0.58H, 86%D), 0.89 (d, J = 8.5 Hz, 6H); 13C NMR (126 MHz, CDCl3)  177.6, 142.5, 136.8, 
128.1, 128.0, 124.0, 122.8, 107.6, 55.9, 55.8, 54.13, 54.07, 54.0, 35.1, 30.5, 19.3, 11.9, 11.8, 11.7; 
IR (neat) 2952, 2928, 2799, 1701, 1615, 1601, 1453, 1254, 762, 719 cm-1.
 432  
 
 433  
 
 434  
 435  
 
N-B h nortript line, 3.9k 
N-B h i i e 3.1k a  eac ed i h ace e- 6 f i g he Ge e a  P ced e B. Af e  
ifica i  b  c  ch a g a h  (E 2O:he a e  = 1:9), 3.9k a  b ai ed a  a e  i id 
(83 g, 96%).  
De e i  i c a i : 1.96 D/ ec e (1H NMR), 2.34 D/ ec e [HRMS (DART)] 
1H NMR (500 MHz, CDCl3)  7.35 (d, J = 7.6 Hz, 4H), 7.22 (dd, J = 8.4, 6.8 Hz, 5H), 7.20  7.09 
(m, 7H), 7.09  7.04 (m, 1H), 7.03 (s, 1H), 5.81 (s, 1H), 4.30 (s, 1H), 3.27 (dt, J = 32.1, 23.1 Hz, 
2H), 2.94 (s, 1H), 2.71 (s, 1H), 2.44 (d, J = 5.3 Hz, 2H), 2.30 (d, J = 7.5 Hz, 0.04H, 98%D), 2.07 
(s, 3H); 13C NMR (126 MHz, CDCl3)  143.3, 141.5, 140.2, 139.4, 137.1, 130.0, 129.8, 128.6, 
128.4, 128.0, 127.3, 126.9, 126.8, 126.0, 125.7, 75.7, 54.9, 40.3, 33.8, 32.1; IR (neat) 3020, 2784, 
1485, 1451, 1265, 1028, 1012, 924, 756, 742, 704 cm-1. 
 436  
 
 437  
 
 438  
 
 439  
 
N-B h, O-TBS propafenone, 3.9l 
N-B h, O-TBS afe e 3.1l a  eac ed i h ace e- 6 f i g he Ge e a  P ced e A. 
Af e  ifica i  b  c  ch a g a h  (E 2O:he a e  = 1:9), 3.9l a  b ai ed a  a e  
i id (114 g, 92%).  
De e i  i c a i : 3.14 D/ ec e (1H NMR), 3.51 D/ ec e [HRMS (DART)] 
1H NMR (600 MHz, CDCl3)  7.72 (d, J = 9.4 Hz, 1H), 7.47  7.40 (m, 1H), 7.27 (d, J = 7.1 Hz, 
2H), 7.23 (d, J = 7.6 Hz, 4H), 7.20  7.08 (m, 9H), 6.99 (dd, J = 15.9, 8.8 Hz, 2H), 4.81 (s, 1H), 
4.18 (d, J = 3.8 Hz, 1H), 4.11 (d, J = 3.3 Hz, 1H), 3.92 (dd, J = 8.7, 4.3 Hz, 1H), 3.35  3.18 (m, 
0.19H, 81%D), 3.11  2.97 (m, 0.24H, 76%D), 2.91 (d, J = 11.4 Hz, 2H), 2.79 (dd, J = 13.5, 8.9 
Hz, 1H), 2.55 (dd, J = 13.5, 4.6 Hz, 1H), 2.51  2.38 (m, 2H), 1.50  1.35 (m, 0.50H, 76%D), 0.79 
(s, 9H), 0.75  0.66 (m, 3H), -0.06 (s, 3H), -0.09 (s, 3H); 13C NMR (151 MHz, CDCl3)  201.4, 
201.3, 158.2, 142.1, 141.7, 141.5, 133.3, 130.5, 128.8, 128.7, 128.5, 128.4, 128.3, 128.22, 128.16, 
128.1, 126.92, 126.89, 125.7, 120.5, 112.3, 71.2, 70.5, 69.9, 54.2, 53.9, 45.0, 29.9, 25.7, 19.0, 17.9, 
11.5, -4.7, -4.8; IR (neat) 2950, 2926, 1669, 1595, 1470, 1293, 1248, 1113, 833, 747, 699 cm-1. 
 440  
 
 
 441  
 
 442  
 443  
 
Clopidogrel, 3.9m 
C id g e  3.1m a  eac ed i h ace e- 6 f i g he Ge e a  P ced e B. Af e  
ifica i  b  c  ch a g a h  (E 2O:he a e  = 1:9), 3.9m a  b ai ed a  a c e  
i id (61 g, 94%).  
De e i  i c a i : 2.65 D/ ec e (1H NMR), 2.88 D/ ec e [HRMS (DART)] 
1H NMR (500 MHz, CDCl3)  7.70 (d, J = 7.4 Hz, 1H), 7.40 (d, J = 7.5 Hz, 1H), 7.36  7.18 (m, 
2H), 7.11  7.00 (m, 1H), 6.75  6.59 (m, 1H), 4.92 (d, J = 2.0 Hz, 0.35H, 65%D), 3.79  3.70 (m, 
4H), 3.63 (d, J = 14.2 Hz, 1H), 2.88 (s, 2.00H, >98%D); 13C NMR (126 MHz, CDCl3)  171.3, 
134.7, 133.8, 133.4, 133.1, 130.0, 129.8, 129.4, 127.15, 125.24, 122.8, 67.9, 52.1, 50.70, 50.65, 
48.2, 48.1, 25.1; IR (neat) 2947, 1735, 1469, 1431, 1245, 1140, 1105, 1064, 752, 704 cm-1; [ ]25 
D = 0.7  (c = 1.0, CH2C 2 abe ed), [ ]25 D = 15.0  (c = 1.0, CH2C 2 abe ed). 
 
 444  
 
 
 445  
 446  
 
 447  
 
Prasugrel, 3.9n 
P a g e  3.1n a  eac ed i h ace e- 6 f i g he Ge e a  P ced e C. Af e  ifica i  
b  c  ch a g a h  (E 2O:he a e  = 1:19), 3.9n a  b ai ed a  a hi e id (64 g, 
85%).  
De e i  i c a i : 1.70 D/ ec e (1H NMR), 1.99 D/ ec e [HRMS (DART)] 
1H NMR (600 MHz, CDCl3)  7.47 ( , 1H), 7.31 ( , 1H), 7.17 ( , 1H), 7.11 ( , 1H), 6.26 ( , 1H), 
4.83 (s, 1H), 3.63  3.43 (m, 2H), 2.89 (d, J = 11.5 Hz, 1H), 2.75 (d, J = 11.4 Hz, 1.30H, 85%D), 
2.25 (s, 4H), 1.03 (dd, J = 26.7, 2.8 Hz, 2H), 0.85 (d, J = 2.7 Hz, 2H); 13C NMR (151 MHz, CDCl3) 
 207.6, 167.7, 162.1, 160.5, 149.5, 130.6, 129.9, 129.8, 129.5, 125.6, 124.37, 124.35, 122.1, 
122.0, 115.9, 115.7, 112.00, 111.96, 71.61, 71.56, 50.50, 50.48, 50.46, 48.3, 25.0, 20.7, 18.3, 12.1, 
11.5; 19F NMR (564 MHz, CDCl3)  -114.68  -118.69 (m); IR (neat) 1776, 1758, 1698, 1486, 
1454, 1369, 1191, 1086, 1037, 1008, 903, 759 cm-1. 
 448  
 
 449  
 
 450  
 
 451  
 
Donepe il, 3.9o 
D e e i  3.1o a  eac ed i h ace e- 6 f i g he Ge e a  P ced e A. Af e  ifica i  
b  c  ch a g a h  (MeOH:DCM = 1:49), 3.9o a  b ai ed a  a hi e id (74 g, 
98%).  
De e i  i c a i : 5.04 D/ ec e (1H NMR), 4.17 D/ ec e [HRMS (DART)] 
1H NMR (600 MHz, CDCl3)  7.39 (d, J = 7.5 Hz, 2H), 7.34 (t, J = 7.4 Hz, 2H), 7.30 (d, J = 7.1 
Hz, 1H), 7.16 (s, 1H), 6.85 (s, 1H), 3.96 (s, 3H), 3.90 (s, 3H), 3.67 (s, 2H), 3.24 (d, J = 16.9 Hz, 
1H), 3.02 (d, J = 10.6 Hz, 2H), 2.68 (d, J = 16.9 Hz, 1.12H, 88%D), 2.15 (s, 2H), 1.89 (dd, J = 
13.8, 7.6 Hz, 1H), 1.781.70 (m, 0.25H, 88%D), 1.59 (s, 1H), 1.561.44 (m, 0.49H, 75%D), 1.43 
 1.32 (m, 1H); 13C NMR (151 MHz, CDCl3)  207.6, 155.5, 149.4, 148.7, 136.2, 129.7, 129.2, 
128.4, 127.6, 107.3, 104.3, 62.7, 56.0, 53.1, 45.2, 38.3, 33.3; IR (neat) 2913, 1691, 1590, 1499, 
1454, 1310, 1269, 1247, 1218, 1114, 727 cm-1. 
 452  
 
 453  
 
 454  
 
 455  
 
Bupivacaine, 3.9p 
B i acai e 3.1p a  eac ed i h ace e- 6 f i g he Ge e a  P ced e A. Af e  
ifica i  b  c  ch a g a h  (MeOH:DCM = 1:49), 3.9p a  b ai ed a  a hi e id 
(55 g, 96%).  
De e i  i c a i : 2.08 D/ ec e (1H NMR), 2.83 D/ ec e [HRMS (DART)] 
1H NMR (600 MHz, CDCl3)  8.25 ( , 1H), 7.06 (d, J = 5.5 H , 3H), 3.18 (d, J = 11.6 H , 1H), 
2.92 (d, J = 9.3 Hz, 1H), 2.86  2.74 (m, 1H), 2.31  2.17 (m, 7H), 2.11  2.01 (m, 2H), 1.77  
1.66 (m, 2.2H, 80%D), 1.65  1.54 (m, 0.86H, 14%D), 1.54  1.39 (m, 0.85H, 15%D and >98%D), 
1.41  1.24 (m, 3H), 0.91 (t, J = 7.4 Hz, 3H); 13C NMR (151 MHz, CDCl3)  172.7, 135.2, 133.6, 
128.2, 127.0, 68.3, 57.4, 57.3, 51.5, 51.4, 30.4, 29.5, 23.9, 23.1, 20.6, 20.5, 20.4, 18.6, 14.0; IR 
(neat) 3224, 2952, 2927, 2855, 1650, 1513, 1463, 1228, 1097, 764 cm-1. 
 456  
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 458  
 
 459  
 
N-Bn paro etine, 3.9q 
N-B  a e i e 3.1q a  eac ed i h ace e- 6 f i g he Ge e a  P ced e A. Af e  
ifica i  b  c  ch a g a h  (E 2O:he a e  = 1:9), 3.9q a  b ai ed a  a hi e id 
(82 g, 98%).  
De e i  i c a i : 1.52 D/ ec e (1H NMR), 1.85 D/ ec e [HRMS (DART)] 
1H NMR (500 MHz, CDCl3)  7.44  7.30 (m, 4H), 7.30  7.21 (m, 1H), 7.15 (ddd, J = 7.1, 5.3, 
2.7 Hz, 2H), 7.04  6.87 (m, 2H), 6.61 (dd, J = 8.5, 1.6 Hz, 1H), 6.31 (t, J = 2.1 Hz, 1H), 6.10 (d, 
J = 8.5 Hz, 1H), 5.86 (d, J = 1.7 Hz, 2H), 3.64 (dd, J = 13.2, 1.6 Hz, 1H), 3.59  3.49 (m, 2H), 
3.43 (s, 1H), 3.31  3.17 (m, 1H), 2.97 (d, J = 11.2 Hz, 1H), 2.46 (d, J = 11.1 Hz, 1H), 2.20 (dd, J 
= 7.5, 3.3 Hz, 1H), 2.14  2.00 (m, 2H), 1.92  1.73 (m, 0.49H, 76%D); 13C NMR (151 MHz, 
CDCl3)  162.5, 160.5, 154.4, 148.1, 141.5, 139.88, 139.86, 138.3, 129.2, 128.9, 128.8, 128.2, 
127.0, 115.4, 115.3, 107.8, 105.6, 101.1, 98.0, 69.7, 63.4, 57.6, 53.7, 44.0, 42.2, 34.4; 19F NMR 
(564 MHz, CDCl3)  -116.68 (td, J = 8.8, 4.5 Hz); IR (neat) 2895, 2799, 1506, 1486, 1466, 1451, 
1222, 1181, 1090, 1037, 830, 744, 705 cm-1; [ ]25 D = -27.3  (c = 1.0, CH2C 2 abe ed), [ ]25 D = -
44.9  (c = 1.0, CH2C 2 abe ed). 
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N-B h Paro etine, 3.9r 
N-B h a e i e 3.1r a  eac ed i h ace e- 6 f i g he Ge e a  P ced e A. Af e  
ifica i  b  c  ch a g a h  (E 2O:he a e  = 1:9), 3.9r a  b ai ed a  a c e  
i id (94 g, 95%).  
De e i  i c a i : 1.88 D/ ec e (1H NMR), 2.09 D/ ec e [HRMS (DART)] 
1H NMR (500 MHz, CDCl3)  7.52  7.37 (m, 4H), 7.28 (t, J = 7.7 Hz, 4H), 7.23  7.08 (m, 4H), 
6.96 (d, J = 8.7 Hz, 2H), 6.57 (d, J = 8.4 Hz, 1H), 6.21 (d, J = 2.4 Hz, 1H), 6.01 (dd, J = 8.5, 2.5 
Hz, 1H), 5.84 (s, 2H), 4.36 (s, 1H), 3.49 (d, J = 2.9 Hz, 1H), 3.39 (d, J = 6.8 Hz, 1H), 3.23 (ddd, J 
= 11.4, 3.6, 2.1 Hz, 1H), 2.97 (s, 1H), 2.47 (d, J = 11.2 Hz, 1H), 2.21 (dt, J = 7.2, 3.5 Hz, 1H), 
1.94 (d, J = 11.3 Hz, 2H), 1.89  1.84 (m, 0.08H, 92%D), 1.75  1.71 (m, 0.08H, 92%D); 13C 
NMR (126 MHz, CDCl3)  162.47, 160.52, 154.3, 148.1, 142.82, 142.79, 141.5, 140.08, 140.05, 
128.91, 128.85, 128.5, 128.4, 128.1, 128.0, 126.9, 115.4, 115.2, 107.8, 105.8, 101.0, 98.1, 76.1, 
69.6, 56.0, 52.42, 52.35, 44.2, 44.1, 42.5, 33.9; 19F NMR (564 MHz, CDCl3)  -116.80 (tt, J = 8.8, 
5.2 Hz); IR (neat) 2895, 2799, 1506, 1486, 1466, 1222, 1182, 1037, 830, 705 cm-1; [ ]25 D = -36.5  
(c = 1.0, CH2C 2 abe ed), [ ]25 D = -43.4  (c = 1.0, CH2C 2 abe ed). 
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O-TBS ralo ifene, 3.9s 
O-TBS a ife e 3.1s a  eac ed i h ace e- 6 f i g he Ge e a  P ced e A. Af e  
ifica i  b  c  ch a g a h  (MeOH:DCM = 1:49), 3.9s a  b ai ed a  a e  
i id (136 g, 97%).  
De e i  i c a i : 4.46 D/ ec e (1H NMR), 5.08 D/ ec e [HRMS (DART)] 
1H NMR (600 MHz, CDCl3)  7.72 (d, J = 8.9 Hz, 2H), 7.57 (d, J = 8.7 Hz, 1H), 7.33  7.22 (m, 
3H), 6.88 (dd, J = 8.8, 2.2 Hz, 1H), 6.72 (d, J = 9.0 Hz, 2H), 6.66 (d, J = 8.6 Hz, 2H), 4.05 (s, 
1.42H, 29%D), 2.77  2.70 (m, 2H), 2.46 (s, 4H), 1.62  1.51 (m, 0.14H, 97%D), 1.40 (s, 2H), 
1.01 (s, 9H), 0.93 (s, 9H), 0.23 (s, 6H), 0.12 (s, 6H); 13C NMR (151 MHz, CDCl3)  193.0, 162.8, 
156.0, 153.4, 143.3, 139.8, 134.4, 132.2, 130.5, 130.4, 130.3, 130.2, 126.7, 123.92, 123.90, 120.2, 
119.18, 119.16, 113.9, 112.03, 112.00, 66.0, 54.81, 54.81, 25.64, 25.57, 25.0, 23.7, 23.6, 18.2, 
18.1, -4.4, -4.5; IR (neat) 2927, 1595, 1463, 1252, 1164, 939, 907, 827, 779, 734 cm-1. 
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Emedastine, 3.9t 
E eda i e 3.1t a  eac ed i h ace e- 6 f i g he Ge e a  P ced e A. Af e  ifica i  
b  c  ch a g a h  (MeOH:DCM = 1:15), 3.9t a  b ai ed a  a c e  i id (53 g, 
88%).  
De e i  i c a i : 1.88 D/ ec e (1H NMR), 2.03 D/ ec e [HRMS (DART)] 
1H NMR (500 MHz, CDCl3)  7.53 (d, J = 7.4 Hz, 1H), 7.28  7.21 (m, 1H), 7.13 (ddd, J = 15.5, 
7.6, 1.4 Hz, 2H), 4.19 (t, J = 6.0 Hz, 2H), 3.78 (t, J = 6.0 Hz, 2H), 3.74  3.68 (m, 1.33H, 33%D), 
3.64 (d, J = 6.1 Hz, 2H), 3.46 (q, J = 7.0 Hz, 2H), 2.86  2.80 (m, 2H), 2.76 (d, J = 5.6 Hz, 2H), 
2.44 (s, 3H), 2.10  1.98 (m, 0.78H, 61%D), 1.15 (t, J = 7.0 Hz, 3H); 13C NMR (126 MHz, CDCl3) 
 159.1, 141.7, 135.5, 121.7, 120.7, 117.3, 109.1, 68.2, 66.8, 58.5, 57.3, 52.2, 51.6, 46.7, 44.8, 
27.8, 15.1; IR (neat) 1522, 1460, 1405, 1375, 1349, 1283, 1115, 1045, 1009, 761, 741cm-1. 
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O-TBS dropropi ine, 3.9u 
O-TBS d i i  3.1u a  eac ed i h ace e- 6 f i g he Ge e a  P ced e B. Af e  
ifica i  b  c  ch a g a h  (MeOH:DCM = 1:99), 3.9u a  b ai ed a  a e  
i id (87 g, 94%).  
De e i  i c a i : 6.96 D/ ec e (1H NMR), 7.61 D/ ec e [HRMS (DART)] 
1H NMR (500 MHz, CDCl3)  7.25 (dd, J = 8.8, 7.3 Hz, 2H), 6.91 (dt, J = 7.8, 1.0 Hz, 2H), 6.83 
(s, 1H), 3.80 (dd, J = 6.0, 4.9 Hz, 1H), 3.66  3.57 (m, 1H), 3.53 (dd, J = 10.0, 5.6 Hz, 1H), 3.12 
(s, 0.24H, 94%D), 2.62 (s, 0.47H, 77%D), 2.55 (s, 0.34H, 83%D), 2.50 (dd, J = 13.0, 4.7 Hz, 1H), 
2.37 (dd, J = 13.0, 6.1 Hz, 1H), 0.90 (d, J = 4.3 Hz, 18H), 0.09 (d, J = 6.1 Hz, 6H), 0.06 (d, J = 
1.6 Hz, 6H); 13C NMR (126 MHz, CDCl3)  151.5, 129.1, 119.4, 115.8, 71.9, 66.2, 62.0, 53.2, 
48.3, 26.03, 25.95, 18.4, 18.2, -4.4, -4.5, -5.2, -5.3; IR (neat) 2925, 2853, 1598, 1499, 1250, 1091, 
1003, 830, 810, 773, 753, 689 cm-1. 
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Appendi  C. E perimental for Section 3.3 
General E perimental Procedures 
A  eac i  e e e f ed i  a da d, e -d ied g a a e fi ed i h bbe  e a de  a  
i e  a he e f i ge  e  he i e de c ibed. S ai e  ee  i ge   ca a  e e 
ed  a fe  ai - a d i e- e i i e i id . Re ed c ce a i  efe   i  
e  a   e e a e. E a a i  a d c ce a i   ac  e e e f ed i g 
h e ac  (ca. 40  Hg). C  ch a g a h  a  e f ed i h Si iaF a h  60 (40
63 ic ) i ica ge  f  Si ic c e. Thi  a e  ch a g a h  (TLC) a  ed f  eac i  
i i g a d d c  de ec i  i g e-c a ed g a  a e  c e ed i h 0.25  i ica ge  
i h f e ce  i dica ; i a i a i  b  UV igh  (Oex = 254 )  KM O4 ai . 
Materials 
Reage  e e cha ed i  eage  g ade f  c e cia  ie  a d ed i h  f he  
ifica i , e  he i e de c ibed. T i ( e af he )b a e a  cha ed f  TCI 
a d ed i h  f he  ifica i . H2O, i  he ic ced e , efe   di i ed a e . Chi a  
iga d  L1-L12 e e e a ed acc di g  he ced e  e i  e ed i  he i e a e. 
A i e  a d DE-unsaturated compounds were prepared according to the procedures reported 
e i .  
Instrumentation 
P  c ea  ag e ic e a ce (1H NMR) ec a a d -dec ed ca b  c ea  
ag e ic e a ce (13C 1H  NMR) ec a e e ec ded a  25 C ( e  a ed he i e)  
I a 600 (600 MH ), Va ia  U i /I a 500 (500 MH )  O f d AS400 (400 MH ) 
ec e e  a  he B  C ege c ea  ag e ic e a ce faci i . Che ica  hif  f  
 a e e ed i  a  e  i i  d fie d f  e a e h i a e a d a e efe e ced  0 
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. Che ica  hif  f  ca b  a e e ed i  a  e  i i  d fie d f  e a e h i a e 
a d a e efe e ced  he ca b  e a ce  f he e . The eak i i  a e ed  e 
deci a  ace e  he  a e i di i g i hab e. The e  eak a  efe e ced  77.2  f  
13C f  CDC 3. Be if ide a  ed a  a  e e a  a da d f  19F NMR a d efe e ced  
63.7 ppm. Data are represented as follows: chemical shift, integration, multiplicity (br = broad, s 
= i g e , d = d b e ,  = i e ,  = a e ,  = i e ), c i g c a  i  He  (H ). 
I f a ed ec a e e ec ded  a B ke  FT-IR A ha (ATR de) ec h e e . Da a a e 
e e e ed a  f : f e e c  f ab i  (c 1). High- e i  a  ec e  a  
e f ed  a JEOL Acc TOF-DART ( i i e de) a  he Ma  S ec e  Faci i , B  
C ege. 
Abbreviations used 
B  = be , B c = -b ca b , COD = 1,5-c c c adie e, COSY = c e a i  
ec c , DART = di ec  a a i  i  ea  i e, DCM = dich e ha e, DMAP = 4-
di e h a i idi e, DMF = N,N-di e h f a ide, e  = e a i e ic a i , HPLC = high 
e e i id ch a g a h , E 3N = i e h a i e, E OAc = e h  ace a e, HR = high-
e i , HSQC = he e c ea  i g e a  c he e ce, LC = i id ch a g a h , MS = 
a  ec e , NOESY = c ea  O e ha e  effec  ec c , OTf = if a e, PMP = -
e h he , PTLC = e a a  hi - a e  ch a g a h , TBAF = e a- -b a i  
f ide, TBME = -b  e h  e he , TBS = -b di e h i , THF = e ah d f a , 
TLC = hi - a e  ch a g a h , TMS = i e h i , TOF = i e- f-f igh . 
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C1. Substrate Preparation 
Preparation of Amine Substrates (Table S3.6) 
Table S3.6A. List of Amine Substrates 
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Table S3.6B. List of Amine Substrates 
 
S b a e  3.21 e e e a ed acc di g  he i e a e ced e . Me h d  ed  e a e he 
e  he i ed a i e  (3.21g-3.21i, 3.21k, 3.21l-d, 3.21m, 3.21r-dD, and 3.21r-dE) and hei  
ec c ic da a a e ided be . 
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N,N-Dibenzylethanamine (3.21a)  
N,N-Dibenzylethanamine was prepared following the General Procedure for the Alkylation of 
Amines using dibenzylamine (2.0 g, 10.1 mmol), iodoethane (1.5 equiv.) and K2CO3 (2 equiv.). 
The unpurified product was subjected to silica gel column chromatography (Et2O:hexanes = 1:49) 
to afford 3.21a as a colorless liquid (1.9 g, 83%).  
1H NMR (500 MHz, CDCl3)  7.37 (d, J = 6.7 Hz, 4H), 7.30 (t, J = 7.6 Hz, 4H), 7.24  7.19 (m, 
2H), 3.57 (s, 4H), 2.50 (q, J = 7.1 Hz, 2H), 1.07 (t, J = 7.1 Hz, 3H). 
 
 
N,N-Dibenzylpropan-1-amine (3.21b)  
N,N-Dibenzylpropan-1-amine was prepared following the General Procedure for the Alkylation of 
Amines using dibenzylamine (2.0 g, 10.1 mmol), 1-bromopropane (1.5 equiv.) and K2CO3 (2 
equiv.). The unpurified product was subjected to silica gel column chromatography (Et2O:hexanes 
= 1:49) to afford 3.21b as a colorless liquid (1.9 g, 78%).  
1H NMR (400 MHz, CDCl3)  7.37 (d, J = 7.5 Hz, 4H), 7.29 (t, J = 7.4 Hz, 4H), 7.26  7.17 (m, 
2H), 3.55 (s, 4H), 2.42  2.32 (m, 2H), 1.52 (h, J = 7.3 Hz, 2H), 0.85 (t, J = 7.4 Hz, 3H). 
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N,N-Dibenzyl-3-methylbutan-1-amine (3.21c)  
N,N-Dibenzyl-3-methylbutan-1-amine was prepared following the General Procedure for the 
Alkylation of Amines using dibenzylamine (5.2 g, 26.1 mmol), 1-bromo-3-methylbutane (1.2 
equiv.) and K2CO3 (2 equiv.). The unpurified product was subjected to silica gel column 
chromatography (Et2O:hexanes = 1:49) to afford 3.21c as a colorless liquid (4.3 g, 62%).  
1H NMR (500 MHz, CDCl3)  7.36 (d, J = 6.7 Hz, 4H), 7.30 (t, J = 7.6 Hz, 4H), 7.22 (t, J = 7.3 
Hz, 2H), 3.54 (s, 4H), 2.45  2.39 (m, 2H), 1.59 (dp, J = 13.3, 6.7 Hz, 1H), 1.43  1.36 (m, 2H), 
0.78 (d, J = 6.6 Hz, 6H). 
 
 
N-Benzhydrylethanamine (3.21d)  
N-Benzhydrylethanamine was prepared following the General Procedure for the Alkylation of 
Amines using diphenylmethanamine (3.7 g, 20 mmol), iodoethane (0.9 equiv.) and K2CO3 (2 
equiv.). The unpurified product was subjected to silica gel column chromatography 
(EtOAc:hexanes = 1:19) to afford 3.21d as a colorless liquid (3.1 g, 82%).  
1H NMR (600 MHz, CDCl3)  7.39 (d, J = 6.9 Hz, 4H), 7.29 (t, J = 7.7 Hz, 4H), 7.19 (t, J = 7.3 
Hz, 2H), 4.83 (s, 1H), 2.61 (q, J = 7.2 Hz, 2H), 1.13 (t, J = 7.1 Hz, 3H). 
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N-Benzhydrylpropan-1-amine (3.21e)  
N-Benzhydrylpropan-1-amine was prepared following the General Procedure for the Alkylation 
of Amines using diphenylmethanamine (7.3 g, 40 mmol), 1-bromopropane (0.8 equiv.) and K2CO3 
(1.2 equiv.). The unpurified product was subjected to silica gel column chromatography 
(EtOAc:hexanes = 1:19) to afford 3.21e as a light yellow liquid (5.6 g, 78%).  
1H NMR (500 MHz, CDCl3)  7.39 (d, J = 7.3 Hz, 4H), 7.29 (t, J = 7.6 Hz, 4H), 7.19 (t, J = 7.3 
Hz, 2H), 4.81 (s, 1H), 2.54 (t, J = 7.1 Hz, 2H), 1.53 (h, J = 7.3 Hz, 2H), 1.46 (s, 1H), 0.91 (t, J = 
7.4 Hz, 3H). 
 
 
N-Benzhydryl-2-phenylethan-1-amine (3.21f)  
N-Benzhydryl-2-phenylethan-1-amine was prepared following the General Procedure for the 
Alkylation of Amines using diphenylmethanamine (1.8 g, 10 mmol), (2-bromoethyl)benzene (0.9 
equiv.) and K2CO3 (1.2 equiv.). The unpurified product was subjected to silica gel column 
chromatography (EtOAc:hexanes = 1:19) to afford 3.21f as a colorless liquid (2.0 g, 77%).  
1H NMR (500 MHz, CDCl3)  7.35 (d, J = 6.8 Hz, 4H), 7.27 (t, J = 7.6 Hz, 6H), 7.22  7.15 (m, 
5H), 4.83 (s, 1H), 2.89  2.80 (m, 4H). 
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(R)-N-Eth l-1-phen l-N-((R)-1-phen leth l)ethan-1-amine (3.21g)  
3.21g a  e a ed h gh he eac i  f (R)-bi ((R)-1- he e h )a i e (2.7 g, 11.8 ), 
i d e ha e (1.5 e i .) a d K2CO3 (2.0 e i .) i  MeCN. The eac i  i e i  e e e e  
a  aced i  a  i  ba h a  100 °C and was allowed to stir f  12 h . U  c e i  
( i ed b  TLC), he i  a  a ed  c   22 °C. H2O a  he  added a d he 
ga ic a e ia  a  e ac ed i h E OAc. The c bi ed ga ic a e  e e d ied e  MgSO4, 
fi e ed, a d c ce a ed  ac . The ified d c  i e a  bjec ed  f a h i ica 
ge  c  ch a g a h  (e h  e he :he a e  = 1:19)  aff d 3.21g a  a c e  i id (2.1 
g, 70%). 1H NMR (500 MH , CDCl3):  7.38 (d, J = 7.6 H , 4H), 7.29 ( , J = 7.6 H , 4H), 7.20 
( , J = 7.2 H , 2H), 4.01 ( , J = 6.8 H , 2H), 2.67 (d , J = 14.1, 7.0 H , 1H), 2.48 (d , J = 14.2, 
7.1 H , 1H), 1.38 (d, J = 6.9 H , 6H), 0.80 ( , J = 7.1 H , 3H). 
 
 
1-Ben l-4-((( e -but ldimeth lsil l)o )meth l)piperidine (3.21h)  
1-Be -4-((( -b di e h i ) ) e h ) i e idi e a  e a ed f i g he Ge e a  
P ced e f  he TBS P ec i  f A c h  i g (1-be i e idi -4- ) e ha  (10 ) 
a  he a c h . The ified d c  a  bjec ed  i ica ge  c  ch a g a h  (e h  
e he :he a e  = 1:4)  aff d 3.21h a  a c e  i id (3.0 g, 94%). 
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1H NMR (500 MH , CDC 3)  7.34  7.28 ( , 4H), 7.26 ( , 1H), 3.49 ( , 2H), 3.43 (d, J = 6.5 H , 
2H), 2.88 (d , J = 11.6, 3.3 H , 2H), 1.93 ( d, J = 11.7, 2.5 H , 2H), 1.73  1.63 ( , 2H), 1.46 (ddd, 
J = 11.4, 7.5, 4.5 H , 1H), 1.28  1.16 ( , 2H), 0.88 ( , 9H), 0.03 ( , 6H). 
 
 
N,N-Dibenzyl-1-(1-benzylpiperidin-4-yl)methanamine (3.21i)  
N,N-Dibenzyl-1-(1-benzylpiperidin-4-yl)methanamine was prepared following the General 
Procedure for the Alkylation of Amines using (1-benzylpiperidin-4-yl)methanamine (0.5 g, 2.5 
mmol), benzyl bromide (2.0 equiv.) and K2CO3 (2 equiv.). The unpurified product was subjected 
to silica gel column chromatography (e h  e he :he a e  = 1:4) to afford 3.21i as a white solid 
(0.9 g, 92%).  
1H NMR (500 MHz, CDCl3)  7.36  7.31 (m, 3H), 7.31  7.25 (m, 10H), 7.25  7.17 (m, 2H), 
3.50 (s, 4H), 3.44 (s, 2H), 2.82 (d, J = 10.6 Hz, 2H), 2.23 (d, J = 7.3 Hz, 2H), 1.89 (td, J = 11.8, 
2.5 Hz, 2H), 1.82  1.72 (m, 2H), 1.57 (s, 1H), 1.07 (qd, J = 12.2, 3.8 Hz, 2H). 
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(R)-1-Benzyl-3-phenylpyrrolidine (3.21j)  
(R)-1-Benzyl-3-phenylpyrrolidine was prepared following the General Procedure for the 
Alkylation of Amines using (R)-3-phenylpyrrolidine hydrochloride (0.5 g, 2.7 mmol), benzyl 
bromide (1.1 equiv.) and K2CO3 (4 equiv.). The unpurified product was subjected to silica gel 
column chromatography (EtOAc:hexanes = 1:19) to afford 3.21j as a colorless liquid (490 mg, 
76%).  
1H NMR (500 MHz, CDCl3)  7.36 (d, J = 7.4 Hz, 2H), 7.31 (t, J = 7.4 Hz, 2H), 7.29  7.22 (m, 
5H), 7.21  7.15 (m, 1H), 3.68 (s, 2H), 3.36 (dt, J = 9.8, 7.5 Hz, 1H), 3.04 (t, J = 8.5 Hz, 1H), 2.84 
(td, J = 8.5, 6.0 Hz, 1H), 2.69 (td, J = 8.9, 5.9 Hz, 1H), 2.50 (t, J = 8.5 Hz, 1H), 2.38  2.29 (m, 
1H), 1.94  1.85 (m, 1H). 
 
 
(R)-2-((( e -But ldimeth lsil l)o )diphen lmeth l)p rrolidine (S2)  
S2 a  e a ed h gh he TBS ec i  f (R)-di he ( idi -2- ) e ha  (S1).  
T  a i  f S7 (20 ) i  DCM a  0 C, E 3N (1.3 e i .) a  added, f ed b  he 
d i e addi i  f TBSOTf (1.3 e i .). Af e  he addi i , he eac i  i e a  a ed  
a   22 °C a d i ed f  12 h . U  c e i  ( i ed b  TLC), H2O a  added 
a d he ga ic a e ia  a  he  e ac ed i h DCM. The c bi ed ga ic a e  e e d ied 
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e  MgSO4, fi e ed, a d c ce a ed  ac . The ified d c  i e a  bjec ed  
f a h i ica ge  c  ch a g a h  (e h  e he :he a e  = 1:9)  aff d S2 a  a c e  
i id (4.1 g, 56%). 1H NMR (500 MH , CDCl3):  7.52 (d, J = 7.6 H , 2H), 7.36 (d, J = 8.2 H , 
2H), 7.32  7.17 ( , 6H), 4.01 ( , J = 7.3 H , 1H), 2.88  2.76 ( , 1H), 2.76  2.64 ( , 1H), 1.59 
( , J = 7.5 H , 2H), 1.55  1.46 ( , 1H), 1.30  1.12 ( , 1H), 0.95 ( , 9H), -0.21 ( , 3H), -0.46 ( , 
3H). 
 
(R)-1-Ben l-2-((( e -but ldimeth lsil l)o )diphen lmeth l)p rrolidine (3.19o)  
3.21k a  e a ed h gh he eac i  f S2 (1.5 g, 4.1 ), be  b ide (1.1 e i .) a d 
K2CO3 (4.0 e i .) i  MeCN. The eac i  i e i  e e e e  a  aced i  a  i  ba h a  
100 °C and was allowed to stir f  12 h . U  c e i  ( i ed b  TLC), he i  
a  c ed  22 °C. H2O a  he  added a d he ga ic a e ia  a  e ac ed i h E OAc. The 
c bi ed ga ic a e  e e d ied e  MgSO4, fi e ed, a d c ce a ed  ac . The 
ified d c  i e a  bjec ed  f a h i ica ge  c  ch a g a h  (e h  
e he :he a e  = 1:19)  aff d 3.21k a  a c e  i id (1.45 g, 78%). 1H NMR (500 MH , 
CDCl3):  7.64 (dd, J = 7.6, 2.2 H , 2H), 7.55 (dd, J = 8.0, 1.8 H , 2H), 7.32  7.25 ( , 6H), 7.25 
 7.19 ( , 2H), 7.17 (d, J = 7.2 H , 1H), 7.11 (d, J = 7.4 H , 2H), 4.36 (d, J = 13.3 H , 1H), 4.00 
(dd, J = 9.4, 4.1 H , 1H), 3.45 (d, J = 13.3 H , 1H), 2.30 ( d, J = 6.5, 3.4 H , 1H), 2.12 ( d, J = 9.2, 
6.6 H , 1H), 1.99 (dd, J = 13.4, 8.9 H , 1H), 1.87 (dd, J = 8.6, 4.3 H , 1H), 1.39  1.26 ( , 1H), 
0.90 ( , 9H), 0.64  0.54 ( , 1H), -0.39 ( , 3H), -0.43 ( , 3H).  
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1-(4-Methoxy-2,6-dimethylphenyl)piperidine (3.21l)  
1-(4-Methoxy-2,6-dimethylphenyl)piperidine was prepared following the General Procedure for 
the Alkylation of Amines using 4-methoxy-2,6-dimethylaniline (1.0 g, 6.6 mmol), 1,5-
dibromopentane (1.5 equiv.) and K2CO3 (3 equiv.). The unpurified product was subjected to silica 
gel column chromatography (Et2O:hexanes = 1:49) to afford 3.21l as a colorless liquid (1.2 g, 
83%).  
1H NMR (500 MHz, CDCl3)  6.52 ( , 2H), 3.74 ( , 3H), 2.98 ( , J = 5.1 Hz, 4H), 2.29 (s, 6H), 
1.65  1.58 (m, 4H), 1.58  1.51 (m, 2H).  
 
 
1-(4-Metho -2,6-dimeth lphen l)piperidine-3,3,5,5-d4 (3.21l-d)  
3.21l-d a  e a ed f i g he e i  e ed i e a e,12h i g 1-(4-Me h -2,6-
di e h he ) i e idi e (877 g, 4.0 ), ace e- 6 (2.0 L, 28 ) a d B(C6F5)3 (102 
g, 0.20 ). The c de eac i  i e a  bjec ed  i ica ge  ch a g a h  (e h  
e he :he a e  = 1:20)  gi e he d c  3.21l-d a  a e  i id i h 88% -i c a i  a  
he E-amino position. This compound was resubjected to the af e e i ed eac i  c di i  
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a d af e  f a h i ica ge  c  ch a g a h  (e h  e he :he a e  = 1:20), 3.21l-d a  
b ai ed i h >95% -i c a i  e e  a  he E-amino position. (0.63 g, 70%). 1H NMR (500 
MH , CDCl3):  6.69  6.35 ( , 2H), 3.77  3.71 ( , 3H), 3.15  2.74 ( , 4H), 2.43  2.15 ( , 
6H), 1.63  1.57 ( , 0.19H, >95%D), 1.56  1.47 ( , 2H). 
 
S nthesis of 1,5-Dibromo-3,3-dimeth lpentane (S5) 
 
1,5-Dib -3,3-di e h e a e (S5) a  e a ed f i g he i e a e e i  
e ed.26d 
3,3-Dimeth lpentane-1,5-diol (S4) 
T  a i  f 3,3-di e h e a edi ic acid S3 (3.0 g, 18.7 ) i  THF, LiA H4 a  added 
i i e a  0 C. The eac i  i e a   a ed  22 C a d a  a ed  i  f  
12 h . U  c e i  f he eac i  ( i ed b  TLC), he i e a  e ched i h 
1.0 M NaOH (a .) a  0 C a d e ac ed i h E OAc (3  50 L). The ga ic a e  a  d ied 
e  MgSO4, fi e ed, a d c ce a ed  ac . The ified d c  a  bjec ed  f a h 
i ica ge  c  ch a g a h  (E OAc:he a e  = 1:1)  gi e 3,3-di e h e a e-1,5-di  S4 
a  a c e  i id (1.8 g, 73%). 1H NMR (600 MH , CDCl3):  3.74 ( , J = 7.1 H , 4H), 1.58 
( , J = 7.0 H , 4H), 0.95 ( , 6H). 
 
1,5-Dibromo-3,3-dimeth lpentane (S5) 
T  a i  f 3,3-di e h e a e-1,5-di  S4 (1.2 g, 9.4 ) i  47% HB  (a .), H2SO4 a  
added d i e a  0 C. The eac i  i e a   hea ed  100 C a d a  a ed  i  
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f  12 h . U  c e i  f he eac i  ( i ed b  TLC), he i e a  e ched 
i h NaHCO3 (a .) a d e ac ed i h e h  e he  (3  20 L). The c bi ed ga ic a e  e e 
a hed i h b i e (30 L), d ied e  MgSO4, fi e ed a d c ce a ed  ac . The ified 
d c  a  he  bjec ed  f a h i ica ge  c  ch a g a h  (100% he a e )  aff d 
1,5-dib -3,3-di e h e a e S5 a  a c e  i id (1.8 g, 75%). 1H NMR (400 MH , 
CDCl3):  3.41  3.33 ( , 4H), 1.90  1.82 ( , 4H), 0.94 ( , 6H). 
 
 
1-(4-Metho -2,6-dimeth lphen l)-4,4-dimeth lpiperidine (3.21m)  
3.21m a  e a ed h gh he eac i  f 4- e h -2,6-di e h a i i e (0.7 g, 4.7 ), 1,5-
dib -3,3-di e h e a e (1.5 e i .) a d K2CO3 (4.0 e i .) i  MeCN. The eac i  i e 
i  e e e e  a  aced i  a  i  ba h a  100 °C and was allowed to stir f  12 h . U  
c e i  ( i ed b  TLC), he i  a  c ed  22 °C. H2O a  he  added a d he 
ga ic a e ia  a  e ac ed i h E OAc. The c bi ed ga ic a e  e e d ied e  MgSO4, 
fi e ed, a d c ce a ed  ac . The ified d c  i e a  bjec ed  f a h i ica 
ge  c  ch a g a h  (e h  e he :he a e  = 1:49)  aff d 3.21m a  a c e  i id (0.7 
g, 61%). 1H NMR (500 MH , CDCl3):  6.53 ( , 2H), 3.74 ( , 3H), 3.01  2.94 ( , 4H), 2.30 ( , 
6H), 1.47  1.39 ( , 4H), 0.98 ( , 6H). 
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N-Ethyl-4-methoxy-N,2,6-trimethylaniline (3.21s)  
N-Ethyl-4-methoxy-N,2,6-trimethylaniline was prepared following the General Procedure for the 
Alkylation of Amines using N-ethyl-4-methoxy-2,6-dimethylaniline2 (0.5 g, 2.8 mmol), methyl 
iodide (1.5 equiv.) and K2CO3 (2.0 equiv.). The unpurified product was subjected to silica gel 
column chromatography (Et2O:hexanes = 1:49) to afford 3.21s as a colorless liquid (0.4 g, 63%).  
1H NMR (400 MHz, CDCl3)  6.54 (d, J = 0.5 Hz, 2H), 3.74 (s, 3H), 3.01 (q, J = 7.1 Hz, 2H), 
2.73 (s, 3H), 2.25 (d, J = 0.5 Hz, 6H), 1.02 (t, J = 7.1 Hz, 3H). 
 
S nthesis of 1-(4-Metho phen l)p rrolidine-2,2,3,3,4,4,5,5-d8 (S8) 
 
1,4-Dib b a e-1,1,2,2,3,3,4,4- 8 (S7) a  e a ed f i g he i e a e e i  
e ed.26b S8 a  e a ed h gh he eac i  f 4- e h a i i e (1.2 g, 10 ), S7 (2.0 
g, 0.9 ) a d K2CO3 (4.1 g, 30 ) i  MeCN. The eac i  i e i  e e e e  a  
aced i  a  i  ba h a  120 °C and was allowed to stir f  12 h . U  c e i  ( i ed 
b  TLC), he i  c ed  22 °C. H2O a  he  added a d he ga ic a e ia  a  e ac ed 
i h E OAc. The c bi ed ga ic a e  e e d ied e  MgSO4, fi e ed, a d c ce a ed  
ac . The ified d c  i e a  bjec ed  f a h i ica ge  c  ch a g a h  
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(e h  e he :he a e  = 1:20)  gi e he d c  S8 a  a hi e id (1.1 g, 82%). 1H NMR (400 
MH , CDCl3):  6.84 (d, J = 8.9 H , 2H), 6.53 (d, J = 9.0 H , 2H), 3.76 ( , 3H), 3.22  3.18 ( , 
0.02H, >95%D), 1.96  1.91 ( , 0.03H, >95%D). 
 
 
1-(4-Metho phen l)p rrolidine-2,2,5,5-d4 (3.21r-dD)  
3.21r-dD was prepared following a method previously reported in the literature12h i g S8 (556 
g, 3.0 ), ace e (1.5 L, 20.4 ) a d B(C6F5)3 (154 g, 0.30 ). The c de 
eac i  i e a  bjec ed  i ica ge  ch a g a h  (e h  e he :he a e  = 1:20)  gi e 
he d c  3.21r-dD  as a yellow liquid with >95% and 40% -i c a i  a  he D- and E-amino 
i i , e ec i e . Thi  c d a  e bjec ed  he af e e i ed eac i  c di i  
a d af e  f a h i ica ge  c  ch a g a h  (e h  e he :he a e  = 1:20), 3.21r-dD was 
b ai ed i h >95% a d <5% -i c a i  e e  a  he D- and E-amino position. (501 mg, 80%). 
1H NMR (600 MH , CDCl3):  6.90  6.78 ( , 2H), 6.60  6.46 ( , 2H), 3.76 ( , 3H), 3.23  
3.19 ( , 0.02H, >95%D), 2.05  1.88 ( , 4H). 
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1-(4-Metho phen l-2,6-d2)p rrolidine-3,3,4,4-d4 (3.21r-dE)  
3.21r-dE was prepared following a method previously reported in the literature12h i g 1-(4-
e h he ) idi e (886 g, 5.0 ), ace e- 6 (2.5 L, 35 ) a d B(C6F5)3 (128 
g, 0.25 ). The c de eac i  i e a  bjec ed  i ica ge  ch a g a h  (e h  
e he :he a e  = 1:20)  gi e he d c  3.21r-dE as a yellow liquid with 70% -i c a i  a  
he E-amino position. This compound was resubjected to the af e e i ed eac i  c di i  
a d af e  f a h i ica ge  c  ch a g a h  (e h  e he :he a e  = 1:20), 3.21r-dE was 
b ai ed i h >95% -i c a i  e e  a  he E-amino position. (686 mg, 74%). 1H NMR (400 
MHz, CDCl3):  6.84 ( , 2H), 6.56  6.51 ( , 0.02H, >95%D), 3.76 ( , 3H), 3.33  3.12 ( , 4H), 
1.98  1.93 ( , 0.15H, >95%D). 
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Preparation of D,E-Unsaturated Compounds (Table S3.7) 
Table S3.7. List of DE-Unsaturated Compounds 
 
DE-Unsaturated compounds 3.22a,4 3.22b,2 and 3.25a3.25j26d-26f were prepared according to the 
procedures previously reported in the literatures. Substrates 3.22c3.22e were obtained from 
commercial sources and used without further purification. 
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Preparation of Diisoprop l Fumarate (3.22a) 
 
Dii  f a a e a  e a ed acc di g  a ced e e ed e i  i  he i e a e. 
A i e f f a ic acid (23.2 g, 200 ), i  a c h  (4.0 e i .), H2SO4 (2.0 L) a d 
be e e (25.0 L) a  hea ed a  80 C and was allowed to stir f  12 h . The eac i  i e 
a  e ched i h NaHCO3 (a .) a  0 C a d e ac ed i h e h  e he  (3  25 L). The c bi ed 
ga ic a e  e e a hed i h b i e, d ied e  MgSO4 a d c ce a ed  ac . The 
ified d c  i e a  di i ed (75 C, 40 Hg)  gi e dii  f a a e 3.22a a  
a c e  i id (24.0 g, 60%). 1H NMR (500 MH , CDCl3):  6.81 ( , 2H), 5.11 (he , J = 6.2 
H , 2H), 1.29 (d, J = 6.3 H , 12H). 
Preparation of Diben l Fumarate (3.22b) 
 
Dibe  f a a e a  e a ed acc di g  a ced e e ed e i  i  he i e a e.26d 
T  a i  f f a ic acid (6.0 g, 51.7 ) i  DMF (6 L), E 3N (2.0 e i ) a d 
(b e h )be e e (1.9 e i .) e e added d i e. The eac i  i e a  a ed  
i  a  100 C f  12 h . U  c e i , he eac i  i e a  ed i  c d a e  a d 
he  fi e ed  gi e a b  id. The ified d c  a  he  bjec ed  i ica ge  c  
ch a g a h  (E OAc:he a e  = 3:17) a d a  f he  ified b  ec a i a i  
(E OAc:he a e  = 1:20)  gi e dibe  f a a e 3.22b a  a hi e id (8.2 g, 56%). 1H NMR 
(600 MH , CDCl3):  7.41  7.30 ( , 10H), 6.92 ( , 2H), 5.23 ( , 4H). 
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General Procedure A for Preparation of 2-Acr lo lp ra olidinone Derivatives 
 
C e di g ca b ic acid (1.0 e .), a idi e26e (1.0 e .) a d 4-di e h a i idi e 
(0.1 e ) e e di ed i  DCM a  22 C. Af e  N,N'-dic c he ca b dii ide (1.1 e ) a  added 
 he i , i  a  a ed  i  e igh   aff d he c e di g DE-unsaturated 
c d. U  c e i , eac i  i e a  fi e ed h gh Ce i e i g DCM a  e . 
The ified d c  i e a  bjec ed  f a h i ica ge  c  ch a g a h . 
 
General Procedure B for Preparation of 2-Acr lo lp ra olidinone Derivatives 
 
-B Li (1.1 e .) a  added  he a ia e a idi e i  d  THF a  78 C, a d he i e 
(Mi ture A) a  a ed  i  a  78 C. O a  ch ide (3.0 e .) a  added d i e i  
c e di g ca b ic acid (1.0 e .) i  DCM i  a  0 C. 2 d  f DMF a  added, a d 
he i e a  a ed  i  f  1 h . The e  a  e ed de  ed ced e e, a d 
he e id e a  added i  Mi ture A. The i e a  i ed a  78 C f  2-3 h  i  he 
eac i  a  c e e. The eac i  a  e ched i h a a ed a e  a i  ch ide 
a d THF a  e ed de  ed ced e e. The e id e a  di ed i  DCM a d a hed 
 500  
i h a . NaHCO3 (a .). The ga ic a e  a  a hed i h b i e, d ied e  MgSO4, fi e ed, a d 
c ce a ed de  ed ced e e. The ified d c  i e a  bjec ed  f a h i ica 
ge  c  ch a g a h . 
 
 
Eth l (E)-4-(2-eth l-3,3-dimeth l-5-o op ra olidin-1- l)-4-o obut-2-enoate (3.25c)  
3.25c a  e a ed f i g General Procedure B for Preparation of 2-
Acr lo lp ra olidinone Derivatives i g (E)-4-e h -4- b -2-e ic acid (3.60 g, 25.0 
), 1-e h -5,5-di e h a idi -3- e (3.60 g, 25.0 ), a  ch ide (9.52 g, 75 
) a d -B Li (27.5 ). The ified d c  a  bjec ed  f a h i ica ge  c  
ch a g a h  (E OAc:he a e  = 1:3)  aff d 3.25c a  a e  i id (4.5 g, 67%). 1H NMR 
(500 MH , CDCl3):  7.93 (d, J = 15.6 H , 1H), 6.96 (d, J = 15.6 H , 1H), 4.27 ( , J = 7.1 H , 
2H), 3.01 ( , J = 7.1 H , 2H), 2.60 ( , 2H), 1.35  1.31 ( , 9H), 1.08 ( , J = 7.2 H , 3H). 
 
 
Eth l (E)-4-(2-ben l-3,3-dimeth l-5-o op ra olidin-1- l)-4-o obut-2-enoate (3.25d)  
3.25d a  e a ed f i g General Procedure B for Preparation of 2-
Acr lo lp ra olidinone Derivatives i g (E)-4-e h -4- b -2-e ic acid (5.04 g, 35.0 
), 1-be -5,5-di e h a idi -3- e (6.79 g, 35.0 ), a  ch ide (13.33 g, 
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105 ) a d -B Li (38.5 ). The ified d c  a  bjec ed  f a h i ica ge  
c  ch a g a h  (E OAc:he a e  = 1:3)  aff d 3.25d a  a e  id (5.0 g, 53%). 1H 
NMR (400 MH , CDCl3):  7.44 (d, J = 15.5 H , 1H), 7.29 (d, J = 5.0 H , 2H), 7.26  7.22 ( , 
3H), 6.49 (d, J = 15.5 H , 1H), 4.21 ( , J = 7.1 H , 2H), 4.00 ( , 2H), 2.61 ( , 2H), 1.34 ( , 6H), 
1.30 ( , J = 7.1 H , 3H). 
 
 
(E)-1-(2-Ben l-3,3-dimeth l-5-o op ra olidin-1- l)-4-phen lbut-2-ene-1,4-dione (3.25e)  
3.25e a  e a ed f i g General Procedure A for Preparation of 2-
Acr lo lp ra olidinone Derivatives i g (E)-4- -4- he b -2-e ic acid (2.64 g, 15.0 
), 1-be -5,5-di e h a idi -3- e (3.06 g, 15.0 ), N,N'-
dic c he ca b dii ide (3.30g, 16.5 ) a d di e h a i idi e (0.18 g, 1.5 ). The 
ified d c  a  bjec ed  f a h i ica ge  c  ch a g a h  (E 3N:E OAc:he a e  
= 1:30:90)  aff d 3.25e a  a e  id (1.5 g, 26%). 1H NMR (400 MH , CDCl3):  7.92 (d, 
J = 7.8 H , 2H), 7.60 ( , J = 7.4 H , 1H), 7.49 ( , J = 7.6 H , 3H), 7.30 (d, J = 7.6 H , 2H), 7.25 
( , 1H), 7.19 ( , J = 7.5 H , 2H), 7.11 ( , J = 7.3 H , 1H), 4.01 ( , 2H), 2.64 ( , 2H), 1.37 ( , 6H). 
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(E)-1-Eth l-5,5-dimeth l-2-(4,4,4-trifluorobut-2-eno l)p ra olidin-3-one (3.25f)  
3.25f a  e a ed f i g General Procedure A for Preparation of 2-
Acr lo lp ra olidinone Derivatives i g (E)-4,4,4- if b -2-e ic acid (2.52 g, 18.0 
), 1-e h -5,5-di e h a idi -3- e (2.66 g, 18.0 ), N,N'-
dic c he ca b dii ide (4.10 g, 20 ) a d di e h a i idi e (0.24 g, 2.0 ). The 
ified d c  a  bjec ed  f a h i ica ge  c  ch a g a h  (E OAc:he a e  = 
1:3)  aff d 3.25f a  a e  i id (3.1 g, 65%). 1H NMR (400 MH , CDCl3):  7.67 (d, J = 
15.6 H , 1H), 6.88 (d , J = 13.8, 6.7 H , 1H), 3.01 ( , J = 7.1 H , 2H), 2.60 ( , 2H), 1.33 ( , 6H), 
1.07 ( , J = 7.1 H , 3H); 19F NMR (376 MH , CDCl3):  -65.20 (d, J = 6.8 H ). 
 
 
1-Ben l-2-cinnamo l-5,5-dimeth lp ra olidin-3-one (3.25g)  
3.25g a  e a ed f i g General Procedure A for Preparation of 2-
Acr lo lp ra olidinone Derivatives i g ci a ic acid (2.67 g, 15.0 ), 1-be -5,5-
di e h a idi -3- e (3.05 g, 15.0 ), N,N'-dic c he ca b dii ide (3.30 g, 16.5 
) a d di e h a i idi e (0.18 g, 1.5 ). The ified d c  a  bjec ed  
f a h i ica ge  c  ch a g a h  (E OAc:he a e  = 1:3)  aff d 3.25g a  a e  id 
(3.0 g, 60%). 1H NMR (500 MH , CDCl3):  7.65 (d, J = 15.7 H , 1H), 7.52 (dd, J = 6.6, 2.9 H , 
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2H), 7.47  7.35 ( , 5H), 7.29  7.24 ( , 3H), 7.23  7.18 ( , 1H), 4.12 ( , 2H), 2.61 ( , 2H), 1.34 
( , 6H). 
 
 
(E)-1-Ben l-5,5-dimeth l-2-(3-(4-(trifluorometh l)phen l)acr lo l)p ra olidin-3-one 
(3.25h)  
3.25h a  e a ed f i g General Procedure A for Preparation of 2-
Acr lo lp ra olidinone Derivatives i g (E)-3-(4-( if e h ) he )ac ic acid (3.24 g, 
15.0 ), 1-be -5,5-di e h a idi -3- e (3.05 g, 15.0 ), N,N'-
dic c he ca b dii ide (3.30 g, 16.5 ) a d di e h a i idi e (0.18 g, 1.5 ). 
The ified d c  a  bjec ed  f a h i ica ge  c  ch a g a h  (E OAc:he a e  
= 1:3)  aff d 3.25h a  a e  id (2.7 g, 45%). 1H NMR (500 MH , CDCl3):  7.66  7.54 
( , 5H), 7.50  7.42 ( , 1H), 7.40 ( , 2H), 7.28  7.23 ( , 2H), 7.20 ( , J = 7.3 H , 1H), 4.11 ( , 
2H), 2.63 ( , 2H), 1.36 ( , 6H); 19F NMR (470 MH , CDCl3):  -62.84. 
 
 
(E)-1-Ben l-2-(3-(4-bromophen l)acr lo l)-5,5-dimeth lp ra olidin-3-one (3.25i)  
3.25i a  e a ed f i g General Procedure A for Preparation of 2-
Acr lo lp ra olidinone Derivatives i g (E)-3-(4-b he )ac ic acid (3.39 g, 15.0 
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), 1-be -5,5-di e h a idi -3- e (3.05 g, 15.0 ), N,N'-
dic c he ca b dii ide (3.30 g, 16.5 ) a d di e h a i idi e (0.18 g, 1.5 ). 
The ified d c  a  bjec ed  f a h i ica ge  c  ch a g a h  (E OAc:he a e  
= 1:3)  aff d 3.25i a  a e  id (1.8 g, 29%). 1H NMR (500 MH , CDCl3):  7.57  7.46 
( , 3H), 7.42  7.35 ( , 5H), 7.26  7.16 ( , 3H), 4.11 ( , 2H), 2.61 ( , 2H), 1.35 ( , 6H). 
 
 
(E)-1-Ben l-2-(3-(4-metho phen l)acr lo l)-5,5-dimeth lp ra olidin-3-one (3.25j)  
3.25j a  e a ed f i g General Procedure A for Preparation of 2-
Acr lo lp ra olidinone Derivatives i g (E)-3-(4- e h he )ac ic acid (2.67 g, 15.0 
), 1-be -5,5-di e h a idi -3- e (3.05 g, 15.0 ), N,N'-
dic c he ca b dii ide (3.30 g, 16.5 ) a d di e h a i idi e (0.18 g, 1.5 ). 
The ified d c  a  bjec ed  f a h i ica ge  c  ch a g a h  (E OAc:he a e  
= 1:3)  aff d 3.25j a  a e  id (2.1 g, 38%). 1H NMR (500 MH , CDCl3):  7.63 (d, J = 
15.7 H , 1H), 7.50  7.46 ( , 2H), 7.43  7.39 ( , 2H), 7.35 (d, J = 15.7 H , 1H), 7.28  7.24 ( , 
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C2. Optimi ation Studies  
Evaluation of Reaction Conditions for (F5C6)3B-Catal ed E-Alkylation involving N-
Alk lamines 
E perimental Procedure for the Evaluation of Solvents (Table S3.8) 
T  a 15 L e -d ied e e e e  a  added N,N-dibe e ha a i e 3.21a (0.20 ), 
B(C6F5)3 (10 %), dii  f a a e 3.22a (0.30 ), a d e  (0.20 L) de  a 
i ge  a he e. The eac i  i e a  aced i  a  i  ba h a  50 °C and was allowed to 
stir f  3 h . Af e  he i  a  c ed  22 qC, it was concentrated  ac . The d c  
ie d a  de e i ed b  he 1H NMR a a i  f he ified d c  i e  i g - e e 
a  he i e a  a da d. 
Table S3.8. Evaluation of Solvents involving Amine 3.21a 
 
 506  
Effect of Concentration of Solution to Chemoselectivit  of (F5C6)3B-Catal ed E-Alkylation 
involving C clic N-Alk lamines 
F  i e idi e b a e  (e.g., N-a i e idi e 3.21l, Tab e S3.9) ha  eac  i h 3.22a  gi e a 
i e f d c  i  he f  f N-a k a i e  (e.g., 3.23o) a d e a i e  (e.g., 3.32), e 
ca ied  a e ie  f i i a i  die  ha  e e ai ed  e ec i e  3.23o (Tab e S3.4). 
S ecifica ,  a 15 L e -d ied e e e e  e e added a i e 3.21l (0.20 ), B(C6F5)3 
(10 %), dii  f a a e 3.22a (0.30 ), a d be e e (0.20 L  0.80 L) de  a 
i ge  a he e. The eac i  i e a  aced i  a  i  ba h a  50 °C and was allowed to 
stir f  12 h . U  c e i , he i  a  c ed d    e e a e a d a  
c ce a ed  ac . The ie d a e  f  3.23o a d 3.32 e e de e i ed b  he 1H NMR 
a a i  f he ified d c  i e  i g - e e a  he i e a  a da d.  
A  h  i  Tab e S3.4, i  a  f d ha , he  he eac i  a   i  e di e c di i  
(0.80 L, 0.25 M i  be e e) ha  he a da d eac i  c di i  (0.20 L, 1.0 M i  be e e), 
he N-a k a i e d c  3.23o ca  be b ai ed e efe ab  e  e a i e 3.32. 
F he e, he  he e a i e d c  (e.g., 3.32) i  ge e a ed, he f a i  f dii  
cci a e (3.33) a  b e ed. Thi  i  ike  d e  he h d ge a i  f 3.22a b    ge e a ed 
b h d ide a d a i  i   ege e a e he Le i  acid a d B ed ba e ca a . We 
h he i ed ha  if a a ge  a i  f 3.22a i  e e  i  he eac i  i e  e e a  a 
ac ificia  H+/H- acce , he f a i  f e a i e d c  d be fa ed.  
T  a 15 L e -d ied e e e e  a  added 1-(4- e h -2,6-di e h he )-4,4-
di e h i e idi e 3.21m (0.2 ), B(C6F5)3 (10 %), dii  f a a e 3.22a (0.3 
, 1.5 e i .) a d DCM (0.1 L) de  a i ge  a he e (Sche e S3.1). The eac i   
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Table S3.9. E a a i  f S e  C ce a i  i i g A i e 3.23o 
 
Scheme S3.1. E a a i  f Reac i  C di i  i i g A i e 3.21m 
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i e a  aced i  a  i  ba h a  50 °C and was allowed to stir f  12 h . Af e  he i  
a  c ed  22 °C, dii  f a a e 2.22a (0.2 , 1.0 e i .) a d DCM (0.05 L) e e 
added de  a i ge  a he e. The  he eac i  i e a  aced agai  i  a  i  ba h a  
50 °C and was allowed to stir f  12 h . U  c e i , he i  a  c ed  22 °C 
a d a  c ce a ed  ac . The d c  ie d a  de e i ed b  he 1H NMR a a i  f he 
ified d c  i e  i g - e e a  he i e a  a da d. I  a  f d ha  addi g 2.5 
e i . f 2.22a i  a ba ch i e a e  i e  he d c  ie d a  e  a  he che e ec i i  
f he eac i   ie d e a i e d c  3.23p (Sche e S3.1B). 
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Optimi ation Studies for Diastereoselective E-Alkylation 
E perimental Procedure for the Optimi ation of Diastereoselective Reaction (Scheme 3.16) 
T  a 15 L e -d ied e e e e  e e added (R)-1-be -2-((( -
b di e h i ) )di he e h ) idi e 3.21k (0.10 ), 3.25 (0.15 ), 
B(C6F5)3 (10 %), Le i  acid c -ca a  (10 %), HBPi  (0 %  70 %), a d be e e 
(0.60 L) de  a i ge  a he e. The eac i  i e a  aced i  a  i  ba h a  60 °C 
and was allowed to stir f  24  36 h . U  c e i , he i  a  c ed  22 °C a d 
c ce a ed  ac . The d c  ie d a d d  e e de e i ed b  he 1H NMR a d 19F NMR 
a a e  f he ified d c  i e  i g e i e e (f  1H NMR a a i ) a d 
e f be e e (f  19F NMR a a i ) a  he i e a  a da d. 
Table S3.10. Optimization of Diastereoselective Reaction  
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Studies for Enantioselective E-Alkylation with a Chiral Boron Lewis Acid Catalyst 
Ba ed  he h he i  ha  B(C6F5)3 i  e ib e f  he ac i a i  f b h he N-a k a i e 
a d D,E-unsaturated compounds, we envisioned the use of chiral boron Lewis acid catalyst to 
achie e he e a i e ec i e E-alkylation reaction.  
N,N-dibe a -1-a i e (3.21b) a d be  ac a e (3.22d) e e ed a  de  b a e  
hich aff ded E-alkylated product 3.23  i  75% ie d (Sche e S3.2). We fi  e a i ed he 
abi i  f a chi a  b a e ca a   e he CC bond forming reaction in an enantioselective 
a e . N  de i ed d c  a  b e ed i g e  Le i  acidic D  ca a  (Sche e S3.3A).22 
Whe  D  ca a  a  ed i  c bi a i  i h B(C6F5)3, he d c  a  b ai ed i  70% ie d 
a d 50:50 e  (Sche e S3.3B).  
Scheme S3.2. E-Amino CH Alkylation Involving 3.21b a d 3.22d 
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Scheme S3.3. E a a i  f D  Ca a  
 
 
E perimental Procedure for the Evaluation of Du s Catal st 
A  e -d ied ea ed be e i ed i h a ag e ic i  ba  a  ed. T  hi  be e e added 
(S)-3,3'-di he -2,2'-di i -1,1'-bi a h ha e e (0.005 ), HB(C6F5)2 (0.01 ), a d 
e e (0.2 L) de  i ge  a he e.22 Thi  eac i  i e a  a ed  i  f  20 
i e  a  22 C  ge e a e he chi a  ga b a e ca a . T  hi  i e e e added 3.21b 
(0.10 ), 3.22d (0.15 ), B(C6F5)3 (0.005 ), a d e e (0.2 L). The eac i  
i e a  aced i  a  i  ba h a  50 C a d a  a ed  i  f  12 h . U  c e i , 
he eac i  i e a  c ce a ed  ac . The d c  ie d a  de e i ed b  he 1H NMR 
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a a i  f he ified d c  i e  i g e i e e a  he i e a  a da d. The d c  
a  i a ed a d ified i g e a a  TLC. The e  a  de e i ed b  HPLC a a i  f he 
i a ed a d ified d c . HPLC (Chi a ce  OD-H; 1.5%/ 98.5% i a / he a e , 0.3 
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Optimization Studies for Enantioselective E-Alkylation with Chiral Mg-based complex 
Experimental Procedure for the Optimization of Ligand (Table S3.11) 
To a 15 mL oven-dried pressure vessel was added Mg(ClO4)2 (0.01 mmol, 10 mol%), ligand (0.01 
mmol, 10 mol%), benzene (0.3 mL) under nitrogen atmosphere. The mixture was allowed to stir 
for 20 minutes at 22 °C. Subsequently, 1-(4-methoxy-2,6-dimethylphenyl)pyrrolidine 3.21q (0.1 
mmol), (E)-3-(4,4,4-trifluorobut-2-enoyl)oxazolidin-2-one 3.25b (0.15 mmol), and benzene (0.3 
mL) were added to the vial under nitrogen atmosphere, and the resulting mixture was allowed to 
stir at 22 °C for 12 h. Upon completion, the reaction mixture was concentrated in vacuo. The 
product yield and dr were determined by the 1H NMR and 19F NMR analyses of the unpurified 
product mixtures using mesitylene (for 1H NMR analysis) and perfluorobenzene (for 19F NMR 
analysis) as the internal standard. The product was purified by preparative TLC (hexanes:EtOAc 
= 3:1). The er values of product 3.26b was determined by HPLC analysis of the isolated and 
purified product. 
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Table S3.11. Optimization of Enantioselective Reaction  
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Evaluation of Various Au iliaries and Chiral Le is Acid Co-Catal sts for Enantioselective 
E-Amino CH Alkylation  
T  achie e high  e a i e ec i e E-alkylation of N-a k a i e , a i  c bi a i  f chi a  
Le i  acid c -ca a  a d e ec hi e  c ai i g diffe e  a i ia ie  e e e a a ed (Sche e 
S3.4).  
U i g achi a  b a e  N-a idi e 3.21q a d a idi e- b i ed 3.25b, e 
e a a ed a i  chi a  ga e a ic c e e   fi d ha  Mg(C O4)2/L1 gi e 3.26b i h 67% 
ie d i    90:10 e . I  c a i , he  a chi a  Z -BOX c e  a  ed, 3.26b a  
d ced i  10 % ie d (10:1 d , 50:50 e ; Sche e S3.4A). 
I  de   ide if  he i a  a i ia , e e a a ed b a e  3.36, 3.38 a d 3.25f i  he 
e e ce f a i  chi a  ga e a ic c -ca a . H e e , he de i ed d c  e e 
b ai ed i  0 30% ie d a d   69:31 e  (Sche e  S3.4BD). 
Scheme S3.4. E a a i  f Diffe e  E ec hi e  a d Chi a  Le i  Acid C -Ca a  
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Optimi ation Studies for Enantioselective E-Alkylation Involving 3.25a with Chiral Lewis 
Acid Co-Catal sts 
E perimental Procedure for the Optimi ation of Le is Acid Co-Catal st (Table S3.12) 
T  a 15 L e -d ied e e e e  a  added Le i  Acid (0.010 , 10 %), 2,6-bi ((S)-
4-i -4,5-dih d a -2- ) idi e L6 (0.012 , 12 %), a d DCM (0.50 L) 
de  i ge  a he e. The i e a  a ed  i  f  20 i  a  22 C. S b e e , 
(E)-1-be -5,5-di e h -2-(4,4,4- if b -2-e ) a idi -3- e 3.25k (0.15 ), 1-
(4- e h -2,6-di e h he ) idi e 3.21q (0.10 ), B(C6F5)3 (0.010 , 10 %) 
a d DCM (0.50 L) e e added  he eac i  e e , a d he e i g i e a  a ed  
i  a  22 °C f  12 h . U  c e i , he i  a  c ce a ed  ac . The d c  
ie d a d d  e e de e i ed b  he 1H NMR a d 19F NMR a a e  f he ified d c  
i e  i g e i e e (f  1H NMR a a i ) a d e f be e e (f  19F NMR a a i ) 
a  he i e a  a da d. The d c  a  ified b  e a a i e TLC (E OAc:he a e  = 1:3). The 
e  a e  f d c  3.40 a  de e i ed b  HPLC a a i  f he i a ed a d ified d c . 
E periments for Evaluation of N-Ar l Substituents (Scheme S3.5) 
We e a a ed N-a idi e i h diffe e  b i e   he a a ic i g (e.g., 3.21q, 3.21r) 
i  he e e ce f B(C6F5)3 a d L10Sc(OTf)3 (Sche e S3.5). The eac i  be ee  3.21q a d 
3.25f ga e 3.41 i  45% ie d (6.5:1 d , 96:4 e ). Whe  e  e ica  hi de ed - e h he  
(PMP)- b i ed 3.21r i  a  eac ed i h 3.25f, 3.26f c d be d ced i  62% ie d, 6.7:1 
d , a d 96:4 e . 
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Table S3.12. O i i a i  f Chi a  Le i  Acid C -Ca a  
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Optimi ation Studies for Enantioselective E-Alkylation Involving 3.25c with Chiral Sc-based 
Comple es 
3.6.2.8.1. Evaluation of Reaction Parameters (Table S3.13) 
T  a 15 L e -d ied e e e e  a  added Sc(OTf)3 (0.020 , 10 %), 2,6-bi ((S)-
4-((S)- ec-b )-4,5-dih d a -2- ) idi e L10 (0.024 , 12 %), a d DCM (1.0 
L) de  i ge  a he e. The i e a  a ed  i  f  20 i  a  22 C. S b e e , 
e h  (E)-4-(2-e h -3,3-di e h -5- a idi -1- )-4- b -2-e a e 3.25c (0.30 ), 
1-(4- e h he ) idi e 3.21r (0.20 ), B(C6F5)3 (0.020 , 10 %) a d DCM 
(1.0 L) e e added  he eac i  e e , a d he e i g i e a  aced i  a  i  ba h a  
60 °C and was allowed to stir f  1 h   3 h . U  c e i , he i  a  c ed  
22 °C a d c ce a ed  ac . The d c  ie d a d d  e e de e i ed b  he 1H NMR 
a a e  f he ified d c  i e  i g a  he i e a  a da d. The d c  a  
ified b  e a a i e TLC (E OAc:he a e  = 1:1). The e  a e  f d c  3.26c a  
de e i ed b  HPLC a a i  f he i a ed a d ified d c . 
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Table S3.13. O i i a i  f Reac i  Pa a e e   
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General Reaction Procedure for Evaluation of Chiral Ligands (See Table 3.9) 
T  a 15 L e -d ied e e e e  a  added Sc(OTf)3 (0.010 , 5.0 %), Ligand 
(0.012 , 6.0 %), a d DCM (1.0 L) de  i ge  a he e. The i e a  a ed 
 i  f  20 i  a  22 C. S b e e , e h  (E)-4-(2-e h -3,3-di e h -5- a idi -1-
)-4- b -2-e a e 3.25c (0.30 ), 1-(4- e h he ) idi e 3.21r (0.20 ), 
B(C6F5)3 (0.020 , 10 %) a d DCM (1.0 L) e e added  he eac i  e e , a d he 
e i g i e a  aced i  a  i  ba h a  60 °C and was allowed to stir f  1 h . U  
c e i , he i  a  c ed  22 °C a d c ce a ed  ac . The d c  ie d a d d  
e e de e i ed b  he 1H NMR a a e  f he ified d c  i e  i g e i e e a  
he i e a  a da d. The d c  a  ified b  e a a i e TLC (E OAc:he a e  = 1:1). The 
e  a e  f d c  3.26c a  de e i ed b  HPLC a a i  f he i a ed a d ified d c . 
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Evaluation of Ac clic Amine Substrates for Enantioselective E-Alkylation with Chiral Sc-
based Comple es 
We ha e e a a ed e e a  ac c ic a i e  (3.21) f  e a i e ec i e E-amino CH alkylation; 
h e e , he c e  c di i  e e f d  be i c a ib e i h hi  c a  f b a e (Sche e 
S3.6). 
Scheme S3.6. E a a i  f Ac c ic A i e S b a e  
 
  
 523  
C3. General Procedures for E-Alkylation of N-Alk lamines 
General Procedure C for the E-Alkylation of N-Alk lamines (See Tables 3.63.9 in the 
Manuscript)  
 
T  a 15 L e -d ied e e e e  a  added a i e (0.20 ), B(C6F5)3 (5.0  10 %), 
DE-unsaturated compound (0.30 mmol, 1.5 equiv.) and benzene under a nitrogen atmosphere. The 
eac i  i e a  aced i  a  i  ba h a  50 °C and was allowed to stir f  12 h . U  
c e i , he i  a  c ed  22 °C a d c ce a ed  ac  f ed b  f a h i ica 
ge  c  ch a g a h .  
 




T  a 15 L e -d ied e e e e  a  added a i e (0.20 ), B(C6F5)3 (5.0  10 %), 
DE-unsaturated compound (0.30 mmol, 1.5 equiv.) and benzene (0.30 mL) under a nitrogen 
a he e. The eac i  i e a  aced i  a  i  ba h a  50 °C and was allowed to stir f  12 
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h . Af e  he i  a  c ed  22 °C, DE-unsaturated compound (0.20 mmol, 1.0 equiv.) 
a d be e e (0.10 L) e e added de  a i ge  a he e a d he eac i  i e a  
agai  aced i  a  i  ba h a  50 °C and was allowed to stir f  12 h .  U  c e i , he 
i  a  c ed  22 °C a d c ce a ed  ac  f ed b  f a h i ica ge  c  
ch a g a h . 
 
General Procedure E for the Enantioselective E-Alkylation of N-Alk lamines (See Tables 
3.10-3.11 in the Manuscript) 
 
 
T  a 15 L e -d ied e e e e  a  added Sc(OTf)3 (5.0  10 %), ligand (6.0  12 
%), a d DCM (0.50 L) de  i ge  a he e. The i e a  a ed  i  f  20 
i  a  22 C. S b e e , DE-unsaturated compound 3.25 (0.15  0.20 ), a i e 3.21 
(0.10 ), B(C6F5)3 (10  20 %) a d DCM (0.50 L) e e added  he eac i  e e , 
a d he e i g i e a  aced i  a  i  ba h a  60 C  80 C a d a  a ed  i  f  
136 h . U  c e i , he i  a  c ed  22 °C a d c ce a ed  ac  
f ed b  f a h i ica ge  c  ch a g a h . 
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Procedure for Large Scale Reaction 
 
T  a 25 L e -d ied ea ed be a  added Sc(OTf)3 (10 %), 2,6-bi ((S)-4-((S)- ec-b )-
4,5-dih d a -2- ) idi e L10 (12 %), a d DCM (5.0 L) de  i ge  a he e. 
The i e a  a ed  i  f  2 h  a  22 C. S b e e , (E)-1-e h -5,5-di e h -2-
(4,4,4- if b -2-e ) a idi -3- e 3.25f (8.0 ), 1-(4- e h -2,6-
di e h he ) i e idi e 3.21l (4.0 ), B(C6F5)3 (10 %) a d DCM (1.0 L) e e added 
 he eac i  e e , a d he e i g i e a  aced i  a  i  ba h a  60 C a d a  a ed 
 i  f  12 h . U  c e i , he e  a  c ed  22 C a d c ce a ed  ac  
f ed b  ifica i  h gh f a h i ica ge  c  ch a g a h   aff d he d c  a  
a igh  e  i  (1.93 g, 95% ie d, 95:5 e ). The e  a e a  de e i ed b  HPLC a a i  f 
he i a ed a d ified d c . 
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C4. Determination of Relative Configuration  
Determination of the Relative Configuration of 3.23i-Major 
The e a i e c fig a i  f 3.23i-major a  de e i ed b  he X- a  c a g a hic a a i  
f i  de i a i e, 3.42i-major (Sche e S3.7). 
Scheme S3.7. De i a i a i  f 3.23i-Major a d C a  S c e f 3.42i-Major 
 
1-Ben l-3-(1,4-diisopropo -1,4-dio obutan-2- l)-4-(h dro meth l)piperidin-1-ium 
chloride (3.42i-major) 
3.42i-Major a  he i ed b  he f i g ced e. T  a i  f 3.23i-major (386 g, 
0.75 ) i  THF (10 L) a  added E 3N(HF)3 (0.50 L) i  a d i e a e . The eac i  
a  a ed  i  a  22 C f  12 h . The eac i  i e a  c ce a ed a d fi e ed 
h gh a g f Ce i e i g DCM a  e . The ified d c  a  he  bjec ed  f a h 
i ica ge  c  ch a g a h  (E OAc:he a e  = 9:1)  aff d dii  2-(1-be -4-
(h d e h ) i e idi -3- ) cci a e 3.42i-major-int a  a c e  i  (295 g, 97%).  
1H NMR (400 MH , CDCl3):  7.34  7.20 ( , 5H), 5.01 (d , J = 9.8, 6.2 H , 2H), 3.83 (dd, J = 
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11.5, 4.1 H , 1H), 3.64 (dd, J = 11.5, 3.2 H , 1H), 3.55 (d, J = 13.2 H , 1H), 3.43 (d, J = 13.2 H , 
1H), 3.18 ( d, J = 6.3, 3.3 H , 1H), 2.98  2.83 ( , 2H), 2.76 (dd, J = 17.3, 8.2 H , 1H), 2.37 (dd, 
J = 17.3, 6.3 H , 1H), 2.23 ( , 1H), 1.94  1.82 ( , 2H), 1.72 ( , J = 11.1 H , 1H), 1.63 (dd, J = 
10.2, 3.9 H , 2H), 1.60  1.46 ( , 2H), 1.30  1.18 ( , 14H). 
 
3.42i-Major-int a  he  di ed i  e h  e he  (0.10 L) a d 2.0 M HC  i  e h  e he  a  added 
d i e  he i  i  a hi e eci i a e a  f ed. The id a  a ed  eci i a e 
 f i , he e  he e  a  e ed  ac   aff d 3.42i-major a  a hi e 
id.  
3.42i-Major a  ec a i ed i g he a - a  diff i  e h d, i g -P OH  di e 
he d c  i  a  i e  ia , a d e h  e he  a  he eci i a  aced i  he e  ia  i  de  f  
 diff i   cc  i  he i e  ia . The i  a  c ed  0 C, he e  a c a  
a  b ai ed f  X- a  c a g a h . The X- a  c a g a hic a a i  e ea ed ha  he 
e a i e c fig a i  f 3.42i-major i  (R,R,R)  (S,S,S). The e a i e c fig a i  f d c  
3.23k-major, 3.23o-major, 3.23q-major, a d 3.23s-major e e a ig ed i  a a g . 
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Determination of the Relative Configuration of 3.23i-Minor  
The e a i e c fig a i  f 3.23i-Minor a  de e i ed b  he X- a  c a g a hic a a i  
f i  de i a i e, 3.42i-minor (Sche e S3.8). 
Scheme S3.8. De i a i a i  f 3.23i-Minor a d C a  S c e f 3.42i-Minor 
 
1-Ben l-3-(1,4-diisopropo -1,4-dio obutan-2- l)-4-(h dro meth l)piperidin-1-ium 
chloride (3.42i-minor) 
3.42i-Minor a  he i ed b  he f i g ced e. T  a i  f 3.23i-minor (150 g, 
0.3 ) i  THF (10 L) a  added E 3N(HF)3 (0.3 L), d i e. The eac i  a  a ed 
 i  a  22 C f  12 h . The eac i  i e a  c ce a ed a d fi e ed h gh a g f 
Ce i e i g DCM a  e . The ified d c  a  he  bjec ed  f a h i ica ge  c  
ch a g a h  (E OAc:he a e  = 9:1)  aff d dii  2-(1-be -4-
(h d e h ) i e idi -3- ) cci a e 3.42i-minor-int a  a c e  i  (116 g, 95%).  
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1H NMR (500 MH , CDCl3):  7.27 (d, J = 4.5 H , 4H), 7.21 ( , J = 4.5 H , 1H), 4.98 ( , J = 6.3 
H , 1H), 4.90 ( , J = 6.2 H , 1H), 3.73 (dd, J = 10.9, 4.4 H , 1H), 3.59 (dd, J = 10.9, 5.9 H , 1H), 
3.50 (d, J = 13.1 H , 1H), 3.38 (d, J = 13.1 H , 1H), 3.17 (d , J = 11.6, 3.7 H , 1H), 2.87 (d, J = 
11.2 H , 1H), 2.68  2.48 ( , 2H), 2.32 (dd, J = 16.6, 3.3 H , 1H), 2.10  2.03 ( , 1H), 1.99 ( , J 
= 11.3 H , 1H), 1.79 (d , J = 27.4, 12.1 H , 2H), 1.61  1.46 ( , 1H), 1.45  1.36 ( , 1H), 1.26 ( , 
J = 7.6 H , 1H), 1.21 ( , J = 6.3 H , 6H), 1.14 (d, J = 6.2 H , 3H), 1.04 (d, J = 6.2 H , 3H). 
 
3.42i-Minor-int a  he  di ed i  e h  e he  (0.10 L) a d 2.0 M HC  i  e h  e he  a  added 
d i e  he i  i  a hi e eci i a e a  f ed. The id a  a ed  eci i a e 
 f i , he e  he e  a  e ed  ac   aff d 3.42i-minor a  a hi e 
id. 3.42i-Minor a  ec a i ed i g he a - a  diff i  e h d, i g -P OH  
di e he d c  i  a  i e  ia , a d e h  e he  a  he eci i a  aced i  he e  ia  i  
de  f   diff i   cc  i  he i e  ia . The i  a  c ed  0 C, he e  
a c a  a  b ai ed f  X- a  c a g a h . The X- a  c a g a hic a a i  e ea ed ha  
he e a i e c fig a i  f 3.42i-minor i  (R,R,S)  (S,S,R). The e a i e c fig a i  f 
d c  3.23k-minor, 3.23o-minor, 3.23q-minor, a d 3.23s-minor e e a ig ed i  a a g . 
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Determination of the Relative Configuration of 3.23b-Major 
The e a i e c fig a i  f 3.23b-major a  de e i ed b  he X- a  c a g a hic a a i  
f 3.23bf-major. 
 
T  a 15 L e -d ied e e e e  a  added dibe a a i e 3.21b (0.40 ), 
B(C6F5)3 (10 %), di e h f a a e 3.22d (0.60 ) a d be e e (0.40 L) de  a 
i ge  a he e. The eac i  i e a  aced i  a  i  ba h a  50 °C and was allowed to 
stir f  12 h . U  c e i , he i  a  c ed  22 °C a d c ce a ed  ac . 
The 1H NMR a a i  f he ified d c  i e e ea ed ha  3.23bf a  b ai ed a  a 
i e f dia e e e  i  2.6:1 a i . Af e  ifica i  b  f a h i ica ge  c  
ch a g a h  (e h  e he :he a e  = 1:19), 3.23bf a  b ai ed a  a i e f dia e e e  
(66 g, 43%). F he  ifica i  a  ca ied  b  PTLC i g e h  e he :DCM = 1:49 a  he 
e e   e a a e 3.23bf-major a d 3.23bf-minor. The aj  dia e e e  a  i a ed a  a hi e 
id (45 g, 29% ie d).  
 
Dimeth l 2-(1-(diben lamino)propan-2- l)succinate (3.23bf-major) 
1H NMR (600 MH , CDCl3):  7.34 (d, J = 6.7 H , 4H), 7.29 ( , J = 7.5 H , 4H), 7.22 ( , J = 7.1 
H , 2H), 3.78 (d, J = 13.2 H , 2H), 3.67 ( , 6H), 3.38 (d, J = 11.9 H , 1H), 3.26 (d, J = 13.3 H , 
2H), 2.37 (dd, J = 16.8, 11.5 H , 2H), 2.24 ( , J = 11.5 H , 1H), 2.14 (dd, J = 13.0, 5.5 H , 1H), 
1.51 (dd, J = 16.9, 2.9 H , 1H), 0.71 (d, J = 6.9 H , 3H).  
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The aj  dia e e e  a  he  ec a i ed i g DCM:he a e  = 1:10  aff d a c a  f  
he X- a  a a i . The X- a  c a g a hic a a i  e ea ed ha  he e a i e c fig a i  f 
3.23bf-major i  (R,R)  (S,S). The e a i e c fig a i  f 3.23b-major a  a ig ed i  a a g . 
 
Figure S3.3. X- a  c a  c e f 3.23bf-major 
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Determination of the Relative Configuration of 3.24 
The e a i e c fig a i  f  3.24 a  de e i ed b  NOESY e e i e . The f i g a e he 
NOE ec  a d a ig e  (Fig e S3.4). 
 
Figure S3.4. 2D NOESY ec a f 3.24 
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Determination of the Relative Configuration of 3.23m-Major 
The e a i e c fig a i  f  3.23m-major a  de e i ed b  NOESY e e i e . The 
f i g a e he NOE ec  a d a ig e  (Fig e S3.5). 
 
Figure S3.5. 2D NOESY ec a f 3.23m-major 
The e a i e c fig a i  f he idi e b i e  f 3.23m-major a  a ig ed  be a . 
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C5. Determination of Absolute Configuration 
Determination of the Absolute Configuration of Product 3.23h-(R,R,R). 
We carried out the following studies in order to determine the absolute configuration of product 
3.23h.  
 
The derivatization of the major diastereomer of 3.23h was performed based on a method 
previously reported in the literature.1 3.23h-Major (79 mg, 0.14 mmol) was dissolved in a solution 
of 4.4% formic acid in MeOH (3.0 mL), whereupon Pd/C (10%, 7.9 mg) was added. The reaction 
mixture was placed in an oil bath at 40 °C and was allowed to stir for 12 hours. After the solution 
was cooled down to 22 °C, the suspension was filtered through a pad of Celite using DCM as 
solvent and the mixture was concentrated to remove the solvent and volatile side products to obtain 
the product 3.43-major-int as a colorless oil (23 mg, >95% yield).  
2-(2-A i e h ) cci ic acid 3.43-major-int a  he  di ed i  DCM, he e  E 3N (20 
PL, 0.15 mmol) and di- -b  dica b a e (30 PL, 0.15 mmol) were added, dropwise. The 
eac i  i e a  a ed  i  a  22 °C f  12 h . U  c e i , he ified 
i e a  c ce a ed  e e he e  a d a i e ide d c   b ai  he d c  
3.43-major a  a c e  i  (25 g, 88% ie d). [ ]25D = + 27.6  (c = 1.0, ace e). Ba ed  he 
b e ed ica  a i  a e, he ab e c fig a i  f he aj  dia e e e  a  a ig ed 
i  a a g  a  3.23h-(R,R,R).28 
                                                          
1  Davies, S. G.; Epstein, S. W.; Garner, A. C.; Ichihara, O.; Smith, A. D. Tetrahedron: Asymmetry 2002, 13, 
15551565. 
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Determination of the Absolute Configuration of 3.23n-(R,R,R) 
The ab e c fig a i  f 3.23n-(R,R,R) a  de e i ed b  he X- a  c a g a hic 
a a i  f 3.44-major (Sche e S3.9). 
Scheme S3.9. De i a i a i  f 3.23n-Major a d C a  S c e f 3.44-Major 
 
(2R,4R)-1-Ben l-2-((( e -but ldimeth lsil l)o )diphen lmeth l)-4-((R)-1,4-diisopropo -
1,4-dio obutan-2- l)p rrolidin-1-ium chloride (3.44-major) 
3.44-major a  he i ed b  he f i g ced e. 3.23n-(R,R,R) a  di ed i  e h  e he  
(0.2 L) a d 2.0 M HC  i  e h  e he  a  added d i e  he i  i  a hi e eci i a e 
a  f ed. The id a  a ed  eci i a e  f i , he e  he e  a  
e ed  ac   aff d 3.44-major a  a hi e id. 3.44-Major a  he  ec a i ed i g 
DCM:e h  e he  = 1:10 a d c ed  0 C  aff d a c a  f  X- a  a a i . The X- a  
c a g a hic a a i  e ea ed ha  he ab e c fig a i  f 3.44-major i  (R,R,R).  
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Determination of the Absolute Configuration of 3.23s-(S,S,R,S) 
The ab e c fig a i  f 3.23s-(S,S,R,S) a  de e i ed h gh 2D NMR die . The 
f i g a e he ec a a d a ig e  (Fig e  S3.6S3.8). 
 
Figure S3.6. 2D HSQCAD ec a f 3.21r-major 
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Figure S3.7. 2D COSY ec a f 3.23s-major 
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Figure S3.8. 2D NOESY ec a f 3.23s-major 
The ab e c fig a i  f 3.23s-major a  a ig ed  be (S,S,R,S) b  he 2D NMR a a e  
a d i  a a g   3.23i-major.   
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Determination of the Absolute Configuration of 3.26a-(R,R,R,S) 
The ab e c fig a i  f 3.26a-(R,R,R,S) a  de e i ed b  he X- a  c a g a hic 
a a i  f i  de i a i e, 3.45 (Sche e S3.10). 
Scheme S3.10. De i a i a i  f 3.26a-(R,R,R,S). 
 
(R)-3-((3R,5R)-1-Ben l-5-(h dro diphen lmeth l)p rrolidin-3- l)-4,4,4-trifluoro-N-((S)-
2-h dro -1-phen leth l)butanamide (3.45) 
3.45 a  he i ed b  he f i g ced e. T  a i  f 3.26a (371 g, 0.50 ) i  
THF (5.0 L) a  added TBAF (2.0 M, 2.5 L), d i e. The eac i  a  aced i  a  i  ba h 
a  60 C a d a  a ed  i  f  12 h . Af e  he eac i  i e a  c ed d   22 
C, i  a  e ched i h NaHCO3 (a .) a d e ac ed i h DCM (3  25 L). The c bi ed 
ga ic a e  e e d ied e  Na2SO4 a d c ce a ed  ac . The ified d c  a  
he  bjec ed  f a h i ica ge  c  ch a g a h  (E OAc:he a e  = 1:4)  aff d 3.45 a  
a hi e id (120 g, 40%). 
1H NMR (500 MH , CDCl3):  7.64 (d, J = 7.3 H , 2H), 7.51 (d, J = 7.0 H , 2H), 7.32 ( , J = 7.5 
H , 2H), 7.29  7.23 ( , 5H), 7.23  7.07 ( , 7H), 6.97 (d, J = 6.2 H , 2H), 6.27 (d, J = 6.9 H , 
1H), 4.90 (d , J = 6.7, 4.8 H , 1H), 3.99 (dd, J = 10.3, 3.1 H , 1H), 3.77 (d, J = 4.9 H , 2H), 3.11 
(d, J = 12.5 H , 1H), 3.06 (b , 1H), 2.95 (d, J = 12.6 H , 1H), 2.77  2.65 ( , 1H), 2.26  2.14 ( , 
3H), 2.10 (dd, J = 15.9, 4.0 H , 1H), 1.90 (ddd, J = 12.5, 6.6, 3.0 H , 1H), 1.81 ( d, J = 10.2, 3.5 
H , 1H); 19F NMR (470 MH , CDCl3):  -69.28 (d, J = 8.7 H ). 
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3.45 a  ec a i ed i g he a - a  diff i  e h d, i g be e e  di e he 
d c  i  a  i e  ia , a d e a e a  he eci i a  aced i  he e  ia  i  de  f   
diff i   cc  i  he i e  ia . The i  a  c ed  0 C, he e  a c a  a  
b ai ed f  X- a  c a g a h  (Fig e S3.9). The X- a  c a g a hic a a i  e ea ed 
ha  he ab e c fig a i  f 3.26a i  (R,R,R,S). 
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Determination of the Absolute Configuration of 3.26f-(R,S) 
The ab e c fig a i  f 3.26f-(R,S) a  de e i ed b  X- a  c a g a hic a a i  f 
3.29-(R,S) (Sche e S3.11).2 
Scheme S3.11. De i a i a i  f 3.26f-(R,S) a d C a  S c e f 3.29-(R,S) 
 
(S)-4,4,4-Trifluoro-3-((R)-1-(4-metho phen l)p rrolidin-3- l)butan-1-ol (3.28-(R,S)) 
A i  f E SH (0.51 g, 8.2 , 3.4 e i ) i  THF (0.1 M) a  c ed  78 C a d ea ed 
i h -B Li (3.8 L, 6.0 , 1.6 M i  he a e, 2.5 e i ). The eac i  a  a ed  i  a  
0 C f  30 i . A i  f he 3.26f-(R,S) (1.04 g, 2.4 , 1.0 e i ) i  THF (0.060 M) a  
he  added d i e. The eac i  a  a ed  i  a  0 C i  he c i  f he a i g 
a e ia  a  c e e a  i ed b  TLC (0.5  1 h). The eac i  a  e ched i h a a ed 
NH4C  (a .) a d he ha e  e a a ed. The a e  a e  a  e ac ed i h e h  e he  (  3), he 
c bi ed ga ic a e  e e d ied e  MgSO4, a d he e  e ed b  a  e a a i . 
The c de d c  a  he  di ed i  e h  e he  (0.10 M) a d added  a e i  f LiA H4 
(0.29 g, 7.2 , 3.0 e i ) i  e h  e he  a  22 C. The i e a  i ed i  he c i  
f he a i g a e ia  a  i ed b  TLC (0.5  2 h). The eac i  a  ca ef  e ched 
b  he addi i  f a e  a  0 C. The a e  a e  a  he  e ac ed i h e h  e he  ( 3) a d 
he c bi ed ga ic a e  e e d ied e  MgSO4 a d he e  e ed  ie d he c de 
                                                          
2 Petrone, D. A.; Isomura, M.; Franzoni, I.; R ssler, S. L.; Carreira, E. M. J. Am. Chem. Soc. 2018, 140, 46974704. 
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d c , hich a  ified b  f a h i ica ge  c  ch a g a h .  
1H NMR (500 MHz, CDCl3):  6.85 (d, J = 9.0 H , 2H), 6.53 (d, J = 9.0 H , 2H), 3.82 (d , J = 
12.0, 6.4 H , 1H), 3.79  3.71 ( , 4H), 3.42 ( , J = 8.4 H , 1H), 3.36 ( d, J = 8.7, 1.8 H , 1H), 3.26 
( d, J = 9.4, 6.6 H , 1H), 3.06 ( , J = 9.1 H , 1H), 2.67  2.55 ( , 1H), 2.41 ( dd, J = 9.7, 6.5, 2.8 
H , 1H), 2.22 (d , J = 13.0, 6.7 H , 1H), 1.96  1.75 ( , 3H), 1.43 ( , 1H); 13C NMR (126 MHz, 
CDCl3):  151.3, 142.8, 128.4 ( , J = 281.0 Hz), 115.2, 112.7, 60.7, 56.1, 51.6, 48.2, 42.5 (q, J = 
24.9 Hz), 38.0, 30.3, 29.7; 19F NMR (470 MHz, CDCl3):  -68.24 (d, J = 9.2 Hz); IR (neat):  
3385, 2933, 2831, 1514, 1485, 1371, 1239, 1158, 1126, 1039, 812 c -1; HRMS (DART): Ca cd 
f  C15H21F3NO2 (MH+): 304.1519; f d: 304.1519; Specific Rotation [ ]25D = -4.5  (c = 1.0, 
DCM). 
 
(S)-4,4,4-Trifluoro-3-((R)-1-(4-metho phen l)p rrolidin-3- l)but l(4 
bromophen l)carbamate (3.29-(R,S)) 
T  a i  f 3.28-(R,S) (330 g, 1.1 , 1.0 e i .) i  e e (0.035 M) e e added -
b he  i c a a e (416 g, 3.3 , 3.0 e i .) a d idi e (434 g, 5.5 , 5.0 
e i .). The e i g he e ge e  i  a  aced i  a  i  ba h a  100 °C and was allowed 
to stir f  1 h . The i  a  he  c ed  22 °C a d fi e ed h gh a h  g f Ce i e 
i g DCM. The fi a e a  c ce a ed a d he e id e a  ified b  f a h i ica ge  c  
ch a g a h  (E OAc:he a e  = 1:9)  aff d c d 3.29-(R,S) (406 g, 74%) a  a hi e 
id.  
1H NMR (600 MHz, CDCl3):  7.41 (dd, J = 8.8, 1.4 H , 2H), 7.30  7.20 ( , 2H), 6.82 (d, J = 
7.6 H , 2H), 6.62 ( , 1H), 6.50 (d, J = 7.6 H , 2H), 4.34 (d , J = 11.8, 6.1 H , 1H), 4.27  4.16 ( , 
1H), 3.75 ( , 3H), 3.42 ( , J = 8.4 H , 1H), 3.36 ( , J = 8.7 H , 1H), 3.25 ( , J = 8.8, 8.3 H , 1H), 
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3.05 ( , J = 8.9 H , 1H), 2.59 (h, J = 8.0 H , 1H), 2.40  2.28 ( , 1H), 2.22 (d , J = 13.4, 6.8 H , 
1H), 2.07  1.92 ( , 2H), 1.87 ( , J = 10.0 H , 1H); 13C NMR (151 MHz, CDCl3):  153.1, 151.2, 
142.6, 136.9, 132.1, 128.0 ( , J = 280.8 H ), 120.4, 115.1, 112.6, 63.3, 56.0, 51.5, 48.0, 42.8 ( , J 
= 25.1 H ), 37.9, 30.2, 26.5; 19F NMR (564 MHz, CDCl3):  -68.15 (d, J = 9.4 Hz); IR (neat):  
3310, 2924, 2831, 1708, 1592, 1511, 1486, 1396, 1371, 1305, 1233, 1212, 1162, 1129, 1073, 1006, 
890, 810, 764, 735, 700, 650, 626, 592, 521, 503, 458 c -1; HRMS (DART): Ca cd f  
C22H25B F3N2O3 (MH+): 501.0995; f d: 501.0964; Specific Rotation [ ]25D = 20.0  (c = 1.0, 
DCM). 
 
3.29-(R,S) a  ec a i ed i g he a - a  diff i  e h d, i g -P OH  di e 
he d c  i  a  i e  ia , a d e a e a  he eci i a  aced i  he e  ia  i  de  f   
diff i   cc  i  he i e  ia . The i  a  c ed  0 C, he e  a c a  a  
b ai ed f  he X- a  c a g a h  (Sche e S11). The X- a  c a g a hic a a i  e ea ed 
ha  he ab e c fig a i  f 3.29 i  (R,S). 
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Determination of the Absolute Configuration of 3.26g 
The ab e c fig a i  f 3.26g a  de e i ed b  a a g   3.26f-major a d b  1D NOESY 







Figure S3.10. 1D NOESY ec a f 3.26g 
 
The NOE d  e ea ed ha  he ab e c fig a i  f 3.26g i  (R,R). 
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C6. Derivati ation of E-Alkylated Amines 
H drogenation of 3.26h 
 
Dia e e e ec i e h d ge a i  f e a i e 3.26h a  achie ed f i g a e i  e ed 
i e a e.19 I  a i ge  fi ed g e b , I [(COD)C ]2 (3.4 g, 5.0 %), (R)-SIPHOS-PE (11.1 
g, 22 %), a d 1.0 L THF e e added  a  e -d ied 7.0 L ia . The i e a  a ed 
 i  a  22  f  30 i  a d he  a fe ed  a  e -d ied 100 L Sch e k f a k. The , I2 
(12.7 g, 0.5 e i ), 3.26h (48.2 g, 0.10 ) a d 1.0 L THF e e added  he i e a d 
he  he Sch e k f a k a  ake   f he g e b . The i ge  a he e i  he Sch e k 
f a k a  e aced b  h d ge  h ee i e  a d fi a  h d ge  ga  a  cha ged a  200 . The 
eac i  i e a   a ed   22  a d a  a ed  i  f  36 h  ( de  4.0 
a  H2 e e). 19F NMR a a i  f he ified d c  i e e ea ed ha  he 
dia e e e ic a i  a  5.0:1. Af e  ifica i  b  f a h i ica ge  c  ch a g a h  
(E OAc:he a e  = 1:3), 3.30 a  b ai ed a  a i e f dia e e e  (40.0 g, 83% ie d). 
F he  ifica i  a  ca ied  b  PTLC i g e h  e he :he a e  = 2:1 a  he e e   b ai  
3.30-major. 
 
3.30-Major. 1H NMR (400 MH , CDCl3):  6.58 (d, J = 3.0 H , 1H), 6.45 (d, J = 3.0 H , 1H), 
3.74 ( , 3H), 3.23 (dd, J = 17.7, 6.2 H , 1H), 3.09  2.90 ( , 7H), 2.85 (d, J = 11.3 H , 1H), 2.63 
 2.53 ( , 2H), 2.26 (d, J = 13.2 H , 6H), 2.10  2.01 ( , 1H), 1.93 (d, J = 13.3 H , 1H), 1.75  
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1.61 ( , 2H), 1.31  1.26 ( , 7H), 1.04 ( , J = 7.1 H , 3H); 13C NMR (101 MH , CDCl3):  175.5, 
168.7, 156.5, 142.5, 139.0, 137.9, 128.1 ( , J = 281.1 H ), 114.2, 113.4, 60.7, 55.4, 54.1, 50.8, 
47.2, 44.1, 41.7 ( , J = 25.1 H ), 37.4, 32.8, 28.7, 27.1, 25.9, 25.8, 20.2, 19.7, 12.8; 19F NMR (376 
MH , CDCl3):  -66.80 (d, J = 10.1 H ); IR (neat):  2930, 2851, 1745, 1711, 1602, 1485, 1466, 
1372, 1309, 1254, 1222, 1189, 1154, 1119, 1067, 990, 855, 616 c -1; HRMS (DART): Ca cd f  
C25H37F3N3O3 (MH+): 484.2782; f d: 484.2785; Specific Rotation [ ]25D = -8.0  (c = 0.35, 
DCM). 
3.30 (major:minor = 1:1.3). 1H NMR (400 MH , CDCl3, ea   d a e e e  a e 
e ed): 6.58 (d, J = 3.1 H , 1H), 6.45 (d, J = 3.0 H , 1H), 3.74 ( , 3H), 3.28  3.15 ( , 1H), 3.10 
 2.92 ( , 7H), 2.89  2.80 ( , 1H), 2.67  2.51 ( , 2H), 2.29  2.21 ( , 6H), 2.11  1.99 ( , 
1H), 1.97  1.84 ( , 1H), 1.76  1.60 ( , 2H), 1.33  1.25 ( , 7H), 1.12  1.01 ( , 3H); 19F NMR 
(376 MH , CDCl3):  -66.80 (d, J = 10.1 H , a ), -67.20 (d, J = 10.2 H , ). 
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Fluoroc anation of 3.26h 
 
F c a a i  f e a i e 3.26h a  achie ed f i g a e i  e ed i e a e.20 T  
a  e -d ied 10 L d b  f a k a  added NFSI (34.7 g, 1.1 e i ), TMSCN (0.02 
L, 1.5 e i ) a d 0.50 L f MeCN. Af e  he i e a  c ed  0 , idi e (0.01 L, 
1.2 e i ) a d 3.26h (48.2 g, 0.10 ) e e added. The eac i  i e a  a ed  i  
a  0  f  1 h . U  c e i , he i e a  e ched i h a a ed a e  NaHCO3 
a d e ac ed i h e h  e he  h ee i e . The c bi ed ga ic a e  a  a hed i h b i e, 
d ied i h MgSO4 a d a  c ce a ed  ac . The 19F NMR a a i  f he ified d c  
i e e ea ed ha  he dia e e e ic a i  a  4.0:1. Af e  ifica i  b  f a h i ica ge  
c  ch a g a h  (E OAc:he a e  = 1:3), 3.31 a  b ai ed a  a i e f dia e e e  
(46.5 g, 88% ie d). F he  ifica i  a  ca ied  b  PTLC i g E OAc:he a e  = 1:3 
a  he e e   e a a e 3.31-major a d 3.31-minor. 
 
3.31-Major. 1H NMR (600 MH , CDCl3):  6.56 (d, J = 3.1 H , 1H), 6.50 (d, J = 3.1 H , 1H), 
4.15 (d, J = 4.9 H , 1H), 3.82  3.70 ( , 4H), 3.64 ( , J = 11.6 H , 1H), 3.47 (ddd, J = 19.1, 6.4, 
2.3 H , 1H), 3.16 (dd, J = 19.4, 4.3 H , 1H), 3.06  2.92 ( , 3H), 2.62 (d, J = 17.3 H , 1H), 2.55 
(d, J = 17.3 H , 1H), 2.47 ( , 3H), 2.35  2.24 ( , 4H), 2.19  2.01 ( , 2H), 1.77  1.67 ( , 1H), 
1.33  1.24 ( , 7H), 1.04 ( , J = 7.1 H , 3H); 13C NMR (151 MH , CDCl3):  175.5, 167.7, 157.4, 
139.1, 138.95, 138.86, 126.4 ( , J = 281.9 H ), 117.1 (d, J = 10.2 H ), 114.7, 114.3, 92.3 (d, J = 
193.6 H ), 60.9, 58.8 (d, J = 29.9 H ), 55.4, 47.5, 47.2, 44.6 ( d, J = 26.1, 21.4 H ), 43.8, 31.8 
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(dd, J = 9.1, 2.6 H ), 28.9 (dd, J = 22.4, 2.7 H ), 26.1, 25.6, 21.6, 21.1, 19.5 (d, J = 7.0 H ), 12.8; 
19F NMR (564 MH , CDCl3):  -63.97  -64.00 ( ), -161.94; IR (neat):  2961, 2839, 1746, 
1711, 1601, 1485, 1466, 1442, 1375, 1304, 1263, 1234, 1216, 1155, 1132, 1094, 1069,992, 975, 
950, 930, 898, 856, 736, 619 c -1; HRMS (DART): Ca cd f  C26H35F4N4O3 (MH+): 527.2640; 
f d: 527.2640; Specific Rotation [ ]25D = +6.9  (c = 1.0, DCM). 
 
3.31-Minor. 1H NMR (400 MH , CDCl3):  6.58 (d, J = 3.0 H , 1H), 6.49 (d, J = 3.0 H , 1H), 
4.50 (d, J = 20.3 H , 1H), 4.10 ( , J = 9.8, 5.7 H , 1H), 3.74 ( , 3H), 3.45 (dd, J = 17.8, 5.1 H , 
1H), 3.27 (ddd, J = 18.0, 6.5, 2.4 H , 1H), 3.19  3.03 ( , 2H), 3.01 ( , J = 7.1 H , 2H), 2.60 (d, 
J = 3.4 H , 2H), 2.40  2.26 ( , 7H), 2.09  1.95 ( , 1H), 1.89  1.63 ( , 3H), 1.31 (d, J = 1.7 
H , 6H), 1.06 ( , J = 7.1 H , 3H); 13C NMR (126 MH , CDCl3):  175.8, 167.0, 157.9, 140.8, 
138.4, 138.1, 125.9 ( , J = 280.2 H ), 114.7 (d, J = 1.9 H ), 114.5, 114.0, 91.8 (d, J = 192.2 H ), 
60.7, 59.4 (dd, J = 20.1, 2.5 H ), 55.3, 49.8, 47.1, 44.9 ( , J = 26.2 H ), 44.2, 31.2 (dd, J = 6.7, 
2.7 H ), 29.1, 29.0, 25.9 (d, J = 13.1 H ), 21.0 (d, J = 2.8 H ), 19.7, 19.6, 12.7; 19F NMR (470 
MH , CDCl3):  -64.16  -64.69 ( ), -159.84; IR (neat):  2925, 2851, 1744, 1712, 1602, 1484, 
1465, 1443, 1374, 1302, 1263, 1225, 1196, 1183, 1144, 1113, 1070, 1023, 992, 949, 855, 835, 796, 
769, 734, 619, 458 c -1; HRMS (DART): Ca cd f  C26H35F4N4O3 (MH+): 527.2640; f d: 
527.2641; Specific Rotation [ ]25D = -8.3  (c = 0.50, DCM). 
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C7. Mechanistic Studies for E-Amino CH Alkylation Reaction 
We ha e de a ed ha  c e a i e f c i  f B(C6F5)3 a d a chi a  Le i  acid c -ca a  
ca  e high  e a i e ec i e i  f N-a k a i e  a d D,E-unsaturated compounds. To 
hed igh   he echa i  f hi  e a i e ec i e ce , e e ba ked  i e iga i  ha  
e e ai ed a  de e i i g i  e - i i i g e , de a di g he a e f h d ide a d 
 a fe  ce e , a d e cida i g he igi  f che e ec i i  be ee  e a i e a d N-
a k a i e d c . 
F i g a e he echa i ic die  ha  e e ca ied   b ai  he ece a  da a: 
De e i a i  f he eac i  de  i i g 3.25g 
De ec i  f he ca a  e i g a e i i g 3.25g 
Ki e ic i e effec  die  i i g 3.25g 
Ha e  die  
M i i g he a i  a  hich diffe e  d c  a e f ed b  he 1H NMR die . 
De e i a i  f he eac i  de  i i g 3.25d 
De ec i  f he ca a  e i g a e i i g 3.25d 
Ki e ic i e effec  die  i i g 3.25d 
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Mechanistic Studies Involving 3.25g 
Determination of the Reaction Orders 
F  he E-C H alkylation reaction involving 1-(4- e h he ) idi e 3.21r a d 1-be -
2-ci a -5,5-di e h a idi -3- e 3.25g, he eac i  de  f each eac a  a  died 
h gh i e c e eac i  i i g b  he 1H NMR ec c ic a a i . 
Reaction Order of B(C6F5)3 
The eac i  be ee  3.21r a d 3.25g a  e f ed i g diffe e  c ce a i  f B(C6F5)3 
a d he g e  f each eac i  a  i ed b  he 1H NMR ec c  (Sche e S12).  
Scheme S3.12. De e i a i  f he Reac i  O de  f B(C6F5)3 
 
I  a i ge -fi ed g e b , L6Sc(OTf)3 (51.4 g, 10 %), 3.21r (115.1 g, 0.65 ), 
3.25g (326.1 g, 1.5 e i ) a d e i e e (78.0 g, 1.0 e i ) e e eighed i  a  e -d ied 
7.0 L ia  a d he e i g i e a  di ed i  3.25 L f CD2C 2 (Stock Solution A). I  
a he  e -d ied 7.0 L ia , B(C6F5)3 (30.7 g, 0.060 ) a  eighed a d di ed i  
1.20 L f CD2C 2 (Stock Solution B). T  each J-Y g be a  added Stock Solution A (0.50 
L), Stock Solution B (0.05, 0.10, 0.15, 0.20, 0.25,  0.30 L) a d CD2C 2 (0.25, 0.20, 0.15, 
0.10, 0.05  0 L)  e a e he eac i  a e  c ai i g diffe e  c ce a i  f B(C6F5)3. 
Af e  he J-Y g be a  igh  ca ed i h he Tef  g, i  a  ake   f he g e b  
a d he 1H NMR ec a e e ac i ed i  he NMR ec e e  ehea ed a  60 C i g a e-
ac i i i  de a  i  a a  de i h a ec  ake  e e  22 ec d  f  he e g h f he 
e e i e . The da a e e ce ed i g Me ReN a f a e a d eak i eg a i  e e 
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a i ed i g e i e e a  he i e a  a da d.  
I i ia - a e ki e ic a a i , hich a  de e i ed ba ed  he da a i  ac i ed i  he fi  
600 ec d , h ed ha  he e i  c -  c   B(C6F5)3 c ce a i  i  he 
eac i  be ee  3.21r a d 3.25g (Fig e  S3.11, 3.12). 
 
 
Figure S3.11. Monitoring the formation of 3.26m under different concentrations of B(C6F5)3 
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Figure S3.12. L g( a e)  g[B(C6F5)3] i  e ed  de e i e he i i ia  eac i  de  f  
B(C6F5)3. The e  gge  ha  he e i  c -  c   B(C6F5)3 c ce a i . 
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Reaction Order of L9Sc(OTf)3 
The eac i  be ee  3.21r a d 3.25g a  e f ed i g diffe e  c ce a i  f 
L6Sc(OTf)3 a d he g e  f each eac i  a  i ed b  he 1H NMR ec c  
(Sche e S3.13).  
Scheme S3.13. De e i a i  f he Reac i  O de  f L6Sc(OTf)3 
 
I  a i ge -fi ed g e b , B(C6F5)3 (26.6 g, 10 %), 3.21r (92.0 g, 0.52 ), 3.25g 
(260.8 g, 1.5 e i ) a d e i e e (26.6 g, 1.0 e i ) e e eighed i  a  e -d ied 7.0 L 
ia  a d he e i g i e a  di ed i  2.10 L f CD2C 2 (Stock Solution A). I  a he  
e -d ied 7.0 L ia , L6Sc(OTf)3 (47.4 g, 0.060 ) a  eighed a d di ed i  1.20 
L f CD2C 2 (Stock Solution B). T  each J-Y g be a  added Stock Solution A (0.40 L), 
Stock Solution B (0.10, 0.20, 0.30  0.40 L) a d ea  CD2C 2 (0.30, 0.20, 0.10  0 L)  
e a e he eac i  a e  c ai i g diffe e  c ce a i  f L6Sc(OTf)3. Af e  he J-
Y g be a  igh  ca ed i h he Tef  g, i  a  ake   f he g e b  a d 1H NMR 
ec a e e ac i ed i  he NMR ec e e  ehea ed a  60 C i g a e-ac i i i  de a  
i  a a  de i h a ec  ake  e e  22 ec d  f  he e g h f he e e i e . The da a 
e e ce ed i g Me ReN a f a e a d eak i eg a i  e e a i ed i g 
e i e e a  he i e a  a da d.  
I i ia - a e ki e ic a a i , hich a  de e i ed ba ed  he da a i  ac i ed i  he fi  
1200 ec d , h ed ha  he e i  -  c   L6Sc(OTf)3 c ce a i  i  he 
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eac i  be ee  3.21r a d 3.25g (Fig e  S3.13, S3.14). 
 
 
Figure S3.13. M i i g he f a i  f 3.26g de  diffe e  c ce a i  f L6Sc(OTf)3 
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Figure S3.14. L g( a e)  g[L6Sc(OTf)3] i  e ed  de e i e he i i ia  eac i  de  
f  L6Sc(OTf)3. The e  gge  ha  he e i  -  c   L6Sc(OTf)3 
c ce a i . 
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Reaction Order of Amine 
The eac i  be ee  3.21r a d 3.25g a  e f ed i g diffe e  c ce a i  f 3.21r a d 
he g e  f each eac i  a  i ed b  he 1H NMR ec c  (Sche e S3.14).  
Scheme S3.14. De e i a i  f he Reac i  O de  f 3.21r 
 
I  a i ge -fi ed g e b , B(C6F5)3 (28.2 g, 0.055 ), L6Sc(OTf)3 (43.5 g, 0.055 
), 3.25g (275.9 g, 0.83 ) a d e i e e (66.1 g, 0.55 ) e e eighed i  a  
e -d ied 7.0 L ia  a d he e i g i e a  di ed i  4.40 L f CD2C 2 (Stock 
Solution A). I  5 e -d ied 7.0 L ia  e e added 3.21r (4.4 g, 8.9 g, 17.7 g, 26.6 g  
35.4 g). T  each e -d ied ia  c ai i g 3.21r a  added Stock Solution A (0.80 L)  
e a e he eac i  a e  c ai i g diffe e  c ce a i  f 3.21r. The eac i  i e 
a  he  a fe ed  a J-Y g be. Af e  he J-Y g be a  igh  ca ed i h he Tef  
g, i  a  ake   f he g e b  a d 1H NMR ec a e e ac i ed i  he NMR 
ec e e  ehea ed a  60 C i g a e-ac i i i  de a  i  a a  de i h a ec  ake  
e e  22 ec d  f  he e g h f he e e i e . The da a e e ce ed i g Me ReN a 
f a e a d eak i eg a i  e e a i ed i g e i e e a  he i e a  a da d.  
I i ia - a e ki e ic a a i , hich a  de e i ed ba ed  he da a i  ac i ed i  he fi  
600 ec d , h ed ha  he e i  -  c   a i e 3.21r c ce a i  i  he 
eac i  be ee  3.21r a d 3.25g (Fig e  S3.15, S3.16). 
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Figure S3.15. M i i g he f a i  f 3.26m de  diffe e  c ce a i  f a i e 3.21r 
 
Figure S3.16. L g( a e)  g[a i e 3.21r] i  e ed  de e i e he i i ia  eac i  de  
f  a i e 3.21r. The e  gge  ha  he e i  -  c   3.21r c ce a i . 
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Reaction Order of D,E-Unsaturated Compound 
The eac i  be ee  3.21r a d 3.25g a  e f ed i g diffe e  c ce a i  f 3.25g a d 
he g e  f each eac i  a  i ed b  he 1H NMR ec c  (Sche e S3.15).  
Scheme S3.15. De e i a i  f he Reac i  O de  f 3.25g 
 
I  a i ge -fi ed g e b , L6Sc(OTf)3 (49.0 g, 10 %), 3.21r (109.7 g, 0.62 ), 
a d e i e e (74.4 g, 1.0 e i ) e e eighed i  a  e -d ied 7.0 L ia  a d he e i g 
i e a  di ed i  3.10 L f CD2C 2 (Stock Solution A). I  a he  e -d ied 7.0 L 
ia , B(C6F5)3 (35.8 g, 0.70 ) a  eighed a d di ed i  2.10 L f CD2C 2 (Stock 
Solution B). I  4 e -d ied 7.0 L ia  e e added 3.25g (33.4 g, 50.2 g, 66.9 g,  100.3 
g). T  each e -d ied ia  c ai i g 3.25g a  added Stock Solution A (0.50 L) a d Stock 
Solution B (0.30 L)  e a e he eac i  a e  c ai i g diffe e  c ce a i  f 3.25g. 
The eac i  i e a  he  a fe ed  a J-Y g be. Af e  he J-Y g be a  igh  
ca ed i h he Tef  g, i  a  ake   f he g e b  a d 1H NMR ec a e e ac i ed 
i  he NMR ec e e  ehea ed a  60 C i g a e-ac i i i  de a  i  a a  de i h a 
ec  ake  e e  22 ec d  f  he e g h f he e e i e . The da a e e ce ed i g 
Me ReN a f a e a d eak i eg a i  e e a i ed i g e i e e a  he i e a  
a da d.  
I i ia - a e ki e ic a a i , hich a  de e i ed ba ed  he da a i  ac i ed i  he fi  
600 ec d , h ed ha  he e i  1-order dependency  D,E-unsaturated compound 3.25g 
c ce a i  i  he eac i  be ee  3.21r a d 3.25g (Fig e  S3.17, S3.18). 
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Figure S3.17. M i i g he f a i  f 3.26m de  diffe e  c ce a i  f 3.25g 
 
Figure S3.18. L g( a e)  g[D,E-unsaturated compound 3.25g] i  e ed  de e i e he 
i i ia  eac i  de  f  3.25g. The e  gge  ha  he e i  1-order dependency  3.25g 
c ce a i  . 
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19F NMR E periments for the Detection of the Resting State 
The echa i ic i e iga i  de c ibed ab e e ea ed ha  he (F5C6)3B/L6Sc(OTf)3 c -
ca a ed E-amino CH functionalization has a 1  c  i h e ec   he 
c ce a i  f 1-be -2-ci a -5,5-di e h a idi -3- e 3.25g. We h he i ed 
ha  3.25g a d B(C6F5)3 c d f  a e i g a e c e  a d he ef e ca ied  he f i g 
19F NMR e e i e   ide if  he c e f he c e  (Fig e  S3.19, S3.20). P e i , 
he g  f Pie  ha  e ed ha  B(C6F5)3 a d be a deh de f  a  acidbase adduct, which 
gi e  cha ac e i ic 19F NMR eak  a  135.3, 156.3, 164.5 . We ac i ed he 19F NMR 
ec  f a a e c ai i g 1:1 a i  f B(C6F5)3 a d 3.25g i  CD2C 2 (Fig e  S3.19B, 
S3.20) a d b e ed e  19F NMR eak  a  134.8, 157.7, 164.7 ppm; ba ed  hi  a a i , 
 ec  i  i  ag ee e  i h he f a i  f 3.25gB(C6F5)3 add c . The e i g a e 
c e  a  a  b e ed i  he eac i  i e i c di g 3.21r, 3.25g, B(C6F5)3, 
a d L6Sc(OTf)3 (Fig e S3.19C). 
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Figure S3.19. 19F NMR e periments for the detection of the resting state 
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Figure S3.20. 19F NMR spectrum of 3.25gB(C6F5)3 adduct. 
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Kinetic Isotope Effect E periments 
A  di c ed ab e, -  c  i h e ec   c ce a i  f L6 Sc(OTf)3 gge  
ha  e a i e ec i e C C b d f i g eac i  cc  af e  he e - i i i g e . I  de  
 be he he  he e - i i i g e  i  he h d ide ab ac i   he de a i  ce , 
e ca ied  he f i g a a e  ki e ic i e effec  e e i e . 
Parallel KIE Measurement for N-Alk lamines Containing D-Amino CH or CD Bonds  
A a a e  ki e ic i e effec  d  a  c d c ed h gh i e c e eac i  i i g b  
he 1H NMR ec c  i g i e a  a da d  i  he diffe e ce i  i i ia  a e  f he 
d c  f a i  i  he eac i  f 1-(4- e h he ) idi e 3.21r  1-(4-
e h he ) idi e-2,2,5,5- 4 3.21r-dD with 1-benzyl-2-cinnamoyl-5,5-
di e h a idi -3- e 3.25g (Sche e S3.16). I  a i ge -fi ed g e b , B(C6F5)3 (20.5 
g, 0.040 ), L6Sc(OTf)3 (31.6 g, 0.040 ), 3.25g (200.8 g, 0.60 ) a d 
e i e e (48 g, 0.40 ) e e eighed i  a  e -d ied 7.0 L ia  a d he e i g 
i e a  di ed i  2.00 L f CD2C 2 (Stock Solution A). I   e -d ied 7.0 L ia  
e e added 3.21r (20.5 g)  3.21r-dD (20.9 mg). To each oven-dried vial containing 3.21r  
3.21r-dD was added CD2C 2 (0.30 L) a d Stock Solution A (0.50 L)  e a e he eac i  
a e  c ai i g 3.21r  3.21r-dD. The reaction mixture was then transferred to a J-Young tube. 
Af e  he J-Y g be a  igh  ca ed i h he Tef  g, i  a  ake   f he g e b  
a d 1H NMR ec a e e ac i ed i  he NMR ec e e  ehea ed a  60 C i g a e-
ac i i i  de a  i  a a  de i h a ec  ake  e e  22 ec d  f  he e g h f he 
e e i e . The ac i ed da a e e ce ed i g Me ReN a f a e a d eak i eg a i  
e e a i ed i g e i e e a  he i e a  a da d.  
F  he ki e ic a a i  ba ed  he i i ia  a e  f he d c  f a i  (Fig e S3.21), KIE 
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a e f 1.28  0.07 (a e age f  e e i e ) a  b ai ed i  he eac i  be ee  3.21r  
3.21r-dD and 3.25g. Thi  gge  ha  he h d ide ab ac i  e  i   ike  he e  
i i i g ce . F  he 1H NMR a a i  f he i a ed a d ified 3.21r-dD in CDCl3, i  a  
e ea ed ha  >95% f -i c a i  e e  a  e ai ed a  he D-amino position (Figures 
S3.223.24). This result suggests that the borohydride reduction step may be irreversible as there 
a   H i c a i  i  he D-amino CD bonds. 
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Scheme S3.16. Ki e ic I e Effec  S die  
 
 
Figure S3.21. M i i g he f a i  f d c  i  a a e  KIE ea e e  
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Figure S3.23. 1H NMR ec  f 3.26m 
 
Figure S3.24. 1H NMR ec  f 3.26m-dD  
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Parallel KIE Measurement for N-Alk lamines Containing E-Amino CH or CD Bonds 
A a a e  ki e ic i e effec  d  a  c d c ed h gh i e c e eac i  i i g b  
he 1H NMR ec c  i g i e a  a da d  i  he diffe e ce i  i i ia  a e  f he 
d c  f a i  i  he eac i  f 1-(4- e h he ) idi e 3.21r  1-(4-
e h he ) idi e-3,3,4,4- 4 3.21r-dE with 1-benzyl-2-cinnamoyl-5,5-
di e h a idi -3- e 3.25g (Sche e S3.17). I  a i ge -fi ed g e b , B(C6F5)3 (20.5 
g, 0.040 ), L6Sc(OTf)3 (31.6 g, 0.040 ), 3.25g (200.8 g, 0.60 ) a d 
e i e e (48 g, 0.40 ) e e eighed i  a  e -d ied 7.0 L ia  a d he e i g 
i e a  di ed i  2.00 L f CD2C 2 (Stock Solution A). I   e -d ied 7.0 L ia  
e e added 3.21r (20.5 g)  3.21r-dE (20.9 mg). To each oven-dried vial containing 3.21r  
3.21r-dE was added CD2C 2 (0.30 L) a d Stock Solution A (0.50 L)  e a e he eac i  
a e  c ai i g 3.21r  3.21r-dE. The eac i  i e a  he  a fe ed  a J-Y g be. 
Af e  he J-Y g be a  igh  ca ed i h he Tef  g, i  a  ake   f he g e b  
a d 1H NMR ec a e e ac i ed i  he NMR ec e e  ehea ed a  60 C i g a e-
ac i i i  de a  i  a a  de i h a ec  ake  e e  22 ec d  f  he e g h f he 
e e i e . The da a e e ce ed i g Me ReN a f a e a d eak i eg a i  e e 
a i ed i g e i e e a  he i e a  a da d. 
Ki e ic a a i  ba ed  he i i ia  a e  f he d c  f a i  (Fig e S3.25) de a e  
ha  3.21r eac  2.5 i e  fa e  ha  3.21r-dE ( H/ D = 2.50  0.13, a e age f  e e i e ) 
i  he eac i  be ee  3.21r  3.21r-dE and 3.25g. Thi  e  gge  ha  he c ea age f E-
a i  CH bond is likely involved in the turnover-limiting step. 
F  he 1H NMR a a i  f he i a ed a d ified 3.21r-dE in CDCl3 a d ace e- 6, -
i c a i  e e  a  de e i ed (Fig e  S3.263.30). It was found that there was a -
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c a b i g be ee  he b a e  a d he d c  a  heE-amino CH/D bonds and the D-
ca b  CH/D bonds that are easily enolizable. 
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Scheme S3.17. Ki e ic I e Effec  S die  
 
 
Figure S3.25. M i i g he f a i  f d c  i  a a e  KIE ea e e  
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Figure S3.26. 1H NMR ec  f 3.26m (i  CDC 3) 
 
Figure S3.27. 1H NMR ec  f 3.26m-dE (i  CDC 3) 
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Figure S3.28. 2D HSQCAD ec a f 3.26m i  ace e- 6 (   a    a )
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Figure S3.29. 1H NMR ec  f 3.26m (i  ace e- 6) 
 
Figure S3.30. 1H NMR ec  f 3.26m-dE (i  ace e- 6) 
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Intermolecular Competition KIE Measurement for N-Alk lamines Containing D-Amino 
CH or CD Bonds 
I  de   f he  be if he e - i i i g e  i  he de a i  ce , e ca ied  
he f i g i e ec a  c e i i  ki e ic i e effec  e e i e . 
A  i e ec a  c e i i  ki e ic i e effec  d  be ee  1-(4-
e h he ) idi e 3.21r a d 1-(4- e h he ) idi e-2,2,5,5- 4 3.21r-da i h 1-
be -2-ci a -5,5-di e h a idi -3- e 3.25g a  c d c ed (Sche e S3.18). 
S ecifica ,  a 15 L e -d ied e e e e  a  added B(C6F5)3 (10.2 g, 0.020 ), 
L6Sc(OTf)3 (15.8 g, 0.020 ), 3.25g (100.4 g, 0.30 ), 3.21r (17.7 g, 0.10 ), 
3.21r-da (18.1 g, 0.10 ) a d DCM (1.6 L) de  i ge  a he e. The i e a  
aced i  a  i  ba h a  60 C a d a  a ed  i  f  1 h . U  c e i , he i  
a  c ed  22 °C a d c ce a ed  ac . The 1H NMR a a i  f he ified d c  
i e i g e i e e a  he i e a  a da d e ea ed ha  d c  3.26m-da a  b ai ed i  
27% ie d (3.5:1 d ). Af e  ifica i  b  c  ch a g a h  (E OAc:he a e  = 1:3), 
3.26m-da a  b ai ed a  a igh  e  i id. 
F  he 1H NMR a a i  f he i a ed a d ified 3.26m-da i  CDC 3 (Fig e  S3.31, S3.32), 
KIE a e f 1.7 a  b ai ed i  he eac i  be ee  3.21r a d 3.26m-da i h 3.25g. Thi  e  
i  i  i e i h he e i  i de e de  ki e ic i e effec  die  a d  ha  he h d ide 
ab ac i  e  i   ike  he e  i i i g ce .  
Scheme S3.18. Ki e ic I e Effec  S die  
 
 575  
 
Figure S3.31. 1H NMR ec  f 3.26m 
 
Figure S3.32. 1H NMR ec  f 3.26m-dD 
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Intermolecular Competition KIE Measurement for N-Alk lamines Containing E-Amino 
CH or CD Bonds 
A  i e ec a  c e i i  ki e ic i e effec  d  be ee  1-(4-
e h he ) idi e 3.21r a d 1-(4- e h he ) idi e-3,3,4,4- 4 3.21r-dE i h 1-
be -2-ci a -5,5-di e h a idi -3- e 3.25g a  c d c ed (Sche e S3.19). 
S ecifica ,  a 15 L e -d ied e e e e  a  added B(C6F5)3 (10.2 g, 0.020 ), 
L6Sc(OTf)3 (15.8 g, 0.020 ), 3.25g (100.4 g, 0.30 ), 3.21r (17.7 g, 0.10 ), 
3.21r-dE- (18.1 g, 0.10 ) a d DCM (1.6 L) de  i ge  a he e. The i e a  
aced i  a  i  ba h a  60 C a d a  a ed  i  f  1 h . U  c e i , he i  
a  c ed  22 °C a d c ce a ed  ac . The 1H NMR a a i  f he ified d c  
i e i g e i e e a  he i e a  a da d e ea ed ha  d c  3.26m-dEwas obtained in 
23% ie d (2.0:1 d ). Af e  ifica i  b  c  ch a g a h  (E OAc:he a e  = 1:3), 
3.26m-dEwas obtained as a igh  e  i id. 
F  he 1H NMR a a i  f he i a ed a d ified 3.26m-dEin CDCl3 (Fig e  S3.33, S3.34), 
i  a  f d ha  3.21r eac  4.3 i e  fa e  ha  3.21r-dE ( H/ D = 4.3) i  he eac i  be ee  
3.21r  3.21r-dE a d 3.26m-dE. This result is in line with the previous independent kinetic isotope 
effec  die  a d  ha  he c ea age f E-amino CH bond is likely involved in the 
e - i i i g e .
It was found that there was a - c a b i g be ee  he b a e  a d he d c  a  heE-amino 
CH/D bonds and the D-carbonyl CH/D bonds that are easily enolizable. 
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Scheme S3.19. Ki e ic I e Effec  S die  
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Figure S3.33. 1H NMR ec  f 3.26m (i  CDC 3) 
 
Figure S3.34. 1H NMR ec  f 3.26m-dE (i  CDC 3) 
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Hammett Studies 
I  de   d  he effec  f a i g he b i e   a  g  f N-a k a i e a  e  a  
D,E-unsaturated substrates on the rate of C H alkylation, we carried out the following Hammett 
die . 
Determination of the Hammett U Value for N-Ar l Substituted P rrolidines  
A Ha e  U value for the reaction of N-a  b i ed idi e  (3.21r, 3.21v3.21x) a d 
(E)-1-be -5,5-di e h -2-(3-(4-( if e h ) he )ac ) a idi -3- e 3.25h a  
de e i ed b  i e c e eac i  i i g b  he 1H NMR ec c  i g e i e e a  
a  i e a  a da d. I  a i ge -fi ed g e b , L6Sc(OTf)3 (39.5 g, 0.050 ), 3.25h 
(302 g, 0.75 ), e i e e (60 g, 0.50 ), a d C6F6 (46.5 g, 0.25 ) e e 
eighed i  a  e -d ied 7.0 L ia  a d he e i g i e a  di ed i  2.00 L f 
CD2C 2 (Stock Solution A). I  a he  e -d ied 7.0 L ia , B(C6F5)3 (30.7 g, 0.060 ) 
a  eighed a d di ed i  1.20 L f CD2C 2 (Stock Solution B). I  4 e -d ied 7.0 L 
ia , e e added 0.10  f each a i e. T  each e -d ied ia  c ai i g a i e a  added 
Stock Solution A (0.40 L), Stock Solution B (0.20 L), a d CD2C 2 (0.20 L)  e a e he 
eac i  a e  c ai i g a i e  3.21r, 3.21v, 3.21 ,  3.21 . The eac i  i e a  he  
a fe ed  a J-Y g be. Af e  he J-Y g be a  igh  ca ed i h he Tef  g, i  
a  ake   f he g e b  a d he 1H NMR ec a e e ac i ed i  he NMR ec e e  
ehea ed a  60 C i g a e-ac i i i  de a  i  a a  de i h a ec  ake  e e  22 
ec d  f  he e g h f he e e i e . The da a e e ce ed i g Me ReN a f a e 
a d eak i eg a i  e e a i ed i g e i e e a  he i e a  a da d. 
The a ge ega i e U value (4.9) obtained implies the development of positive charge at the 
eac i  ce e  i  he a i i  a e a   i   he e - i i i g e . Thi  e  he eb  
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 he ed echa i  i  hich B(C6F5)3 ab ac  a h d ide f  N-a idi e  
f  a  N-a  i i i  ca i , a d i  i e i a i  i  a i i e  cha ged e a i  
ecie ; b h ce e  ake ace a   i   he e - i i i g e  (Fig e S3.35). 
 
 
Figure S3.35. L g(kX/kF)  V is employed to determine the U value 
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Determination of the Hammett U Value for Aryl Substituted D,E-Unsaturated Compounds 
A Ha e  U value for the reaction of 1-(4-methoxyphenyl)pyrrolidine (3.21r) a d a  b i ed 
D,E-unsaturated compounds (3.25g3.25j) a  de e i ed b  i e c e eac i  i i g b  
he 1H NMR ec c  i g e i e e a  a  i e a  a da d. I  a i ge -fi ed g e b , 
L6Sc(OTf)3 (39.5 g, 0.050 ), 3.21r (88.5 g, 0.50 ), a d e i e e (60 g, 0.50 
) e e eighed i  a  e -d ied 7.0 L ia  a d he e i g i e a  di ed i  2.00 
L f CD2C 2 (Stock Solution A). I  a he  e -d ied 7.0 L ia , B(C6F5)3 (30.7 g, 0.060 
) a  eighed a d di ed i  1.20 L f CD2C 2 (Stock Solution B). I  4 e -d ied 7.0 
L ia , e e added 0.15  f each D,E-unsaturated compounds 3.25. T  each e -d ied 
ia  c ai i g a i e a  added Stock Solution A (0.40 L), Stock Solution B (0.20 L), a d 
CD2C 2 (0.20 L)  e a e he eac i  a e  c ai i g D,E-unsaturated compounds 3.25g, 
3.25h, 3.25i,  3.25j. The eac i  i e a  he  a fe ed  a J-Y g be. Af e  he J-
Y g be a  igh  ca ed i h he Tef  g, i  a  ake   f he g e b  a d he 1H 
NMR ec a e e ac i ed i  he NMR ec e e  ehea ed a  60 C i g a e-ac i i i  
de a  i  a a  de i h a ec  ake  e e  22 ec d  f  he e g h f he e e i e . The 
da a e e ce ed i g Me ReN a f a e a d eak i eg a i  e e a i ed i g 
e i e e a  he i e a  a da d. 
The V+ a  ed i  he Ha e   i ce he e ec -d a i g abi i  f he -OMe b i e  
a  e ha ced h gh c j ga i  i  he D,E-unsaturated compound 3.25. The i i e U value 
(0.92) b ai ed i ie  he de e e  f ega i e cha ge a  he eac i  ce e  i  he a i i  
a e a   i   he e - i i i g e . Thi  e  he eb   he echa i ic 
h he i  ha  3.25 eac  i h i  i  ge e a ed [(F5C6)3B H]   aff d a ega i e  cha ged 
b e a e i e edia e, a d ha  hi  h d ide a fe  cc  a   i   he e - i i i g 
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e  (Fig e S3.36). 
 
 
Figure S3.36. L g(kY/kH)  V is employed to determine the U value 
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Catal tic C cle Consistent ith the Results of Mechanistic Studies 
Ba ed  he ki e ic die  a  de c ibed ab e, e e he f i g ca a ic c c e (Fig e 
S3.38). Z -  c  i h e ec   c ce a i  f L6 Sc(OTf)3 gge  ha  
e a i e ec i e C C b d f i g eac i  be ee  i  i  ge e a ed e a i e a d [L6
Sc(OTf)3]-ac i a ed 3.25g (XXVII o XXVIII, Fig e S3.38) cc  af e  he e - i i i g 
e . 1-O  c   he c ce a i  f 3.25g gge  ha  he a f a i  ha  a 
e i g a e f 3.25gB(C6F5)3 add c  (XXIII), hich a  gge ed b  19F NMR die . Ki e ic 
i e effec  die  de a e ha  c ea age f E-amino CH bond is likely the turnover-
i i i g e . The a ge ega i e U value (-4.9) obtained from Ha e  d  f N-a  b i ed 
idi e   he ed echa i  ha  (F5C6)3B-ca a ed h d ide ab ac i   
ge e a e N-a  i i i  ca i , a d i  i e i a i  i  a  e a i  ecie  aki g ace a  
 i   he e - i i i g e . 
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Figure S3.37. A ca a ic c c e c i e  i h he e  f he echa i ic i e iga i  
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Origin of Enamine and N-Alk lamine Products 
I  he E-amino C H alkylation process, the products were obtained either as 3.26-enamine, 3.26-
alk lamine,  a i e f he  (Fig e S3.37). We e i ed if he N-a k a i e d c  
e e f ed h gh a fe  h d ge a i  f XXVIII (XXVIIIo 3.26-alk lamine). 
A e a i e , 3.26-alk lamine c d be ge e a ed h gh ed c i  f 3.26-enamine (XXVIII 
o 3.26-enamine o 3.26-alk lamine). I  de   de a d he igi  f 3.26-enamine a d 
3.26-alk lamine d c , e c d c ed he f i g e e i e . 
 
Ki e ic P fi e f  he E-Alkylation of N-A i e idi e 
T a fe  H d ge a i  f C d 3.21v  
Deh d ge a i  f C d 3.21i 
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Kinetic Profile for the E-Alkylation of N-Ar lpiperidine 
A  h  i  Sche e 3.23 i  he a c i , he eac i  f N-a i e idi e 3.21l a d 
dii f a a e 3.22a i h 10 % B(C6F5)3 i  be e e (1.0 M) a  f d  gi e N-
a k a i e 3.23o a d e a i e 3.32 i  57% ie d a d 29% ie d, e ec i e . Si ce he d c  
e e b ai ed a  a i e f 3.23o a d 3.32, i  d be a g d a f   d  he he  he N-
a k a i e a d e a i e d c  a e i e c e ib e. T  de e i e if 3.23o ca  be ge e a ed b  
(F5C6)3B-ca a ed a fe  h d ge a i  f 3.32, e i ed he g e  f hi  eac i  b  
he 1H NMR ec c  (Fig e S3.38). T  a  e -d ied 7.0 L ia , a i e 3.21l (88 g, 0.40 
), dii  f a a e 3.22a (120 g, 0.60 ), e i e e (48 g, 0.40 ), 
B(C6F5)3 (10 %) a d 0.4 L C6D6 e e added de  i ge  a he e. The , he eac i  
i e a  a fe ed  a J-Y g be hich a  igh  ca ed i h he Tef  g a d ake  
 f he g e b . The 1H NMR ec a e e ac i ed i  he NMR ec e e  ehea ed a  
50 C i g a e-ac i i i  de a  i  a a  de i h a ec  ake  e e  22 ec d  f  he 
e g h f he e e i e . The da a e e ce ed i g Me ReN a f a e a d eak 
i eg a i  e e a i ed i g - e e a  he i e a  a da d. 
A  h  i  Fig e S36, i  a  f d ha  he e a  i i a  a f a i  f 3.32 i  3.23o, 
e ide ced b  he  cha ged c ce a i  f 3.32 ce >85% f a i e 3.21l a  
c ed (af e  ca. 100 i e ). 
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Figure S3.38. P g e  f he eac i  be ee  3.21l a d 3.22a 
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Transfer H drogenation of Compound 3.32 
A  h  i  Sche e 3.23 i  he a c i , a fe  h d ge a i  f c d 3.32 a  
c d c ed  f he  be he he  he e a i e d c  ca  be ed ced  ge e a e he N-
a k a i e d c  3.23o.  
T  a 15 L e -d ied e e e e , 3.32 (0.050 ), B(C6F5)3 (20 %) a d be e e (0.20 
L) e e added de  a i ge  a he e (Sche e S3.20). The eac i  i e a  aced 
i  a  i  ba h a  50 °C f  12 h . U  c e i , he i  a  c ed  22 °C and 
c ce a ed  ac . Th gh he 1H NMR a a i  f he ified d c  i e i g 
e i e e a  he i e a  a da d, i  a  f d ha  3.23o a  f ed i  30% ie d, ge he  i h 
a  i ic c e  f [ idi i ]+[C6F5]  (3.34) hich a  ge e a ed i  15% ie d. Thi  
e e i e  i ie  ha  e a i e 3.32 ca  e e a  H+/H- ce i  (F5C6)3B-ca a ed a fe  
h d ge a i  f 3.32  aff d N-a k a i e d c  3.23o. 
 
Scheme S3.20. T a fe  H d ge a i  S die  i i g C d 3.32 
 
 
3-(1,4-Diisopropo -1,4-dio obutan-2- l)-1-(4-metho -2,6-dimeth lphen l)p ridin-1-ium 
perfluoroben en-1-ide (3.34) 
1H NMR (600 MH , CDCl3):  8.72 ( , 1H), 8.60 (d, J = 8.2 H , 1H), 8.37 (dd, J = 6.0, 1.3 H , 
1H), 8.13  8.08 ( , 1H), 6.80 (d, J = 4.2 H , 2H), 5.06 (d , J = 12.2, 6.5 H , 1H), 4.88 ( , J = 6.7 
H , 1H), 4.26 (dd, J = 8.7, 4.8 H , 1H), 3.87 ( , 3H), 3.10 (dd, J = 18.1, 4.9 H , 1H), 3.03 (dd, J = 
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17.7, 8.7 H , 1H), 1.97 ( , 3H), 1.94 ( , 3H), 1.26 (d, J = 5.1 H , 3H), 1.21 (d, J = 5.7 H , 3H), 
1.18 (d, J = 6.2 H , 3H), 1.14 (d, J = 6.2 H , 3H); 19F NMR (564 MH , CDCl3):  -137.48 (d, J 
= 23.9 H ), -160.45 ( , J = 20.1 H ), -165.00 ( , J = 19.4 H ); HRMS (DART): Calcd for 
C30H33F5NO5 (MH+): 582.2273; found: 582.2253. 
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(F5C6)3B-ca a ed a fe  h d ge a i  f e a i e  a  e i  e ed b  S e ha  a d 
c - ke ; 1-(1-c c he e -1- )- i e idi e a  ed ced  aff d 1-c c he i e idi e i  he 
e e ce f 20 % B(C6F5)3 a d a ge e ce  f ( -P )2NH ( he i e a  a ed  i  a  
100 °C f  24 h ).3 I   a f a i  (Fig e 2), a i e b a e 3.21l a  e e a  H+/H- 
ce i  a fe  h d ge a i  f 3.32. T  de e i e if hi  i  ib e,  a 15 L e -d ied 
e e e e  e e added e a i e 3.32 (0.050 ), a i e 3.21l-d (0.05 , 1.0 e i ), 
B(C6F5)3 (20 %) a d be e e (0.20 L) de  a i ge  a he e (Sche e S3.21). The 
eac i  i e a  aced i  a  i  ba h a  50 °C f  12 h . U  c e i , he i  
a  c ed  22 °C and c ce a ed  ac . Th gh he 1H NMR a a i  f he ified 
d c  i e i g e i e e a  he i e a  a da d, i  a  f d ha  3.23o-d a  f ed 
i  50% ie d i h <5% f 3.34 f a i  he  58% f 3.19g-d a  ec e ed. F he e, 
de e i  i c a i  e e  a  de e i ed af e  he i a i  a d ifica i  f 3.23o-d a d 
3.21l-d, hich e ea ed ha  he e a  - c a b i g a  he E-position of 3.23o-d a d 3.21l-d ( ee 
1.62.0 ppm in Figures S3.39, S3.40) when there was no significant deuterium incorporation at 
he E-amino position of recovered 3.32. The e e  i  ha  a i e 3.21l-d ca  e e a  D+ 
a d H- ce i  (F5C6)3B-ca a ed a fe  h d ge a i  f 3.32  aff d N-a k a i e d c  
3.23o-d. 
Scheme S3.21. T a fe  H d ge a i  S die  i i g C d 3.32 
 
 
                                                          
3 Farrell, J. M.; Heiden, Z. M.; Stephan, D. W. Organometallics 2011, 30, 44974500. 
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Figure S3.39. 1H NMR Spectrum of 3.23o 
 
Figure S3.40. 1H NMR Spectrum of 3.23o-d 
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Deh drogenation of Compound 3.23o 
A  di c ed i  e i  ec i , de  he a da d eac i  c di i , N-a k a i e 3.23o i  
ike  ge e a ed b  a fe  h d ge a i  f XXVIII (Fig e S3.37) i h  he i e ediac  f 
e a i e 3.32. I  de   be he he  e a i e 3.32 ca  be ge e a ed f  N-a k a i e 3.23o 
h gh ida i , deh d ge a i  f c d 3.23o (Sche e  S3.22-S3.23) a  c d c ed.  
T  a 15 L e -d ied e e e e  a  added a i e 3.23o (21 g, 0.050 ), B(C6F5)3 (20 
%) a d be e e (0.20 L) de  a i ge  a he e (Sche e S3.22). The eac i  i e 
a  aced i  a  i  ba h a  50 °C and a  a ed  i  f  12 h . U  c e i , he 
eac i  i e a  c ed  22 °C a d c ce a ed  ac . Th gh he 1H NMR a a i  
f he ified d c  i e i g e i e e a  he i e a  a da d, i  a  f d ha  3.23o 
a  f  ec e ed a d f a i  f 3.32 a   b e ed.  
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We h he i ed ha  i  de   b ai  e a i e 3.32, he e e ce f dii f a a e 3.22a 
igh  be ece a   e e a  a H+/H- acce . The ef e, 3.22 (10 g, 0.05 , 1.0 e i .) 
a  added  he eac i  i e f a i e 3.23o (21 g, 0.05 ), B(C6F5)3 (20 %) a d 
be e e (0.2 L) de  a i ge  a he e (Sche e S3.23). The eac i  i e a  aced 
i  a  i  ba h a  50 °C and a  a ed  i  f  12 h . U  c e i , he eac i  i e 
a  c ed  22 °C a d c ce a ed  ac . H e e , af e  1H NMR a a i  f he ified 
d c  i e i g e i e e a  he i e a  a da d, f a i  f 3.32 a   b e ed.  
The e e e i e  e ea ed ha  3.23o ca  be eadi  c e ed  3.32 b  B(C6F5)3, ega d e  
f he he  D,E-unsaturated compound 3.22a i  e e  i  he eac i  i e  . Thi  e  
i ie  ha  3.32 i  ge e a ed f  he de a i  f XXVIII (Fig e S3.37),  h gh he 
ida i  f 3.23o. The ef e, he i e c e i  be ee  3.23o a d 3.32 de  he a da d 
eac i  c di i  i  ike   ake ace. 
 
Scheme S3.23. Deh d ge a i  S die  i i g C d 3.23o 
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Mechanistic Studies Involving Ester Substituted D,E-Unsaturated Compound 3.25c 
We e f ed echa i ic i e iga i   he eac i  be ee  N-a k a i e 3.21r a d e h  
e e - b i ed e ec hi e 3.25c  be if he echa i  f E-C H alkylation may be 
diffe e  de e di g  hich e ec hi e i  ed (  he ce e  i i g a - b i ed 
e ec hi e ). 
Determination of the Reaction Orders Involving 3.25c 
F  he E-C H alkylation reaction involving 1-(4- e h he ) idi e 3.21r a d 3.25c, he 
eac i  de  f each eac a  a  died h gh i e c e eac i  i i g b  he 1H 
NMR ec c ic a a i . 
Reaction Order of B(C6F5)3 
The eac i  be ee  3.21r a d 3.25c a  e f ed i g diffe e  c ce a i  f B(C6F5)3 
a d he g e  f each eac i  a  i ed b  he 1H NMR ec c  (Sche e S3.24).  
Scheme S3.24. De e i a i  f he Reac i  O de  f B(C6F5)3 
 
I  a i ge -fi ed g e b , L10Sc(OTf)3 (24.6 g, 10 %), 3.21r (106.2 g, 0.60 ), 
3.25c (241.2 g, 1.5 e i ) a d e e (55.2 g, 1.0 e i ) e e eighed i  a  e -d ied 7.0 
L ia  a d he e i g i e a  di ed i  2.40 L f CD2C 2 (Stock Solution A). I  
a he  e -d ied 7.0 L ia , B(C6F5)3 (35.8 g, 0.070 ) a  eighed a d di ed i  
1.40 L f CD2C 2 (Stock Solution B). T  each J-Y g be a  added Stock Solution A (0.40 
L), Stock Solution B (0.10, 0.15, 0.20,  0.25 L) a d CD2C 2 (0.30, 0.25, 0.20,  0.15 L) 
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 e a e he eac i  a e  c ai i g diffe e  c ce a i  f B(C6F5)3. Af e  he J-Y g 
be a  igh  ca ed i h he Tef  g, i  a  ake   f he g e b  a d he 1H NMR 
ec a e e ac i ed i  he NMR ec e e  ehea ed a  40 C i g a e-ac i i i  de a  
i  a a  de i h a ec  ake  e e  22 ec d  f  he e g h f he e e i e . The da a 
e e ce ed i g Me ReN a f a e a d eak i eg a i  e e a i ed i g e e 
a  he i e a  a da d.  
I i ia - a e ki e ic a a i , hich a  de e i ed ba ed  he da a i  ac i ed i  he fi  
600 ec d , h ed ha  he e i  -  c   B(C6F5)3 c ce a i  i  he 
eac i  be ee  3.21r a d 3.25c (Fig e  S3.41, S3.42). 
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Figure S3.41. Monitoring the formation of 3.26c under different concentrations of B(C6F5)3 
 
Figure S3.42. L g( a e)  g[B(C6F5)3] i  e ed  de e i e he i i ia  eac i  de  f  
B(C6F5)3. The e  gge  ha  he e i  -  c   B(C6F5)3 c ce a i . 
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Reaction Order of L10Sc(OTf)3 
The eac i  be ee  3.21r a d 3.25c a  e f ed i g diffe e  c ce a i  f 
L10Sc(OTf)3 a d he g e  f each eac i  a  i ed b  he 1H NMR ec c  
(Sche e S3.25).  
Scheme S3.25. De e i a i  f he Reac i  O de  f L10Sc(OTf)3 
 
I  a i ge -fi ed g e b , B(C6F5)3 (30.7 g, 10 %), 3.21r (106.2 g, 0.6 ), 3.25c 
(241.2 g, 1.5 e i ) a d e e (55.2 g, 1.0 e i ) e e eighed i  a  e -d ied 7.0 L ia  
a d he e i g i e a  di ed i  2.40 L f CD2C 2 (Stock Solution A). I  a he  
e -d ied 7.0 L ia , L10Sc(OTf)3 (57.4 g, 0.070 ) a  eighed a d di ed i  1.40 
L f CD2C 2 (Stock Solution B). T  each J-Y g be a  added Stock Solution A (0.40 L), 
Stock Solution B (0.10, 0.15, 0.20,  0.25 L) a d CD2C 2 (0.30, 0.25, 0.20,  0.15 L)  
e a e he eac i  a e  c ai i g diffe e  c ce a i  f L10Sc(OTf)3. Af e  he J-
Y g be a  igh  ca ed i h he Tef  g, i  a  ake   f he g e b  a d 1H NMR 
ec a e e ac i ed i  he NMR ec e e  ehea ed a  40 C i g a e-ac i i i  de a  
i  a a  de i h a ec  ake  e e  22 ec d  f  he e g h f he e e i e . The da a 
e e ce ed i g Me ReN a f a e a d eak i eg a i  e e a i ed i g e e 
a  he i e a  a da d.  
I i ia - a e ki e ic a a i , hich a  de e i ed ba ed  he da a i  ac i ed i  he fi  
1100 ec d , h ed ha  he e i  1-order dependency  L10Sc(OTf)3 c ce a i  i  he 
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eac i  be ee  3.21r a d 3.25c (Fig e  S3.43, S3.44). 
 
Figure S3.43. M i i g he f a i  f 3.26c de  diffe e  c ce a i  f L10Sc(OTf)3 
 
Figure S3.44. L g( a e)  g[L10Sc(OTf)3] i  e ed  de e i e he i i ia  eac i  de  
f  L10Sc(OTf)3. The e  gge  ha  he e i  1-order dependency  L10Sc(OTf)3 
c ce a i . 
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Reaction Order of Amine 
The eac i  be ee  3.21r a d 3.25c a  e f ed i g diffe e  c ce a i  f 3.21r a d 
he g e  f each eac i  a  i ed b  he 1H NMR ec c  (Sche e S3.26).  
Scheme S3.26. De e i a i  f he Reac i  O de  f 3.21r 
 
I  a i ge -fi ed g e b , B(C6F5)3 (30.7 g, 0.060 ), L10Sc(OTf)3 (24.6 g, 0.030 
), 3.25c (241.2 g, 0.90 ) a d e e (55.2 g, 0.60 ) e e eighed i  a  e -
d ied 7.0 L ia  a d he e i g i e a  di ed i  3.00 L f CD2C 2 (Stock Solution 
A). I  a he  e -d ied 7.0 L ia , 3.21r (177 g, 1.0 ) a  eighed a d di ed i  
1.00 L f CD2C 2 (Stock Solution B). T  each J-Y g be a  added Stock Solution A (0.50 
L), Stock Solution B (0.05, 0.07, 0.10,  0.15 L) a d CD2C 2 (0.25, 0.23, 0.20,  0.15 L) 
 e a e he eac i  a e  c ai i g diffe e  c ce a i  f 3.21r. The eac i  i e 
a  he  a fe ed  a J-Y g be. Af e  he J-Y g be a  igh  ca ed i h he Tef  
g, i  a  ake   f he g e b  a d 1H NMR ec a e e ac i ed i  he NMR 
ec e e  ehea ed a  40 C i g a e-ac i i i  de a  i  a a  de i h a ec  ake  
e e  22 ec d  f  he e g h f he e e i e . The da a e e ce ed i g Me ReN a 
f a e a d eak i eg a i  e e a i ed i g e e a  he i e a  a da d.  
I i ia - a e ki e ic a a i , hich a  de e i ed ba ed  he da a i  ac i ed i  he fi  
800 ec d , h ed ha  he e i  -  c   a i e 3.21r c ce a i  i  he 
eac i  be ee  3.21r a d 3.25c (Fig e  S3.45, S3.46). 
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Figure S3.45. M i i g he f a i  f 3.26c de  diffe e  c ce a i  f a i e 3.21r 
 
Figure S3.46. L g( a e)  g[a i e 3.21r] i  e ed  de e i e he i i ia  eac i  de  
f  a i e 3.21r. The e  gge  ha  he e i  -  c   3.21r c ce a i .
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Reaction Order of D,E-Unsaturated Compound 
The eac i  be ee  3.21r a d 3.25c a  e f ed i g diffe e  c ce a i  f 3.25c a d 
he g e  f each eac i  a  i ed b  he 1H NMR ec c  (Sche e S3.27).  
Scheme S3.27. De e i a i  f he Reac i  O de  f 3.25c 
 
I  a i ge -fi ed g e b , B(C6F5)3 (30.7 g, 10 %), L10Sc(OTf)3 (24.6 g, 5.0 %), 
3.21r (106.2 g, 0.60 ), a d e e (55.2 g, 1.0 e i ) e e eighed i  a  e -d ied 7.0 
L ia  a d he e i g i e a  di ed i  3.00 L f CD2C 2 (Stock Solution A). I  
a he  e -d ied 7.0 L ia , 3.25c (322 g, 1.20 ) a  eighed a d di ed i  1.20 L 
f CD2C 2 (Stock Solution B). T  each J-Y g be a  added Stock Solution A (0.50 L), 
Stock Solution B (0.10, 0.15, 0.20,  0.25 L) a d CD2C 2 (0.20, 0.15, 0.10,  0.05 L)  
e a e he eac i  a e  c ai i g diffe e  c ce a i  f 3.25c. The eac i  i e 
a  he  a fe ed  a J-Y g be. Af e  he J-Y g be a  igh  ca ed i h he Tef  
g, i  a  ake   f he g e b  a d 1H NMR ec a e e ac i ed i  he NMR 
ec e e  ehea ed a  40 C i g a e-ac i i i  de a  i  a a  de i h a ec  ake  
e e  22 ec d  f  he e g h f he e e i e . The da a e e ce ed i g Me ReN a 
f a e a d eak i eg a i  e e a i ed i g e e a  he i e a  a da d.  
I i ia - a e ki e ic a a i , hich a  de e i ed ba ed  he da a i  ac i ed i  he fi  
800 ec d , h ed ha  he e i  3-order dependency  D,E-unsaturated compound 3.25c 
c ce a i  i  he eac i  be ee  3.21r a d 3.25c (Fig e  S3.47, S3.48). 
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Figure S3.47. M i i g he f a i  f 3.26c de  diffe e  c ce a i  f 3.25c 
 
Figure S3.48. L g( a e)  g[D,E-unsaturated compound 3.25c] i  e ed  de e i e he 
i i ia  eac i  de  f  3.25c. The e  gge  ha  he e i  -order dependency  3.25c 
c ce a i . 
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Kinetic Isotope Effect E periments Involving 3.25c 
I  de   be he he  he e - i i i g e  i e  he c ea age f D- or E-amino CH 
b d , e ca ied  a a e  ki e ic i e effec  e e i e . 
Parallel KIE Measurement for D-Amino CH and CD Bond Cleavage 
A a a e  ki e ic i e effec  d  a  c d c ed h gh i e c e eac i  i i g b  
he 1H NMR ec c  i g i e a  a da d  i  he diffe e ce i  i i ia  a e  f he 
d c  f a i  i  he eac i  f 1-(4- e h he ) idi e 3.21r  1-(4-
e h he ) idi e-2,2,5,5- 4 3.21r-dD with ethyl (E)-4-(2-e h -3,3-di e h -5-
a idi -1- )-4- b -2-e a e 3.25c (Sche e S3.28).  
I  a i ge -fi ed g e b , B(C6F5)3 (20.4 g, 0.040 ), L10Sc(OTf)3 (16.4 g, 0.020 
), 3.25c (160.8 g, 0.60 ) a d e e (36.8 g, 0.40 ) e e eighed i  a  e -
d ied 7.0 L ia  a d he e i g i e a  di ed i  2.00 L f CD2C 2 (Stock Solution 
A). I   e -d ied 7.0 L ia  e e added 3.21r (17.7 g)  3.21r-dD (18.1 mg). To each 
e -d ied ia  c ai i g 3.21r  3.21r-dD was added CD2C 2 (0.30 L) a d Stock Solution A 
(0.50 L)  e a e he eac i  a e  c ai i g 3.21r  3.21r-dD. The eac i  i e a  
he  a fe ed  a J-Y g be. Af e  he J-Y g be a  igh  ca ed i h he Tef  g, 
i  a  ake   f he g e b  a d 1H NMR ec a e e ac i ed i  he NMR ec e e  
ehea ed a  40 C i g a e-ac i i i  de a  i  a a  de i h a ec  ake  e e  22 
ec d  f  he e g h f he e e i e . The da a e e ce ed i g Me ReN a f a e 
a d eak i eg a i  e e a i ed i g e e a  he i e a  a da d.  
Ki e ic a a i  ba ed  he i i ia  a e  f he d c  f a i  (Fig e S3.49) de a e  
ha  3.21r eac  1.3 i e  fa e  ha  3.21r-dD ( H/ D = 1.34) i  he eac i  be ee  3.21r  
3.21r-dD and 3.25c. F  1H NMR a a i  f he i a ed a d ified 3.26c-dD in CDCl3, i  a  
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e ea ed ha  94% f -i c a i  e e  a  e ai ed a  he D-amino position (Figures 
S3.50). This result suggests that the borohydride reduction step may be irreversible as there 
a   H i c a i  i  he D-amino CD bonds. 
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Scheme S3.28. Ki e ic I e Effec  S die  
 
 
Figure S3.49. M i i g he f a i  f d c  i  a a e  KIE ea e e  
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Figure S3.50. 1H NMR ec  f 3.26c (CDC 3) 
  
Figure S3.51. 1H NMR ec  f 3.26c-dD (CDC 3) 
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Parallel KIE Measurement for E-Amino CH and CD Bond Cleavage 
A a a e  ki e ic i e effec  d  a  c d c ed h gh i e c e eac i  i i g b  
he 1H NMR ec c  i g i e a  a da d  i  he diffe e ce i  i i ia  a e  f he 
d c  f a i  i  he eac i  f 1-(4- e h he ) idi e 3.21r  1-(4-
e h he ) idi e-3,3,4,4- 4 3.21r-dE with ethyl (E)-4-(2-e h -3,3-di e h -5-
a idi -1- )-4- b -2-e a e 3.25c (Sche e S3.29). I  a i ge -fi ed g e b , 
B(C6F5)3 (20.4 g, 0.040 ), L10Sc(OTf)3 (16.4 g, 0.020 ), 3.25c (160.8 g, 0.60 
) a d e e (36.8 g, 0.40 ) e e eighed i  a  e -d ied 7.0 L ia  a d he 
e i g i e a  di ed i  2.00 L f CD2C 2 (Stock Solution A). I   e -d ied 7.0 
L ia  e e added 3.21r (17.7 g)  3.21r-dE (18.1 mg). To each oven-dried vial containing 
3.21r  3.21r-dE was added CD2C 2 (0.30 L) a d Stock Solution A (0.50 L)  e a e he 
eac i  a e  c ai i g 3.21r  3.21r-dE. The eac i  i e a  he  a fe ed  a J-
Y g be. Af e  he J-Y g be a  igh  ca ed i h he Tef  g, i  a  ake   f 
he g e b  a d 1H NMR ec a e e ac i ed i  he NMR ec e e  ehea ed a  40 C 
i g a e-ac i i i  de a  i  a a  de i h a ec  ake  e e  22 ec d  f  he e g h 
f he e e i e . The da a e e ce ed i g Me ReN a f a e a d eak i eg a i  
e e a i ed i g e e a  he i e a  a da d.  
Ki e ic a a i  ba ed  he i i ia  a e  f he d c  f a i  (Fig e S3.52) de a e   
ki e ic i e effec  ( H/ D = 1.00) i  he eac i  be ee  3.21r  3.21r-dE and 3.25c. F  1H 
NMR a a i  f he i a ed a d ified 3.26c-dE d i  CDC 3 a d ace e- 6, -i c a i  
e e  a  de e i ed (Fig e  S3.53S56). 
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Scheme S3.29. Ki e ic I e Effec  S die  
 
 
Figure S3.52. M i i g he f a i  f d c  i  a a e  KIE ea e e  
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Figure S3.53. 1H NMR ec  f 3.26c (CDC 3) 
 
Figure S3.54. 1H NMR ec  f 3.26c-dE (CDC 3) 
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Figure S3.55. 1H NMR ec  f 3.26c-dD (acetone- 6) 
 
Figure S3.56. 1H NMR ec  f 3.26c-dE (acetone- 6)  
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The 13C NMR E periments for Characteri ation of Resting State Comple es 
The echa i ic i e iga i  e ea ed ha  he (F5C6)3B/L10Sc(OTf)3 c -ca a ed E-amino 
CH functionalization has a 1  c  i h e ec   he c ce a i  f 
L10Sc(OTf)3 a d3  c  i h e ec   he c ce a i  f e h  (E)-4-(2-e h -
3,3-di e h -5- a idi -1- )-4- b -2-e a e 3.25c. We h he i ed ha  
[L10Sc(OTf)3]3.25cB(C6F5)3 add c  c d be he e i g a e a d ca ied  he 13C NMR 
e e i e   ide if  he c e f he e i g a e c e  (Fig e  S3.57, S3.58). 
P e i , he g  f Pie  ha  e ed ha  B(C6F5)3 a d be a deh de f  
(F5C6)3Bcarbonyl compound adduct which showed that 13C NMR eak f ca b  ie  
hif ed f he  d fie d  199.4 . We ac i ed he 13C NMR ec a f a a e c ai i g 
B(C6F5)3 a d/  L10Sc(OTf)3 a d 3.25c i  CD2C 2 (Fig e  S3.57, S3.58). 
I  he 13C NMR ec  f a eac i  i e c ai i g 3.25c a d 50 % B(C6F5)3, i  a  
b e ed ha  he ca b  eak f 3.25c a  175.3  ha  hif ed  178.1  (Fig e S55A, 
S51B. See he eak a ked i h a ed a ). Si i a  e d a  b e ed i  a i e f 3.25c, 
50 % B(C6F5)3, a d 25 % L10Sc(OTf)3 h i g hif ed eak a  178.4  (Fig e S55C, 
S56). F he e, he eak a  162.5  f 3.25c hif ed  163.5 , hich a  a  de ec ed 
i  he i  f 3.25c a d 25 % L10Sc(OTf)3 (Fig e S55C, S55D, a d S56. See he eak 
a ked i h a b e a ). 
The e e  a e i  ag ee e  i h  h he i  ha  Le i  acidic B(C6F5)3 a d L10Sc(OTf)3 
c di a e  Le i  ba ic ca b  f c i a  g  f 3.25c a d f  
[L10Sc(OTf)3]3.25cB(C6F5)3 add c  a  he ca a  e i g a e. 
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Figure S3.57. 13C NMR e periments for the detection of the resting state 
 
Figure S3.58. 13C NMR spectrum of 3.25c, B(C6F5)3, and L10Sc(OTf)3 
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Catal tic C cle for the Enantioselective E-Amino CH Functionalization Involving 3.25c 
I  Fig e S3.59, e h  he ca a ic c c e  ha  a e c i e  i h he ab e- e i ed 
echa i ic i e iga i . The echa i ic die  e ea ed ha  he e i  1  c  
i h e ec   he c ce a i  f L10Sc(OTf)3 a d 3  c  i h e ec   he 
c ce a i  f 3.25c. The e e  gge  ha  he e i  a e i g a e c e  c i ed f 
[L10Sc(OTf)3], 3.25c and B(C6F5)3 (XXIX) hich a  e ified b  he 13C NMR die  (Fig e  
S3.57, S3.58). B(C6F5)3 e ea ed f  XXIX ab ac  a h d ide f  3.21r  f  a  i  ai  
c i i g f i i i  i  a d b h d ide (XXX). The   c  i h e ec   
he c ce a i  f B(C6F5)3 a d he ki e ic i e effec  die  gge  ha  he b h d ide 
ed c i  f (F5C6)3B-ac i a ed 3.25c i  he e - i i i g e  (XXX o XXXI). Af e  he 
a i  f e a e (XXXI o XXXII), c e hi ic e a i e ca  de g  e a i e ec i e 
CC b d f a i  i h [L10Sc(OTf)3]-ac i a ed 3.25c  f  i e i ic XXXIV. We 
e ha  3.21r c d e e a  H+/H- ce  ed ce XXXIV i  de   aff d he de i ed E-
a k a i  d c  3.26c.  
The e  f  he echa i ic i e iga i  i i g 3.25c a e i  i i a  e d i h he 
ed ca a ic c c e ha  a  ba ed  he echa i ic die  i i g a - b i ed 
e ec hi e 3.25g (Fig e S3.37). H e e , i  a  f d ha  he e - i i i g e  c d be 
diffe e  de e di g  he e ec hi e ha  i  ed. Whe  e h  e e - b i ed e ec hi e 3.25c 
i  i ed, he b h d ide ed c i  e  ( e - i i i g) bec e  i e e ib e a  he a ic 
CH bond of the boronen a e (b e H i  XXXI, Fig e S3.59) i   a  h d idic d e  he 
e ec  i hd a i g e e  i  (  he  b i e  i  3.25g). 
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Figure S3.59. P ed ca a ic c c e f  he e a i e ec i e E-amino CH functionalization 
i i g 3.25c 
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C8. Anal tical Data 
 
Diisoprop l 2-(2-(diben lamino)eth l)succinate (3.23a)  
N,N-Dibenzylethanamine 3.21a was reacted with diisopropyl fumarate 3.22a following the 
General Procedure C using B(C6F5)3 (10 mol%) as the Lewis acid catalyst and benzene (0.80 
mL) as the solvent. After purification by column chromatography (ethyl ether:hexanes = 1:19), 
3.23a was obtained as a colorless liquid (75 mg, 88%).  
 
1H NMR (600 MHz, CDCl3):  7.34 (d, J = 7.5 Hz, 4H), 7.29 (t, J = 7.5 Hz, 4H), 7.22 (t, J = 7.3 
Hz, 2H), 4.95 (dp, J = 26.6, 6.2 Hz, 2H), 3.61 (d, J = 13.6 Hz, 2H), 3.46 (d, J = 13.5 Hz, 2H), 2.88 
(dq, J = 12.4, 6.6 Hz, 1H), 2.51  2.39 (m, 3H), 2.16 (dd, J = 16.4, 5.1 Hz, 1H), 1.92 (dq, J = 14.4, 
7.3 Hz, 1H), 1.61 (h, J = 7.3 Hz, 1H), 1.20 (d, J = 6.3 Hz, 6H), 1.16 (d, J = 6.3 Hz, 3H), 1.12 (d, J 
= 6.3 Hz, 3H); 13C NMR (151 MHz, CDCl3):  174.3, 171.3, 139.5, 128.8, 128.2, 126.9, 67.78, 
67.77, 58.3, 50.5, 39.1, 35.9, 29.0, 21.81, 21.78, 21.69, 21.65; IR (neat):Q 2976, 2932, 2796, 
1724, 1452, 1372, 1260, 1168, 1104, 745, 698 cm-1; HRMS (ESI): Calcd for C26H36NO4 (MH+): 
426.2639; found: 426.2643. 
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Tetraisoprop l 5-(diben lamino)c clohe ane-1,2,3,4-tetracarbo late (3.24)  
The relative configuration was assigned based on NOESY.  
 
1H NMR (500 MHz, CDCl3):  7.34  7.27 (m, 8H), 7.22 (t, J = 6.6 Hz, 2H), 5.06 (hept, J = 6.4 
Hz, 1H), 5.02  4.89 (m, 3H), 3.89 (d, J = 13.6 Hz, 2H), 3.48 (d, J = 13.6 Hz, 2H), 3.38 (t, J = 8.3 
Hz, 1H), 3.30 (t, J = 8.3 Hz, 1H), 2.81  2.66 (m, 3H), 2.57 (dd, J = 16.7, 10.1 Hz, 1H), 2.44 (dd, 
J = 16.8, 3.6 Hz, 1H), 1.31 (d, J = 6.3 Hz, 3H), 1.27 (d, J = 6.2 Hz, 3H), 1.21 (td, J = 6.0, 3.7 Hz, 
12H), 1.16 (d, J = 6.2 Hz, 3H), 1.11 (d, J = 6.3 Hz, 3H); 13C NMR (126 MHz, CDCl3):  172.3, 
172.2, 172.1, 171.1, 139.1, 128.9, 128.4, 127.3, 68.4, 68.3, 67.9, 60.8, 54.8, 45.3, 42.3, 41.2, 39.4, 
34.2, 22.0, 21.91, 21.88, 21.87, 21.78, 21.76, 21.7; IR (neat):Q 2977, 2934, 1725, 1493, 1373, 
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Diisoprop l 2-(1-(diben lamino)propan-2- l)succinate (3.23b)  
N,N-Dibe a -1-a i e 3.21b a  eac ed i h dii  f a a e 3.22a f i g he 
General Procedure C i g B(C6F5)3 (10 %) a  he Le i  acid ca a  a d be e e (0.2 L) 
a  he e . 1H NMR a a i  f he ified d c  i e e ea ed ha  he dia e e e ic 
a i  a  1.3:1. Af e  ifica i  b  c  ch a g a h  (e h  e he :he a e  = 1:19), 3.23b 
a  b ai ed a  a i e f dia e e e  (51 g, 58%). 3.23c a  b ai ed a  a c e  i id 
(29 g, 33%). F he  ifica i  a  ca ied  b  PTLC i g e h  e he :DCM = 1:49 a  he 
e e   e a a e 3.23b-major a d 3.23b-minor. The e a i e c fig a i  f 3.21b-major a  
a ig ed i  a a g . 
 
3.23b-Major: 1H NMR (600 MHz, CDCl3)  7.35 (d, J = 7.1 Hz, 4H), 7.28 (t, J = 7.5 Hz, 4H), 
7.21 (t, J = 7.3 Hz, 2H), 4.99 (h, J = 6.3 Hz, 2H), 3.75 (d, J = 13.3 Hz, 2H), 3.34  3.26 (m, 3H), 
2.39  2.30 (m, 2H), 2.24 (dd, J = 12.8, 9.7 Hz, 1H), 2.14 (dd, J = 12.9, 6.0 Hz, 1H), 1.56 (dd, J = 
16.7, 3.2 Hz, 1H), 1.27  1.19 (m, 9H), 1.16 (d, J = 6.2 Hz, 3H), 0.73 (d, J = 6.9 Hz, 3H); 13C 
NMR (151 MHz, CDCl3)  174.5, 172.0, 139.5, 129.1, 128.2, 126.9, 67.6, 67.5, 58.7, 56.8, 42.1, 
32.1, 29.8, 21.9, 21.84, 21.83, 21.7, 13.9; IR (neat)Q 2976, 2930, 2799, 1723, 1452, 1372, 1232, 
1172, 1105, 745, 698 cm-1; HRMS (DART) Calcd for C27H38NO4 (MH+): 440.2795; found: 
440.2789.  
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3.21b-Minor: 1H NMR (600 MHz, CDCl3)  7.34 (d, J = 7.5 Hz, 4H), 7.29 (t, J = 7.5 Hz, 4H), 
7.22 (t, J = 7.2 Hz, 2H), 4.96 (dp, J = 22.6, 6.3 Hz, 1H), 3.71 (d, J = 13.6 Hz, 2H), 3.32 (d, J = 
13.6 Hz, 2H), 2.91 (dt, J = 10.7, 4.1 Hz, 1H), 2.62 (dd, J = 16.6, 10.7 Hz, 1H), 2.41 (dd, J = 12.7, 
5.8 Hz, 1H), 2.32 (dd, J = 12.7, 8.8 Hz, 1H), 2.15 (dd, J = 16.6, 4.3 Hz, 1H), 1.98 (ddp, J = 9.8, 
6.4, 3.7, 3.1 Hz, 1H), 1.21 (dd, J = 11.4, 6.2 Hz, 6H), 1.16 (d, J = 6.3 Hz, 3H), 1.06 (d, J = 6.3 Hz, 
3H), 0.88 (d, J = 6.9 Hz, 3H); 13C NMR (151 MHz, CDCl3)  173.1, 171.8, 139.5, 128.9, 128.1, 
126.8, 107.3, 67.8, 59.0, 58.7, 44.3, 34.2, 33.5, 21.82, 21.79, 21.76, 21.7, 15.2; HRMS (DART) 
Calcd for C27H38NO4 (MH+): 440.2795; found: 440.2780. 
 
 
Diisopropyl 3-(dibenzylamino)-4-methylcyclobutane-1,2-dicarboxylate (3.23c) 
 
1H NMR (600 MH , CDC 3)  7.33 (d, J = 7.6 H , 4H), 7.28 ( , J = 7.5 H , 4H), 7.21 ( , J = 7.3 
H , 2H), 5.00 (d , J = 16.7, 6.3 H , 2H), 3.79 (d, J = 14.0 H , 2H), 3.63 (d, J = 14.1 H , 2H), 3.30 
( , J = 8.7 H , 1H), 3.11 ( , J = 8.4 H , 1H), 2.51  2.36 ( , 2H), 1.27 (d, J = 6.2 H , 3H), 1.24 (d, 
J = 6.2 H , 3H), 1.21 ( , J = 6.1 H , 6H), 1.10 (d, J = 5.8 H , 3H); 13C NMR (151 MH , CDC 3) 
 172.7, 172.5, 139.6, 128.4, 128.2, 126.9, 67.91, 67.90, 64.2, 54.7, 43.0, 41.7, 37.3, 21.9, 21.81, 
21.78, 21.76, 18.7; IR ( ea )Q 2977, 2927, 1723, 1453, 1373, 1233, 1174, 1107, 746, 698 cm-1; 
HRMS (DART) Ca cd f  C27H36NO4 (MH+): 438.2639; f d: 438.2623. 
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Diisoprop l 3-(diben lamino)-4-isoprop lc clobutane-1,2-dicarbo late (3.23d) 
N,N-Dibenzyl-3-methylbutan-1-amine 3.21c was reacted with diisopropyl fumarate 3.22a 
following the General Procedure D using B(C6F5)3 (10 mol%) as the Lewis acid catalyst and 
benzene as the solvent. 1H NMR analysis of the unpurified product mixture revealed that the 
diastereomeric ratio was >20:1. After purification by column chromatography (ethyl ether:hexanes 
= 1:33), 3.23d was obtained as a colorless liquid (64 mg, 69%). The relative configuration was 
assigned based on NOESY experiments. 
 
1H NMR (600 MHz, CDCl3)  7.34 (d, J = 6.8 Hz, 4H), 7.29 (t, J = 7.6 Hz, 4H), 7.22 (t, J = 7.2 
Hz, 2H), 5.02 (dp, J = 32.2, 6.3 Hz, 2H), 3.92 (d, J = 13.6 Hz, 2H), 3.50 (d, J = 13.6 Hz, 2H), 3.34 
(t, J = 8.6 Hz, 1H), 3.26 (t, J = 8.7 Hz, 1H), 2.55 (t, J = 8.8 Hz, 1H), 2.28 (q, J = 8.7 Hz, 1H), 1.56 
 1.49 (m, 1H), 1.31 (d, J = 6.3 Hz, 3H), 1.25 (d, J = 6.2 Hz, 3H), 1.21 (dd, J = 9.3, 6.3 Hz, 6H), 
0.86 (d, J = 6.7 Hz, 3H), 0.78 (d, J = 6.7 Hz, 3H); 13C NMR (151 MHz, CDCl3)  173.4, 172.8, 
139.6, 128.8, 128.2, 126.9, 68.0, 67.9, 60.9, 54.7, 48.5, 41.0, 39.1, 32.7, 21.9, 21.82, 21.80, 21.6, 
20.2, 19.7; IR (neat)Q 2976, 2931, 1720, 1453, 1372, 1227, 1171, 1105, 747, 698 cm-1; HRMS 
(DART) Calcd for C29H40NO4 (MH+): 466.2952; found: 466.2941. 
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Diisoprop l 2-(2-(ben h dr lamino)eth l)succinate (3.23e)  
N-Benzhydrylethanamine 3.21d was reacted with diisopropyl fumarate 2.22a following the 
General Procedure D using 10 mol% B(C6F5)3 as the Lewis acid catalyst, benzene as the solvent. 
After purification by column chromatography (EtOAc:hexanes = 1:19) 3.23e was obtained as a 
colorless liquid (77 mg, 93%).  
 
1H NMR (500 MHz, CDCl3)  7.41  7.34 (m, 4H), 7.28 (td, J = 7.5, 1.5 Hz, 4H), 7.22  7.16 (m, 
2H), 4.98 (h, J = 6.3 Hz, 2H), 4.78 (s, 1H), 2.91 (ddt, J = 8.9, 7.5, 5.8 Hz, 1H), 2.68  2.55 (m, 
3H), 2.37 (dd, J = 16.4, 5.4 Hz, 1H), 1.91  1.80 (m, 1H), 1.77  1.66 (m, 1H), 1.22 (d, J = 2.5 Hz, 
3H), 1.20 (d, J = 2.5 Hz, 3H), 1.19 (d, J = 6.2 Hz, 3H), 1.14 (d, J = 6.2 Hz, 3H); 13C NMR (151 
MHz, CDCl3)  174.2, 171.3, 144.0, 144.0, 128.4, 127.2, 126.4, 67.9, 67.5, 45.4, 39.5, 36.4, 32.2, 
21.8, 21.74, 21.68, 21.6; IR (neat)Q 2977, 2933, 1727, 1452, 1373, 1265, 1173, 1105, 745, 703 
cm-1; HRMS (DART) Calcd for C25H34NO4 (MH+): 412.2482; found: 412.2478. 
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Diisoprop l 2-(1-(ben h dr lamino)propan-2- l)succinate (3.23f)  
N-Benzhydrylpropan-1-amine 3.21e was reacted with diisopropyl fumarate 2.22a following the 
General Procedure C using B(C6F5)3 (10 mol%) as the Lewis acid catalyst and benzene (0.2 mL) 
as the solvent. 1H NMR analysis of the unpurified product mixture revealed that the diastereomeric 
ratio was 1.1:1. After purification by column chromatography (EtOAc:hexanes = 1:19) 3.23f was 
obtained as a mixture of diastereomers (56 mg, 66%). Further purification was carried out by PTLC 
using ethyl ether:DCM = 1:49 as the eluent to separate 3.23f-major and 3.23f-minor. The relative 
configuration of 3.23f-major and 3.23f-minor was assigned in analogy. 
 
3.23f-Major: 1H NMR (600 MHz, CDCl3)  7.41  7.36 (m, 4H), 7.28 (q, J = 7.8 Hz, 4H), 7.22 
 7.17 (m, 2H), 5.00 (dq, J = 12.2, 6.2 Hz, 2H), 4.76 (s, 1H), 3.13 (ddd, J = 11.1, 4.7, 3.6 Hz, 1H), 
2.58 (dd, J = 16.6, 11.1 Hz, 1H), 2.49 (dd, J = 11.9, 6.6 Hz, 1H), 2.42 (dd, J = 11.9, 7.4 Hz, 1H), 
2.19 (dd, J = 16.6, 3.6 Hz, 1H), 2.13 (pd, J = 7.0, 4.6 Hz, 1H), 1.25  1.20 (m, 9H), 1.17 (d, J = 
6.2 Hz, 3H), 0.87 (d, J = 6.9 Hz, 3H); 13C NMR (151 MHz, CDCl3)  174.1, 172.0, 144.2, 144.0, 
128.5, 128.4, 127.3, 127.2, 127.0, 67.8, 67.6, 51.8, 43.6, 35.3, 31.5, 21.83, 21.80, 21.78, 21.7, 14.6; 
IR (neat)Q 2976, 2930, 1725, 1452, 1373, 1260, 1173, 1105, 745, 703 cm-1; HRMS (DART) 
Calcd for C26H36NO4 (MH+): 426.2639; found: 426.2638. 
 
3.23f-Minor: 1H NMR (500 MHz, CDCl3)  7.38 (d, J = 7.3 Hz, 4H), 7.31  7.26 (m, 4H), 7.22 
 7.16 (m, 2H), 4.98 (pd, J = 6.3, 2.4 Hz, 2H), 4.75 (s, 1H), 2.97 (dt, J = 10.6, 4.3 Hz, 1H), 2.71 
(dd, J = 16.6, 10.7 Hz, 1H), 2.57 (dd, J = 12.0, 7.0 Hz, 1H), 2.45 (dd, J = 12.0, 6.7 Hz, 1H), 2.27 
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(dd, J = 16.5, 4.2 Hz, 1H), 2.00 (qd, J = 7.0, 4.6 Hz, 1H), 1.22 (t, J = 6.2 Hz, 6H), 1.19 (d, J = 6.3 
Hz, 3H), 1.13 (d, J = 6.3 Hz, 3H), 0.93 (d, J = 7.0 Hz, 3H); 13C NMR (126 MHz, CDCl3)  173.3, 
171.9, 144.2, 144.1, 128.43, 128.41, 127.3, 127.2, 126.96, 126.95, 67.8, 67.7, 51.9, 44.0, 35.8, 
34.0, 21.82, 21.81, 21.77, 21.7, 15.5; HRMS (DART) Calcd for C26H36NO4 (MH+): 426.2639; 
found: 426.2626. 
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Diisoprop l 2-(2-(ben h dr lamino)-1-phen leth l)succinate (3.23g)  
N-Benzhydryl-2-phenylethan-1-amine 3.21f was reacted with diisopropyl fumarate 2.22a 
following the General Procedure C using B(C6F5)3 (10 mol%) as the Lewis acid catalyst and 
benzene (0.2 mL) as the solvent. 1H NMR analysis of the unpurified product mixture revealed that 
the diastereomeric ratio was 2.1:1.  After purification by column chromatography (EtOAc:hexanes 
= 1:19), 3.23g was obtained as a mixture of diastereomers (85 mg, 87%). Further purification was 
carried out by PTLC using ethyl ether:DCM = 1:49 as the eluent to separate 3.23g-major and 
3.23g-minor. The relative configuration of 3.23g-major and 3.23g-minor was assigned in 
analogy. 
 
3.23g-Major: 1H NMR (600 MHz, CDCl3)  7.30 ( , J = 7.4 Hz, 2H), 7.27 (d, J = 8.0 Hz, 2H), 
7.25  7.19 (m, 6H), 7.19  7.12 (m, 4H), 4.89 (dhept, J = 12.5, 6.2 Hz, 2H), 4.71 (s, 1H), 3.06 
(qd, J = 9.5, 8.5, 3.9 Hz, 2H), 2.87 (dd, J = 12.0, 8.5 Hz, 1H), 2.81 (dd, J = 12.0, 4.6 Hz, 1H), 2.47 
(dd, J = 16.8, 10.7 Hz, 1H), 2.08 (dd, J = 16.7, 2.9 Hz, 1H), 1.15 (d, J = 6.2 Hz, 3H), 1.13 (d, J = 
6.3 Hz, 6H), 1.04 (d, J = 6.3 Hz, 3H); 13C NMR (151 MHz, CDCl3)  173.6, 171.3, 144.0, 143.8, 
140.1, 128.8, 128.40, 128.35, 127.3, 127.18, 127.16, 126.94, 126.88, 68.1, 67.9, 67.2, 50.9, 48.1, 
45.5, 35.3, 21.8, 21.69, 21.66, 21.5; IR (neat)Q 2976, 2931, 1725, 1451, 1372, 1263, 1170, 1105, 
745, 700 cm-1; HRMS (DART) Calcd for C31H38NO4 (MH+): 488.2795; found: 488.2772. 
 
3.23g-Minor: 1H NMR (600 MHz, CDCl3)  7.30 (d, J = 7.1 Hz, 2H), 7.29  7.19 (m, 9H), 7.19 
 7.13 (m, 4H), 4.93 (p, J = 6.2 Hz, 1H), 4.79 (p, J = 6.3 Hz, 1H), 4.74 (s, 1H), 3.21  3.10 (m, 
 624  
2H), 2.95  2.85 (m, 2H), 2.60 (dd, J = 16.6, 10.4 Hz, 1H), 2.33 (dd, J = 16.6, 3.8 Hz, 1H), 1.18 
(t, J = 6.9 Hz, 6H), 1.08 (d, J = 6.2 Hz, 3H), 0.91 (d, J = 6.2 Hz, 3H); 13C NMR (151 MHz, CDCl3) 
 172.8, 171.4, 143.9, 140.0, 128.6, 128.43, 128.40, 127.3, 127.2, 127.1, 127.0, 126.9, 67.92, 
67.88, 67.4, 49.5, 47.7, 45.5, 34.4, 21.8, 21.7, 21.6, 21.3; HRMS (DART) Calcd for C31H38NO4 
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Dibenzyl 2-(2-(bis((R)-1-phenylethyl)amino)ethyl)succinate (3.23h)  
(R)-N-Ethyl-1-phenyl-N-((R)-1-phenylethyl)ethan-1-amine 3.21g was reacted with dibenzyl 
fumarate 3.22b following the General Procedure C using B(C6F5)3 (10 mol%) as the Lewis acid 
catalyst and benzene (0.80 mL) as the solvent. 1H NMR analysis of the unpurified product mixture 
revealed that the diastereomeric ratio was 1.4:1. After purification by column chromatography 
(ethyl ether:hexanes = 1:9), 3.23h was obtained as a mixture of diastereomers (99 mg, 90% yield). 
Further purification was carried out by PTLC using ethyl ether:DCM = 1:49 as the eluent to 
separate 3.23h-(R,R,R) and 3.23h-(R,R,S). The absolute configuration of product 3.23h-(R,R,R) 
and 3.23h-(R,R,S) was assigned in analogy to a previously synthesized molecule.16 
 
3.23h-(R,R,R). 1H NMR (500 MHz, CDCl3):  7.37  7.21 (m, 18H), 7.20  7.14 (m, 2H), 5.03 
(d, J = 12.4 Hz, 1H), 4.98 (d, J = 12.4 Hz, 1H), 4.94 (s, 2H), 3.93 (q, J = 6.8 Hz, 2H), 2.70  2.49 
(m, 3H), 2.40 (ddd, J = 14.0, 10.5, 5.3 Hz, 1H), 2.19 (dd, J = 16.5, 4.9 Hz, 1H), 1.62  1.47 (m, 
1H), 1.31 (d, J = 6.8 Hz, 6H), 1.28  1.15 (m, 1H); 13C NMR (126 MHz, CDCl3):  174.3, 171.5, 
144.9, 135.9, 135.7, 128.5, 128.4, 128.2, 128.1, 128.0, 127.8, 126.6, 66.33, 66.29, 57.9, 44.0, 39.2, 
36.0, 33.1, 18.2; IR (neat):Q 3027, 2965, 1729, 1492, 1452, 1258, 1211, 1150, 971, 736, 696 cm-
1; HRMS (DART): Calcd for C36H40NO4 (MH+): 550.2952; found: 550.2951; Specific Rotation 
[ ]25D = 3.1° (c = 0.9, EtOH). 
 
 626  
3.23h-(R,R,S). 1H NMR (600 MHz, CDCl3):  7.37  7.25 (m, 14H), 7.23 (t, J = 7.5 Hz, 4H), 
7.14 (t, J = 7.2 Hz, 2H), 5.04  4.93 (m, 4H), 3.95 (q, J = 7.1 Hz, 2H), 2.75 (dq, J = 11.4, 6.1 Hz, 
1H), 2.59 (ddd, J = 14.2, 8.8, 5.1 Hz, 1H), 2.44  2.33 (m, 2H), 1.88 (dd, J = 16.8, 4.7 Hz, 1H), 
1.57  1.49 (m, 1H), 1.33 (d, J = 6.9 Hz, 6H), 1.30  1.27 (m, 1H); 13C NMR (126 MHz, CDCl3): 
 174.8, 171.6, 144.8, 135.9, 135.8, 128.5, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 126.6, 66.3, 
57.3, 43.0, 38.6, 35.1, 32.3, 17.3; HRMS (DART): Calcd for C36H40NO4 (MH+): 550.2952; found: 
550.2967. 
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Diisoprop l 2-(1-ben l-4-((( e -but ldimeth lsil l)o )meth l)piperidin-3- l)succinate 
(3.23i)  
1-Benzyl-4-(((tert-butyldimethylsilyl)oxy)methyl)piperidine 3.21h was reacted with diisopropyl 
fumarate 2.22a following the General Procedure C using B(C6F5)3 (10 mol%) as the Lewis acid 
catalyst and benzene (0.2 mL) as the solvent. 1H NMR analysis of the unpurified product mixture 
revealed that the diastereomeric ratio was 1.1:1. After purification by column chromatography 
(ethyl ether:hexanes = 1:4), 3.23i was obtained as a mixture of diastereomers (77.0 mg, 74%). 
Further purification was carried out by PTLC using ethyl ether:DCM = 1:6 as the eluent to separate 
3. 23i-major and 3. 23i-minor. The relative configuration for 3. 23i-major and 3. 23i-minor were 
assigned based on X-ray crystallography data. 
 
3.23i-Major: 1H NMR (600 MHz, CDCl3)  7.27 (d , J = 22.0, 7.5 Hz, 5H), 4.98 (dp, J = 16.3, 
6.4 Hz, 2H), 3.71 (dd, J = 10.0, 2.6 Hz, 1H), 3.65 (dd, J = 10.1, 5.1 Hz, 1H), 3.52 (d, J = 13.4 Hz, 
1H), 3.41 (d, J = 13.4 Hz, 1H), 3.09 (dt, J = 11.2, 3.4 Hz, 1H), 2.82 (tt, J = 16.1, 10.8 Hz, 3H), 
2.22 (dd, J = 16.7, 3.7 Hz, 1H), 1.85 (t, J = 11.2 Hz, 1H), 1.82  1.77 (m, 1H), 1.76  1.63 (m, 
2H), 1.46 (pt, J = 11.9, 6.7 Hz, 2H), 1.21 (dt, J = 12.1, 6.0 Hz, 12H), 0.87 (d, J = 3.2 Hz, 9H), 0.03 
(d, J = 2.9 Hz, 6H); 13C NMR (151 MHz, CDCl3)  172.7, 171.6, 138.2, 129.1, 129.0, 128.2, 
128.1, 126.9, 67.91, 67.86, 64.6, 63.3, 55.4, 53.3, 40.7, 40.4, 40.0, 35.3, 29.3, 26.0, 25.9, 21.9, 
21.82, 21.80, 21.75, 18.3, -5.4, -5.5; IR (neat)Q 2950, 2854, 1727, 1466, 1372, 1254, 1173, 1104, 
834, 775 cm-1; HRMS (DART) Calcd for C29H50NO5Si (MH+): 520.3453; found: 520.3454. 
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3.23i-Minor: 1H NMR (500 MH , CDC 3)  7.31  7.23 ( , 4H), 7.23  7.17 ( , 1H), 5.03  4.93 
( , 1H), 4.93  4.84 ( , 1H), 3.61 (dd, J = 10.3, 4.1 H , 1H), 3.55 ( , J = 5.2 H , 1H), 3.50 (d, J 
= 13.2 H , 1H), 3.36 (d, J = 13.2 H , 1H), 3.19 (d , J = 12.2, 3.6 H , 1H), 2.86 (d, J = 11.2 H , 
1H), 2.67  2.50 ( , 2H), 2.35  2.24 ( , 1H), 2.09 (d, J = 11.0 H , 1H), 1.95 ( , J = 11.5 H , 1H), 
1.70 (dd, J = 21.8, 11.1 H , 3H), 1.54 ( , J = 14.2, 7.1 H , 1H), 1.33 (d , J = 11.0, 5.3 H , 1H), 
1.20 (dd, J = 10.0, 6.3 H , 6H), 1.13 (d, J = 6.3 H , 3H), 1.03 (d, J = 6.3 H , 3H), 0.89 ( , 9H), 
0.04 (d, J = 5.8 H , 6H); 13C NMR (151 MH , CDC 3)  173.7, 172.0, 138.3, 129.0, 128.1, 126.9, 
125.5, 67.9, 67.8, 65.0, 63.3, 54.4, 53.9, 41.3, 39.8, 39.3, 31.0, 29.0, 25.95, 25.94, 21.8, 21.74, 
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Diisoprop l 2-(1-ben l-4-((( e -but ldimeth lsil l)o )meth l)-1,4,5,6-tetrah drop ridin-
3- l)succinate (3.23j)  
1H NMR analysis of the unpurified product mixture revealed that the diastereomeric ratio of 3.23j 
was 1.4:1. After purification by column chromatography (ethyl ether:hexanes = 1:9), 3.23j was 
obtained as a mixture of diastereomers (26.9 mg, 26%). Further purification was carried out by 
PTLC using ethyl ether:DCM = 1:49 as the eluent to separate 3.23j-major and 3.23j-minor. The 
relative configuration of 3.23j-major and 3.23j-minor was assigned in analogy. 
 
3.23j-Major: 1H NMR (600 MHz, CDCl3)  7.29 ( , J = 7.4 Hz, 2H), 7.27  7.21 (m, 1H), 7.19 
(d, J = 7.5 Hz, 2H), 6.06 (s, 1H), 5.05  4.90 (m, 2H), 4.08  3.89 (m, 2H), 3.57 (dd, J = 10.1, 4.3 
Hz, 1H), 3.29 (dd, J = 10.0, 5.7 Hz, 1H), 3.21 (t, J = 9.9 Hz, 1H), 2.87 (dd, J = 16.4, 10.1 Hz, 1H), 
2.79  2.64 (m, 2H), 2.45 (dd, J = 16.3, 5.7 Hz, 1H), 2.37 (d, J = 7.8 Hz, 1H), 1.95 (dt, J = 13.4, 
2.8 Hz, 1H), 1.65  1.46 (m, 1H), 1.32  1.11 (m, 12H), 0.86 (s, 9H), 0.06  -0.08 (m, 6H); 13C 
NMR (151 MHz, CDCl3)  173.8, 171.6, 138.4, 135.5, 128.3, 127.8, 127.1, 102.6, 67.73, 67.66, 
65.0, 59.3, 44.3, 41.8, 36.4, 36.3, 26.0, 25.94, 25.90, 23.2, 21.84, 21.82, 21.77, 21.75, 21.7, 18.3, 
-5.2, -5.4; IR (neat)Q 2950, 2854, 1726, 1676, 1466, 1372, 1256, 1172, 1143, 1105, 836 cm-1; 
HRMS (DART) Calcd for C29H48NO5Si (MH+): 518.3296; found: 518.3284. 
 
3.23j-Minor: 1H NMR (500 MH , CDC 3)  7.35  7.20 ( , 3H), 7.20  7.14 ( , 2H), 6.09 ( , 
1H), 5.05  4.88 ( , 2H), 3.99 (d, J = 3.7 H , 2H), 3.78 (dd, J = 10.4, 4.0 H , 1H), 3.26 (dd, J = 
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10.0, 5.5 H , 1H), 3.19 ( , J = 10.1 H , 1H), 2.87  2.74 ( , 2H), 2.74  2.62 ( , 1H), 2.48 (dd, J 
= 16.5, 5.5 H , 1H), 2.22  2.08 ( , 1H), 1.99 (dd, J = 13.6, 2.9 H , 1H), 1.67  1.59 ( , 1H), 1.27 
 1.16 ( , 12H), 0.88 ( , 9H), 0.03 (d, J = 8.5 H , 6H); 13C NMR (151 MH , CDC 3)  173.4, 
171.6, 138.3, 135.5, 128.3, 127.8, 127.1, 103.0, 67.7, 67.6, 65.3, 59.3, 45.0, 41.6, 38.5, 37.6, 26.0, 
23.2, 21.9, 21.8, 21.6, 18.3, -5.2, -5.4; HRMS (DART) Ca cd f  C29H48NO5Si (MH+): 518.3296; 
f d: 518.3283. 
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Diisopropyl 2-(1-benzyl-4-((dibenzylamino)methyl)piperidin-3-yl)succinate (3.23k)  
N,N-Dibenzyl-1-(1-benzylpiperidin-4-yl)methanamine 3.21i was reacted with diisopropyl 
fumarate 3.22a following the General Procedure A using B(C6F5)3 (10 mol%) as the Lewis acid 
catalyst and benzene (0.2 mL) as the solvent. 1H NMR analysis of the unpurified product mixture 
revealed that the diastereomeric ratio was 1.8:1. After purification by column chromatography 
(ethyl ether:hexanes = 1:4), 3.23k was obtained as a mixture of diastereomers (59.6 mg, 51%). 
Further purification was carried out by PTLC using ethyl ether:DCM = 3:7 as the eluent to separate 
3.23k-major and 3.23k-minor. The relative configuration of 3.23k-major and 3.23k-minor was 
assigned in analogy. 
 
3.23k-Major: 1H NMR (600 MHz, CDCl3)  7.42  7.32 (m, 5H), 7.32  7.25 (m, 5H), 7.25  
7.17 (m, 5H), 5.09  4.90 (m, 2H), 3.72 (d, J = 13.5 Hz, 2H), 3.46 (d, J = 13.1 Hz, 1H), 3.44  
3.39 (m, 1H), 3.36 (d, J = 13.1 Hz, 1H), 3.31 (d, J = 13.6 Hz, 2H), 2.77 (d, J = 4.3 Hz, 3H), 2.67 
 2.59 (m, 1H), 2.16 (d, J = 9.5 Hz, 1H), 2.11 (dd, J = 16.5, 4.2 Hz, 2H), 1.87  1.72 (m, 2H), 1.67 
(t, J = 11.1 Hz, 1H), 1.52  1.44 (m, 1H), 1.22 (dd, J = 6.1, 1.5 Hz, 6H), 1.18 (dd, J = 13.0, 6.3 Hz, 
6H), 1.05 (d, J = 10.5 Hz, 1H); 13C NMR (151 MHz, CDCl3)  172.9, 171.7, 139.7, 138.1, 129.2, 
128.8, 128.8, 128.2, 128.13, 128.10, 127.0, 126.8, 68.0, 67.9, 63.4, 59.0, 57.6, 55.8, 53.3, 42.9, 
40.6, 35.1, 35.0, 30.4, 21.91, 21.85, 21.82, 21.78; IR (neat)Q 2976, 2933, 2789, 1724, 1493, 1409, 
1314, 1225, 1144, 745, 698 cm-1; HRMS (DART) Calcd for C37H49N2O4 (MH+): 585.3687; found: 
585.3668. 
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3.23k-Minor: 1H NMR (500 MHz, CDCl3)  7.34 ( , J = 4.1 Hz, 4H), 7.32  7.27 (m, 4H), 7.27 
 7.15 (m, 7H), 5.09  4.94 (m, 1H), 4.90  4.76 (m, 1H), 3.64 (d, J = 13.4 Hz, 2H), 3.45  3.33 
(m, 3H), 3.28 (d, J = 13.0 Hz, 1H), 3.23  3.11 (m, 1H), 2.73  2.60 (m, 1H), 2.58  2.45 (m, 2H), 
2.31 (d, J = 11.3 Hz, 1H), 2.25 (td, J = 10.9, 9.4, 2.5 Hz, 1H), 2.14 (ddt, J = 20.0, 16.7, 3.5 Hz, 
2H), 1.93 (t, J = 11.1 Hz, 1H), 1.79 (dt, J = 9.8, 4.5 Hz, 1H), 1.69 (q, J = 10.8, 10.1 Hz, 2H), 1.43 
(d, J = 10.0 Hz, 1H), 1.24 (dd, J = 6.4, 2.3 Hz, 6H), 1.10 (dt, J = 6.2, 1.9 Hz, 3H), 1.01  0.93 (m, 
3H); 13C NMR (126 MHz, CDCl3)  173.8, 172.0, 139.5, 138.4, 129.0, 128.9, 128.8, 128.2, 128.1, 
126.9, 68.0, 67.8, 63.3, 59.3, 56.9, 53.7, 53.6, 41.3, 40.8, 34.9, 31.3, 29.5, 21.9, 21.8, 21.7, 21.5 
HRMS (DART) Calcd for C37H49N2O4 (MH+): 585.3687; found: 585.3655. 
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Diisopropyl 2-(1-benzyl-4-((dibenzylamino)methyl)-1,4,5,6-tetrahydropyridin-3-
yl)succinate (3.23l)  
1H NMR analysis of the unpurified product mixture revealed that the diastereomeric ratio of 3.23l 
was 1.7:1. After purification by column chromatography (ethyl ether:hexanes = 1:9), 3.23l was 
obtained as a mixture of diastereomers (54.8 mg, 47%). Further purification was carried out by 
PTLC using ethyl ether:DCM = 1:50 as the eluent to separate 3.23l-major and 3.23l-minor. The 
relative configuration of 3.23l-major and 3.23l-minor was assigned in analogy. 
 
3.23l-Major: 1H NMR (500 MHz, CDCl3)  7.37  7.21 (m, 10H), 7.18 (t, J = 7.3 Hz, 3H), 7.07 
(d, J = 7.2 Hz, 2H), 5.93 (s, 1H), 4.98 (dt, J = 12.6, 6.4 Hz, 2H), 3.85 (s, 2H), 3.83 (d, J = 13.3 Hz, 
2H), 3.35  3.26 (m, 1H), 3.20 (d, J = 13.4 Hz, 2H), 2.85 (dd, J = 16.4, 10.3 Hz, 1H), 2.45 (t, J = 
12.3 Hz, 2H), 2.37 (dd, J = 16.4, 5.6 Hz, 1H), 2.32  2.21 (m, 1H), 2.12 (t, J = 11.9 Hz, 1H), 2.07 
 1.87 (m, 2H), 1.49 (t, J = 4.9 Hz, 1H), 1.21 (d, J = 6.3 Hz, 9H), 1.17 (d, J = 6.3 Hz, 3H); 13C 
NMR (126 MHz, CDCl3)  173.7, 171.6, 139.9, 138.4, 134.7, 129.0, 128.3, 128.1, 127.7, 127.0, 
126.7, 104.1, 67.74, 67.66, 59.2, 58.9, 56.7, 44.2, 41.3, 36.1, 31.4, 30.3, 29.7, 24.0, 21.9, 21.84, 
21.82, 21.7; IR (neat)Q 2975, 2927, 1724, 1647, 1493, 1320, 1295, 1144, 1074, 749, 698 cm-1; 
HRMS (DART) Calcd for C37H47N2O4 (MH+): 583.3530; found: 585.3540. 
 
3.23l-Minor: 1H NMR (400 MHz, CDCl3)  7.38  7.21 (m, 10H), 7.21  7.13 (m, 3H), 7.11  
7.00 (m, 2H), 5.97 (s, 1H), 5.07  4.88 (m, 2H), 3.92  3.76 (m, 4H), 3.26  3.10 (m, 3H), 2.90  
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2.75 (m, 1H), 2.53  2.40 (m, 2H), 2.40  2.33 (m, 1H), 2.29  2.11 (m, 2H), 2.11  2.02 (m, 1H), 
2.02  1.91 (m, 1H), 1.45 (t, J = 13.1 Hz, 1H), 1.32  1.18 (m, 12H); 13C NMR (151 MHz, CDCl3) 
 173.4, 171.7, 139.9, 138.4, 134.8, 129.0, 128.2, 128.1, 127.7, 126.9, 126.7, 104.3, 67.7, 67.5, 
59.1, 59.1, 57.2, 45.2, 41.1, 38.5, 32.4, 23.9, 21.9, 21.8, 21.7, 21.6; HRMS (DART) Calcd for 
C37H47N2O4 (MH+): 583.3530; found: 585.3528. 
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Diisoprop l 2-((4R)-1-ben l-4-phen lp rrolidin-3- l)succinate (3.23m)  
(R)-1-Benzyl-3-phenylpyrrolidine 3.21j was reacted with diisopropyl fumarate 2.22a following 
the General Procedure C using B(C6F5)3 (10 mol%) as the Lewis acid catalyst and benzene (0.2 
mL) as the solvent. 1H NMR analysis of the unpurified product mixture revealed that the 
diastereomeric ratio was 1.6:1. After purification by column chromatography (ethyl ether:hexanes 
= 1:4), 3.23m was obtained as a mixture of diastereomers (78.7 mg, 90%). Further purification 
was carried out by PTLC using ethyl ether:DCM:hexanes = 2:8:3 as the eluent to separate 3.23m-
(R,R,R) and 3.23m-minor. The absolute configuration of 3.23m-(R,R,R) was assigned based on 
analogy to 3.23m-(R,R,R) and by NOESY experiments. 
 
3.23m-(R,R,R): 1H NMR (500 MHz, CDCl3)  7.29 (dd , J = 19.6, 15.2, 4.7 Hz, 8H), 7.23 (d, J = 
6.9 Hz, 1H), 7.18 (d, J = 6.9 Hz, 1H), 4.99  4.82 (m, 2H), 3.64 (d, J = 12.9 Hz, 1H), 3.57 (d, J = 
12.9 Hz, 1H), 3.17  3.10 (m, 1H), 2.96  2.88 (m, 2H), 2.85 (t, J = 8.6 Hz, 1H), 2.70  2.61 (m, 
1H), 2.61  2.55 (m, 2H), 2.55  2.48 (m, 1H), 2.40 (dd, J = 16.8, 3.9 Hz, 1H), 1.21  1.14 (m, 
9H), 1.02 (d, J = 6.3 Hz, 3H); 13C NMR (151 MHz, CDCl3)  173.0, 171.5, 145.0, 139.0, 128.6, 
128.5, 128.2, 127.7, 126.9, 126.3, 68.0, 67.9, 63.3, 60.2, 58.1, 48.7, 47.7, 44.7, 34.9, 21.78, 21.75, 
21.7, 21.5; IR (neat)Q 2975, 2932, 2788, 1725, 1492, 1372, 1261, 1173, 1144, 1105, 754, 699 cm-
1; [ ]25D = ° (c = 0.9, EtOH);  HRMS (DART) Calcd for C27H36NO4 (MH+): 438. 2639; found: 
438.2627. 
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3.23m-Minor: 1H NMR (500 MHz, CDCl3)  7.35  7.22 (m, 8H), 7.17 (q, J = 7.0 Hz, 2H), 4.99 
 4.91 (m, 1H), 4.82  4.70 (m, 1H), 3.61 (d, J = 7.9 Hz, 2H), 3.17 (t, J = 7.0 Hz, 1H), 2.88 (dq, J 
= 24.7, 8.0, 7.6 Hz, 3H), 2.69  2.53 (m, 3H), 2.47 (t, J = 8.1 Hz, 1H), 2.37 (dd, J = 16.9, 3.9 Hz, 
1H), 1.21  1.16 (m, 6H), 1.12 (d, J = 6.3 Hz, 3H), 0.95 (d, J = 6.3 Hz, 3H); HRMS (DART) Calcd 
for C27H36NO4 (MH+): 438. 2639; found: 438.2639. 
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Diisoprop l 2-((5R)-1-ben l-5-((( e -but ldimeth lsil l)o )diphen lmeth l)p rrolidin -3-
l)succinate (3.23n)  
(R)-1-Benzyl-2-(((tert-butyldimethylsilyl)oxy)diphenylmethyl)pyrrolidine 3.21k was reacted with 
diisopropyl fumarate 2.22a following the General Procedure C using B(C6F5)3 (10 mol%) as the 
Lewis acid catalyst and benzene (0.2 mL) as the solvent. 1H NMR analysis of the unpurified 
product mixture revealed that the diastereomeric ratio was 2.5:1. After purification by column 
chromatography (ethyl ether:hexanes = 1:9) 3.23n was obtained as a mixture of diastereomers (74 
mg, 56%). Further purification was carried out by PTLC using ethyl ether:DCM = 1:49 as the 
eluent to separate 3.23n-(R,R,R) and 3.23n-minor. The absolute configuration of 3.23n-(R,R,R) 
was assigned based on X-ray crystallography data. 
 
3.23n-(R,R,R): 1H NMR (600 MHz, CDCl3)  7.60 ( , 2H), 7.55 (d, J = 7.3 Hz, 2H), 7.35  7.26 
(m, 6H), 7.19 (t, J = 7.4 Hz, 2H), 7.14 (t, J = 7.2 Hz, 1H), 7.04 (d, J = 7.4 Hz, 2H), 4.90 (p, J = 6.2 
Hz, 1H), 4.78 (p, J = 5.9 Hz, 1H), 4.41 (br, 1H), 4.01 (d, J = 10.1 Hz, 1H), 3.35 (d, J = 12.8 Hz, 
1H), 2.46 (t, J = 7.8 Hz, 1H), 2.39  2.28 (m, 2H), 2.13 (d, J = 14.4 Hz, 1H), 1.98 (t, J = 10.1 Hz, 
2H), 1.66 (q, J = 11.6 Hz, 2H), 1.15 (t, J = 5.8 Hz, 6H), 1.08 (d, J = 6.4 Hz, 3H), 0.94 (d, J = 6.3 
Hz, 3H), 0.88 (s, 9H), -0.41 (s, 3H), -0.45 (s, 3H); 13C NMR (151 MHz, CDCl3)  173.1, 171.3, 
143.4, 140.3, 130.1, 129.9, 128.4, 128.0, 127.4, 127.2, 127.1, 126.4, 70.6, 67.9, 67.5, 61.8, 59.1, 
45.0, 38.3, 35.4, 26.3, 21.8, 21.70, 21.67, 21.4, 19.0, -2.9, -3.0; IR (neat)Q 2975, 2927, 2853, 
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1727, 1372, 1254, 1173, 1105, 1060, 833, 774, 702 cm-1; [ ]25D = 43.1 ° (c = 0.7, EtOH); HRMS 
(DART) Calcd for C40H56NO5Si (MH+): 658.3922; found: 658.3905. 
 
3.23n-Minor: 1H NMR (600 MHz, CDCl3)  7.63  7.56 (m, 2H), 7.54 (d, J = 6.3 Hz, 2H), 7.37 
 7.27 (m, 6H), 7.22 (t, J = 7.5 Hz, 2H), 7.16 (t, J = 7.4 Hz, 1H), 7.05 (d, J = 7.6 Hz, 2H), 4.90 (p, 
J = 6.3 Hz, 1H), 4.85 (p, J = 6.3 Hz, 1H), 4.45 (br, 1H), 4.05 (dd, J = 10.2, 2.6 Hz, 1H), 3.36 (d, J 
= 13.1 Hz, 1H), 2.58 (dd, J = 8.8, 6.4 Hz, 1H), 2.35  2.25 (m, 2H), 2.10 (s, 1H), 2.00  1.89 (m, 
2H), 1.89  1.80 (m, 2H), 1.19 (d, J = 6.2 Hz, 3H), 1.15 (d, J = 6.3 Hz, 3H), 1.11 (d, J = 6.2 Hz, 
3H), 1.09 (d, J = 6.2 Hz, 3H), 0.87 (s, 9H), -0.42 (s, 3H), -0.46 (s, 3H); 13C NMR (151 MHz, 
CDCl3)  173.1, 171.2, 143.5, 140.4, 130.0, 129.9, 128.2, 128.1, 127.4, 127.2, 127.1, 126.7, 126.4, 
70.8, 67.8, 67.7, 61.8, 59.5, 45.4, 38.4, 35.8, 33.5, 26.3, 21.8, 21.74, 21.70, 21.6, 18.9, -2.9, -3.0; 
HRMS (DART) Calcd for C40H56NO5Si (MH+): 658.39223; found: 658.38954. 
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Diisoprop l 2-(1-(4-metho -2,6-dimeth lphen l)piperidin-3- l)succinate (3.23o)  
1-(4-Methoxy-2,6-dimethylphenyl)piperidine 3.21l was reacted with diisopropyl fumarate 2.22a 
following the General Procedure C using B(C6F5)3 (5.0 mol%) as the Lewis acid catalyst and 
benzene (0.8 mL) as the solvent. 1H NMR analysis of the unpurified product mixture revealed that 
the diastereomeric ratio was 1.3:1. After purification by column chromatography (ethyl 
ether:hexanes = 1:19) 3.23o was obtained as a mixture of diastereomers (75 mg, 89%). Further 
purification was carried out by PTLC using ethyl ether:DCM = 1:49 as the eluent to separate 3.23o-
major and 3.23o-minor. The relative configuration of 3.23o-major and 3.23o-minor was 
assigned in analogy. 
 
3.23o-Major: 1H NMR (600 MHz, CDCl3)  6.57 (d, J = 3.0 Hz, 1H), 6.46 (d, J = 3.1 Hz, 1H), 
5.04 (hept, J = 5.9 Hz, 1H), 4.96 (hept, J = 12.6, 6.3 Hz, 1H), 3.74 (s, 3H), 3.02 (td, J = 11.2, 2.9 
Hz, 1H), 2.90 (d, J = 7.0 Hz, 2H), 2.85 (dt, J = 11.8, 3.8 Hz, 1H), 2.77  2.63 (m, 2H), 2.44  2.37 
(m, 1H), 2.26 (s, 3H), 2.24 (s, 3H), 1.96  1.85 (m, 1H), 1.78 (dt, J = 13.0, 3.9 Hz, 1H), 1.72 (dt, 
J = 12.7, 3.5 Hz, 1H), 1.68  1.55 (m, 2H), 1.25 (t, J = 6.2 Hz, 6H), 1.19 (dd, J = 7.6, 6.2 Hz, 6H); 
13C NMR (126 MHz, CDCl3)  173.7, 171.6, 156.3, 142.4, 138.7, 137.9, 114.0, 113.3, 67.9, 67.8, 
55.2, 54.6, 50.7, 44.9, 39.5, 34.5, 28.5, 26.5, 21.9, 21.8, 21.7, 19.9, 19.5; IR (neat)Q 2976, 2932, 
1727, 1485, 1372, 1220, 1173, 1156, 1106, 1067 cm-1; HRMS (DART) Calcd for C24H38NO5 
(MH+): 420.2745; found: 420.2741. 
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3.23o-Minor: 1H NMR (600 MHz, CDCl3)  6.56 (d, J = 3.0 Hz, 1H), 6.45 (d, J = 3.1 Hz, 1H), 
4.99 (dq, J = 11.8, 6.1 Hz, 2H), 3.74 (s, 3H), 3.02 (td, J = 11.2, 2.6 Hz, 1H), 2.93  2.86 (m, 2H), 
2.84 (dt, J = 11.9, 3.9 Hz, 1H), 2.76  2.64 (m, 2H), 2.46 (dd, J = 15.7, 3.4 Hz, 1H), 2.26 (s, 3H), 
2.24 (s, 3H), 1.92 (dq, J = 11.6, 6.2 Hz, 1H), 1.84 (dd, J = 13.1, 3.7 Hz, 1H), 1.73  1.56 (m, 3H), 
1.25 (t, J = 7.0 Hz, 1H), 1.21 (dd, J = 6.2, 2.6 Hz, 9H), 1.17 (d, J = 6.5 Hz, 3H); 13C NMR (151 
MHz, CDCl3)  173.4, 171.7, 156.2, 142.5, 138.7, 137.7, 114.0, 113.2, 67.9, 67.8, 55.2, 54.7, 50.8, 
45.0, 39.5, 34.5, 28.6, 26.6, 21.81, 21.80, 21.76, 20.0, 19.5; HRMS (DART) Calcd for C24H38NO5 
(MH+): 420.2745; found: 420.2734. 
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Diisoprop l 2-(1-(4-metho -2,6-dimeth lphen l)-4,4-dimeth lpiperidin-3- l)succinate 
(3.23p)  
1-(4-Methoxy-2,6-dimethylphenyl)-4,4-dimethylpiperidine 3.21m was reacted with diisopropyl 
fumarate 2.22a following the General Procedure D using B(C6F5)3 (10 mol%) as the Lewis acid 
catalyst, DCM (0.1 mL) as the solvent, and a second batch of 2.22a in DCM (0.05 mL) was added. 
After purification by column chromatography (ethyl ether:hexanes = 1:33) 3.23p was obtained as 
a colorless liquid (89 mg, 93%).  
 
1H NMR (600 MHz, CDCl3)  6.55 (d, J = 13.5 Hz, 2H), 5.82 (s, 1H), 4.96 (dp, J = 17.2, 6.3 Hz, 
2H), 3.75 (s, 3H), 3.41 (dd, J = 10.9, 4.6 Hz, 1H), 3.22 (ddd, J = 12.3, 8.9, 3.7 Hz, 1H), 3.11 (ddd, 
J = 11.9, 6.4, 4.0 Hz, 1H), 2.78 (dd, J = 16.8, 10.9 Hz, 1H), 2.40 (dd, J = 16.7, 4.7 Hz, 1H), 2.18 
(s, 3H), 2.13 (s, 3H), 1.76 (ddd, J = 12.9, 8.9, 4.0 Hz, 1H), 1.70 (ddd, J = 12.9, 6.4, 3.7 Hz, 1H), 
1.23 (d, J = 6.3 Hz, 3H), 1.21 (d, J = 3.5 Hz, 3H), 1.20 (d, J = 3.5 Hz, 3H), 1.19 (s, 3H), 1.17 (d, 
J = 6.3 Hz, 3H), 1.11 (s, 3H); 13C NMR (126 MHz, CDCl3)  174.5, 171.8, 157.3, 138.8, 138.3, 
138.2, 132.0, 113.4, 113.3, 108.1, 67.6, 67.3, 55.3, 44.1, 39.9, 39.6, 39.2, 31.6, 29.1, 28.2, 21.9, 
21.82, 21.80, 21.5, 18.4, 18.3; IR (neat)Q 2977, 2933, 1723, 1639, 1466, 1259, 1162, 1102, 1065 
cm-1; HRMS (ESI) Calcd for C26H40NO5 (MH+): 446.2901; found: 446.2906. 





-3- )(4-(2-( i e idi -1- )e h ) he ) e ha e 3.21n (0.20 ) a  eac ed i h 
dii  f a a e 2.22a f i g he General Procedure C i g B(C6F5)3 (10 %) a  he 
Le i  acid ca a  a d be e e a  he e . 1H NMR a a i  f he ified d c  i e 
e ea ed ha  he dia e e e ic a i  a  2.5:1. Af e  ifica i  b  c  ch a g a h  
(e h  e he :DCM = 1:4), 3.23q a  b ai ed a  a i e f dia e e e  (145 g, 80%). F he  
ifica i  a  ca ied  b  PTLC i g MeOH:DCM = 1:49 a  he e e   e a a e 3.23q-
major a d 3.23q-minor. The e a i e c fig a i  f 3.23q-major a d 3.23q-minor a  
a ig ed i  a a g . 
 
3.23q-major. 1H NMR (500 MHz, CDCl3):  7.73 (d, J = 8.9 Hz, 2H), 7.54 (d, J = 8.8 Hz, 1H), 
7.28 (d, J = 2.2 Hz, 1H), 7.27  7.25 (m, 1H), 7.25  7.23 (m, 1H), 6.88 (dd, J = 8.8, 2.2 Hz, 1H), 
6.72 (d, J = 8.9 Hz, 2H), 6.66 (d, J = 8.5 Hz, 2H), 4.99 (dp, J = 12.5, 6.3 Hz, 2H), 4.03 (t, J = 6.0 
Hz, 2H), 2.87 (dd, J = 16.7, 9.2 Hz, 2H), 2.80  2.62 (m, 4H), 2.46  2.32 (m, 1H), 2.06  1.82 (m, 
3H), 1.67 (dt, J = 16.5, 12.7 Hz, 2H), 1.54 (q, J = 12.8 Hz, 1H), 1.21 (td, J = 6.0, 1.8 Hz, 12H), 
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1.05 (dt, J = 10.5, 6.2 Hz, 1H), 1.01 (s, 9H), 0.93 (s, 9H), 0.23 (s, 6H), 0.12 (s, 6H). 13C NMR 
(126 MHz, CDCl3):  193.2, 173.2, 171.6, 162.8, 156.1, 153.5, 143.2, 139.8, 134.5, 132.3, 130.6, 
130.5, 130.3, 126.8, 123.9, 120.2, 119.2, 114.0, 112.1, 68.0, 67.9, 66.1, 58.3, 57.4, 54.3, 45.1, 45.0, 
38.1, 34.0, 27.8, 25.7, 25.6, 25.3, 21.80, 21.79, 21.7, 18.23, 18.18, -4.4, -4.5. HRMS (DART): 
Calcd for C50H72NO8SSi2+ (MH+): 902.4512; found: 902.4522. 
 
3.23q-minor. 1H NMR (600 MHz, CDCl3):  7.73 (d, J = 8.4 Hz, 2H), 7.54 (d, J = 8.7 Hz, 1H), 
7.28 (t, J = 1.8 Hz, 1H), 7.24 (d, J = 1.3 Hz, 1H), 6.88 (d, J = 8.7 Hz, 1H), 6.76  6.69 (m, 2H), 
6.66 (d, J = 8.0 Hz, 2H), 5.06  4.93 (m, 2H), 4.03 (s, 2H), 2.93  2.81 (m, 2H), 2.79  2.66 (m, 
4H), 2.37 (q, J = 10.0 Hz, 1H), 2.00 (t, J = 11.4 Hz, 1H), 1.94 (t, J = 10.9 Hz, 1H), 1.90  1.81 (m, 
1H), 1.74  1.64 (m, 2H), 1.55 (d, J = 15.3 Hz, 1H), 1.20 (d, J = 1.7 Hz, 12H), 1.10  0.99 (m, 
10H), 0.93 (s, 9H), 0.23 (s, 6H), 0.12 (s, 6H). 13C NMR (151 MHz, CDCl3):  195.8, 175.9, 174.2, 
165.5, 158.7, 156.1, 145.9, 142.5, 137.1, 134.9, 133.21, 133.15, 133.0, 129.4, 126.6, 122.9, 121.9, 
116.7, 114.7, 70.7, 70.6, 68.7, 60.8, 60.0, 57.0, 47.6, 40.9, 36.9, 30.4, 28.34, 28.27, 27.8, 24.48, 
24.45, 24.4, 20.9, 20.8, 2.6, -1.7, -1.8. HRMS (DART): Calcd for C50H72NO8SSi2+ (MH+): 
902.4512; found: 902.4519. 
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Diisoprop l 2-(4-(6-fluoroben o[d]iso a ol-3- l)-1-(2-(2-meth l-4-o o-6,7,8,9-tetrah dro-
4H-p rido[1,2-a]p rimidin-3- l)eth l)-1,4,5,6-tetrah drop ridin-3- l)succinate (3.23r)  
3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-2-methyl-6,7,8,9-tetrahydro-4H-
pyrido[1,2-a]pyrimidin-4-one 3.21o (1g, 2.4 mmol) was reacted with diisopropyl fumarate 3.22a 
following the General Procedure C using B(C6F5)3 (10 mol%) as the Lewis acid catalyst and 
DCM as the solvent. 1H NMR analysis of the unpurified product mixture revealed that the 
diastereomeric ratio was 1.7:1. After purification by column chromatography (methanol:DCM = 
1:49), 3.23r was obtained as a mixture of diastereomers (470 mg, 32%). Further purification was 
carried out by PTLC using methanol:DCM = 1:49 as the eluent to separate 3.23r-major. 
 
3.23r-Major. 1H NMR (500 MHz, CDCl3):  7.66 (dd, J = 8.8, 5.2 Hz, 1H), 7.21 (dd, J = 8.4, 
2.1 Hz, 1H), 7.06  7.00 (m, 1H), 6.15 (s, 1H), 4.95  4.81 (m, 1H), 4.81  4.68 (m, 1H), 4.08 (d, 
J = 5.1 Hz, 1H), 3.94 (t, J = 6.3 Hz, 2H), 3.22  3.12 (m, 3H), 3.10 (s, 2H), 2.89 (d, J = 6.9 Hz, 
3H), 2.74 (d, J = 7.6 Hz, 2H), 2.40 (dd, J = 16.4, 4.8 Hz, 1H), 2.30 (s, 3H), 2.19  2.11 (m, 1H), 
2.01 (d, J = 7.3 Hz, 1H), 1.98 (t, J = 6.2 Hz, 2H), 1.93  1.83 (m, 2H), 1.20  1.09 (m, 12H); 13C 
NMR (151 MHz, CDCl3):  173.0, 171.3, 163.9, 163.2, 162.5, 161.3, 158.6, 156.2, 135.7, 135.6, 
122.9, 122.8, 118.2, 118.0, 112.4, 112.2, 99.1, 97.3, 97.1, 67.9, 67.84, 67.80, 67.7, 53.3, 45.7, 44.5, 
42.9, 42.8, 36.1, 31.7, 31.5, 29.7, 28.7, 28.4, 25.8, 22.0, 21.8, 21.74, 21.70, 21.62, 21.55, 21.5, 
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21.4, 19.2; 19F NMR (470 MHz, CDCl3):  -109.99; IR (neat):Q 2975, 2931, 1723, 1649, 1612, 
1533, 1411, 1268, 1167, 1141, 1105, 919, 830 cm-1; HRMS (DART): Calcd for C33H42FN4O6 
(MH+): 609.3083; found: 609.3072. 
 
1H NMR (500 MH , CDCl3, ea   d a e e e  a e e ed):  7.67 (dd, J = 9.0, 5.1 H , 
1H), 7.22 ( , J = 6.8 H , 1H), 7.03 ( , J = 9.2 H , 1H), 6.24  6.10 ( , 1H), 4.88 (d , J = 12.7, 6.4 
H , 1H), 4.81  4.71 ( , 1H), 4.09 (dd, J = 5.8, 3.1 H , 1H), 3.94 ( , J = 5.0, 4.0 H , 2H), 3.27  
3.04 ( , 5H), 2.87 (d , J = 23.5, 9.0 H , 3H), 2.74 ( , J = 7.7 H , 2H), 2.64  2.35 ( , 1H), 2.31 
(d, J = 3.9 H , 3H), 2.21  2.08 ( , 1H), 2.08  2.02 ( , 1H), 2.02  1.94 ( , 2H), 1.94  1.83 ( , 
2H), 1.20  1.06 ( , 12H); 13C NMR (126 MH , CDCl3):  172.9, 172.8, 171.22, 171.16, 164.0 
(d, J = 250.3 H ), 164.0 (d, J = 250.3 H ), 163.9, 163.8, 163.7, 162.4, 161.7, 161.2, 158.51, 158.47, 
156.11, 156.07, 135.9, 135.6, 123.4 (d, J = 10.9 H ), 122.8 (d, J = 11.0 H ), 118.07, 118.05, 117.9, 
117.6, 112.16 (d, J = 25.2 H ), 112.22 (d, J = 25.1 H ), 98.9, 98.5, 97.2 (d, J = 26.7 H ). 97.1 (d, 
J = 26.7 H ), 67.8, 67.7, 67.6, 53.2, 53.0, 45.6, 44.4, 42.9, 42.8, 42.6, 37.0, 36.0, 31.6, 31.38, 
31.37, 31.1, 28.6, 28.4, 25.70, 25.67, 21.9, 21.7, 21.64, 21.61, 21.59, 21.53, 21.45, 21.4, 21.3, 19.2, 
19.1. 
  
 646  
  
Diisoprop l 2-((4R,5S)-5-((ben o[d][1,3]dio ol-5- lo )meth l)-1-ben l-4-(4-
fluorophen l)piperidin-3- l)succinate (3.23s)  
For 0.2 mmol scale: 
(3S,4R)-3-((Be [ ][1,3]di -5- ) e h )-1-be -4-(4-f he ) i e idi e 3.21p 
a  eac ed i h dii  f a a e 2.22a f i g he General Procedure D i g B(C6F5)3 
(10 %) a  he Le i  acid ca a  a d be e e a  he e .  1H NMR a a i  f he 
ified d c  i e e ea ed ha  he dia e e e ic a i  f 3.23s a  2.3:1. Af e  
ifica i  b  c  ch a g a h  (e h  e he :he a e  = 3:2), 3.23s a  b ai ed a  a 
i e f dia e e e  (48 g, 39%). The e a i e c fig a i  f 3.23s-major a d 3.23s-
minor a  a ig ed i  a a g . 
 
3.23s-Major: 1H NMR (500 MHz, CDCl3)  7.38  7.19 (m, 5H), 7.00 (s, 2H), 6.61 (d, J = 8.4 
Hz, 1H), 6.31 (d, J = 2.5 Hz, 1H), 6.09 (dd, J = 8.5, 2.5 Hz, 1H), 5.88 (s, 2H), 4.94  4.76 (m, 2H), 
3.64 (d, J = 13.1 Hz, 1H), 3.48 (d, J = 2.6 Hz, 1H), 3.45 (d, J = 13.1 Hz, 1H), 3.41  3.33 (m, 1H), 
3.20  3.13 (m, 1H), 2.83  2.74 (m, 1H), 2.61  2.48 (m, 3H), 2.42 (t, J = 11.2 Hz, 1H), 2.29  
2.17 (m, 2H), 2.13 (t, J = 11.1 Hz, 1H), 1.84 (t, J = 11.1 Hz, 1H), 1.15 (d, J = 6.2 Hz, 6H), 1.08 (d, 
J = 6.3 Hz, 3H), 1.02 (d, J = 6.2 Hz, 3H); 13C NMR (151 MHz, CDCl3)  173.3, 171.4, 161.8 (d, 
JCF = 245.3 Hz), 154.2, 148.1, 141.6, 137.9, 136.4, 136.3, 129.1, 128.2, 127.1, 115.8, 107.8, 105.6, 
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101.1, 97.9, 69.4, 68.1, 67.8, 63.3, 57.6, 54.7, 46.3, 43.2, 42.8, 41.5, 30.4, 21.71, 21.67, 21.6, 21.5; 
19F NMR (470 MHz, CDCl3)  -115.52, -115.53, -115.54, -115.55, -115.56, -115.58; IR (neat)Q 
2978, 2917, 2870, 1724, 1508, 1502, 1486, 1224, 1182, 1104, 1037, 779 cm-1; [ ]25D = 22.1° (c 
= 1.0, EtOH); HRMS (DART) Calcd for C36H43FNO7 (MH+): 620.3018; found: 620.3004. 
 
3.23s-Minor: 1H NMR (500 MHz, CDCl3)  7.42  7.29 (m, 4H), 7.29  7.23 (m, 1H), 7.20 (t, J 
= 7.0 Hz, 2H), 6.98 (s, 2H), 6.60 (dd, J = 8.5, 1.7 Hz, 1H), 6.27 (t, J = 2.1 Hz, 1H), 6.06 (dt, J = 
8.6, 2.1 Hz, 1H), 5.87 (d, J = 1.8 Hz, 2H), 4.97 (td, J = 6.3, 1.7 Hz, 1H), 4.88 (td, J = 6.2, 1.7 Hz, 
1H), 3.58 (q, J = 13.2 Hz, 2H), 3.45 (dt, J = 9.4, 2.2 Hz, 1H), 3.40  3.23 (m, 1H), 3.19  3.09 (m, 
1H), 3.09  2.97 (m, 1H), 2.83  2.64 (m, 2H), 2.64  2.51 (m, 1H), 2.25  2.08 (m, 3H), 2.05 (d, 
J = 11.1 Hz, 1H), 1.83 (t, J = 11.4 Hz, 2H), 1.30 (dd, J = 6.2, 1.7 Hz, 3H), 1.23 (dd, J = 6.3, 1.7 
Hz, 3H), 1.15 (dt, J = 5.6, 2.3 Hz, 6H); 13C NMR (126 MHz, CDCl3)  172.1, 171.2, 161.7 (d, 
JCF = 244.8 Hz), 154.3, 148.1, 141.5, 137.8, 137.04, 137.02, 129.0, 128.3, 127.1, 115.5, 107.8, 
105.4, 101.0, 97.8, 69.3, 68.1, 67.9, 63.3, 57.1, 55.6, 46.3, 44.2, 43.1, 40.9, 35.2, 22.0, 21.9, 21.73, 
21.72; 19F NMR (470 MHz, CDCl3)  -115.96, -115.98, -115.99, -116.00, -116.02; HRMS (DART) 
Calcd for C36H43FNO7 (MH+): 620.3018; found: 620.3001. 
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Diisoprop l 2-((4R,5S)-5-((ben o[d][1,3]dio ol-5- lo )meth l)-1-ben l-4-(4-fluorophen l)-
1,4,5,6-tetrah drop ridin-3- l)succinate (3.23t)  
From 0.2 mmol of N-Bn paro etine (3.23t): 1H NMR a a i  f he ified d c  i e 
e ea ed ha  he dia e e e ic a i  f 3.23t a  1.9:1. Af e  ifica i  b  c  
ch a g a h  (e h  e he :he a e  = 1:4), 3.23t a  b ai ed a  a i e f dia e e e  (19 
g, 14%). The e a i e c fig a i  f 3.23t-major a d 3.23t-minor a  a ig ed i  a a g . 
 
3.23t-Major: 1H NMR (500 MHz, CDCl3)  7.35  7.24 (m, 4H), 7.24  7.19 (m, 2H), 7.07 (s, 
2H), 6.89 (s, 2H), 6.69 (d, J = 8.4 Hz, 1H), 6.43 (d, J = 2.4 Hz, 1H), 6.35 (s, 1H), 6.27 (dd, J = 8.5, 
2.5 Hz, 1H), 5.91 (s, 2H), 5.00  4.83 (m, 2H), 4.17  3.99 (m, 2H), 3.78 (d, J = 23.9 Hz, 2H), 3.31 
(s, 1H), 3.22 (dd, J = 10.3, 4.9 Hz, 1H), 2.81  2.67 (m, 2H), 2.56 (dd, J = 16.9, 10.3 Hz, 1H), 2.17 
(dd, J = 16.9, 4.9 Hz, 1H), 2.09  1.99 (m, 1H), 1.21 (d, J = 6.2 Hz, 3H), 1.19  1.12 (m, 9H); 13C 
NMR (151 MHz, CDCl3)  173.0, 171.4, 161.5 (d, JCF = 244.4 Hz), 154.4, 148.2, 141.5 (d, JCF 
= 2.9 Hz), 137.6, 134.9, 129.9 (d, JCF = 7.7 Hz), 128.4, 128.1, 127.4, 114.8 (d, JCF = 21.1 Hz), 
107.9, 105.9, 101.10, 101.07, 98.2, 70.2, 67.9, 67.8, 59.3, 45.9, 42.0, 40.8, 40.4, 37.4, 21.84, 21.78, 
21.75, 21.7, 21.6; 19F NMR (470 MHz, CDCl3)  -117.23, -117.24, -117.25, -117.26, -117.27, -
117.28, -117.29; IR (neat)Q 2977, 2927, 2872, 1721, 1649, 1502, 1486, 1372, 1219, 1180, 1137, 
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1104, 817, 788, 701 cm-1; [ ]25D = 84.8° (c = 1.0, EtOH); HRMS (DART) Calcd for C36H41FNO7 
(MH+): 618.2861; found: 618.2847.  
 
3.23t-Minor: 1H NMR (600 MHz, CDCl3)  7.38  7.15 (m, 5H), 7.06 (dd, J = 8.3, 5.4 Hz, 2H), 
6.89 (t, J = 8.5 Hz, 2H), 6.68 (d, J = 8.4 Hz, 1H), 6.43 (d, J = 2.4 Hz, 1H), 6.30 (s, 1H), 6.26 (dd, 
J = 8.5, 2.5 Hz, 1H), 5.98  5.84 (m, 2H), 4.92 (q, J = 6.3 Hz, 1H), 4.67 (q, J = 6.2 Hz, 1H), 4.09 
(q, J = 14.6 Hz, 2H), 3.82 (dd, J = 9.1, 6.6 Hz, 1H), 3.75 (t, J = 8.3 Hz, 1H), 3.46 (s, 1H), 3.12 (dd, 
J = 10.5, 5.1 Hz, 1H), 2.90 (dd, J = 16.5, 10.6 Hz, 1H), 2.83  2.69 (m, 2H), 2.34 (dd, J = 16.5, 
5.1 Hz, 1H), 2.07 (dd, J = 6.9, 3.8 Hz, 1H), 1.17 (d, J = 6.3 Hz, 6H), 1.10 (dd, J = 10.2, 6.3 Hz, 
6H); 13C NMR (151 MHz, CDCl3)  173.1, 171.3, 161.5 (d, JC-F = 244.5 Hz), 154.4, 148.2, 141.6, 
140.9 (d, JC-F = 3.1 Hz), 137.6, 134.7, 129.8 (d, JC-F = 7.7 Hz), 128.5, 128.1, 127.5, 114.9 (d, JC-F 
= 21.0 Hz), 107.9, 105.8, 101.8, 101.1, 98.2, 70.2, 68.0, 67.9, 59.5, 44.8, 42.4, 41.4, 40.5, 36.6, 
21.79, 21.75, 21.60, 21.56; 19F NMR (470 MHz, CDCl3)  -117.14, -117.15, -117.16, -117.17, -
117.18, -117.19, -117.20 HRMS (DART) Calcd for C36H41FNO7 (MH+): 618.2861; found: 
618.2859.  
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Dibenzyl 2-(1-(dibenzylamino)propan-2-yl)succinate (3.23u)  
N,N-Dibenzylpropan-1-amine 3.21b was reacted with dibenzyl fumarate 3.22b following the 
General Procedure A using B(C6F5)3 (10 mol%) as the Lewis acid catalyst and benzene (0.8 mL) 
as the solvent. 1H NMR analysis of the unpurified product mixture revealed that the diastereomeric 
ratio was 2.5:1. After purification by column chromatography (ethyl ether:hexanes = 1:33) 3.23u 
was obtained as a mixture of diastereomers (85 mg, 79%). Further purification was carried out by 
PTLC using ethyl ether:DCM = 1:49 as the eluent to separate 3.23u-major and 3.23u-minor. The 
relative configuration of 3.23u-major and 3.23u-minor was assigned by analogy. 
 
3.23u-Major: 1H NMR (500 MHz, CDCl3)  7.39  7.25 (m, 14H), 7.20 (t, J = 7.4 Hz, 4H), 7.14 
(t, J = 7.3 Hz, 2H), 5.17  5.00 (m, 4H), 3.75 (d, J = 13.2 Hz, 2H), 3.49 (d, J = 12.1 Hz, 1H), 3.21 
(d, J = 13.2 Hz, 2H), 2.49  2.34 (m, 2H), 2.22 (dd, J = 12.9, 10.3 Hz, 1H), 2.11 (dd, J = 13.0, 5.5 
Hz, 1H), 1.56 (dd, J = 16.8, 2.9 Hz, 1H), 0.67 (d, J = 6.9 Hz, 3H); 13C NMR (151 MHz, CDCl3) 
 175.0, 172.2, 139.3, 136.1, 136.0, 129.1, 128.5, 128.4, 128.23, 128.18, 128.0, 126.9, 66.2, 58.69, 
58.65, 56.6, 41.79, 41.77, 32.1, 29.2, 13.7; IR (neat)Q 3027, 2956, 1730, 1494, 1453, 1254, 1154, 
976, 747, 697 cm-1; HRMS (DART) Calcd for C35H38NO4 (MH+): 536.2795; found: 536.2799. 
 
3.23u-Minor: 1H NMR (600 MHz, CDCl3)  7.39  7.26 (m, 13H), 7.26  7.24 (m, 3H), 7.24  
7.21 (m, 2H), 7.20 (t, J = 7.0 Hz, 2H), 5.08 (d, J = 12.4 Hz, 1H), 5.02 (d, J = 10.6 Hz, 2H), 4.94 
(d, J = 12.2 Hz, 1H), 3.54 (d, J = 13.6 Hz, 2H), 3.34 (d, J = 13.6 Hz, 2H), 3.08 (dt, J = 10.8, 4.0 
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Hz, 1H), 2.70 (dd, J = 16.8, 10.7 Hz, 1H), 2.38 (dd, J = 12.7, 6.7 Hz, 1H), 2.25  2.15 (m, 2H), 
2.03 (qd, J = 7.1, 4.0 Hz, 1H), 0.81 (d, J = 6.9 Hz, 3H); 13C NMR (151 MHz, CDCl3)  173.5, 
172.1, 139.3, 135.8, 129.0, 128.50, 128.46, 128.4, 128.2, 128.1, 126.9, 66.4, 66.3, 58.9, 58.4, 44.0, 
33.3, 15.6; HRMS (DART) Calcd for C35H38NO4 (MH+): 536.2795; found: 536.2789. 
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Methyl 2-(dibenzylamino)-3-methyl-4-(trifluoromethyl)cyclobutane-1-carboxylate (3.23v)  
N,N-Dibenzylpropan-1-amine 3.21b was reacted with methyl 4,4,4-trifluorobut-2-enoate 3.22c 
following the General Procedure B using B(C6F5)3 (10 mol%) as the Lewis acid catalyst and 
benzene as the solvent. 1H NMR analysis of the unpurified product mixture revealed that the 
diastereomeric ratio was >20:1. After purification by column chromatography (ethyl ether:hexanes 
= 1:49) 3.23v was obtained as a colorless liquid (58 mg, 74%). The relative configuration of 3.23v 
was assigned by analogy. 
 
1H NMR (600 MHz, CDCl3)  7.37  7.27 (m, 8H), 7.25  7.20 (m, 2H), 3.80 (d, J = 13.9 Hz, 2H), 
3.72 (s, 3H), 3.61 (d, J = 13.9 Hz, 2H), 3.20 (t, J = 8.6 Hz, 1H), 3.14 (t, J = 8.6 Hz, 1H), 2.51  
2.44 (m, 1H), 2.44  2.36 (m, 1H), 1.09 (d, J = 6.4 Hz, 3H); 13C NMR (151 MHz, CDCl3)  172.6, 
139.1, 128.4, 128.3, 127.1, 64.1, 54.7, 52.1, 40.6 (q, JCF = 30.7 Hz), 39.9, 33.40, 33.38, 18.2; 19F 
NMR (470 MHz, CDCl3)  -71.84; IR (neat)Q 2923, 2800, 1709, 1498, 1378, 1178, 747, 697 cm-
1; HRMS (DART) Calcd for C22H25NO2F3 (MH+): 392.1832; found: 392.1824. 
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Benzyl 5-(dibenzylamino)-4-methylpentanoate (3.23w)  
N,N-Dibenzylpropan-1-amine 3.21b was reacted with benzyl acrylate 3.22d following the 
General Procedure A using B(C6F5)3 (5.0 mol%) as the Lewis acid catalyst and benzene (0.8 mL) 
as the solvent.  After purification by column chromatography (ethyl ether:hexanes = 1:33) 3.23w 
was obtained as a colorless liquid (60 mg, 75%).  
 
1H NMR (600 MHz, CDCl3)  7.34 (d, J = 5.4 Hz, 9H), 7.28 (t, J = 7.5 Hz, 4H), 7.20 (t, J = 7.3 
Hz, 2H), 5.10 (s, 2H), 3.48 (s, 4H), 2.33  2.25 (m, 2H), 2.23 (dd, J = 12.4, 7.3 Hz, 1H), 2.14 (dd, 
J = 12.5, 7.3 Hz, 1H), 1.86  1.79 (m, 1H), 1.79  1.71 (m, 1H), 1.40  1.31 (m, 1H), 0.84 (d, J = 
6.6 Hz, 3H); 13C NMR (151 MHz, CDCl3)  173.8, 139.8, 136.1, 128.9, 128.5, 128.2, 128.14, 
128.10, 126.7, 66.1, 60.3, 58.8, 31.7, 30.4, 29.7, 17.8; IR (neat)Q 2951, 2926, 1733, 1493, 1452, 
1256, 1167, 746, 697 cm-1; HRMS (DART) Calcd for C27H32NO2 (MH+): 402.2428; found: 
402.2427. 
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3-(2-(dibenzylamino)ethyl)-1-phenylpyrrolidine-2,5-dione (3.23x)  
N,N-Dibenzylethanamine 3.21a was reacted with 1-phenyl-1H-pyrrole-2,5-dione 3.22e following 
the General Procedure B using B(C6F5)3 (10 mol%) as the Lewis acid catalyst and benzene as the 
solvent. After purification by column chromatography (ethyl ether:hexanes = 1:33) 3.23x was 
obtained as a colorless liquid (39 mg, 49%).  
 
1H NMR (600 MHz, CDCl3)  7.45 (dd, J = 8.4, 7.2 Hz, 2H), 7.40  7.36 (m, 1H), 7.35  7.29 (m, 
8H), 7.29  7.22 (m, 4H), 3.73 (d, J = 13.3 Hz, 2H), 3.43 (d, J = 13.4 Hz, 2H), 3.11 (tdd, J = 9.5, 
5.3, 3.8 Hz, 1H), 2.56 (dd, J = 7.6, 5.2 Hz, 2H), 2.47 (dd, J = 18.5, 9.3 Hz, 1H), 2.33 (dtd, J = 14.0, 
7.7, 4.0 Hz, 1H), 2.20 (dd, J = 18.5, 5.3 Hz, 1H), 1.63 (ddt, J = 14.1, 10.3, 5.2 Hz, 1H); 13C NMR 
(126 MHz, CDCl3)  179.3, 175.7, 139.2, 132.0, 129.1, 129.0, 128.5, 128.3, 127.2, 126.4, 58.6, 
50.0, 38.0, 34.1, 29.1; IR (neat)Q 2922, 2801, 1707, 1498, 1452, 1377, 1177, 747, 697 cm-1; 
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(S)-3-((R)-3-((3R,5R)-1-Ben l-5-((( e -but ldimeth lsil l)o )diphen lmeth l) 
p rrolidin-3- l)-4,4,4-trifluorobutano l)-4-phen lo a olidin-2-one (3.26a) 
T  a 15 L e -d ied e e e e  a  added (R)-1-be -2-((( -
b di e h i ) )di he e h ) idi e 3.21k (0.10 ), (S,E)-4- he -3-(4,4,4-
if b -2-e ) a idi -2- e 3.25a (0.15 ), B(C6F5)3 (10 %), Z I2 (10 %), 
HB i  (70 %) a d be e e (0.60 L) de  a i ge  a he e. The eac i  i e a  
a ed  hea  f  36 h  a  70 °C. U  c e i , he eac i  i e a  c ce a ed  
ac . Af e  ifica i  b  c  ch a g a h  (E OAc:he a e  = 1:6), 3.26a a  b ai ed 
a  a hi e id (61 g, 82%). The ab e c fig a i  f 3.26a-(R,R,R,S) a  a ig ed ba ed 
 X- a  c a g a h  da a f 3.29. 
 
1H NMR (600 MHz, CDCl3):  7.59 (d, J = 8.3 H , 2H), 7.54 (d, J = 6.6 H , 2H), 7.37  7.27 ( , 
9H), 7.21 ( , J = 7.3 H , 4H), 7.15 ( , J = 7.2 H , 1H), 7.04 (d, J = 7.4 H , 2H), 5.33 (dd, J = 8.8, 
4.1 H , 1H), 4.65 ( , J = 8.8 H , 1H), 4.46 (b , 1H), 4.25 (dd, J = 9.0, 4.0 H , 1H), 4.02 (d, J = 9.8 
H , 1H), 3.40 (d, J = 13.3 H , 1H), 3.02 (dd, J = 18.4, 6.2 H , 1H), 2.80 (dd, J = 18.4, 5.0 H , 1H), 
2.63 ( , J = 7.8 H , 1H), 2.59  2.51 ( , 1H), 1.96  1.84 ( , 2H), 1.69 ( , J = 11.7 H , 1H), 1.33 
 1.18 ( , 1H), 0.87 ( , 9H), -0.44 (d, J = 17.4 H , 6H); 13C NMR (151 MHz, CDCl3):  170.2, 
153.6, 143.2, 140.3, 138.6, 130.2, 130.1, 130.1, 129.4, 129.0, 128.3, 128.2, 128.2, 127.7, 127.4, 
127.2 ( , J = 266.8 H ), 127.1, 126.6, 125.8, 70.2, 69.8, 61.7, 59.0, 58.1, 40.7 ( , J = 26.3 H ), 
35.4, 33.1, 29.9, 26.5, 19.1, -2.7, -2.9; 19F NMR (376 MHz, CDCl3):  -69.82 (d, J = 9.3 Hz); IR 
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(neat):  2952, 2926, 2892, 2853, 1783, 1710, 1493, 1452, 1384, 1359, 1326, 1252, 1197, 1155, 
1120, 1095, 1061, 854, 834, 774, 702 c -1; HRMS (DART): Ca cd f  C43H50F3N2O4Si (MH+): 
743.3486; f d: 743.3486; Specific Rotation: [ ]25D = -6.9  (c = 0.88, DCM). 
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3-((S)-4,4,4-Trifluoro-3-(1-(4-metho -2,6-dimeth lphen l)p rrolidin-3-
l)butano l)o a olidin-2-one (3.26b) 
T  a 15 L e -d ied e e e e  a  added Mg(C O4)2 (0.010 , 10 %), L1 (0.010 
, 10 %), be e e (0.30 L) de  i ge  a he e. The i e a  a ed  i  
f  20 i e  a  22 C. S b e e , 1-(4- e h -2,6-di e h he ) idi e 3.21q (0.10 
), (E)-3-(4,4,4- if b -2-e ) a idi -2- e 3.25b (0.15 ), a d be e e (0.30 
L) e e added  he ia  de  i ge  a he e, a d he e i g i e a  a ed  
i  a  22 C f  12 h. U  c e i , he eac i  i e a  c ce a ed  ac . 1H NMR 
a d 19F NMR a a e  f he ified d c  i e i g e i e e a d e f be e e 
a  he i e a  a da d e ea ed ha  he dia e e e ic a i  a  1.6:1. Af e  ifica i  b  
c  ch a g a h  (E OAc:he a e  = 1:3), 3.26b a  b ai ed a  a c e  i id (28 g, 
67%). F he  ifica i  a  ca ied  b  PTLC i g e h  E OAc:he a e  = 1:2 a  he e e  
 e a a e 3.26b-a  a d 3.26b- .  
 
3.26b-a . 1H NMR (400 MHz, CDCl3):  6.55 ( , 2H), 4.41 ( , J = 7.9 H , 2H), 4.09  3.93 ( , 
2H), 3.73 ( , 3H), 3.41 (dd, J = 18.5, 7.2 H , 1H), 3.28 ( , J = 8.7 H , 1H), 3.22  3.09 ( , 3H), 
3.08  2.92 ( , 2H), 2.65 (h, J = 8.3 H , 1H), 2.36  2.12 ( , 7H), 1.85 ( , J = 10.3 H , 1H); 13C 
NMR (101 MHz, CDCl3):  170.6, 157.0, 153.6, 139.8, 137.5, 127.8 ( , J = 280.5 H ), 113.7, 
62.3, 55.3, 53.9, 50.4, 42.8, 41.4 ( , J = 25.7 H ), 39.0, 33.1, 33.0, 31.6, 19.0; 19F NMR (376 MHz, 
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CDCl3):  -69.12 (d, J = 9.3 Hz); IR (neat):  2921, 2837, 1778, 1701, 1601, 1480, 1387, 1363, 
1319, 1280, 1222, 1194, 1124, 1067, 1040, 956, 856, 709, 671, 626 c -1; HRMS (DART): Ca cd 
f  C20H26F3N2O4 (MH+): 415.1839; f d: 415.1819; HPLC (CHIRACPAK IA-3; 5%/ 95% 
i a / he a e , 0.5 L/ i ;  = 25.7 i  ( i ), 36.0 i  ( aj ); 90:10 e ); Specific 
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3.26b- . 1H NMR (400 MHz, CDCl3):  6.55 ( , 2H), 4.44 ( , J = 8.1 H , 2H), 4.09  4.00 ( , 
2H), 3.73 ( , 3H), 3.45  3.34 ( , 1H), 3.32  3.19 ( , 2H), 3.19  3.10 ( , 3H), 3.07 ( , J = 8.8 
H , 1H), 2.62 (d , J = 16.7, 7.9 H , 1H), 2.21 ( , 6H), 2.10  2.01 ( , 1H), 1.79 ( , J = 10.2 H , 
1H); 19F NMR (470 MHz, CDCl3):  -69.62 (d, J = 9.2 Hz); IR (neat):  2920, 2852, 1780, 1701, 
1660, 1602, 1480, 1466, 1388, 1364, 1318, 1261, 1223, 1194, 1157, 1126, 1066, 1039 c -1; 
HRMS (DART): Ca cd f  C20H26F3N2O4 (MH+): 415.1839; f d: 415.1837. HPLC 
(CHIRACPAK IA-3; 5%/ 95% i a / he a e , 0.5 L/ i ;  = 22.0 i  ( aj ), 30.7 i  
( i ); 84:16 e ); Specific Rotation [ ]25D = -5.3  (c = 0.15, DCM). 
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Eth l (S)-4-(2-eth l-3,3-dimeth l-5-o op ra olidin-1- l)-2-(1-(4-metho phen l) p rrolidin-
3- l)-4-o obutanoate (3.26c) 
1-(4-Me h -2,6-di e h he ) idi e 3.21r a  eac ed i h e h  (E)-4-(2-e h -3,3-
di e h -5- a idi -1- )-4- b -2-e a e 3.25c f i g he General Procedure E 
f  1 h  i g B(C6F5)3 (10 %), Sc(OTf)3 (5.0 %), L10 (6.0 %) a d DCM a  he 
e . 1H NMR a a i  f he ified d c  i e i g e i e e a  he i e a  
a da d e ea ed ha  he dia e e e ic a i  a  2.0:1. Af e  ifica i  b  c  
ch a g a h  (E OAc:he a e  = 1:2), 3.26c a  b ai ed a  a c e  i id (36 g, 80%). 
F he  ifica i  a  ca ied  b  PTLC i g e h  E OAc:he a e  = 1:2 a  he e e   
e a a e 3.26c-(R,S) a d 3.26c-(S,S). The ab e c fig a i  f  hi  d c  a  a ig ed i  
a a g   ha  de e i ed f  d c  3.26f. 
 
3.26c-(R,S). 1H NMR (500 MH , CDCl3):  6.84 (d, J = 9.0 H , 2H), 6.51 (d, J = 9.0 H , 2H), 
4.22  4.08 ( , 2H), 3.75 ( , 3H), 3.46  3.37 ( , 2H), 3.33 ( d, J = 8.7, 2.7 H , 1H), 3.29  3.21 
( , 1H), 3.05 ( , J = 8.7 H , 1H), 3.03  2.93 ( , 4H), 2.59 ( , 2H), 2.51 ( , J = 8.4 H , 1H), 2.14 
 2.05 ( , 1H), 1.90 (d , J = 12.2, 8.9 H , 1H), 1.31 (d, J = 5.1 H , 6H), 1.25 ( , J = 7.1 H , 3H), 
1.07 ( , J = 7.1 H , 3H); 13C NMR (126 MH , CDCl3):  175.5, 174.3, 169.6, 151.1, 142.8, 115.2, 
112.6, 60.88, 60.85, 56.1, 52.3, 48.1, 47.3, 44.3, 43.9, 40.9, 37.9, 29.7, 26.1, 25.8, 14.4, 12.9; IR 
(neat):  2968, 2929, 2829, 1727, 1514, 1485, 1465, 1370, 1302, 1238, 1176, 1128, 1095, 1038, 
812 c -1; HRMS (DART): Ca cd f  C24H36N3O5 (MH+): 446.2650; f d: 446.2656; HPLC 
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(CHIRACPAK IA-3; 10%/ 90% i a / he a e , 1.0 L/ i ;  = 15.6 i  ( i ), 21.7 
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3.26c-(S,S). 1H NMR (600 MH , CDCl3):  6.82 (d, J = 8.9 H , 2H), 6.49 (d, J = 9.0 H , 2H), 
4.14 ( , J = 7.1 H , 2H), 3.74 ( , 3H), 3.44  3.29 ( , 3H), 3.28  3.20 ( , 1H), 3.12 ( , J = 8.8 
H , 1H), 3.03 (dd, J = 18.0, 3.7 H , 1H), 3.02  2.90 ( , 3H), 2.58 ( , 2H), 2.56  2.48 ( , 1H), 
2.18 (ddd, J = 12.6, 7.7, 5.3 H , 1H), 1.83  1.71 ( , 1H), 1.30 (d, J = 3.7 H , 6H), 1.25 ( , J = 7.1 
H , 3H), 1.05 ( , J = 7.1 H , 3H); IR (neat):  2969, 2924, 2849, 1727, 1513, 1485, 1464, 1371, 
1302, 1238, 1177, 1127, 1095, 1034, 813 c -1; HRMS (DART): Ca cd f  C24H36N3O5 (MH+): 
446.2650; f d: 446.2643; HPLC (CHIRACPAK IA-3; 10%/ 90% i a / he a e , 1.0 
L/ i ;  = 29.0 i  ( aj ), 38.5 i  ( i ); 98:2 e ); Specific Rotation [ ]25D = -2.0  (c = 
0.10, DCM).  
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Eth l (S)-4-(2-ben l-3,3-dimeth l-5-o op ra olidin-1- l)-2-(1-(4-metho phen l) 
p rrolidin-3- l)-4-o obutanoate (3.26d) 
1-(4-Me h -2,6-di e h he ) idi e 3.21r a  eac ed i h e h  (E)-4-(2-be -3,3-
di e h -5- a idi -1- )-4- b -2-e a e 3.25d f i g he General Procedure E 
f  1 h  i g B(C6F5)3 (10 %), Sc(OTf)3 (10 %), L6 (12 %) a d DCM a  he e . 
1H NMR a a i  f he ified d c  i e i g e i e e a  he i e a  a da d 
e ea ed ha  he dia e e e ic a i  a  3.0:1. Af e  ifica i  b  c  ch a g a h  
(e he :he a e  = 3:2), 3.26d a  b ai ed a  a c e  i id (42 g, 83%). F he  ifica i  
a  ca ied  b  PTLC i g e h  e he :he a e  = 3:2 a  he e e   b ai  3.26d-(R,S). The 
ab e c fig a i  f  hi  d c  a  a ig ed i  a a g   ha  de e i ed f  d c  
3.26f. 
 
3.26d-(R,S). 1H NMR (600 MH , CDCl3):  7.39 (d, J = 7.4 H , 2H), 7.30 ( , J = 7.4 H , 2H), 
7.26 (d, J = 7.3 H , 1H), 6.83 (d, J = 8.9 H , 2H), 6.49 (d, J = 8.8 H , 2H), 4.11 ( d, J = 7.2, 2.0 
H , 2H), 4.06 (d, J = 13.6 H , 1H), 3.99 (d, J = 13.9 H , 1H), 3.75 ( , 3H), 3.38  3.26 ( , 2H), 
3.21 ( d, J = 8.7, 6.5 H , 2H), 2.91 ( , J = 7.0 H , 1H), 2.79 ( , J = 10.0 H , 1H), 2.70  2.47 ( , 
3H), 2.42 ( , J = 8.4 H , 1H), 2.06  2.01 ( , 1H), 1.81 ( , J = 9.5 H , 1H), 1.27 (d, J = 6.5 H , 
6H), 1.21 ( , J = 7.1 H , 3H); 13C NMR (151 MH , CDCl3):  174.6, 174.2, 169.1, 151.1, 142.8, 
137.3, 129.6, 128.6, 127.8, 115.2, 112.6, 61.4, 60.8, 57.0, 56.1, 52.3, 48.1, 44.0, 43.6, 40.8, 37.5, 
29.8, 29.7, 26.5, 26.0, 14.4; IR (neat):  2924, 2851, 1771, 1728, 1702, 1513, 1370, 1301, 1238, 
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1176, 1125, 1038, 812 c -1; HRMS (DART): Ca cd f  C29H38N3O5 (MH+): 508.2806; f d: 
508.2805; HPLC (CHIRACPAK IA-3; 5%/ 95% i a / he a e , 0.45 L/ i ;  = 82.9 
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3.26d ((R,S):(S,S)= 2.3:1). 1H NMR (600 MH , CDCl3, ea   d a e e e  a e e ed): 
 7.40 (dd, J = 7.4, 2.3 H , 2H), 7.35  7.29 ( , 2H), 7.29  7.23 ( , 1H), 6.89  6.79 ( , 2H), 
6.55  6.44 ( , 2H), 4.20  4.09 ( , 2H), 4.09  4.03 ( , 1H), 4.03  3.95 ( , 1H), 3.83  3.70 
( , 3H), 3.39  3.27 ( , 2H), 3.27  3.14 ( , 2H), 3.09  2.87 ( , 1H), 2.87  2.75 ( , 1H), 2.74 
 2.36 ( , 4H), 2.13  1.98 ( , 1H), 1.86  1.63 ( , 1H), 1.31  1.25 ( , 6H), 1.25  1.19 ( , 
3H); 13C NMR (151 MH , CDCl3):  174.51, 174.47, 174.1, 173.9, 169.0 ( a ), 151.01, 
151.00, 142.8, 142.7, 137.3, 137.2, 129.5, 129.4, 128.51, 128.48, 127.7, 127.6, 115.0 ( a ), 
112.5 ( a ), 61.3, 61.2, 60.72, 60.70, 56.84, 56.80, 56.00, 55.99, 52.15, 52.13, 48.0, 47.9, 
44.0, 43.9, 43.5, 43.4, 40.6, 40.4, 37.4, 37.0, 29.8, 29.6, 26.4 ( a ), 25.9 ( a ), 
14.30, 14.26; HPLC (CHIRACPAK IA-3; 5%/ 95% i a / he a e , 0.45 L/ i ;  = 
107.5 i  ( aj ), 191.0 i  ( i ); 95:5 e ).  
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(S)-4-(2-Ben l-3,3-Dimeth l-5-o op ra olidin-1- l)-2-(1-(4-metho phen l) p rrolidin-3-
l)-1-phen lbutane-1,4-dione (3.26e) 
1-(4-Me h -2,6-di e h he ) idi e 3.21r a  eac ed i h (E)-1-(2-be -3,3-
di e h -5- a idi -1- )-4- he b -2-e e-1,4-di e 3.25e f i g he General 
Procedure E f  12 h  i g B(C6F5)3 (10 %), Sc(OTf)3 (10 %), L6 (12 %) a d 
DCM a  he e . 1H NMR a a i  f he ified d c  i e i g e i e e a  he 
i e a  a da d e ea ed ha  he dia e e e ic a i  a  3.5:1. Af e  ifica i  b  c  
ch a g a h  (e h  e he :he a e  = 3:2), 3.26e a  b ai ed a  a c e  i id (42 g, 
78%). F he  ifica i  a  ca ied  b  PTLC i g e h  e he :he a e  = 3:2 a  he e e  
 e a a e 3.26e-(R,S) a d 3.26e-(S,S). The ab e c fig a i  f  hi  d c  a  a ig ed 
i  a a g   ha  de e i ed f  d c  3.26f. 
 
3.26e-(R,S). 1H NMR (600 MHz, CDCl3):  7.97 (d, J = 7.7 H , 2H), 7.52 ( , J = 7.4 H , 1H), 
7.42 ( , J = 7.6 H , 2H), 7.35 (d, J = 8.1 H , 2H), 7.30 ( , J = 7.4 H , 2H), 7.29  7.22 ( , 1H), 
6.83 (d, J = 8.6 H , 2H), 6.45 (d, J = 8.7 H , 2H), 4.04 (d, J = 13.3 H , 1H), 3.94 (d, J = 13.6 H , 
1H), 3.91  3.82 ( , 1H), 3.75 ( , 3H), 3.57  3.40 ( , 1H), 3.32  3.23 ( , 1H), 3.20 ( d, J = 8.6, 
2.3 H , 1H), 3.11 ( , J = 8.6 H , 1H), 2.97  2.87 ( , 1H), 2.59 (d, J = 17.1 H , 1H), 2.49 (d, J = 
17.2 H , 1H), 2.47  2.37 ( , 1H), 1.86  1.77 ( , 1H), 1.62  1.53 ( , 2H), 1.31  1.23 ( , 7H); 
13C NMR (151 MHz, CDCl3):  203.3, 174.6, 169.7, 151.1, 142.7, 138.1, 137.1, 133.0, 129.8, 
128.8, 128.63, 128.60, 127.8, 115.1, 112.5, 61.5, 57.1, 56.1, 52.2, 48.1, 44.3, 43.4, 41.4, 38.0, 30.1, 
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26.7, 25.8; IR ( ea )  2924, 2850, 1742,1674, 1511, 1464, 1446, 1359, 1300, 1234, 1178, 1001, 
957, 811, 729, 700, 595, 564 c -1; HRMS (DART): Ca cd f  C33H38N3O4 (MH+): 540.2857; 
f d: 540.2856; HPLC (CHIRACPAK IA-3; 10%/ 90% i a / he a e , 1.0 L/ i ;  = 
23.8 i  ( i ), 28.5 i  ( aj ); 95:5 e ); Specific Rotation [ ]25D = +35.0  (c = 0.40, DCM).  
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3.26e-(S,S). 1H NMR (600 MH , CDCl3):  7.96 (d, J = 6.7 H , 2H), 7.54 ( , J = 7.4 H , 1H), 
7.43 ( , J = 7.7 H , 2H), 7.34 (d, J = 7.1 H , 2H), 7.28 (d, J = 7.3 H , 2H), 7.22 ( , J = 7.1 H , 1H), 
6.77 (d, J = 9.0 H , 2H), 6.35 (d, J = 9.0 H , 2H), 4.02 (d, J = 13.4 H , 1H), 3.99  3.90 ( , 2H), 
3.72 ( , 3H), 3.53  3.38 ( , 1H), 3.27 ( d, J = 8.7, 2.8 H , 1H), 3.17 ( , J = 8.8 H , 1H), 3.13 ( , 
J = 8.3 H , 1H), 2.83 ( , J = 8.6 H , 1H), 2.57 (d, J = 17.0 H , 1H), 2.54  2.45 ( , 2H), 2.08  
1.99 ( , 1H), 1.75  1.62 ( , 1H), 1.31  1.23 ( , 7H); 13C NMR (151 MHz, CDCl3):  202.9, 
182.3, 174.6, 151.1, 142.7, 137.6, 137.1, 133.1, 129.7, 128.75, 128.67, 128.6, 127.8, 115.1, 112.6, 
61.4, 57.0, 56.1, 52.2, 47.9, 44.3, 43.5, 41.1, 37.4, 29.5, 26.6, 25.9; IR (neat):  2922, 2850, 
1744,1676, 1513, 1484, 1447, 1364, 1301, 1237, 1179, 1038, 812, 699 c -1; HRMS (DART): 
Ca cd f  C33H38N3O4 (MH+): 540.2857; f d: 540.2828; HPLC (CHIRACPAK IA-3; 10%/ 90% 
i a / he a e , 1.0 L/ i ;  = 26.2 i  ( i ), 47.0 i  ( aj ); 95:5 e ); Specific 
Rotation [ ]25D = +12.0  (c = 0.20, DCM).  
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1-Eth l-5,5-dimeth l-2-((S)-4,4,4-trifluoro-3-(1-(4-metho phen l)p rrolidin-3-
l)butano l)p ra olidin-3-one (3.26f) 
1-(4-Me h -2,6-di e h he ) idi e 3.21r a  eac ed i h (E)-1-e h -5,5-di e h -
2-(4,4,4- if b -2-e ) a idi -3- e 3.25f f i g he General Procedure E f  3 
h  i g B(C6F5)3 (10 %), Sc(OTf)3 (10 %), L10 (12 %) a d DCM a  he e . 
1H NMR a d 19F NMR a a e  f he ified d c  i e i g e i e e a d 
e f be e e a  he i e a  a da d e ea ed ha  he dia e e e ic a i  a  6.7:1.  Af e  
ifica i  b  c  ch a g a h  (E OAc:he a e  = 1:2), 3.26f a  b ai ed a  a c e  
i id (27 g, 62%). F he  ifica i  a  ca ied  b  PTLC i g E OAc:he a e  = 1:2 a  
he e e   e a a e 3.26f-(R,S) a d 3.26f-(S,S). The ab e c fig a i  f d c  a  
a ig ed ba ed  X- a  c a g a h  da a f 3.29. 
 
3.26f-(R,S). 1H NMR (500 MH , CDCl3):  6.83 (d, J = 8.9 H , 2H), 6.50 (d, J = 9.0 H , 2H), 
3.75 ( , 3H), 3.41 (dd, J = 18.3, 6.9 H , 1H), 3.38  3.32 ( , 2H), 3.31  3.22 ( , 2H), 3.09 ( , J 
= 9.1 H , 1H), 3.02 ( d, J = 6.9, 2.7 H , 2H), 2.89 (dd, J = 18.4, 4.3 H , 1H), 2.69  2.54 ( , 3H), 
2.23 (d , J = 13.0, 7.3 H , 1H), 1.83 ( , J = 10.3 H , 1H), 1.32 ( , 6H), 1.09 ( , J = 7.1 H , 3H); 
13C NMR (101 MH , CDCl3):  175.5, 168.4, 151.3, 142.6, 127.8 ( , J = 280.4 H ), 115.1, 112.7, 
60.8, 56.1, 51.3, 48.1, 47.2, 44.0, 40.9 ( , J = 26.0 H ), 37.8, 33.2, 30.2, 26.1, 25.7, 12.9; 19F NMR 
(470 MH , CDCl3):  -69.19 (d, J = 9.5 H ); IR (neat):  2974, 2934, 2853, 2833, 1745, 1709, 
1514, 1373, 1303, 1260, 1238, 1159, 1125, 1038, 813, 690 c -1; HRMS (DART): Ca cd f  
 680  
C22H31F3N3O3 (MH+): 442.2312; f d: 442.2305; HPLC (CHIRACPAK IA-3; 5%/ 95% 
i a / he a e , 1.0 L/ i ;  = 15.8 i  ( aj ), 31.5 i  ( i ); 96:4 e ); Specific 
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3.26f ((R,S):(S,S)= 1:4.7). 1H NMR (600 MH , CDCl3, ea   d a e e e  a e e ed): 
 6.86  6.81 ( , 2H), 6.53  6.48 ( , 2H), 3.77  3.73 ( , 3H), 3.50  3.39 ( , 1H), 3.39  3.30 
( , 2H), 3.30  3.20 ( , 2H), 3.11  2.86 ( , 4H), 2.67  2.54 ( , 3H), 2.27  2.06 ( , 1H), 1.84 
( , J = 10.4 H , 1H), 1.33  1.28 ( , 6H), 1.11  1.05 ( , 3H); 19F NMR (470 MH , CDCl3):  -
69.18 (d, J = 9.6 H , 7f-(S,S)), -69.48 (d, J = 9.2 H , 3.26d-(R,S)); HRMS (DART) Ca cd f  
C22H31F3N3O3 (MH+): 442.2312; f d: 442.2305; HPLC (CHIRACPAK IA-3; 5%/ 95% 
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1-Eth l-2-((3R,4R)-1-(4-metho -2,6-dimeth lphen l)-4-(trifluorometh l)piperidine-3-
carbon l)-5,5-dimeth lp ra olidin-3-one (3.26g) 
N-E h -4- e h -N,2,6- i e h a i i e 3.21s a  eac ed i h (E)-1-e h -5,5-di e h -2-
(4,4,4- if b -2-e ) a idi -3- e 3.25f f i g he General Procedure E f  24 
h  i g B(C6F5)3 (10 %), Sc(OTf)3 (20 %), L10 (24 %) a d DCM a  he e . 
Af e  ifica i  b  c  ch a g a h  (E 3N:e h  e he :he a e  = 1:50:50), 3.26g a  
b ai ed a  a i g e dia e e e  a d a  c e  i id (31 g, 67%). The ab e c fig a i  
f  hi  d c  a  a ig ed i  a a g   ha  de e i ed f  d c  3.26f.  
 
1H NMR (600 MHz, CDCl3):  6.61 (d, J = 3.0 H , 1H), 6.46 (d, J = 3.0 H , 1H), 4.38  4.23 ( , 
1H), 3.74 ( , 3H), 3.24 ( d, J = 12.1, 2.6 H , 1H), 3.19 (d, J = 7.3 H , 2H), 3.07 (d , J = 14.2, 7.2 
H , 1H), 3.04  2.93 ( , 2H), 2.91 (d , J = 13.8, 7.1 H , 1H), 2.62 (d, J = 17.3 H , 1H), 2.54 (d, 
J = 17.3 H , 1H), 2.37 ( , 3H), 2.25 ( , 3H), 1.98 (dd, J = 12.8, 4.3 H , 1H), 1.82 ( d, J = 12.4, 4.6 
H , 1H), 1.29 ( , 6H), 1.03 ( , J = 7.1 H , 3H); 13C NMR (126 MHz, CDCl3):  175.3, 169.9, 
157.0, 141.3, 139.5, 138.1, 127.5 ( , J = 280.2 H ), 114.2, 113.5, 60.2, 55.4, 53.4, 48.9, 46.9, 44.4, 
41.9, 41.1 ( , J = 26.0 H ), 26.4, 25.3, 25.1, 20.0, 19.7, 12.7; 19F NMR (376 MHz, CDCl3):  -
70.88 (d, J = 7.7 Hz); IR (neat):  2960, 2836, 1742,1701, 1601, 1485, 1467, 1443, 1388, 1373, 
1303, 1227, 1191, 1151, 1130, 1085, 1034, 999, 855, 731, 619 c -1; HRMS (DART): Ca cd f  
C23H32F3N3O3 (MH+): 456.2468; f d: 456.2460; HPLC (CHIRACPAK IA-3; 5%/ 95% 
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i a / he a e , 0.5 L/ i ;  = 12.5 i  ( i ), 16.0 i  ( aj ); 95:5 e ); Specific 
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(S)-1-Eth l-5,5-dimeth l-2-(4,4,4-trifluoro-3-(1-(4-metho -2,6-dimeth lphen l)-1,4,5,6-
tetrah drop ridin-3- l)butano l)p ra olidin-3-one (3.26h) 
1-(4-Me h -2,6-di e h he ) i e idi e 3.21l a  eac ed i h (E)-1-e h -5,5-di e h -2-
(4,4,4- if b -2-e ) a idi -3- e 3.25f f i g he General Procedure E f  12 
h  i g B(C6F5)3 (10 %), Sc(OTf)3 (10 %), L10 (12 %) a d DCM a  he e . 
Af e  ifica i  b  c  ch a g a h  (e h  e he :he a e = 1:1), 3.26h a  b ai ed a  a 
c e  i id (46 g, 95%). The ab e c fig a i  f  hi  d c  a  a ig ed i  a a g  
 ha  de e i ed f  d c  3.26f.  
 
1H NMR (400 MHz, CDCl3):  6.55 ( , 2H), 5.91 ( , 1H), 3.75 ( , 3H), 3.43  3.29 ( , 2H), 3.20 
 3.07 ( , 3H), 2.96 ( , J = 7.0 H , 2H), 2.57 ( , 2H), 2.29  2.10 ( , 8H), 2.05  1.83 ( , 2H), 
1.29 ( , 6H), 1.06 ( , J = 7.1 H , 3H); 13C NMR (126 MHz, CDCl3):  175.3, 168.2, 157.5, 138.8, 
138.38, 138.37, 135.6, 127.7 ( , J = 280.9 H ), 113.53, 113.50, 95.9, 60.6, 55.4, 47.3, 47.2, 44.8 
( , J = 27.0 H ), 44.0, 34.32, 34.30, 25.9, 25.8, 23.2, 22.7, 18.44, 18.41, 13.0; 19F NMR (376 MHz, 
CDCl3):  -70.18 (d, J = 9.3 Hz); IR (neat):  2925, 2840, 1743, 1708, 1654, 1602, 1487, 1467, 
1442, 1374, 1319, 1301, 1274, 1152, 1099, 1068, 999, 857, 616 c -1; HRMS (DART): 
C25H35F3N3O3 (MH+): 482.2625; f d: 482.2617; HPLC (CHIRACPAK IA-3; 2.5%/ 97.5% 
i a / he a e , 0.5 L/ i ;  = 15.4 i  ( i ), 38.7 i  ( aj ); 95:5 e ); Specific 
Rotation [ ]25D = +12.9  (c = 1.0, DCM). 
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(S)-1-Eth l-5,5-dimeth l-2-(4,4,4-trifluoro-3-(1-(4-metho -2,6-dimeth lphen l)-1,4,5,6-
tetrah drop ridin-3- l-5,5-d2)butano l)p ra olidin-3-one (3.26h-d) 
1-(4-Me h -2,6-di e h he ) i e idi e-3,3,5,5- 4 3.21l-d a  eac ed i h (E)-1-e h -5,5-
di e h -2-(4,4,4- if b -2-e ) a idi -3- e 3.25f f i g he General Procedure 
E f  12 h  i g B(C6F5)3 (10 %), Sc(OTf)3 (10 %), L10 (12 %) a d DCM a  he 
e . Af e  ifica i  b  c  ch a g a h  (e h  e he :he a e  = 1:1), 3.26h-d a  
b ai ed a  a c e  i id (41 g, 84%). The ab e c fig a i  f  hi  d c  a  
a ig ed i  a a g   ha  de e i ed f  d c  3.26f.  
 
1H NMR (500 MHz, CDCl3):  6.55 ( , 2H), 5.91 ( , 1H), 3.75 ( , 3H), 3.42  3.30 ( , 1.78H, 
11%D), 3.22  3.08 ( , 3H), 2.97 ( , J = 7.2 H , 2H), 2.60  2.50 ( , 1.53H, 23%D), 2.20  2.08 
( , 8H), 1.98  1.87 ( , 0.32H, 81%D), 1.29 ( , 6H), 1.06 ( , J = 7.1 H , 3H); 13C NMR (126 
MH , CDCl3):  175.3, 168.2, 157.5, 138.8, 138.41, 138.40, 135.6, 127.7 ( , J = 281.0 H ), 
113.55, 113.52, 96.0, 60.63, 60.56, 55.4, 47.3, 47.22, 47.20, 44.8 ( , J = 27.0 H ), 44.0, 34.3, 25.9, 
23.0, 18.5, 18.4, 13.0; 19F NMR (564 MH , CDCl3):  -70.18 (d, J = 8.6 H ); IR (neat):  2971, 
2934, 2840, 1744, 1707, 1655, 1601, 1486, 1467, 1374, 1319, 1155, 1102, 856, 616 c -1; HRMS 
(DART) Ca cd f  C25H33D2F3N3O3 (MH+): 484.5804; f d: 484.2746; HPLC (CHIRACPAK 
IA-3; 2.5%/ 97.5% i a / he a e , 0.5 L/ i ;  = 12.8 i  ( i ), 33.6 i  ( aj ); 
95:5 e ); Specific Rotation [ ]25D = +2.1  (c = 0.53, DCM). 
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(S)-1-Eth l-5,5-dimeth l-2-(4,4,4-trifluoro-3-(1-(4-metho -2,6-dimeth lphen l)-4,4-
dimeth l-1,4,5,6-tetrah drop ridin-3- l)butano l)p ra olidin-3-one (3.26i) 
1-(4-Me h -2,6-di e h he )-4,4-di e h i e idi e 3.21m a  eac ed i h (E)-1-e h -
5,5-di e h -2-(4,4,4- if b -2-e ) a idi -3- e 3.25f f i g he General 
Procedure E f  36 h  i g B(C6F5)3 (10 %), Sc(OTf)3 (10 %), L10 (12 %) a d 
DCM a  he e  a  80 . Af e  ifica i  b  c  ch a g a h  (E OAc:DCM = 1:16), 
3.26i a  b ai ed a  a c e  i id (38 g, 74%). The ab e c fig a i  f  hi  d c  
a  a ig ed i  a a g   ha  de e i ed f  d c  3.26f. 
 
1H NMR (500 MH , CDCl3):  6.58 ( , 2H), 5.97 ( , 1H), 3.76 ( , 3H), 3.70 (d , J = 9.8, 6.7 H , 
1H), 3.34 (dd, J = 17.4, 6.2 H , 1H), 3.25  3.08 ( , 3H), 2.97 ( , J = 7.1 H , 2H), 2.60  2.48 ( , 
2H), 2.17 (d, J = 9.7 H , 6H), 1.72 ( , J = 5.8 H , 2H), 1.29 ( , 6H), 1.14 (d, J = 9.1 H , 6H), 1.05 
( , J = 7.1 H , 3H); 13C NMR (126 MH , CDCl3):  175.2, 168.4, 157.6, 138.80, 138.75, 138.1, 
134.2, 127.7 ( , J = 280.1 H ), 113.63, 113.56, 104.9, 60.6, 55.4, 47.2, 44.3, 44.1, 39.2, 38.5, 37.6 
( , J = 26.9 H ), 31.5, 29.0, 28.7, 26.0, 25.7, 18.4, 18.3, 12.9; 19F NMR (376 MH , CDCl3):  -
69.40 (d, J = 9.5 H ); IR (neat):  2959, 2927, 2842, 1744, 1711, 1637, 1466, 1442, 1374, 1302, 
1250, 1228, 1150, 1123, 1096, 856, 670 c -1; HRMS (DART): Ca cd f  C27H39F3N3O3 (MH+): 
510.2938; f d: 510.2922; HPLC (CHIRACPAK IA-3; 2.5%/ 97.5% i a / he a e , 0.2 
L/ i ;  = 24.3 i  ( aj ), 28.8 i  ( i ); 94:6 e ); Specific Rotation [ ]25D = -4.6  (c = 
0.62, DCM). 








 697  
 
(S)-1-Eth l-5,5-dimeth l-2-(4,4,4-trifluoro-3-(1-(4-metho -2,6-dimeth lphen l)-4,5,6,7-
tetrah dro-1H-a epin-3- l)butano l)p ra olidin-3-one (3.26j) 
1-(4-Me h -2,6-di e h he )a e a e 3.21t a  eac ed i h (E)-1-e h -5,5-di e h -2-
(4,4,4- if b -2-e ) a idi -3- e 3.25f f i g he General Procedure E f  24 
h  i g B(C6F5)3 (10 %), Sc(OTf)3 (10 %), L10 (12 %) a d DCM a  he e . 
Af e  ifica i  b  c  ch a g a h  (e h  e he :he a e  = 1:1) 3.26j a  b ai ed a  a 
c e  i id (39 g, 78%). The ab e c fig a i  f  hi  d c  a  a ig ed i  a a g  
 ha  de e i ed f  d c  3.26f. 
 
1H NMR (600 MHz, CDCl3):  6.55 ( , 2H), 5.84 ( , 1H), 3.75 ( , 3H), 3.40  3.22 (m, 4H), 3.15 
(d, J = 12.8 Hz, 1H), 3.01  2.90 (m, 2H), 2.61  2.50 (m, 2H), 2.41  2.25 (m, 2H), 2.20 (d, J = 
4.3 Hz, 6H), 1.84  1.70 (m, 4H), 1.28 (d, J = 3.6 Hz, 6H), 1.04 (t, J = 7.1 Hz, 3H); 13C NMR (151 
MHz, CDCl3):  175.4, 168.1, 157.4, 141.8, 140.5, 138.1, 137.9, 127.7 (q, J = 280.8 Hz), 113.6, 
113.5, 104.1, 60.6, 55.4, 54.7, 47.2, 46.7 (q, J = 26.7 Hz), 44.0, 34.5, 30.5, 29.3, 26.8, 25.9, 18.9, 
18.8, 13.0; 19F NMR (470 MHz, CDCl3):  -70.17 (d, J = 9.1 Hz); IR (neat):  2925, 2849, 1744, 
1709, 1648, 1602, 1485, 1466, 1442, 1374, 1308, 1261, 1207, 1152, 1104, 1066, 1031, 895, 732, 
701, 618 cm-1; HRMS (DART): Calcd for C26H37F3N3O3 (MH+): 496.2782; found: 496.2774; 
HPLC (CHIRACPAK IA-3; 5%/ 95% isopropanol/ hexanes, 1.0 mL/min; tr = 4.2 min (minor), 
11.0 min (major); 94:6 er); Specific Rotation [ ]25D = -17.3° (c = 0.47, DCM). 
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2-((3S)-3-(1-(2-((4-Chlorophen l)(phen l)metho )eth l)-1,4,5,6-tetrah drop ridin-3- l)-
4,4,4-trifluorobutano l)-1-eth l-5,5-dimeth lp ra olidin-3-one (3.26k) 
1-(2-((4-Ch he )( he ) e h )e h ) i e idi e 3.21u a  eac ed i h (E)-1-e h -5,5-
di e h -2-(4,4,4- if b -2-e ) a idi -3- e 3.25f f i g he General Procedure 
General Procedure E f  24 h  i g B(C6F5)3 (20 %), Sc(OTf)3 (10 %), L8 (12 %) 
a d DCM a  he e  a  80 . 1H NMR a d 19F NMR a a i  f he ified d c  i e 
i g e i e e a d e f be e e a  he i e a  a da d e ea ed ha  he dia e e e ic 
a i  a  1.0:1. Af e  ifica i  b  c  ch a g a h  (E OAc:he a e  = 1:4), 3.26k a  
b ai ed a  a  i e a ab e i e f dia e e e  (31 g, 53%). The ab e c fig a i  f  
hi  d c  a  a ig ed i  a a g   ha  de e i ed f  d c  3.26f. 
 
1H NMR (400 MHz, CDCl3, ea   d a e e e  a e e ed):  7.33  7.20 (m, 8H), 5.96 
(s, 1H), 5.27 (s, 1H), 3.48  3.40 (m, 2H), 3.39  3.27 (m, 2H), 3.14  2.83 (m, 7H), 2.61  2.48 
(m, 2H), 2.03 (t, J = 6.2 Hz, 2H), 1.83  1.67 (m, 2H), 1.25 (d, J = 9.6 Hz, 6H), 1.01 (t, J = 7.1 Hz, 
3H); 13C NMR (126 MHz, CDCl3):  175.3, 168.3, 141.88, 141.87, 141.0, 136.9, 133.3, 128.7, 
128.6, 128.34, 128.31, 127.8, 127.6 ( , J = 281.3 H ), 127.00, 126.96, 97.8, 83.4, 67.55, 67.53, 
60.6, 55.0, 47.2, 47.0, 45.0 ( , J = 27.1 H ), 44.1, 34.2, 26.0, 25.7, 22.8, 22.6, 12.9; 19F NMR (470 
MHz, CDCl3):  -69.70  -69.87 (m); IR (neat):  2919, 2849, 1742, 1710, 1654, 1513, 1488, 
1465, 1450, 1373, 1337, 1303, 1256, 1237, 1177, 1138, 1096, 1038, 812, 757, 718, 616 c -1; 
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HRMS (DART): Ca cd f  C31H38C F3N3O3 (MH+): 592.2548; f d: 592.2542; HPLC 
(CHIRACPAK AD-H; 5%/ 95% i a / he a e , 0.2 L/ i ;  = 49.2 i  ( aj 1), 53.6 
i  ( aj 2), 61.7 i  ( i 1), 65.5 i  ( i 2); 90:10 e ); Specific Rotation [ ]25D = +2.0  
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(S)-2-(3-(1-(2-(4-(6-(( e -But ldimeth lsil l)o )-2-(4-(( e -but ldimeth lsil l)o ) 
phen l)ben o[b]thiophene-3-carbon l)pheno )eth l)-1,4,5,6-tetrah drop ridin-3- l)-4,4,4-
trifluorobutano l)-1-eth l-5,5-dimeth lp ra olidin-3-one (3.26l) 
(6-(( -B di e h i ) )-2-(4-(( -b di e h i ) ) he )be [b] hi he  
-3- )(4-(2-( i e idi -1- )e h ) he ) e ha e 3.21n a  eac ed i h (E)-1-e h -5,5-
di e h -2-(4,4,4- if b -2-e ) a idi -3- e 3.25f f i g he General Procedure 
General Procedure E f  24 h  i g B(C6F5)3 (20 %), Sc(OTf)3 (10 %), L8 (12 %) 
a d DCM a  he e  a  80 . Af e  ifica i  b  c  ch a g a h  (E OAc:he a e  
= 1:4), 3.26l a  b ai ed a  a hi e id (55 g, 57%). The ab e c fig a i  f  hi  
d c  a  a ig ed i  a a g   ha  de e i ed f  d c  3.26f. 
 
1H NMR (500 MHz, CDCl3):  7.72 (d, J = 8.9 H , 2H), 7.54 (d, J = 8.7 H , 1H), 7.29  7.22 ( , 
3H), 6.87 (dd, J = 8.8, 2.3 H , 1H), 6.70 (d, J = 9.0 H , 2H), 6.66 (d, J = 8.6 H , 2H), 5.95 ( , 1H), 
3.93 ( , J = 5.6 H , 2H), 3.40  3.30 ( , 2H), 3.22  3.12 ( , 2H), 3.11  3.03 ( , 1H), 3.00  2.93 
( , 2H), 2.91 ( , J = 7.1 H , 2H), 2.59  2.48 ( , 2H), 2.01 ( , J = 6.3 H , 2H), 1.85  1.69 ( , 
2H), 1.25 (d, J = 10.2 H , 6H), 1.02  0.98 ( , 12H), 0.92 ( , 9H), 0.22 ( , 6H), 0.11 ( , 6H); 13C 
NMR (101 MHz, CDCl3):  193.3, 175.3, 168.3, 162.8, 156.2, 153.6, 143.4, 140.0, 136.5, 134.6, 
132.4, 130.7, 130.6, 130.4, 127.5 ( , J = 281.1 H ), 126.9, 124.0, 120.4, 119.4, 114.1, 112.2, 99.3, 
66.6, 60.6, 54.1, 47.2, 47.1, 44.9 ( , J = 27.2 H ), 43.9, 34.2, 30.4, 29.8, 25.8, 25.7, 22.7, 22.5, 
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18.4, 18.3, 12.9, -4.2, -4.4; 19F NMR (376 MHz, CDCl3):  -69.86 (d, J = 9.2 Hz); IR (neat):  
2952, 2927, 2856, 1744, 1710, 1655, 1597, 1530, 1465, 1304, 1255, 1165, 1137, 1038, 942, 909, 
838, 642 c -1; HRMS (DART): Ca cd f  C51H69F3N3O6SSi2 (MH+): 964.4392; f d: 964.4392; 
HPLC (CHIRACPAK IA-3; 5%/ 95% i a / he a e , 1.0 L/ i ;  = 11.8 i  ( i ), 
15.7 i  ( aj ); 95:5 e ); Specific Rotation [ ]25D = -4.6  (c = 0.82, DCM). 
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C11. X-Ra  Cr stallograph  Data 
X-Ra  Cr stallograph  Data of 3.42i-major 
 
Table S3.7.  C a  da a a d c e efi e e  f  C23H36NO5+C -. 
Identification code  C23H36NO5+Cl- 
Empirical formula  C23 H37 Cl N O5.50 
Formula weight  450.98 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P21/c 
 795  
Unit cell dimensions a = 15.0369(10) Å D= 90°. 
 b = 15.1361(9) Å E= 109.486(2)°. 
 c = 11.4130(7) Å J = 90°. 
Volume 2448.8(3) Å3 
Z 4 
Density (calculated) 1.223 Mg/m3 
Absorption coefficient 1.662 mm-1 
F(000) 972 
Crystal size 0.570 x 0.250 x 0.220 mm3 
Theta range for data collection 4.273 to 66.688°. 
Index ranges -17<=h<=17, -17<=k<=18, -13<=l<=13 
Reflections collected 26897 
Independent reflections 4324 [R(int) = 0.0346] 
Completeness to theta = 66.688° 99.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7528 and 0.5887 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4324 / 4 / 296 
Goodness-of-fit on F2 1.145 
Final R indices [I>2sigma(I)] R1 = 0.0506, wR2 = 0.1303 
R indices (all data) R1 = 0.0511, wR2 = 0.1306 
Extinction coefficient n/a 
Largest diff. peak and hole 0.409 and -0.389 e.Å-3 
 796  
X-Ra  Cr stallograph  Data of 3.42i-Minor 
 
Table S3.8. C a  da a a d c e efi e e  f  C23H36NO5+C -. 
Identification code  (C23H36NO5)+Cl- 
Empirical formula  C27 H46 Cl N O6 
Formula weight  516.10 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 12.7945(13) Å a= 90°. 
 797  
 b = 16.9523(16) Å b= 90.019(5)°. 
 c = 13.6116(13) Å g = 90°. 
Volume 2952.3(5) Å3 
Z 4 
Density (calculated) 1.161 Mg/m3 
Absorption coefficient 1.449 mm-1 
F(000) 1120 
Crystal size 0.600 x 0.280 x 0.220 mm3 
Theta range for data collection 3.454 to 66.915°. 
Index ranges -15<=h<=15, -20<=k<=0, -16<=l<=16 
Reflections collected 9581 
Independent reflections 5139 [R(int) = 0.0569] 
Completeness to theta = 66.915° 97.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7528 and 0.5470 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5139 / 1 / 335 
Goodness-of-fit on F2 1.065 
Final R indices [I>2sigma(I)] R1 = 0.0789, wR2 = 0.2343 
R indices (all data) R1 = 0.0836, wR2 = 0.2389 
Extinction coefficient n/a 
Largest diff. peak and hole 1.050 and -0.299 e.Å-3 
 
 798  
X-Ra  Cr stallograph  Data of 3.23bf-Major 
Table S3.9. Crystal data and structure refinement for C23H29NO4. 
Identification code  C23H29NO4 
Empirical formula  C23 H29 N O4 
Formula weight  383.47 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 10.2867(8) Å D= 90°. 
 799  
 b = 7.8024(7) Å E= 94.248(4)°. 
 c = 13.1792(10) Å J = 90°. 
Volume 1054.87(15) Å3 
Z 2 
Density (calculated) 1.207 Mg/m3 
Absorption coefficient 0.659 mm-1 
F(000) 412 
Crystal size 0.600 x 0.320 x 0.220 mm3 
Theta range for data collection 3.363 to 66.626°. 
Index ranges -9<=h<=12, -9<=k<=7, -15<=l<=15 
Reflections collected 6116 
Independent reflections 2950 [R(int) = 0.0250] 
Completeness to theta = 66.626° 99.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7528 and 0.5979 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2950 / 1 / 255 
Goodness-of-fit on F2 1.076 
Final R indices [I>2sigma(I)] R1 = 0.0275, wR2 = 0.0732 
R indices (all data) R1 = 0.0276, wR2 = 0.0734 
Extinction coefficient n/a 
Largest diff. peak and hole 0.170 and -0.145 e.Å-3 
 800  
X-Ra  Cr stallograph  Data of 3.44-Major 
Table S3.10. Crystal data and structure refinement for (C40H56NO5Si)+Cl- 
Identification code  (C40H56NO5Si)+Cl- 
Empirical formula  C44 H66 Cl N O6 Si 
Formula weight  768.51 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 13.8219(7) Å D= 90°. 
 801  
 b = 25.0250(14) Å E= 90°. 
 c = 26.0978(14) Å J = 90°. 
Volume 9027.0(8) Å3 
Z 8 
Density (calculated) 1.131 Mg/m3 
Absorption coefficient 1.348 mm-1 
F(000) 3328 
Crystal size 0.540 x 0.100 x 0.080 mm3 
Theta range for data collection 2.446 to 66.712°. 
Index ranges -15<=h<=16, -29<=k<=29, -31<=l<=25 
Reflections collected 46423 
Independent reflections 15586 [R(int) = 0.0733] 
Completeness to theta = 66.712° 99.2 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7528 and 0.5629 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 15586 / 793 / 965 
Goodness-of-fit on F2 1.050 
Final R indices [I>2sigma(I)] R1 = 0.0642, wR2 = 0.1605 
R indices (all data) R1 = 0.0698, wR2 = 0.1646 
Absolute structure parameter 0.037(7) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.742 and -0.534 e.Å-3 
 802  
X-Ra  Cr stallograph  Data of 3.45 
 
Table S3.11. Crystal data and structure refinement for C36H37F3N2O3(C6H6)2. 
Identification code  C36H37F3N2O3(C6H6)2 
Empirical formula  C48 H49 F3 N2 O3 
Formula weight  758.89 
Temperature  173(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 13.7584(15) Å D= 90°. 
 803  
 b = 6.1841(7) Å E= 100.009(6)°. 
 c = 24.281(3) Å J = 90°. 
Volume 2034.4(4) Å3 
Z 2 
Density (calculated) 1.239 Mg/m3 
Absorption coefficient 0.698 mm-1 
F(000) 804 
Crystal size 0.360 x 0.180 x 0.120 mm3 
Theta range for data collection 1.848 to 67.096°. 
Index ranges -16<=h<=16, -7<=k<=7, -28<=l<=28 
Reflections collected 52023 
Independent reflections 7082 [R(int) = 0.0633] 
Completeness to theta = 67.096° 98.1 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7528 and 0.6627 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7082 / 33 / 514 
Goodness-of-fit on F2 1.061 
Final R indices [I>2sigma(I)] R1 = 0.0399, wR2 = 0.0896 
R indices (all data) R1 = 0.0503, wR2 = 0.0949 
Absolute structure parameter -0.06(8) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.143 and -0.173 e.Å-3 
 804  
X-Ra  Cr stallograph  Data of 3.29 
 
Table S3.12. Crystal data and structure refinement for C22H24BrF3N2O3. 
Identification code  C22H24BrF3N2O3 
Empirical formula  C22 H24 Br F3 N2 O3 
Formula weight  501.34 
Temperature  173(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  C2 
Unit cell dimensions a = 46.369(4) Å D= 90°. 
 805  
 b = 5.7157(5) Å E= 91.434(2)°. 
 c = 7.9867(7) Å J = 90°. 
Volume 2116.0(3) Å3 
Z 4 
Density (calculated) 1.574 Mg/m3 
Absorption coefficient 3.128 mm-1 
F(000) 1024 
Crystal size 0.560 x 0.380 x 0.160 mm3 
Theta range for data collection 3.814 to 66.565°. 
Index ranges -54<=h<=54, -6<=k<=6, -9<=l<=9 
Reflections collected 32823 
Independent reflections 3675 [R(int) = 0.0304] 
Completeness to theta = 66.565° 98.4 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7528 and 0.4622 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3675 / 1 / 280 
Goodness-of-fit on F2 1.059 
Final R indices [I>2sigma(I)] R1 = 0.0218, wR2 = 0.0587 
R indices (all data) R1 = 0.0218, wR2 = 0.0587 
Absolute structure parameter -0.007(7) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.388 and -0.506 e.Å-3 
